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Abstract 
Mephedrone is a synthetic cathinone known for its psychostimulant properties. Despite 
its ban in the United Kingdom in 2010, mephedrone use in London remains popular and 
there are reports describing an increasing problem of the drug being injected. 
Nevertheless, there is little known about the distribution of mephedrone and its 
metabolites in humans as only two controlled mephedrone administration studies and 
one dose-finding pilot study have been previously reported. In recent years, there has 
been a growing interest in the use of alternative biological matrices for determining drug 
abuse. The collection of these samples is usually non-invasive, fast and cost effective 
which allows for drug testing in the workplace, by the roadside and in addiction 
treatment centres. 
 
A single dose administration study of 100 mg mephedrone hydrochloride via nasal 
insufflation to six healthy male volunteers was performed to determine the distribution 
and pharmacokinetics of mephedrone and its metabolites in conventional (whole blood, 
plasma, urine) and alternative (oral fluid, fingerprint sweat, dried blood spots, head hair) 
biological matrices. Samples were collected at different timepoints after mephedrone 
administration and were analysed for the presence of mephedrone, 
dihydro-mephedrone (DHM), nor-mephedrone (NOR), hydroxytolyl-mephedrone 
(HYDROXY), 4-carboxy-mephedrone (4-CARBOXY) and dihydro-nor-mephedrone 
(DHNM) by validated liquid chromatography-tandem mass spectrometry methods. 
 
All analytes were detected in whole blood and plasma, where 4-CARBOXY reached the 
highest concentration. The mean Tmax for mephedrone (55.0 ± 18.2 min in whole blood 
and 52.5 ± 20.7 min in plasma) correlated well between both matrices, indicating rapid 
absorption of the drug after nasal insufflation. Other analytes had a more delayed Tmax 
but were all detected up to 6 h in both matrices, with mephedrone also being detectable 
on Day 2 in one participant in whole blood. Mephedrone had a mean half-life of 2.12 ± 
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0.33 h and 1.98 ± 0.30 h in whole blood and plasma, respectively. In addition, statistical 
analysis showed that median whole blood to plasma distribution ratios, reported here 
for the first time, were statistically different from 1 (unity) for mephedrone (median: 
1.11), DHM (median: 1.30) and NOR (median: 0.765). Chiral analysis revealed that 
R-mephedrone reached higher concentrations than S-mephedrone in whole blood and 
had comparable pharmacokinetic parameters to total mephedrone. It has been shown 
that the two enantiomers of mephedrone exhibit different pharmacokinetic profiles in 
humans, but the clinical significance of this finding is not yet fully understood. In urine, 
4-CARBOXY and DHNM were the only metabolites detectable on Day 3, making them 
promising markers of mephedrone use. 
 
In the alternative biological matrices, mephedrone metabolites were detected for the 
first-time in head hair one month after mephedrone administration. Calculated 
NOR:mephedrone and DHNM:mephedrone ratios were 0.19 (n=1) and 0.21 (n=1), 
respectively. However, sample size was too small to suggest robust metabolite to 
mephedrone ratios that would differentiate external drug contamination from drug 
consumption. In fingerprint sweat, mephedrone and NOR were detected above the limit 
of detection in 62% and 3.8% of all post administration samples, respectively. Inter- and 
intra-subject variability was observed which can be attributed to the differences in 
pressure applied during fingerprint deposition, the angle and duration of contact with 
the deposition surface coupled with an inability to control the ‘amount’ of collected 
sweat. Given these limitations fingerprint sweat may not be ideal for use in quantitative 
analysis until practical solutions to these problems are found. In dried blood spots, 
mephedrone, NOR and 4-CARBOXY were the only analytes detected in the majority of 
samples. In oral fluid, mephedrone and NOR were detected but their concentrations 
peaked earlier than in whole blood and plasma which may be due to the contamination 
of the oral cavity with mephedrone after nasal insufflation. 
 
It is hoped that this work will help with interpreting results and reporting findings from 
the analysis of conventional and alternative biological matrices following mephedrone 
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use in forensic (drug-related deaths and crime) and clinical (acute drug toxicity and drug 
dependence) toxicology as well as in the workplace and roadside drug testing. 
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CHAPTER 1  
INTRODUCTION 
 New psychoactive substances 
The last decade has seen the emergence of new psychoactive substances (NPS), defined 
by the United Nations as “new narcotic or psychotropic drugs, in pure form or in a 
preparation, that are not scheduled under the Single Convention on Narcotic Drugs of 
1961 or the Convention on Psychotropic Substances of 1971” 1,2. NPS were designed to 
mimic the pharmacological effects of the traditional drugs (e.g. heroin, cannabis or 
amphetamine) and to avoid existing drug legislation, which has earned them the name 
“legal highs”. Although most NPS are structural analogues of the traditional drugs, 
synthetic cannabinoids are a notable example of NPS which are not structurally derived 
from tetrahydrocannabinol (psychoactive constituent of cannabis) 3. 
 
NPS are often sold in bright and colourful packaging labelled “bath salts”, “research 
chemical” or “plant food” alongside the disclaimer “not for human consumption” and a 
list of ingredients which often does not accurately indicate their content 4. Information 
about dosing, adverse effects and warnings are often missing from the packaging while 
active ingredients vary in their amount within same brands/suppliers 5. NPS are often 
adulterated with other drugs of abuse (e.g. amphetamine or cocaine), pharmaceuticals, 
herbal blends or contain synthetic impurities, such as unreacted starting materials or 
reaction by-products 5,6.  
 
NPS represent a diverse family of compounds which sometimes overlap in terms of their 
pharmacological effects but is usually divided into several groups as shown in Figure 1-1. 
The total number of newly reported NPS peaked in 2014 when 101 new compounds, 
predominantly synthetic cathinones and cannabinoids, were reported to the European 
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Union (EU) Early Warning System run by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA). The number dropped to 55 in 2018 which indicates fewer 
new compounds being reported, however, it is not necessarily correlated to a decrease 
in overall NPS availability. By the end of 2018, more than 730 NPS were monitored by 
EMCDDA, 55 of which were detected for the first-time in Europe in 2018 7. Moreover, 
almost 10,000 more seizures of synthetic cannabinoids were reported in 2016 than in 
2015, making this group of drugs most frequently seized. Synthetic cathinones were the 
most seized NPS by quantity (1.9 tonnes in 2016 compared with 1.8 tonnes in 2015) and 















Figure 1-1. Numbers and categories of new psychoactive substances submitted to the EU Early 
Warning System for the first-time between 2005 and 2018; adapted from the European Drug 
Report 2019 7 
 
 
A concerning trend showing the number of new synthetic opioids increasing every year 
can also be observed in Figure 1-1. The scale of the problem is not as serious as in the 
United States of America (USA), however, 11 new opioids were reported for the 
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first-time in Europe in 2018 compared to 9 in 2016 9. Seizures of opioids have also 
increased from 1.8 litres in 2015 to 4.6 litres in 2016.  
1.1.1 Legal responses 
Legal responses to the emergence of NPS differed across the globe. The UK Government 
introduced the Psychoactive Substances Act in 2016 which controls all substances 
capable of producing psychoactive effects that are not already controlled by the Misuse 
of Drugs Act 1971 10. However, it is not clear how the psychoactivity could be proved 
without the data from human clinical trials or controlled administration studies. Under 
the Psychoactive Substances Act 2016, possession of NPS for personal use is not an 
offence, except in the custodial institutions. Similar “blanket bans” were introduced in 
other European countries, such as Poland 11 and the Republic of Ireland 12. New Zealand 
employed a similar model where a “blanket ban” was imposed on the psychoactive 
drugs which have not been shown to have a low risk of harm 13. Countries like Brazil and 
Australia took a different approach and have enacted generic bans based on chemical 
structure rather than psychoactive effects. 
1.1.2 Reasons for use 
Reasons for choosing NPS instead of traditional drugs can be either internal or external. 
Internal reasons include curiosity, often sparked by the media reports on NPS, as well as 
enjoyable and desired effects. External reasons include the price, availability, ease of 
purchasing, legal status, perceived purity and non-detectability in routine laboratory 
drug tests 14,15. The latter has especially been an attractive feature to those who have to 
undergo mandatory drug testing (e.g. prisoners, transport workers, military personnel) 
16. In prisons, smoking synthetic cannabinoids tend to be preferred to smoking cannabis, 
which is detected in routine drug screens and has an easily recognisable smell that could 
attract attention of probation officers or prison guards 17. 
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Undoubtedly, information found on the Internet about new compounds, reliable online 
sellers, buyers’ reviews as well as the ease of purchasing have contributed to NPS 
popularity. Online fora became places where users described their subjective effects, 
drug preferences, dangerous drug interactions and routes of administration 18,19. In 
addition, anonymity provided to buyers and sellers on the dark web, which cannot be 
accessed with standard search engines, made it an appealing drug selling platform. 
Research shows that in September 2013, 1,031 vendors and 10,927 individual drug 
listings appeared on the dark web 20. Furthermore, popular social media sites like 
Facebook, YouTube and picture sharing websites have also seen drug users engaging in 
drug-related conversations and uploading pictures and videos of their experiences 19.  
 
The cost of NPS has been reported to be one of the more important factors driving 
people to use these emerging drugs of abuse. “Value for money” reported by 59% of 
psychostimulant users in Australia was the main motivation for taking NPS 21. Similar 
results were seen in an online survey of 619 international drug users, where 66% and 
56% chose synthetic cannabinoids and synthetic opioids, respectively, due to “price, 
legal status, availability and non-detectability in screening tests” 22. Brunt et al. have 
shown that the cost of NPS per gram differed considerably between countries, such as 
Poland, Czech Republic, UK, France and the Netherlands in 2014/15 23. For example, 
synthetic cathinones were the cheapest in Poland whereas synthetic cannabinoids were 
least expensive in the UK. 
 
Legal status of NPS was a more motivating factor for the new drug users than for the 
long-term drug users who have established contacts with drug suppliers 21. According to 
a survey conducted by Sutherland et al., legality and availability were the two 
predominant driving forces for use of synthetic cannabinoids compared to other types 
of NPS. However, the introduction of the Psychoactive Substances Act in 2016 in the UK 
imposed a “blanket ban” on “legal highs” 17,24. As a result, “head shops” and online shops 
with a domain location in the UK closed down while other remained open but stopped 
selling NPS 10. 
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1.1.3 Analytical challenges 
With immunoassays lacking discriminating power to accurately identify NPS due to 
cross-reactivity, sensitive and selective liquid chromatography-mass spectrometry 
(LC-MS) based on the initial intelligence from the material safety data sheets is a 
technique of choice for drug testing in many forensic laboratories. However, 
non-targeted approaches (e.g. high-resolution mass spectrometry) can also be of value 
in determining a potential molecular formula and/or a chemical structure. Moreover, 
the use of ion ratios and UV spectra may be further employed to identify isomers in 
biological samples. 
 
The influx of constantly changing NPS poses a challenge to the drug testing companies 
which are constantly under pressure to update their assays. While many NPS may no 
longer be present on the market by the time methods have been re-validated, other 
drugs, such as mephedrone, remain popular. In addition, unavailability of certified 
reference standards or their prohibitive costs further delay development of analytical 
techniques, making it difficult to keep pace with the ever-changing nature of NPS 25. The 
absence of reference standards also hinders prompt identification of new NPS which 
may be present in complex mixtures/matrices or may exist as positional isomers or 
stereoisomers. 
 
Because animal and human administration studies require ethical approvals, 
information about in vivo metabolism of NPS and their pharmacokinetics is often 
unknown. As a result, informative data is usually derived from less reliable sources, such 
as in vitro metabolism studies, analysis of samples collected from hospitalised patients 
or post-mortem samples. However, these approaches do not provide reliable 
information about human drug metabolism, which is vital when metabolites have to be 
targeted because the parent drug is rapidly eliminated from the body 26. 
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1.1.4 Synthetic cathinones 
Synthetic or substituted cathinones are chemical analogues of cathinone (Figure 1-2), 
which is naturally present in the leaves of Catha edulis (Khat). Synthetic cathinones are 
one of the largest groups of NPS, accounting for 24% of all seized NPS in 2017 7. They 
cross the blood-brain barrier (BBB) and exert stimulating and sympathomimetic effects 
on the central nervous system (CNS) 27. Adverse effects include elevated blood pressure, 
heart arrhythmia, palpitations, dizziness, light-headedness, paranoia, tachycardia, 
short-term memory problems, vomiting, sweating and migraines 28,29. Mephedrone is 








Mephedrone (4-methyl methcathinone; 4-methylephedrone; 4-MMC; “meow meow”; 
“meph”; “bubble”; “M-Cat”; “drone”) is a synthetic cathinone (a β-keto amphetamine 
derivative) known for its psychostimulant properties 30–32. Addition of the ketone 
functionality increases the overall polarity of cathinones compared to phenethylamines 
(Figure 1-3). Figure 1-4 shows the generic structure of a cathinone derivative and 
possible substitution patterns.  
 
  Chapter 1 | Introduction 
Page | 41 
 
 
Figure 1-4. Generic structure of a cathinone derivative 
 
 
The most common substitutions at the N-terminus include methyl (methcathinone) or 
ethyl (ethcathinone) groups or a pyrrolidine ring (α-pyrrolidinopropiophenone or α-PPP 
in short). In addition, substitutions on the phenyl ring lead to the formation of 
mephedrone (methyl group at the 4’ position on the ring), 3-methylmethcathinone 
(methyl group at the 3’ position on the ring) or methylone (dioxolane ring attached to 
the phenyl ring). The addition of both dioxolane (methylenedioxy) and pyrrolidine rings 
results in methylenedioxypyrovalerone (MDPV) and its analogues. Figure 1-5 shows 





Figure 1-5. Chemical structures of selected synthetic cathinones 
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1.2.1 Synthesis and by-products 
Even though mephedrone use in Europe began in 2009, its synthesis was first described 
in 1929 33. The main synthetic route involves α-bromination of 4-methylpropiophenone 
and a subsequent reaction with methylamine hydrochloride and triethylamine, the 
latter acting as an acid scavenger (Figure 1-6a). The resulting mixture is treated with 
gaseous or aqueous HCl and is recrystallised to yield mephedrone hydrochloride. Yields 
of 30% 34 and 51% 35 have been reported. As shown in Figure 1-6b, another potential 
synthetic pathway involves a one-step oxidation of 4-methylephedrine with potassium 
permanganate, a synthetic route also used for the preparation of methcathinone 32,33. 
Inadequate purification of the product can lead to manganese poisoning which has been 
reported in methcathinone users 36–40. Both methods produce racemic mixtures, but 
only one enantiomer of mephedrone can be produced if a single enantiomeric form of 
4-methylephedrine is used 32. As shown in Figure 1-7, a stereoselective synthesis of 
(S)-mephedrone via Friedel-Crafts acylation carried out with (S)-N-trifluoroacetylalanyl 
chloride and aluminium chloride (AlCl3) can also be performed 41. Even though 
stereoselective synthesis is possible, “street mephedrone” has been sold as a racemic 
mixture 42, which is most likely attributed to the simplicity of the synthesis and the 




Figure 1-6. Synthesis of a racemic mephedrone via α-bromination (a) and oxidation (b) 
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Figure 1-7. Stereoselective synthesis of (S)-mephedrone 
 
 
Information about synthetic mephedrone impurities or reaction by-products, which 
could link a clandestine lab to the type of produced drugs, is limited. A recent publication 
reported the formation of precipitate following addition of diethyl ether to the crude 
mephedrone product. Initially, the precipitate was thought to be mephedrone itself, but 
it was later confirmed to also contain 1,2,3,5-tetramethyl-4-(4-methylphenyl)-1H-
imidazol-3-ium salt (TMMPI) 43. Another study identified thirteen mephedrone pyrolysis 
products formed during smoking. The major components were iso-mephedrone, 
4-methylpropiophenone (precursor in mephedrone synthesis), 4-methylphenylacetone, 
two hydroxylated oxidation products, two pyrazine derivatives, N-methylated 
mephedrone and a diketone. Amongst minor compounds, α-chloro ketones were 
identified which are known respiratory irritants 44.       
1.2.2 Availability and legal response 
Mephedrone was first detected in the UK in 2008/9 and rapidly gained popularity. The 
2013/14 Crime Survey for England and Wales reported mephedrone to be the fourth 
most frequently used substance amongst all recreational drugs 45. This was reflected in 
the number of people seeking support for problematic and/or dependent mephedrone 
use, which increased from 839 in 2010/11 to 1,630 in 2012/13 46. 
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Even though EMCDDA reported seizures and detection of mephedrone in 28 European 
and neighbouring countries, data on mephedrone prevalence and use from outside the 
UK is scarce 47. González et al. conducted a cross-sectional survey with 230 NPS users in 
Spain in 2010 and 2011 48. The most frequently used substances were hallucinogenic 
phenethylamines and cathinones, including mephedrone (35.2% of surveyed NPS users). 
Mephedrone use was also reported on other continents. In the USA, 1.1% of clubgoers 
in New York City between May and October 2012 used mephedrone 49. In Australia, 
one-fifth (21%) of 693 recreational users of MDMA (commonly known as “ecstasy”) 
reported lifetime use of mephedrone and 17% took the drug in the six months preceding 
the interview conducted in 2010 50. 
 
Research shows that mephedrone’s popularity was largely attributed to its price, 
availability and purity rather than its legal status. In semi-structured interviews carried 
out in 2010 none of the 23 mephedrone users pointed to its legality as a motivation for 
use 51. Similar findings were reported by Corazza et al. who found that legal status of 
mephedrone did not influence drug choice of 52.9% of 446 UK students surveyed 52. 
 
The emergence and sudden popularity of mephedrone in 2009 has also been attributed 
to the low purity and reduced availability of MDMA and cocaine powder 53. Reported 
seizures of MDMA in west and central Europe fell from 1.5 tonnes in 2007 to 0.3 tonnes 
in 2008 54. At the same time the decline in drug purity was reported in the EU, where 
only 40% of “ecstasy” tablets contained MDMA-like substances in the first half of 2009 
in the Netherlands 55, and the all-time low purity of seized cocaine was reported 56. 
Moreover, Google searches for the word “mephedrone” peaked in the first quarter of 
2009 compared to search requests for “MDMA” (Figure 1-8). A preference for “legal 
highs” started to emerge, with poly-drug users explaining the shift to be due to low 
purity of cocaine powder and “ecstasy” pills in particular 57. However, more recent 
reports tend to suggest that at the time NPS, including mephedrone, did not displace or 
replace established drugs but rather were added to the drug repertoire 53,58.  
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After being briefly legal in the UK, mephedrone was classified as a Class B substance and 
banned under the Misuse of Drugs Act, 1971 (Amendment) Order 2010 passed by the 
Parliament in April 2010. This was followed by an EU wide ban on mephedrone 
introduced by the European Council in December 2010 and a subsequent decision of the 
Drug Enforcement Administration to make mephedrone a controlled substance in the 
USA 4. Following the 2010 ban and classification, mephedrone use declined in the UK 59. 
As seen in Figure 1-9, prevalence of mephedrone use in the young generation (16-24 
year olds) and in the general population (16-59 year olds) fell by 1% and 0.3%, 
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Figure 1-9. Annual prevalence of mephedrone use in England and Wales in 2010/11 and 
2011/12; adapted from the United Nations World Drug Report 2013 59 
 
 
One month after the EU ban on mephedrone in 2010, 63% of 150 surveyed mephedrone 
users had continued using the drug 60. Several years after the ban, mephedrone has not 
completely disappeared from the market. Recent data on patients admitted to 
Nowowiejski Hospital in Warsaw (Poland) after a mephedrone binge started to increase 
steadily, reaching 100 admissions in 2017 compared to 16 in August 2010. During the 
mephedrone binges, which lasted on average 12.4 days, patients consumed on average 
1.52 g of mephedrone a day. Almost all patients engaged in poly-drug use and took 
mephedrone in combination with alcohol, heroin, benzodiazepines, opioids and 
cannabinoids 61. Moreover, according to the European Drug Emergencies Network 
published in 2015 cathinones were most frequently reported in presentations to 
hospitals around Europe, with mephedrone being the most common NPS 62. In the UK, 
there is some evidence to suggest that mephedrone use in London remains popular and 
may even be increasing 63. According to the correspondence from the Toxicology Unit at 
Imperial College London published in The Lancet, mephedrone was detected in 1.0% 
(n=34) of the Unit’s death cases in 2014 and this number increased to 1.5% (n=22) in 
2015. On the national scale mephedrone use among 16- to 34-year olds has decreased 
from 1.1% in 2014/15 to 0.3% in 2016/17 and hospitalisations due to mephedrone 
intoxication are also less frequent 8. However, there is new evidence describing an 
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increasing problem with people injecting mephedrone which leads to higher rates of 
hepatitis C, human immunodeficiency virus (HIV) and lethal overdose 64. This data 
indicates that mephedrone not only continues to be produced and distributed but also 
that the demand for the drug remains. 
1.2.3 Routes of administration and dose  
Mephedrone is typically sold as a white crystalline powder with a hue of yellow which is 
soluble in water allowing users to dissolve the powder prior to oral/rectal use or 
injection 33,65. Other reports also indicate that mephedrone is supplied as tablets or in 
capsules filled with powder 57,66. Most mephedrone users report “snorting” (nasal 
insufflation) to be the most common route of use followed by swallowing dissolved 
powders or powders wrapped in cigarette paper (known as “bombing”) 65,67. Even 
though the onset of drug action is delayed when taken orally compared to nasal 
insufflation, some users may want to avoid “snorting” because of reported nose bleeds 
and irritation associated with it 33. Less common administration methods involve 
smoking as well as intravenous (see 1.2.9.3) and rectal use 65. 
 
The initial dose of mephedrone taken by recreational mephedrone users ranges from 
15 mg to more than 300 mg for oral ingestion and from 5 mg to 250 mg for nasal 
insufflation 66. Because of mephedrone’s short duration of action, recreational users 
commonly re-dose a number of times in a single session such that they use 1 g or more 
per session 68. Case reports and series of acute mephedrone toxicity have generally 
reported use of 300-7,000 mg 33,69. 
1.2.4 Human metabolism 
Metabolism studies have been performed in vitro 70,71 and in vivo, both in animal (rat) 
72,73 and humans 74. As shown in Figure 1-10, the main Phase I metabolic pathways in 
humans include N-demethylation of the secondary amine to yield nor‐mephedrone, 
reduction of the ketone moiety to the hydroxyl group to produce dihydro‐mephedrone, 
  Chapter 1 | Introduction 
Page | 48 
 
and oxidation of the tolyl moiety, leading to the formation of hydroxytolyl‐mephedrone 
and 4-carboxy‐mephedrone. A simultaneous reduction of the ketone moiety and 
N-demethylation of the secondary amine produces dihydro‐nor‐mephedrone. Phase II 
metabolites are produced mainly by O-glucuronidation and N-glucuronidation to form 
hydroxylmephedrone-3-O-glucuronide, 4-carboxymephedrone-N-glucuronide and 
hydroxyl-nor-mephedrone-3-O-glucuronide (see Figure 1-11) 74. Conjugation with the 
succinic acid which gives rise to N-succinyl-nor-mephedrone has also been reported and 
its formation confirmed by the comparison with the synthesised material 74. To the best 
of my knowledge, sulphur conjugation has not been reported.  
 
Hepatic cytochrome P450 2D6 (CYP2D6) was found to be the main enzyme responsible 
for the metabolism of mephedrone in humans, with only a negligible contribution from 
other cytochrome P450 enzymes 70. Moreover, Olesti et al. demonstrated that 
significantly altered mephedrone plasma concentrations are a result of CYP2D6 activity, 
with users of no or low CYP2D6 functionality being at risk of unwanted acute toxicity 75. 
Cytochrome P450 enzymes are not only expressed in the liver but can also be found in 
the CNS which brings forward a possibility of drug metabolism in the brain and a 
subsequent formation of the metabolites in situ. 
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Figure 1-10. Phase I metabolites of mephedrone identified in vitro in human by Pedersen et al. 
70 and in vivo in human by Pozo et al. 74 Pink - metabolites identified only by Pozo et al.; Red - 
metabolites identified only by Pedersen et al.; Blue - metabolites identified by both 
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Figure 1-11. Phase II metabolites of mephedrone identified in vivo in human by Pozo et al. 74 
 
1.2.5 Mode of action 
Studies have demonstrated that mephedrone stimulates the release of monoamines 
through the interaction with noradrenaline (NA), dopamine (DA) and serotonin (SER) 
transporters, and inhibits their reuptake 28,32,76. A study performed on rat’s tissue from 
the cortex and striatum showed that mephedrone had a greater affinity to DA than SER 
membrane transporters 77. Researchers have also postulated that mephedrone’s 
interaction with the SER receptor leads to entactogenic effects while the activation of 
DA and NA systems is responsible for the psychostimulant effects of the drug 78. 
Moreover, animal studies demonstrated that mephedrone readily crosses the BBB. 
Following a 5 mg/kg intravenous dose, mephedrone reached the highest mean 
concentration (826.2 ng/mL) in a rat brain after 30 min, yielding a brain to serum ratio 
of 1 to 1.19 79.  
 
Chemical structure plays an important role in the interaction of cathinone analogues 
with monoamine transporters. A para-methyl group added to the cathinone structure 
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results in an increased potency at the serotonin transporter (SERT), decreased potency 
at the dopamine transporter (DAT) and an overall decrease in DAT vs SERT selectivity 80. 
As seen in Table 1-1, when methcathinone was compared with mephedrone (4-methyl 
substituted methcathinone), methcathinone displayed a 309-fold greater selectivity at 
DAT in rat brain synaptosomes whereas mephedrone displayed only 2.41 DAT vs SERT 
selectivity 81. Having investigated multiple substituents at the 4-position of the 
methcathinone scaffold, modelling studies have demonstrated that it influences drug 
interactions with the binding site on DAT and SERT. Large volumes of hydrophobic 
substituents at 4-position, like in the case of mephedrone, were shown to display 
greater potency at SERT 82. Chemical modifications to the cathinone scaffold have also 
been shown to influence their pharmacokinetics 83. A study done in rats investigated the 
effects of an α-alkyl chain length on plasma and CNS pharmacokinetics (PK). Following a 
20 mg/kg subcutaneous dose of methylone (-CH3), butylone (-CH2CH3) and pentylone 
(-CH2CH2CH3), blood samples were collected. Significant decrease in the Cmax, area under 
the curve (AUC) and half-life (t1/2) corresponded with a decrease in the chain length. 
Pentylone, which is the most lipophilic of the three, reached the highest plasma 
concentration (Cmax = 5,735.7 ± 799.6 µg/L), AUC (AUC0-∞ = 535,430 ± 41,932 µg/L x min) 
and displayed longest t1/2 (t1/2 = 253.2 ± 85.9 min) 84. 
 
 
Table 1-1. In vitro release at half maximal effective concentration (EC50) for methcathinone and 
mephedrone 81 
Drug name DAT (nM) SERT (nM) 
DAT vs SERT 
selectivity 
Methcathinone 12.5 ± 1.1 3860 ± 520 309 
Mephedrone 49.1 ± 8.3 118 ± 26 2.41 
 
 
The ability of mephedrone to cross into placenta during pregnancy has also been 
studied. Strange et al. have intraperitoneally injected mice with 5 mg/kg drug cocktail 
including mephedrone, methylone and MDPV. All 3 drugs were detected in the fetal 
brain and placenta where MDPV and mephedrone, respectively, achieved the highest 
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Cmax. However, potential drug-drug interactions might have had an impact on the results 
85. 
 
Pharmacokinetic and pharmacodynamic data based on animal studies is described in 
1.2.7. 
1.2.5.1 Chirality of mephedrone 
Due to a single chiral centre at the α-carbon, mephedrone exists as two enantiomers: 
(R) and (S), which are a mirror image of one another (Figure 1-12). Enantiomers usually 
differ in their chemical activity which may result in one enantiomer being biologically 
active while the other is inactive or may even produce different or adverse effects. There 
is some preliminary data suggesting that (R) and (S) enantiomers of mephedrone may 
have a different metabolic pathway and may exhibit different neurological effects. A 
study in rats has shown that (R)-mephedrone rather than (S)-mephedrone resulted in 
more stimulant-like effects due to its predominant interaction with dopaminergic 
receptors 86. (R)-mephedrone displayed 50-fold higher DAT vs SERT selectivity and was 
responsible for increased intracranial self-stimulation (ICSS), demonstrating greater 
abuse-related effects. A different study looking at 56 biomarkers (including 
mephedrone) in wastewater reported a successful enantiomeric separation of 
mephedrone on a chiral column and found mephedrone in the wastewater samples to 
be enriched with (S)-mephedrone. This finding may suggest a possibility of an 
enantioselective metabolism in humans 87. 
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Figure 1-12. Chemical structures of mephedrone and nor-mephedrone enantiomers 
 
 
A study conducted by Castrignanò et al. investigated metabolism of mephedrone in vitro 
(in human liver microsomes) and in vivo (in rat urine and human urine collected from 
music festivals) looking specifically at the enantiomeric ratio of (R)-mephedrone and 
(S)-mephedrone in the samples 88. The researchers found human liver microsomes and 
human urine to be enriched with (R)-mephedrone. In rat urine, (S)-mephedrone was 
more predominant which might indicate differences in metabolism between humans 
and rats. However, there is limited information about the purity of administered 
mephedrone to rats as authors only state that the drug was collected from the amnesty 
bins at a music festival in the UK in 2014 (at the time when mephedrone was sold as a 
racemic mixture). 
1.2.5.2 Chirality of nor-mephedrone 
The stereochemistry of nor-mephedrone, which also exists as two enantiomers (see 
Figure 1-12), has been studied by Hutsell et al 81. The authors investigated the effects of 
(S)-nor-mephedrone and (R)-nor-mephedrone on ICSS in rats and in vitro monoamine 
release. (S)-nor-mephedrone was more potent at DAT, NET and SERT but 
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(R)-nor-mephedrone displayed about 3.5 times greater DAT vs SERT selectivity. In ICSS 
experiments, (R)-nor-mephedrone facilitated ICSS demonstrating greater abuse-related 
effects whereas (S)-nor-mephedrone resulted in ICSS depression. These results follow 
the ICSS pattern reported for mephedrone enantiomers 86.  
 
Mayer et al. reported that following a chiral analysis of urine samples collected from one 
mephedrone user, (S)-enantiomer of nor-mephedrone was approximately 2 times more 
abundant in urine than the (R)-enantiomer 89. This finding is in agreement with a 
research published by Castrignano et al. who also found (S)-nor-mephedrone to 
predominantly exist in urine samples collected from festival urinals 88.   
1.2.5.3 Mephedrone metabolites 
There is little known about the effects or biological activity of mephedrone metabolites. 
Mayer et al. have investigated the effects of mephedrone, nor-mephedrone and 
hydroxytolyl-mephedrone on transporter-mediated uptake and release in cells and in 
rat brain synaptosomes 90. All analytes were effective inhibitors of DA, SER and NA in 
cells expressing transporters. In synaptosomes and cells, mephedrone metabolites were 
shown to be substrates of monoamine transporters. In addition, in vivo microdialysis of 
rats’ nucleus accumbens was performed after intravenous injections of mephedrone 
and its metabolite (1 mg/kg and 3 mg/kg doses). Mephedrone and nor-mephedrone 
elevated dialysate extracellular SER concentration by 15-fold (1 mg/kg dose) and 25-fold 
(3 mg/kg dose), respectively. Mephedrone also increased DA concentration after the 
1 mg/kg dose whereas both mephedrone and nor-mephedrone elevated DA 
concentrations after the 3 mg/kg dose. Hydroxytolyl-mephedrone did not have a 
significant impact on SER or DA concentration at either dose. Mephedrone and 
nor-mephedrone were also responsible for significantly increasing locomotor activity, 
with mephedrone being more potent in this respect. 
 
The permeability of the BBB for mephedrone and its metabolites has been recently 
studied in rats’ prefrontal cortex brain area. Following a 30 mg/kg intraperitoneally 
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mephedrone administration, mephedrone and nor-mephedrone were the most 
abundant in the brain tissue 1 h post drug administration, reaching concentrations of 
approximately 2,400 ng/g and 5,400 ng/g, respectively 91. These results suggest that 
nor-mephedrone crosses the BBB in rats and likely contributes to the psychoactive 
effects produced by mephedrone. Higher lipophilicity of nor-mephedrone (logD7.4 = 
1.29) and mephedrone (logD7.4 = 1.39) compared with hydroxytolyl-mephedrone 
(logD7.4 = 0.14) likely facilitates their penetration through the BBB. 
1.2.6 Reasons for mephedrone use 
Mephedrone users choose to take the drug because it induces a state of euphoria, 
increases talkativeness, enhances appreciation for music, elevates mood and reduces 
hostility 33,60. In addition, mephedrone causes mild sexual stimulation and increases sex 
drive, which has been reported by 60% of UK clubgoers. When 947 UK clubbers were 
asked to compare desired effects of mephedrone with cocaine, 54.6% preferred the high 
associated with the use of mephedrone and 65.2% said that it was longer-lasting 65.  
1.2.7 Animal data 
Up to 60 mg/kg oral mephedrone has been administered to rats with no fatal toxicity 
reported 92. An intravenous bolus of 10 mg/kg mephedrone resulted in the t1/2 of 0.37 h 
(22.4 min) and undetectable plasma mephedrone concentrations by 4 h. After an oral 
dose of 30 mg/kg mephedrone, peak plasma concentration occurred within 
25.8-55.8 min and mephedrone was undetectable after 6 h (Figure 1-13).  
 
Cardiovascular effects of mephedrone have also been studied in rats and its effects were 
compared to the amphetamine group of stimulants. Sprague-Dawley rats given 
intravenous injections of mephedrone or methamphetamine showed similar increases 
in mean arterial blood pressure (MAP, 15-20 mmHg) and heart rate (80-90 bpm) 
following 1 mg/kg of methamphetamine and 3 mg/kg of mephedrone 93. These 
cardiovascular effects showed a linear dose-response for MAP from 0.01 mg/kg to 
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9 mg/kg for mephedrone. MAP increased by approximately 10 mmHg at 0.1 mg/kg and 
20 mmHg at 9 mg/kg (Figure 1-14). Heart rate increased by approximately 55 bpm at 
0.1 mg/kg and 90 bpm at 9 mg/kg. Effects peaked within 2-5 min and lasted from 5 min 
24 s ± 1 min 12 s (0.1 mg/kg dose, n=5) to 1 h 32 min ± 16 min (9 mg/kg dose, n=6) for 
MAP, and from 18 min ± 13 min 48 s (0.1 mg/kg dose) to 1 h 16 min ± 34 min (9 mg/kg 
dose) for the tachycardic response 93. 
 
In animal studies comparing behavioural effects of mephedrone with MDMA, 
intra-peritoneal doses of 10 mg/kg of both MDMA and mephedrone produced similar 
behavioural effects but showed no neurotoxicity over a chronic period of 
administration. Mephedrone is less likely than MDMA to cross the BBB, and thus it is 





Figure 1-13. Semi-logarithmic plot of mephedrone plasma concentration after intravenous 
(10 mg/kg) and oral (30 mg/kg and 60 mg/kg) administrations in rats (n=4-5 rats/group); 
adapted from Martínez-Clemente et al. 92 
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Figure 1-14. MAP and heart rate responses elicited in conscious rats by the intravenous 
injection of mephedrone (n=5-7) or methamphetamine (n=7) at doses of 0.01 mg/kg to 
9 mg/kg. Asterisks indicate doses of mephedrone or methamphetamine that were significantly 
different from saline administration (p < 0.05); S = saline solution 
Adapted from Varner et al.93 
 
 
Bioavailability of mephedrone in humans is unknown but animal studies suggest that 
the absorbed fraction of mephedrone is very low. Mephedrone bioavailability was found 
to be approximately 10% in rats 92 and 7% in pigs 94 which was based on the investigation 
of mephedrone’s structural isomer, 3-methyl-methcathinone. 
1.2.8 Human data 
At the time of this research there has only been one dose-finding pilot study (presented 
in a poster format) 95 and two controlled human mephedrone administration studies 
96,97 published in the literature. The pilot study was a double-blind, randomised 
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mephedrone administration study undertaken in Spain. The study recruited 9 occasional 
male users of psychostimulants who were given placebo, mephedrone or MDMA on 3 
different occasions, with oral doses ranging from 50 mg to 200 mg. It is important to 
note that both mephedrone and MDMA were obtained from police seizures and no 
information was provided on their purity. Therefore, it is possible that the actual doses 
used were lower/higher and/or that adulterants may have been present. Furthermore, 
there is limited data available on oral bioavailability of mephedrone and so it is difficult 
to determine how these oral doses compare to doses administered by the intranasal 
route. In the pilot study plasma and urine samples were collected and analysed for 
mephedrone (but not for the metabolites). Physiological effects and safety (heart rate, 
blood pressure, body temperature and subjective measurement of the “high” associated 
with drug administration) were also reported as shown in Figure 1-15. Fifty milligram 
and 100 mg doses of mephedrone administrated orally did not produce significant 
changes in heart rate (HR) and blood pressure (i.e. there was no difference with the 
placebo group). Mephedrone plasma concentration peaked between 1-1.5 h and the 
drug was undetectable after 12 h. ”More pronounced” physiological effects were 
reported after 150 mg and 200 mg doses, however, the poster does not include data on 
the changes in heart rate and blood pressure for the 200 mg dose. A one hundred 
milligram dose resulted in increases in heart rate of 10 ± 4 bpm, systolic blood pressure 
(SBP) of 9.7 ± 8 mmHg and diastolic blood pressure (DBP) of 3.7 ± 5 mmHg from the 
baseline. As seen in Figure 1-16, PK profiles for 150 mg and 200 mg doses were similar 
to the ones reported for the lower doses, with peak mephedrone plasma concentration 
between 1-1.5 h and the drug being undetectable after 24 h. 
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Figure 1-15. Mephedrone effects on systolic blood pressure, diastolic blood pressure and heart 




Figure 1-16. Mephedrone plasma concentrations after oral administration of 50 mg, 100 mg, 
150 mg and 200 mg in human; adapted from Papaseit et al. 95 
 
 
The results from the pilot study have shown that oral doses of up to 200 mg were well 
tolerated. Papaseit et al. has subsequently conducted a double-blind, randomised, 
crossover, controlled administration study where 12 healthy male volunteers were 
orally given 200 mg of mephedrone, 100 mg of MDMA or a placebo on 3 separate 
occasions 96. Mean mephedrone concentration peaked at 1.25 h in plasma (Cmax = 
134.6 ng/mL) and the drug was undetectable after 24 h. Mean t1/2 was 2.15 h. Two 
hundred milligrams of mephedrone also produced increases from the baseline level in 
SBP (33.67 ± 10.80 mmHg), DBP (12.33 ± 9.97 mmHg) and HR (28.25 ± 17.47 bpm). 
Serious adverse events were not reported. Similarly to the pilot study, only plasma 
samples were collected and analysed for mephedrone (mephedrone metabolites were 
not quantified). 
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More recently, plasma and urine samples collected during the controlled administration 
study described above (Papaseit et al. 96) have been analysed for mephedrone by GC-MS 
97 and for mephedrone and four of its metabolites by LC-MS 91. The former study 
demonstrated that mephedrone is rapidly absorbed (Tmax = 1 h) and eliminated (plasma 
t1/2 = 2.2 h). The latter study focused on the quantification of nor-mephedrone (NOR), 
4-carboxy-mephedrone (COOH-MEPH), dihydro-mephedrone (DIHYDRO-MEPH) and 
N-succinyl-nor-mephedrone (SUCC-NOR-MEPH) in plasma (at 1 h, 2 h, 4 h, 6 h and 8 h) 
and in urine (between 0-4 h, 4-8 h, 8-12 h, 12-24 h and 24-48 h). As shown in Figure 1-17, 
COOH-MEPH reached the highest concentration in plasma after approximately 1.2 h 
followed by NOR (Tmax = 1.5 h) and DIHYDRO-MEPH (Tmax = 1.7 h) post drug 
administration. SUCC-NOR-MEPH, being a derivative of NOR, peaked much later (Tmax = 
3.7 h). COOH-MEPH and NOR were the most abundant metabolites reaching nearly the 
same and half of the AUC0-8h described for mephedrone (MEPH), respectively. 
Moreover, COOH-MEPH and MEPH also had similar elimination kinetics characterised 
by the t1/2 of 2.2 h for MEPH and 1.9 h for COOH-MEPH. Other metabolites exhibited t1/2 
greater than 4.5 h. In urine COOH-MEPH was the most abundant analyte reaching 
concentrations roughly 10 times higher than those of MEPH. 
 
 
Figure 1-17. Mean concentration ± standard error of the mean for mephedrone and its 
metabolites in plasma collected from 6 male subjects after oral administration of 150 mg of 
mephedrone hydrochloride; adapted from Olesti et al. 91 
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1.2.9 Harms 
1.2.9.1 Adverse clinical effects 
Despite its desired effects, such as increased energy, euphoria, empathy, openness and 
sexual arousal, 20% of mephedrone users reported significant negative effects while 
28% reported a friend or an associate having an adverse reaction to the drug 98. 
Unwanted effects may involve the gastrointestinal system (nausea, dry mouth, lack of 
appetite), cardiovascular system (vasoconstriction, elevated blood pressure, 
tachycardia, chest pain) or central nervous system (bruxism, dizziness, blurred vision, 
anxiety, agitation, seizures, hypertonia, insomnia,  psychosis) 4,57,65,99. 
 
In a total of 16 presentations to hospital with acute toxicity associated with self-reported 
mephedrone use, including a series of 7 with analytically confirmed mephedrone 
toxicity, the incidence of severe stimulant toxicity was low. Across these case reports, 
13.9% had significant hypertension (> 160 mmHg systolic), 8.3% tachycardia 
(> 140 bpm), and no patients had hyperpyrexia (temp ≥ 39°C). In the case series of seven 
patients with confirmed mephedrone ingestion, mean ± standard deviation (SD) heart 
rate was 109.1 ± 21.8 bpm and SBP was 153.0 ± 39.6 mmHg 100. In another published 
series of 57 Accident and Emergency Department (A&E) presentations with 
mephedrone ingestion alone or in conjunction with alcohol, 79% presented with a 
tachycardia > 90 bpm (mean 110.6 ± 6.7 bpm) and 74% had systolic hypertension 
(SBP > 130 mmHg, mean 137.6 ± 4.5 mmHg) 101. 
 
Unusual and previously unreported conditions attributed to mephedrone have been 
described in the literature. A case report from the University Hospital of Gran Canaria 
described fingertip necrosis in a 28-year old man who was a regular recreational drug 
user. A few hours after an intravenous injection of an unknown dose of mephedrone, 
the man developed a rash, pain and edema in his thumb. Following hospitalisation and 
treatment, patient recovered but the mechanism of fingertip necrosis remains unknown 
102. In another report from the Colchester Hospital University NHS Foundation Trust, a 
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30-year old man presented to the hospital with tightness in his chest, painful neck and 
chest swelling following nasal insufflation of mephedrone hours earlier. The patient has 
been diagnosed with a spontaneous cervical emphysema attributed to the use of the 
drug 103. Another case affecting the respiratory system was reported in a 17-year old 
man who presented to the A&E with neck pain and dysphoria. The patient had inhaled 
mephedrone 3 days prior to hospitalisation. X-ray and computerised tomography scans 
showed pneumomediastinum and subcutaneous emphysema 104. 
1.2.9.2 Addiction 
The dependence potential of mephedrone has not been a focus of many publications 
but given its pharmacology it is unlikely to cause long term physical dependency. In a 
web-based survey, 51% of mephedrone users found it extremely or moderately 
addictive and 49% experienced cravings 98. However, 52% said that it would be easy for 
them to stop taking it. Moreover, a study of 1,006 individuals attending schools, 
universities and colleges in Scotland found only 17.5% users reporting 
“addiction/dependency” 105.  
1.2.9.3 Chemsex 
Chemsex is defined as men having sex with other men (MSM) under the influence of 
drugs, most commonly mephedrone, 4-hydroxybutanoic acid or crystallised 
methamphetamine 106,107. In a survey of HIV-positive patients, one in ten reported 
engaging in the practice known colloquially as “slamming”, where MSM inject drugs 
during sexual activities 108. Needle sharing carries a risk of sexually transmitted diseases 
(STD) and viral infections, such as HIV and hepatitis C. Since 2018, a 148% increase (from 
2,874 to 7,137) has been recorded in syphilis diagnoses mostly among gay and MSM 
community 109. Data from the Antidote Clinic in London shows that the number of gay 
men injecting crystal methamphetamine or mephedrone in sexual context went up from 
20% in 2011 to 80% in 2012 110. Seventy five percent of these users took mephedrone 
solely to facilitate sex though increased arousal, euphoria, confidence and disinhibition 
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107,111. “Slamming” has also been associated with psychiatric problems. In 2016 
Dolengevich-Segal et al. reported a case of a 25-year old man presenting psychotic 
symptoms after “slamming“ mephedrone almost every week over a 4 month period at 
chemsex parties 112. The patient re-dosed 0.1-0.2 g of mephedrone diluted in 
physiological serum multiple times. In another study, intravenous users of mephedrone 
reported intense paranoia, with two of them showing violent behaviour and aggression 
113.  
1.2.9.4 Fatalities 
Mephedrone alone or in combination with other substances was attributed to several 
deaths 114–117. The first reported case was of a 18-year-old female in Sweden in 2009 
who suffered cardiorespiratory arrest 118. Post-mortem analysis of urine and blood 
showed presence of mephedrone only but its concentration was not reported. In 2011 
in Scotland mephedrone and two metabolites (nor-mephedrone and 
4-carboxy-dihydro-mephedrone) were detected in four fatal cases but due to the lack of 
available reference standards quantification of the metabolites was not possible. 
Measured mephedrone concentration in femoral blood ranged from 1.2 mg/L to 
22 mg/L 116. Fatalities attributed to a sole mephedrone use are rare but cases involving 
use of MDMA 119, heroin 117 or methadone 115 alongside mephedrone have also been 
reported. 
1.2.10 Stability in biological matrices 
1.2.10.1 Whole blood 
The stability of mephedrone has previously been investigated in human whole blood 
containing different preservatives and stored under different conditions 120–123. 
Mephedrone has been reported to be most stable at -20°C when preserved with acidic 
preservatives, such as sodium fluoride/potassium oxalate (NaF/KOx) and sodium 
fluoride/citrate buffer (NaF/citrate buffer). The underlying cause of its instability in 
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biological matrices is unknown but a previous study looking at mephedrone degradation 
in alkaline solution suggests the involvement of oxidants such as dissolved oxygen 124. 
 
Studies investigating stability of mephedrone in human whole blood have been 
published before. Sørensen investigated the stability of cathinones (including 
mephedrone) and related ephedrines in human whole blood spiked with analytes at 
100 µg/mL and preserved with NaF/KOx or NaF/citrate buffer. Samples were stored at 
either +4°C or +20°C for up to 5 or 6 days 121. After 5 days of storage mephedrone was 
more stable at +4°C than +20°C. Busardò et al. reported on the stability of mephedrone 
in ante-mortem and post-mortem blood preserved with NaF/KOx or 
ethylenediaminetetraacetic acid (EDTA) 122. Whole blood samples were spiked at 
1 mg/mL and stored at -20°C, +4°C or +20°C for up to 185 days. Mephedrone was shown 
to be most stable in ante-mortem samples at all tested storage conditions, with -20°C 
being the best storage temperature. This study showed that mephedrone stability is pH 
dependent and acidic preservatives are better suited (6.6% vs 9.4% loss after 185 days 
at -20°C when preserved with NaF/KOx rather than EDTA). Johnson and Botch-Jones 
investigated the stability of four designer drugs (including mephedrone) stored at -20°C, 
+4°C or +22°C over 14 days 120. Human whole blood (preservative not stated), plasma 
and urine samples were spiked at 1 µg/mL. This study showed a mean 48% reduction in 
mephedrone concentration in whole blood kept at +4°C for 14 days. Over the same 
period of time mephedrone was undetected when stored at room temperature whereas 
there was no measurable degradation at -20°C. The most recent study looked at the 
stability of mephedrone and other synthetic cathinones in bovine blood fortified with 
NaF/KOx at 100 ng/mL (quality control low (QC Low)) and 1,000 ng/mL (quality control 
high (QC High)) stored at -20°C, +4°C, +20°C and +32°C. At QC Low a complete 
degradation of mephedrone was observed after 11 days when stored at the elevated 
temperature. Degradation was much slower at +4°C and -20°C where a 20% loss was 
observed after 55 days and 130 days, respectively 123. These results follow the stability 
pattern reported in our recent publication where mephedrone and its metabolites have 
been shown to be more stable at -20°C than +4°C (see Section 2.6.1.8 in Chapter 2 for 
more details) 125. 
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1.2.10.2 Urine 
In urine, stability of mephedrone was investigated at pH 4 and pH 8 after sample storage 
at -20°C, +4°C, +20°C and +32°C over 6 months 126. Mephedrone was more stable in 
acidified urine, where losses of no more than 20% were observed in frozen and 
refrigerated samples. Similar results have been reported by Al-Saffar et al. who also 
evaluated stability of mephedrone in urine at 1,000 ng/mL over the period of 3 months 
at -20°C, +6°C and +22°C 127. Significant losses were observed at +22°C after 1 month 
(100% loss), 1 week (95.4% loss) and 1 day (23.2% loss). Mephedrone was stable at -20°C 
for up to 3 months. 
1.2.10.3 Oral fluid 
One stability study was carried out at 2.5 ng/mL (QC Low) and 150 ng/mL (QC High) in 
neat oral fluid and in buffered oral fluid collected with Quantisal® and Oral-Eze® 
collection devices. Samples were stored at room temperature (RT), +4ᵒC and -20ᵒC for 
up to 1 month 128. In neat oral fluid mephedrone was most unstable at RT where it lost 
91 ± 6% and 95 ± 0.3% at QC Low and QC High, respectively, compared to 61 ± 3.5% and 
52 ± 2.5% losses at QC Low and QC High, respectively, at +4ᵒC after 1 month. The use of 
Quantisal® and Oral-Eze® devices for oral fluid collection has greatly increased analyte 
stability. After 1 month at RT mephedrone lost 32 ± 11.4% at QC Low and 32.8 ± 2.4% at 
QC High (Quantisal® collection device), and 63 ± 11.1% at QC Low and 61 ± 0% at QC 
High (Oral-Eze® collection device). At -20ᵒC mephedrone showed good stability at both 
concentration levels, losing no more than 5.3 ± 0.9% of its initial concertation in neat 
oral fluid after 1 month. 
 Alternative biological matrices 
Urine and blood are the most commonly tested biological matrices. However, in recent 
years there has been an increasing interest in the use of alternative biological matrices 
(breath, oral fluid, dried blood spots, sweat, nails, meconium and other) for determining 
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and confirming drug use. The interest in the alternative biological matrices has been 
re-ignited in recent years thanks to the advances in hyphenated LC-MS instruments and 
new levels of achievable sensitivity 129. 
 
The collection of alternative biological matrices is usually non-invasive, fast and cost 
effective, which allows for the workplace drug testing, assessment of driving impairment 
due to drug use and drug monitoring in addiction treatment centres. Alternative 
biological matrices are usually easier and cheaper to transport than the conventional 
matrices (whole blood/plasma, urine) because smaller volumes/quantities are collected 
and some of the matrices (head hair, dried blood spots in some cases) can be stored at 
ambient conditions. 
1.3.1 Brief introduction to sample preparation techniques 
The aim of sample preparation is to remove interferences, concentrate samples and 
reconstitute them in an appropriate solvent required for instrumental analysis. Even 
though there are many different sample preparation techniques, by far the most 
commonly used are protein precipitation, liquid/liquid extraction and solid phase 
extraction.  
 
Protein precipitation (PPT) is a quick plasma/serum or whole blood sample clean-up 
technique. The most common way of precipitating proteins out of a sample is by 
addition of an organic solvent, usually acetonitrile, which denatures proteins resulting 
in their precipitation. The precipitated proteins can then be removed by either filtration 
or centrifugation. PPT is a fast extraction method but It does not remove other 
interferences, such as lipids, which may have an impact on sensitivity and contribute to 
matrix effects. 
 
In liquid/liquid extraction (LLE) organic, immiscible solvent is added to the aqueous 
sample, creating two separate layers. Following agitation by shaking, rotating or vortex 
mixing, analytes of interest migrate usually from the aqueous sample matrix to the 
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organic layer although that is dependent on their physico-chemical properties. The 
organic layer, where the analytes have been extracted to, is then used for further sample 
manipulation. The opposite scenario where analytes remain in the original sample whilst 
other components of the sample are extracted to the organic layer is also possible. In 
this case analytes remain in the original (aqueous) sample which may not be desired if 
for example samples need to be quickly evaporated. Even though LLE provides some 
degree of sample clean-up (e.g. removal of proteins, phospholipids, salts), it may require 
the use of hazardous organic solvents. Moreover, emulsions may form making the 
layers difficult to identify, which results in incomplete analyte diffusion and difficult 
solvent transfers. Because LLE can be difficult to automate, a new and quick technique 
called supported liquid extraction (SLE) has been gaining popularity due to the 96-well 
plate format. Following sample loading on a SLE plate, aqueous samples soak into the 
highly polar support phase, concentrating non-polar analytes on its surface. The analytes 
are then washed off with a non-polar solvent, such as ethyl acetate or dichloromethane. 
 
Solid phase extraction (SPE) is the most selective and powerful sample preparation 
technique. SPE products come in a variety of formats, such as cartridges and 96-well 
plates which are well suited for automation. Silica-based sorbent or polymer sorbents 
are widely used in SPE, which offer different polarities ranging from non-polar C18 to 
more polar phenyl sorbents. The sorbent is chosen in such a way to selectively target 
the analytes of interests and to remove matrix interferences. Before samples are loaded 
onto the cartridge/plate, the sorbent is conditioned first with a water-miscible organic 
solvent (e.g. methanol) to ‘wet’ the surface of the sorbent and to ensure adequate 
interactions. In order to maximise retention of the analytes, the sorbent is then 
equilibrated with a solvent similar in its composition to the samples. Samples are loaded 
onto the SPE media, where the target analytes are retained on the sorbent by the 
specifically chosen chemistry while the sample matrix flows through the sorbent to 
waste. SPE cartridges/plates are then washed to remove matrix interferences (salts, 
proteins, phospholipids and other endogenous compounds) while keeping the analytes 
of interest retained on the sorbent. To ensure the cleanest extract and the removal of 
the greatest amount of interferences, washing should be performed with the strongest 
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solvent which does not cause elution of the analytes. After a series of washes, analytes 
are eluted by disrupting interactions between the functional groups on the analytes and 
the sorbent. Nowadays, sorbents offering multiple retention mechanisms, referred to 
as “mixed mode”, are commonly used in pharmaceutical and toxicology industry for the 
simultaneous extraction of basic and acidic drugs. SPE offers an effective sample 
clean-up, can be used to extract a wide range of analytes and concentrates samples. 
However, SPE methods are time-consuming, more expensive than PPT or LLE and 
require longer method development. 
1.3.2 Oral fluid 
Oral fluid permits detection of a very recent drug use and does not present problems 
with sample adulteration which is often associated with urine collection 130,131. 
Moreover, concentration of an unbound/free drug in oral fluid can often be correlated 
with the actual concentration of the drug in the systemic circulation, allowing 
impairment/intoxication to be assessed 132 (notable exceptions are drugs likely to 
deposit in the oral cavity, such as smoked cannabis). On the other hand, people may 
suffer from the dry mouth syndrome, which results in no or too little oral fluid collected 
for analysis and sample analysis requires sensitive instrumentation 131. 
 
The use of oral fluid has been evaluated in the  workplace drug testing 133, roadside drug 
testing 134–136 and drug treatment programmes 137,138. Oral fluid has been chosen as a 
preferred matrix in the roadside drug testing in France 139, Belgium 140 and several states 
in Australia 141. In 2014 in the UK, section 5A of the Road Traffic Act 1988 was amended 
to allow police officers to use approved drug testing devices (such as Securetec 
DrugWipe 3S®) for oral fluid collection during roadside drug testing. A positive result of 
the presumptive test was to be followed by a collection of a urine or blood sample at a 
police station 142.     
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1.3.2.1 Oral fluid composition 
There is a difference between saliva and oral fluid. Saliva, which contains water (> 97%) 
and small amount of proteins, is excreted by the salivary glands whereas oral fluid is a 
mixture of saliva, cellular debris, food and bacteria 143. The composition of oral fluid 
changes continuously throughout a day and is influenced by the circadian rhythm, 
disease state, emotional state and consumed food 144. Several millilitres of saliva are 
usually produced every minute, but this number can be as low as zero or much higher 
depending on several factors. Salivation is stimulated by pain, chewing, taste or 
olfactory stimuli, pregnancy related hormones as well as certain drugs. On the other 
hand, a so called dry mouth syndrome can be caused by stress, dehydration, menopause 
related hormones and certain drugs 144. 
 
Normal pH of saliva ranges from 6.7 to 7.4 but can be easily lowered by acids being 
released by bacteria breaking down carbohydrates originating from sweet beverages, 
chocolates and other products 145. On the other hand, stimulation of the salivary glands 
can increase the pH to 8. Other ways of changing the pH of oral fluid include chewing a 
gum 146 or using collection devices which may stimulate saliva production 147. The latter 
has been shown to lower concentrations of codeine by about two to six-fold 146,148 and 
concentrations of cocaine by about five-fold in oral fluid 149. 
1.3.2.2 Drug incorporation into oral fluid 
Drugs can get incorporated into oral fluid either through an active transport, passive 
diffusion through the phospholipid bilayer across the concentration gradient (suitable 
for lipid soluble and non-ionised molecules) or diffusion through pores in the membrane 
(molecules smaller than 300 Da) 143,144. The ability of a drug to transition into oral fluid 
from blood is dependent on its pKa, lipophilicity/partition coefficient and drug-protein 
binding. Unlike blood/plasma, saliva does not offer much drug-protein binding 
capabilities and so free drugs are usually found in this matrix. Drugs of abuse usually 
contain a readily ionisable amine group which is characterised by a pKa value greater 
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than the pH of oral fluid (pH 6.7-7.4). Once a basic drug gets incorporated into oral fluid, 
it becomes ionised which prevents its back diffusion into the blood (pH 7.4). Basic drugs 
will, therefore, be present for longer and at higher concentrations in oral fluid than 
acidic drugs, such as cannabis (tetrahydrocannabinol and its carboxy metabolite) 137. 
1.3.2.3 Correlation of oral fluid drug concentrations with 
whole blood and plasma 
Because oral fluid is an ultrafiltrate of the interstitial fluid which contains free drugs, it 
should in theory represent the current concentration of the unbound drugs in the 
bloodstream, which could further be translated into impairment. A large body of 
research has been dedicated to the investigation of the correlation between oral fluid 
drug concentrations with whole blood and plasma 134,135,150–153. This is most commonly 
done by calculating oral fluid to blood or plasma (OF/B or OF/P) drug concentration 
ratios from experimental results or from a theoretical model shown in Equation 1-1, 
where fs (fraction of an unbound drug in saliva) is generally assumed to be negligible 
because of small presence of proteins in the matrix. Saliva to plasma (S/P) ratios rather 
than oral fluid ratios have been used in literature 146,154. 
 (1)   𝑆𝑃 = 1 + 10(𝑝𝐻𝑠− 𝑝𝐾𝑎)1 + 10(𝑝𝐻𝑝− 𝑝𝐾𝑎)  𝑥 𝑓𝑝𝑓𝑠  (2)   𝑆𝑃 = 1 + 10(𝑝𝐾𝑎− 𝑝𝐻𝑠)1 + 10(𝑝𝐾𝑎− 𝑝𝐻𝑝)  𝑥 𝑓𝑝𝑓𝑠  
 
Equation 1-1. The equation showing calculations for the S/P ratio for weak acids (1) and weak 
bases (2), where fp and fs is the fraction of an unbound drug in plasma and saliva, respectively; 
pHs is salivary pH; pHp is the pH in plasma; S is the drug concentration in saliva; P is the drug 
concentration in plasma 155 
 
 
Neutral drugs (e.g. ethanol or antipyrine) exhibiting no protein binding will have OF/B 
or OF/P ratio of approximately 1. Weak acids or highly protein bound drugs, such as 
  Chapter 1 | Introduction 
Page | 71 
 
caffeine or diazepam will have a ratio smaller than 1. Benzodiazepines are known to be 
highly protein bound in plasma 130, resulting in the concentration of these drugs in oral 
fluid to be low (OF/P ratio of 0.03 has been reported for diazepam 156). The opposite 
trend is observed for weak bases or drugs exhibiting low protein binding, such as 
methadone or prilocaine. They will have the OF/P ratio greater than 1, however, falsely 
elevated results have been reported in cases of drugs being nasally insufflated, taken 
orally or smoked, resulting in a potential contamination of the oral cavity 154. Once a 
drug has reached an equilibrium between oral fluid and plasma, the oral fluid to plasma 
drug concentration ratio will be solely dependent upon the pH of both matrices 157. 
 
In general, drug concentration in blood tend to correlate well with oral fluid, but the 
strength of the correlation needs to be individually investigated for every drug. A 
number of controlled administration studies of cocaine 158, cannabis 150 as well as 
sampling of the drug users 134,153,159 have shown diverse and inconclusive results. For 
example, Scheidweiler et al. have reported that following a controlled administration, 
concentration of cocaine, benzoylecgonine (BZE) and ecgonine methyl ester (EME) was 
strongly correlated in plasma and oral fluid 158. This was contradicted by Langel et al. 
who reported only a weak correlation for cocaine and BZE in people suspected of driving 
under the influence of drugs 154. Both studies found considerable inter- and 
intra-individual variations and concluded that oral fluid drug concentration should not 
be used to infer blood concentrations of the studied drugs.  
1.3.2.4 Collection devices 
Decades ago, neat oral fluid was collected by spitting into a tube. The viscous fluid was, 
however, difficult to work with and often required centrifugation to separate food or 
other debris from the sample. Problems also arose with obtaining an adequate volume 
which would be sufficient to detect analytes of interest on the instruments used at the 
time 131. Nowadays, commercial collection devices use a diluent which is mixed with oral 
fluid. A Certus® collection device is an example of a commercial device where oral fluid 
is collected onto an absorptive pad which is placed in the mouth (Figure 1-18). An 
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indicator changes colour to inform the user that sufficient volume has been collected. A 
pad is then placed in a tube containing a buffer solution, which dilutes the sample but 




Figure 1-18. A Certus® device used for oral fluid collection 
 
 
High inter- and intra-individual variability in reported drug concentrations in oral fluid 
has been observed 146,152. Collection devices have also been shown to vary greatly in the 
collected volume recovered from the devices, resulting in varied recoveries of 
amphetamines (16-59%), opiates (33-50%), cocaine and BZE (61-97%) 146. It is equally 
important to study the influence of toothpaste, mouthwash, food, beverages and 
commercial adulterants on drug concentrations in oral fluid. The effectiveness of a 
commercial device Oratect® has been extensively evaluated in respect to the above and 
showed that the aforementioned factors do not affect drug concentrations in oral fluid 
30 min after drug use 160. 
1.3.2.5 Detection of drugs in oral fluid 
As drug concentrations in oral fluid are typically found in low ng/mL range, highly 
sensitive assays are required. Immunoassays utilising antibodies with drug class 
specificity are employed as a screening tool followed by a confirmatory analysis of 
presumptive positive samples on LC-MS or gas chromatography coupled to mass 
spectrometry (GC-MS). Alternatively, oral fluid point of care devices for on-site 
screening might be used but a positive result requires chromatographic confirmation. 
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SPE is a recommended sample preparation technique 161,162, but LLE 163 and in some 
cases centrifugation followed by an instrumental analysis 164 have also been reported. 
Several illicit drugs, such as cocaine 158,165, mephedrone 166, MDMA 167, amphetamine 152 
and cannabis 150 have been detected in oral fluid. Distribution of cannabinoids have been 
extensively studied following cannabis smoking, which is of great importance in cases of 
driving under the influence of drugs (DUID). Tetrahydrocannabinol, being highly 
lipophilic, has been shown to deposit in the oral cavity during smoking, with 
concentrations of up to 1,000 ng/mL detected approximately 15 min after smoking 168. 
In addition to parent drugs being detected in oral fluid, several metabolites such as BZE 
169, methamphetamine 152, cannabidiol (CBD) 170 and 3,4-methylenedioxy-N-
ethylamphetamine (MDEA) 167 have also been found in this matrix. 
1.3.3 Head hair 
Human head hair is composed of proteins (65-85%, mostly keratin), water (15-35%), 
lipids (1-9%) and minerals (< 1%) 171–173. It starts growing from a follicle located 3-4 cm 
below the epithelial membrane, with sebaceous and apocrine glands excreting directly 
into the follicle 171. Hair growth cycle is divided into three stages: anagenesis (growth 
phase), catagenesis (regression phase) and telogenesis (quiescence phase) 171,172. It is 
assumed that head hair grows on average 1 cm per month but age, pregnancy and 
seasonal variations can influence the growth rate, which has been shown to vary from 
0.6 cm to 3.36 cm per month 174,175. 
 
As shown in Figure 1-19, each hair strand is composed of a cuticle, cortex and medulla 
171. An extensive network of blood vessels feed into the root of a hair, allowing 
substances circulating in the bloodstream to be absorbed. It takes approximately 2 
weeks for a new hair to reach the scalp, and thus hair collection for drug testing should 
not be carried out immediately after a suspected drug intake. 
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Interest in hair analysis started in 1960s when exposure to heavy metals was evaluated 
in head hair 176. Nowadays, hair with its unique characteristic of allowing retrospective 
detection of drug use is analysed in the workplace drug testing 133,177, in cases of 
drug-facilitated sexual assault 178, pre-natal drug exposure 179,180, historical patterns of 
drug use 181, doping control in sport 182,183, alcohol abuse 184,185 or when drug 
administration to vulnerable groups (e.g. child custody cases) is suspected 186. Owing to 
drugs being highly stable in hair, the matrix has been used to assess drug consumption 
in ancient North Chilean 187 and Peruvian tribes 188.  When head hair is unavailable (bald 
individuals or babies), pubic, arm, leg, armpit or auxiliary hair may be considered as 
suitable replacements. However, their growth rate is slower and more variable whereas 
collection of pubic hair may lead to privacy concerns 174,189. 
 
As shown in Figure 1-20, analysis of matrices, such as blood, urine and oral fluid can 
provide a relatively short detection window compared to hair analysis, which can detect 
historical drug use weeks to months earlier 190. The qualitative results from hair analysis 
are widely accepted by the scientific community but translation of detected drug 
concentrations in hair into an actual impairment/intoxication at the time of drug 
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administration still remains problematic 191. This is further complicated in cases of single 
dose administration (e.g. drug-facilitated crimes), which may not result in drugs being 
detectable in hair 192,193. 
 
 
Figure 1-20. Drug detection windows for different matrices. Note that this is an estimate which 
is dependent on a substance, its physio-chemical properties and frequency of use; adapted 
from Hadland et al. 190 
* As long as sweat patchs is worn 




Another reasons as to why hair has become a matrix of interest is the fact that hair does 
not easily decompose after death 172, offers non-invasive sample collection and ambient 
sample storage and transpiration 174. However, care needs to be taken when 
interpreting results of hair analysis collected from children or the elderly. Lower 
excretion rates, more permeable BBB and varying degrees of protein binding in children 
as well as renal and hepatic failure in the elderly will affect blood drug concentration 
and, therefore, the level of impairment and drug incorporation rate into hair 194. In 
addition, P450 enzymes responsible for drug metabolism mature at different rates in 
children 195. CYP2D6 can take more than five years to reach adult levels while CYP3A4 
matures rapidly in the first 6-12 months of life 194. Furthermore, there are differences in 
the hair structure and growth. Compared to adults’ hair, children’s hair is more porous 
and its growth rate may not always follow the assumed 1 cm per month 194. 
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1.3.3.1 Drug incorporation into hair 
Drugs can accumulate in hair growing out of follicles. As the hair located on the posterior 
vertex of the scalp grows 0.5 cm to 2 cm per month (often quoted as roughly 1 cm a 
month), the drug band in the hair closest to the scalp shows most recent drug use 174. 
The exact mechanism of drug incorporation is still unknow but scientists recognise three 
mechanism: passive diffusion from the bloodstream during hair growth, drug excretion 
with sebum or sweat into the hair follicle or scalp and external contamination 171,172,174.  
 
Physio-chemical parameters such as lipophilicity, membrane permeability and hair 
melanin content influence drug incorporation into hair. Favourable pH gradient 
between blood (pH 7.4) and the acidic hair matrix (pH 4.5-5.5) aids transportation of 
basic drugs into hair 192,196. Once drugs have been trapped in the hair shaft, they will 
form ionic bonds with melanin and bind to lipids 197. This may explain why cationic drugs, 
such as cocaine, tend to deposit more readily in hair than anionic drugs 198. Age and sex 
also influence drug incorporation into hair. With age hair loses pigmentation (turns grey) 
and becomes thinner leading to poorer drug incorporation. In addition, female hair is 
usually longer and more damaged due to hair treatments. 
 
Natural hair colour has been shown to play an important role in drug incorporation into 
hair. Drugs of abuse bind to a hair pigment called melanin which is present as either 
eumelanin (black and brown hair) or pheomelanin (red and blond hair) 171,199. Darker 
hair has higher melanin content resulting in greater drug binding. Therefore, natural hair 
colour will have a direct influence on drug concentration in hair, with lighter hair 
incorporating less drug compared to darker hair. This has led to concerns of racial bias 
in hair testing 200. Rollins et al. administered 30 mg of codeine phosphate syrup three 
times a day for five days followed by a 30 mg codeine 24 h after the end of the treatment 
to Caucasians and non-Caucasians with black, brown, blond or red hair 201. Five weeks 
later codeine was found at 1,429 ± 249 pg/mg in black hair, 208 ± 17 pg/mg in brown 
hair, 99 ± 10 pg/mg in blond hair and 69 ± 11 pg/mg in red hair. In black Asian hair 
codeine concentrations were nearly three times higher than in black Caucasian hair. 
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According to the federal guidelines, 100% of subjects with black hair, 50% with brown 
hair and 0% with blond hair would have been positive for codeine. Other drugs, such as 
nicotine 202 and cocaine 203,204 have also been found at higher concentrations in darker 
hair. Seeing that drug binding to melanin leads to variable drug concentrations in 
different hair colours, Hold et al. investigated the impact of melanin removal from hair 
digests on cocaine quantification in the samples. Melanin removed by centrifugation did 
not, however, eliminate the bias 205. Interestingly, concentrations of cannabinoids have 
not been found to be affected by hair pigmentation 206.  
1.3.3.2 Hair treatments 
Another common issue associated with hair analysis is the impact of hair treatments 
(bleaching, dying, perming, waving, curling and straightening), hair products (shampoo, 
conditioner) and exposure to UV light on drug concentrations in hair. Aggressive 
treatments as well as mechanical actions (brushing, banding) can damage hair and alter 
its porosity. Increased porosity leads to higher rates of external contaminants being 
incorporated into hair and compounds present in hair being washed out 207. For 
example, porous hair has been shown to absorb 10-20 times more cocaine than normal 
hair 208. Moreover, damaged and bleached hair has been shown to result in lower 
concentration of amphetamine-type-stimulants when compared to non-bleached hair 
209. Bleaching has also been reported to affect stability of opiates, benzodiazepines and 
cocaine in hair 189,210–212. 
 
Washing hair with shampoo has been demonstrated to effectively remove external 
contaminants without extracting drugs incorporated in hair 213. Cirimele et al. studied 
the risk of the ingredients in the cannabis shampoo being incorporated into hair 
following daily washing 214. Many cannabis shampoos contain < 1% 
tetrahydrocannabinol (THC) but there are reports of some containing up to 3% THC. In 
the study three subjects washed their hair with the Cannabio® shampoo once a day for 
two weeks. The shampoo contained 412 ng/mL of THC, 4,079 ng/mL of cannabidiol 
(CBD) and 380 ng/mL of cannabinol (CBN). Hair samples were negative for THC, CBD and 
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CBN following extraction and analysis on GC-MS. To investigate long term effects of the 
shampoo, hair samples were incubated in 10 mL water:Cannabio® shampoo (20:1 v/v) 
for 30 min, 2 h and 5 h. The 30 min sample was negative but samples collected at 2 h 
and 5 h contained CBD and CBN. THC was not detected. 
1.3.3.3 Hair collection and storage 
There is a general consensus that hair should be collected from the back of the head, 
the area called posterior vertex. In this region, the rate of hair growth exhibits less 
variability and is less influenced by sex or age 174.  A typical protocol lists the following 
stages of hair collection 171,174: 
a) hair sample (usually pencil thickness) should be tied with a thread, 
b) scissors should be levelled with the scalp to cut as close to the scalp as possible, 
c) hair sample should be placed on an aluminium foil with the root clearly labelled 
and sticking out from the foil, 
d) aluminium foil should then be folded and stored in a paper envelope at room 
temperature in a dark place. 
1.3.3.4 Segmentation 
The ability to detect a single dose administration is of highest importance in 
drug-facilitated sexual assault cases. Segmental analysis of hair is usually employed in 
such cases, where hair is cut into small (10 mm to 30 mm) segments. Each segment 
corresponds to a narrow timeframe which can help link the time of the crime with 
drug(s) detected in hair 215. However, it should be noted that hair is susceptible to 
natural “wash-out”, which may result in drug concentration being lower in the distal end 
of the hair compared to the root 215. 
1.3.3.5 Decontamination 
Environmental contamination is a significant pitfall of hair testing. Passive exposure, 
where an individual is exposed to a drug (pollution, running dirty hands through hair or 
  Chapter 1 | Introduction 
Page | 79 
 
smoked drugs) can often lead to false-positive results 173,216,217. In order to minimise the 
chance of false-positive results, effective hair decontamination protocols are developed 
in testing labs, cut-off values are established and metabolites targeted in the samples 
171. Metabolites, being usually more polar then the parent drug, may not be readily 
detected in hair, but where possible it is recommended to use the metabolite to parent 
drug ratios to report positive results 173. 
 
The first step in sample preparation is hair decontamination. Substances deposited in 
hair due to external sources are weakly bound to the matrix, and thus can be removed 
by washing with solvent(s). It is generally assumed that a complete drug removal is not 
achievable even after an extensive decontamination procedure. It is, however, 
important to use an appropriate washing solvent which will decontaminate the surface 
of the hair but will not extract drugs from inside the hair. The choice of solvent varies 
between labs, with organic solvents, water, buffers and soaps or their combinations 
being commonly employed 218–223. Prolonged decontamination with some solvents, such 
as methanol, can make the hair shaft swell and lead to the loss of analytes from hair 224. 
It has been recommended by Tsanaclis and Wicks to compare drug levels in washes (W) 
and hair (H). The W/H ratio greater than 0.5 is likely to indicate external contamination 
whereas the ratio smaller than 0.1 or zero would indicate drug consumption 225. 
1.3.3.6 Digestion 
Typically, 10-50 mg of decontaminated hair per each segment is weighed. Hair is then 
cut into smaller segments or pulverised in a ball-mill. Pulverised/cut hair then undergoes 
digestion which aims to extract analytes from the hair. Acidic or alkaline digestion, 
enzymatic hydrolysis or incubation with different buffers is usually used but care should 
be taken at this stage. Inappropriate digestion method, such as alkaline conditions, may 
degrade heroin, cocaine or benzodiazepines 226. Extraction with methanol in an 
ultrasonic bath is time-consuming and usually takes 5-18 h 168. Extraction with aqueous 
acids or buffers is well suited for basic compounds. Even though these extracts are 
usually cleaner than methanol extracts, partial hydrolysis of cocaine to benzoylecgonine 
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and 6-monoacetylmorphine to morphine is sometimes observed 218,227. Digestion with 
aqueous sodium hydroxide (NaOH) at an elevated temperature is commonly used for 
drugs stable under alkaline conditions, such as nicotine 228,229 or amphetamines 230. 
Other common methods employ the use of Proteinase K which hydrolyses hair proteins 
231–233 or urea which breaks down hydrogen and disulphide bonds in hair 211. 
1.3.3.7 Extraction 
Digested hair contains interferences and requires sample clean-up, which usually 
involves LLE or SPE. The need for better sensitivity and cleaner extracts, to prevent ion 
suppression or enhancement on LC-MS or GC-MS, has resulted in a number of innovative 
extraction methods and sorbents. In headspace-solid phase microextraction (HS-SPME) 
lipophilic drugs of even low volatility (e.g. methadone, tricyclic antidepressants) are 
absorbed onto the fibre placed in the headspace above the digestion solution (usually 
aqueous NaOH). The retracted fibre can then be exposed again inside the GC-MS 
injection port. High temperature desorbs the substances from the fibre allowing them 
to be analysed 234–237. The advantage of HS-SPME is automation and the solvent-free 
nature of sample extraction. Strano-Rossi et al. has applied this technique to the 
detection of cannabinoids in hair by immersing the fibre in the sample digest 238. Sample 
clean-up by hollow-fibre liquid-phase microextraction 239 and microextraction by packed 
sorbent have also been reported 240. 
1.3.3.8 Detection of drugs in head hair 
GC-MS has been used for drug analysis for decades, showing good accuracy, specificity 
and limits of detection 171,174. However, it requires sample derivatisation which makes 
sample pre-treatment a laborious process. Owing to the non-volatile, thermally unstable 
and polar nature of many drugs of abuse, LC-MS is usually a preferred choice. 
 
In recent years, development of multi-target methods has gained pace as they offer 
analysis of dozen compounds in the same run, thus saving money and time. Nielsen et 
  Chapter 1 | Introduction 
Page | 81 
 
al. have developed an ultra-high-performance liquid chromatography/time-of-flight 
mass spectrometry (UPLC-ToF-MS) method for the simultaneous detection of 52 
common pharmaceuticals and drugs of abuse in hair. The limit of detection (LOD) in a 
17 min run ranged from 0.01 ng/mg to 0.10 ng/mg 241. More recently, Montesano et al. 
presented a UPLC-MS method for quantification of 96 drugs in 10 mg of hair 242. The LOD 
ranged from 0.002 ng/mg to 0.050 ng/mg for basic drugs and from 0.10 ng/mg to 
5.0 ng/mg for acidic and neutral drugs. The authors stated that low LODs may allow 
identification of a single dose administration. The need for high sensitivity levels in hair 
analysis might be further achieved by nano-electrospray ionisation which introduces 
mobile phase into the MS source at a flow rate of nanolitres/min. This results in the 
formation of smaller droplets in the ionisation process. Droplets have high 
surface-to-volume ratio which results in a larger proportion of ionised analytes 
compared to conventional electrospray ionisation (ESI) 243,244. A nano-HPLC-Chip-MS, 
using a special nano-Chip-LC instrumentation was used to develop a highly sensitive 
method for the simultaneous detection of ketamine and norketamine in human hair 245. 
Extraction of 2 mg of hair resulted in the LOD of 0.5 pg/mg for both analytes which is 
approximately 1000 times more sensitive than a conventional method. 
 
Current GC-MS and LC-MS analytical methods require extensive sample preparation 
which is time consuming and is destructive to samples. Novel methods, such as 
matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) imaging 
and direct analysis in real time-mass spectrometry (DART-MS) aim to detect analytes in 
an intact hair strand or a lock of hair. 
 
Vogliardi et al. have developed a fast screening method for the detection of cocaine in 
hair that was pulverised and digested. One microlitre of the reconstituted samples was 
deposited on the graphite MALDI holder and the sample was sprayed with 
alpha-cyano-4-hydroxycinnamic acid (matrix) solution. Researchers were able to 
achieve the LOD of 100 pg/mg 246. MALDI-MS imaging has also been used to map the 
distribution of cannabinoids in a hair strand following an in situ derivatisation 247. 
Interestingly, MALDI ionisation process has been shown to be reproducible between 
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individuals and not influenced by the natural hair colour (melanin content) in hair 248. 
Even though MALDI-MS imaging offers quick analysis with little or no sample pre-
treatment, analysis of intact single hair strands may lead to false-positive results. 
Mussholf et al. have reported that the analysis of four different hair strands from the 
same individual produced contradicting results, showing some samples to be negative 
and other samples to be positive for cocaine and its metabolites. This may be due to the 
growth cycle of hair strands, where 80-90% are in the growing phase while the 
remainder is in the regression phase 249.  
 
Another ambient imaging ionisation technique, which does not require the addition of 
the MALDI matrix, is DART-MS. This relatively new ionisation technique, developed in 
2005 by Cody et al., uses a glow discharge inside the source which generates metastable 
species of a heated gas 250. At elevated temperatures these species desorb analyte ions 
from the surface. DART-Orbitrap MS has been used to develop a rapid analysis of THC in 
human locks of hair without the need for any sample pre-treatment, reporting LODs in 
sub ng/mg range 251. The use of entire locks of hair as opposed to single strands 
overcomes the problem of hair being in different growth cycles as described above. Even 
though MALDI-MS imaging and DART-MS are suitable for rapid analysis, large sample 
throughput and high cost of these instruments prevent widespread use. 
1.3.4 Dried blood spots 
Collection of dried blood spots (DBS) relies on sampling capillary blood from a finger or 
a heel. Capillaries, which are the smallest blood vessel in the human body, connect the 
smallest arteries with the smallest veins. Therefore, a sample of capillary blood is a 
mixture of arterial and venous blood as well as interstitial and intercellular fluid 252. 
1.3.4.1 Collection devices 
Capillary blood is collected by pricking a finger with a lancet. The first drop of blood, 
which contains tissue fluid, is discarded. Samples are then collected on a filter paper or 
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on a microsampling device. Before extraction/analysis, collected capillary blood is left to 
dry at room temperature.  
1.3.4.2 Filter paper 
There is a variety of filter papers used for DBS collection. Some filter papers have been 
specifically designed for use in drug metabolism and pharmacokinetics (DMPK) studies. 
DMPK-A and DMPK-B filter papers lyse cells and denature proteins on contact with blood 
while DMPK-C filter papers are chemical-free and are, therefore, more suitable for 
protein analysis 252. Recently, non-cellulose filter paper (Agilent Bond Elut DMS) which 
is less influenced by the haematocrit (Hct) effect has been developed. However, it has 
been shown to suffer from an inconsistent saturation, fragility and poor precision 
attributed to the thickness of the paper 253. More recently alginate and chitosan foam 
has been suggested for DBS sampling 254. The new material gave higher recoveries than 
more conventional Whatman FTA DMPK and Agilent Bond Elut DMS, but the influence 
of the Hct was not assessed.  
 
Spotting drops of blood onto filter paper may seem like an easy and quick collection 
method, but it suffers from the Hct problem which can impact precision and accuracy of 
an assay 252,255,256. The ease at which a drop of blood spreads on the paper is dependent 
on many factors, such us donor’s hydration level, type of filter paper used as well as 
chemical and physical properties of a drug 252,255. The most significant factor, however, 
is the Hct which is defined as the percentage volume of red blood cells in a drop of blood. 
The higher the Hct (more red blood cells present), the more viscous the blood is. This 
leads to limited spreading and higher concentration of analyte(s) in the spot. On the 
contrary, the lower the Hct (fewer red blood cells present), the less viscous the blood. It 
is, therefore, prone to greater spreading yielding lower analyte(s) concentration in the 
spot 255 (this is illustrated in Figure 1-21). Therefore, when a fixed diameter punch-out is 
taken from the filter paper, punches with high Hct will contain larger volume of blood 
than punches from blood samples with low Hct. Furthermore, if a calibration curve is 
prepared in blood with a normal Hct the concentration of the samples with low Hct will 
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Figure 1-21. Appearance of 50 µL of human whole blood prepared at haematocrit = 0.18 (a); 
haematocrit = 0.35 (b); haematocrit = 0.50 (c); adapted from Wilhelm et al.252 
 
 
Inter-individual variations in the Hct are mainly caused by age, diet and disease state. 
Newborns, people living in high altitudes, people suffering from polycythaemia or 
chronic obstructive pulmonary disease tend to have higher Hct whereas patients 
receiving chemotherapy or having anaemia tend to have lower Hct 257.  
 
The Hct problem attributed to the use of filter paper has prompted scientists to propose 
new solutions. Youhnovski et al. suggested using pre-cut filter papers which would not 
only ensure better spreading and spot definition but would also eliminate potential 
carry-over caused by mechanical punching 255. Li et al. used perforated filter papers, 
where a single use pipette tip was used to push the samples into the extraction wells 258. 
Even though these methods successfully overcame the Hct problem, they required 
accurate sample volume to be deposited on filter paper. 
 
Potassium has been proposed to be a useful marker of the Hct level 259–261. Because red 
blood cells (RBC) are the main blood component which contains potassium, its 
concentration in RBC should correlate well with the Hct 262,263. This has been shown to 
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be true by Capiau et al. who successfully predicted Hct in 3 mm DBS punches 259. 
However, the authors pointed out that venous blood (preserved with lithium heparin) 
rather than capillary blood was used in these experiments. This might have affected 
their findings because heparin decreases blood viscosity 264. 
1.3.4.3 Dried plasma spots 
Another approach to the Hct problem focuses on the use of dried plasma spots (DPS) 
rather than DBS. This method has been used to detect a range of different compounds 
265–269, but requires blood centrifugation and so would not be practical for home 
sampling. 
 
To overcome the need for centrifugation and to eliminate the Hct problem, Ryona et al. 
developed a book-type DPS cards 270. Capillary blood is spotted on a card, but RBC are 
filtered through the membrane allowing plasma samples to be collected on the layer 
below. This new technique has been successfully validated for quantification of opioids 
and stimulants in whole blood at 30%, 45% and 60% Hct levels. However, the method is 
not suitable for drugs with high affinity to RBC for which venous blood remains the best 
matrix. 
1.3.4.4 Volumetric absorptive microsampling 
Several methods which overcome the Hct problem have been described here, from 
using modified filter paper, filtering RBC to produce DPS to calculating Hct by correlating 
it with the concentration of potassium in blood. A different approach relies on the use 
of volumetric absorptive microsampling devices (VAMS; for example a Mitra® device), 
which accurately collect a fixed volume of capillary blood independently of its Hct 271–
273. VAMS consist of a hydrophilic polymeric tip (see Figure 1-22) and come in a clamshell 
(2-4 samplers) or 96-rack format. Each individual device has been designed to collect 
either 10 µl or 20 µl of matrix. 
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Figure 1-22. Mitra® device before (left) and after (right) absorbing capillary blood; adapted 
from Spooner et al. 274 
 
Samples are collected by wicking up capillary blood after a finger prick. The white tip on 
the device turns red when enough blood has been absorbed and it is usually 
recommended to keep it in the matrix for another 2-5 s 272,273. Samples are then usually 
left for 2 h or longer at room temperature to dry. Because samples collected by VAMS 
do not require sample pre-treatment (centrifugation to obtain plasma or mechanical 
punching) they can be easily incorporated into the workflow. 
 
VAMS have been shown to have less than 5% variation in the volume of collected blood 
across 20-70% Hct 272. Similarly, a small variation has been observed when Mitra® 
devices were investigated in 6 different laboratories with both human and rat blood 274. 
However, the difference in the minimum (9.1 µL) and maximum (13.1 µL) volume of 
blood taken up by the tip varied. The reasons for that are not clear but may be attributed 
to the differences in pipetting blood, manufacturing inconsistencies or used sampling 
procedure (dipping the tip too deep or not leaving it in the matrix long enough). 
Mercolini et al. have also demonstrated that Mitra® devices can be used for accurate 
collection of other matrices, such as urine and plasma 166. In addition, Mitra® devices 
have been used for blood collection in several in vivo experiments after controlled drug 
administrations 275,276. 
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1.3.4.5 Application 
Originally DBS were used to monitor glucose levels in rabbits 277, but more recently they 
have been proven useful in analysing samples from the newborns and from people 
collecting samples at home 278. 
 
DBS are often chosen as a preferred matrix due to their relatively non-invasive nature 
and an ease of collection, which doesn’t require a phlebotomist or hospital visit. From a 
pre-clinical point of view, the use of microsampling devices plays a significant role in the 
reduction of the number of rodents and the volume of matrix taken in clinical trials and 
toxicology studies, which fits well with the 3R (replacement, reduction and refinement) 
concept 258,279. Moreover, DBS are not considered a hazardous biological material so 
they can be sent at room temperature by normal postal system. The fact that sample 
shipment does not have to be done on dry ice not only further reduces costs but can 
also be used in remote areas where electricity is not available 258. Finally, DBS may offer 
increased analyte stability 256,275,280,281 and extended photo-stability 282. For example 
cocaine has been shown to be more stable in DBS than whole blood stored for 72 h at 
+4ᵒC 275. Another study looking at incurred sample repeats analysed again after 25 
months showed that lopinavir was within ± 20% of its original concentration in 14 out of 
19 DBS samples whereas only 2 out of 19 plasma samples fulfilled that criterium 256. 
 
DBS are not without their disadvantages. Because only a small sample volume is 
collected and very often a back-up sample is not available, sensitive and reliable 
analytical methods are required. For home sampling, training is usually needed although 
the collection process has been made easier thanks to the development of VAMS. Very 
often in the home setting there is an increased risk of contamination because the person 
collecting the sample is also the one taking prescribed medications. One of the remining 
concerns is the mismatch between capillary blood collected by VAMS and whole blood 
samples containing preservatives and anticoagulants used for the preparation of 
calibration standards and quality control samples. One way of mitigating this problem is 
the addition of the preservative onto the VAMS tip or during the extraction stage as 
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previously suggested by Denniff et al 272. This approach has produced acceptable 
precision and accuracy, but a bioanalytical community is urged to discuss the problem 
in detail and publish an agreed solution.   
1.3.4.6 Correlation of DBS drug concentrations with 
whole blood 
Given a growing interest in DBS it is crucial to investigate drug concentration differences 
between capillary and whole blood. Literature suggests that this has to be done 
independently for each drug because drug concentrations in capillary blood may not  
always correlate well with whole blood 275,283,284. This could be due to the differences 
between arterial and venous drug concentration. Whole blood is usually collected from 
a vein in a forearm whereas capillary blood obtained from a finger prick contains a 
mixture of arterial and venous blood. Higher arterial concentrations of fentanyl 285, 
nicotine 286 and diacetylmorphine 287 have been reported previously, where a shorter 
Tmax, higher Cmax and larger AUC in the arterial samples was observed. These differences 
are usually seen shortly after drug administration (when the drug is in the distribution 
phase) and become less significant once the equilibrium has been reached 287. 
1.3.4.7 Detection of drugs in DBS collected on filter paper 
After drying DBS collected on filter paper for 2-3 h, samples of a fixed diameter (usually 
3-6 mm) are punched out and extracted using an appropriate solvent. Methanol is 
usually considered a good starting point for method optimisation followed by an 
extraction or a dilute and shoot approach 288. Because manual extraction of DBS is a 
laborious and time-consuming process, fully or semi-automated methods have been 
reported. These can be divided into three categories: on-line desorption 289,290, paper 
spray 291,292 and fully automated extraction 293–297. On-line desorption is a partly 
automated process where manually punched-out disks are extracted with a mobile 
phase or an organic solvent. The method can be further coupled up with an on-line SPE. 
Even though the extraction process can be sped up this way, the need for manual 
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punching and the need to determine the volume of spotted blood are main 
disadvantages. The use of paper spray for the extraction of drugs has presented itself as 
a promising analytical method. Paper spray, being a direct MS analysis, benefits from 
low sample volumes, does not require analytical columns for separation and offers quick 
analysis. However, samples need to be applied onto specially prepared triangular pieces 
of chromatography paper. Lastly, a fully automated method with barcoded DBS has 
been reported before but it comes at a cost. Robotic arms and handlers are quite 
expensive which may prevent laboratories from purchasing the equipment. It is also 
worth pointing out that many methods analyse DBS collected in a controlled 
environment whereas samples encountered in real life are likely to vary in shape, 
volume of deposited blood and Hct. 
 
Drug concentration in DBS have mostly been analysed by LC-MS/MS 295,298–300, but a 
number of different quantitative methods, such as GC-MS 301, liquid 
chromatography-high accuracy mass spectrometry (LC-HRMS) 253,302, HPLC-UV 303, 
LC-fluorescence 304 and immunoassay 305 have also been reported. DBS have not only 
been applied to the quantification of small molecules but has also been shown to work 
with large molecules, such as hepcidin (a peptide hormone) 298 and insulin 302.  
1.3.4.8 Detection of drugs in DBS collected by VAMS 
VAMS tips are either removed and taken through the extraction individually or a 
complete 96-rack with tips is extracted as part of an automated process. The removal of 
tips prevents the extraction of any excess blood that might have been deposited on the 
handle. This problem has been reported before when a high flow of blood flowing out 
of rat’s tail has overloaded the Mitra® device and left a visible deposit of blood on the 
handle 276.  
 
Optimisation of the drying time and the selection of an appropriate extraction solvent 
are crucial (see Figure 1-23). In many publications samples are dried for 2-3 h at RT, 
however, changes in recovery and drug concentrations have been observed with the 
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prolonged drying step. Solvent extraction is the easiest and fastest procedure where 
formic acid and ammonium hydroxide are often used to improve recoveries of acidic 
and basic compounds, respectively. Sometimes a more time-consuming clean-up 
method is required, such PPT or SPE. The former is usually achieved by precipitating 
proteins out with methanol of acetonitrile or by using salts. VAMS manufacturers have 
found zinc sulfate to be the most effective salt at disrupting protein-drug binding. SPE 
can be further incorporated into an extraction protocol to remove interferences. 
 
DBS collected by VAMS have been mainly analysed by LC-MS/MS 166,272,298,306–309 and 
HPLC-MS/MS 276,310. Because Mitra® devices come in 96-rack format, automation is easy 











Even though a wide range of analytes can be found in breath, it is less complex than 
blood and can be collected painlessly without the need for trained phlebotomists 311,312. 
The use of breath sampling has been evaluated in prisons where inmates and members 
of staff preferred it to urine collection 313. However, breath can only be used to detect 
very recent drug use 129. Moreover, drugs are usually found in breath at low pg/mL level 
which requires sensitive detection methods 314. Lastly, contamination of the oral cavity 
due to smoking or taking drugs intranasally may lead to inaccurate results. 
 
 
Figure 1-23. Suggested extraction protocols for small and large molecules of different 
polarities; acidic and basic modifiers can be added to improve recoveries. 
  Chapter 1 | Introduction 
Page | 91 
 
The mechanism of drug incorporation from the bloodstream into the exhaled air is not 
clearly understood. Drugs need to cross an alveolar membrane in order to be found in 
the alveoli. The alveolar membrane is made of collagen, and thus is relatively non-polar, 
allowing lipophilic compounds to diffuse more effectively through the membrane. Other 
factors, such as molecular weight and drug-protein binding, may also impact drugs 
ability to reach the alveoli 312.  
1.3.5.1 Exhaled breath condensate 
Breath analysis is usually divided into the analysis of the volatile part and the aqueous 
part of breath. The latter contains non-volatile and water-soluble compounds, 
commonly referred to as exhaled breath condensate (EBC). Collection of EBC is relatively 
easy as it requires breath to flow down a cooled tube. At low temperatures, compounds 
present in breath condensate and are collected 315. A number of portable and highly 
advanced benchtop EBC collection devices have been developed and applied in the field 
of toxicology. However, a significant limitation of the EBC analysis is the lack of 
standardisation. Moreover, because EBC consists of 99.9% water, compounds found in 
EBC are highly diluted, which not only calls for sensitive instrumentation but also leads 
to high inter- and intra-subject variability 315. 
1.3.5.2 Exhaled particles 
In addition to EBC, a new method for capturing microscopic particles from breath has 
been developed by a Swedish company, Pexa. The company use a stationary collection 
system which captures particles, separates them according to size and allows each 
fraction to be analysed by time-of-flight secondary ion mass spectrometry (ToF-SIMS). 
Thanks to this method researchers were able to characterise phospholipid composition 
in the exhaled particles from patients with asthma and cystic fibrosis 316.  
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1.3.5.3 Particle filter devices 
Another way of breath collection uses a particle filter device which relies on analytes 
exhaled in breath being trapped on a polymeric filter. A commercial design of a particle 
filter device has been released by SensAbuse®. The device was used to detect a panel of 
12 illicit drugs in breath samples collected from 47 patients 317. All drugs were detected 
in breath samples, but low levels of detection were observed for benzodiazepines. 
Stephenson et al. have recently published a fully validated routine screening method for 
quantification of 9 drugs and have successfully applied it to the analysis of 1,096 breath 
samples. Positive findings were reported in 3.6% of all cases, with amphetamine (25 
cases), methamphetamine (10 cases) and THC (8 cases) being the most frequently 
detected 314. 
1.3.5.4 Application 
One of the well-established areas where breath testing is widely used and accepted is 
the measurement of blood alcohol level in impaired drivers 190. Exhaled breath contains 
over 3,500 endogenous compounds, many of which characterise the function of the 
respiratory system 318. At the moment only a handful number of diseases can be 
effectively diagnosed by breath analysis, such as diabetes 312,319 or an infection with 
Helicobacter pylori 320. In addition, biomarkers of lung diseases (e.g. asthma, lung cancer, 
chronic obstructive pulmonary disease) are likely to be found in breath. Several 
compounds have already been studied as potential biomarkers, but the search for the 
most effective biomarker(s) is still ongoing 315,318,321. 
1.3.5.5 Detection of drugs in breath 
First attempts of drug detection in exhaled breath started in early 1980s. GC-MS was 
initially used to detect a range of volatile small molecules, such as ethanol, THC and 
γ-butyrolactone 322–324. More recently amphetamine and methamphetamine 325 as well 
as proteins, peptides, lipids and other endogenous compounds have been detected in 
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human breath by LC-MS/MS 315,318. Other techniques, such as ion mobility spectroscopy 
326, selected ion flow tube mass spectrometry 327, surface-enhanced Raman 
spectroscopy 328 and electronic noses 329 have also been used for detection of volatile 
compounds in breath. 
 
The detection of fentanyl in breath samples from six patients who received intravenous 
fentanyl was firstly reported by Wang et al 330. Breath samples were collected from the 
expiratory circuits of an anaesthetic machine and were analysed by GC-MS after 
solid-phase microextraction. Takita et al. used proton transfer reaction mass 
spectrometer to measure propofol concentrations in plasma and breath. Good 
agreement between propofol concentrations in both matrices was reported 331. 
Methadone has been detected in EBC collected from patients undergoing methadone 
maintenance treatment 332. Methadone excretion in breath ranged from 0.390 ng/min 
to 78 ng/min but the study did not aim to detect the metabolite of methadone, 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). The presence of EDDP in 
breath was confirmed in a different study which collected samples from patients on the 
methadone substitution programme 333. Metabolites of other illicit drugs have also been 
detected in breath. CBN, which is a metabolite of THC, was found in breath samples 
collected from a controlled administration study where chronic and occasional cannabis 
smokers were given cannabis cigarettes containing 6.8% THC (54 mg) 334. Moreover, 
Beck et al. detected 6-monoacetylmorphine at concentrations ranging from 
42 pg/sample to 6,080 pg/sample in 6 breath samples collected from 47 patients 
undergoing recovery from acute drug intoxication 317. 
1.3.6 Sweat 
Sweat is an important biological matrix responsible for maintaining homeostasis by 
keeping bodily temperature in a narrow range. Sweat is mostly composed of water 
(approximately 99%) 335 as well as inorganic salts, fatty acids, urea, ions, amino acids and 
a range of other compounds excreted through the skin or picked up from the 
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environment. The wide range of compounds present in sweat illustrates its complexity 
and a potential for inter-subject variability 129. 
 
As shown in Figure 1-24, there are two types of sweat glands: eccrine and apocrine. 
Eccrine glands are distributed almost all over the human body and play an important 
role in cooling by performing water-based secretion. Apocrine glands secret 
concentrated fatty sweat and are found in certain places on the human body, such as 




Figure 1-24. Schematic representation of sweat glands (image taken from: http://medical-
dictionary.thefreedictionary.com/gland)  
 
Collection of sweat is non-invasive 300,336 and marked with high subject acceptability 337. 
Compared to urine, sweat offers a longer drug detection window and is more difficult to 
adulterate 336. Sweat patches allow drug intake over several weeks to be monitored 337 
and cumulative exposure to be measured 133. However, external contamination remains 
a problem. Several court cases from individuals under supervised pre-trial or 
probationary release have been dismissed following positive sweat patch results for 
methamphetamine, contradicting individuals’ claims of being drug free. Urine tests 
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came back negative and so false positive nature of the patches was concluded to be a 
result of environmental contamination 338. Moreover, the use of patches suffers from 
high inter-subject variability, accidental or deliberate removal and difficulties with data 
interpretation in cases of lipophilic drugs which tend to be excreted over time. Lastly, 
the need for sensitive analytical instrumentation is vital 337. 
1.3.6.1 Drug incorporation into sweat 
The exact mechanism describing the incorporation of drugs into sweat is not well 
understood but the process is regulated by the physico-chemical properties (protein 
binding, molecular weight, pKa, lipophilicity) 339. Lipophilic drugs cross membrane 
barriers more easily than their hydrophilic metabolites or polar drugs, and thus will be 
found in sweat at higher concentrations 340. Basic drugs will concentrate in fluids of 
lower pH than that of blood/plasma (mean pH: 7.4) 339. Sweat has a slightly acidic pH 
(mean pH: 6.3) which means that basic drugs will become ionised in sweat. 
 
It has been postulated that the concentration gradient allows for passive diffusion of the 
unbound drugs from the bloodstream into sweat glands through the lipid bilayer 335. 
Another proposed mechanism of drug incorporation is a passive diffusion through the 
dermal and epidermal layers in the skin as well as excretion of substances via sebum 
336,337,340. 
1.3.6.2 Collection devices 
Stimulation of sweating by electrical diffusion of pilocarpine into the skin 341 or by 
warming the skin (wrapping/gloves) 157 have been reported before but is not practical 
for drug testing/remote sampling. 
 
Sweat patches are most commonly used to collect sweat over days/weeks. PharmChek® 
is an example of the most commonly used sweat patch 336. The patch consists of an 
absorptive cellulose layer covered with a semi-permeable membrane which is usually 
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worn for a week when approximately 2 mL of sweat is absorbed onto the patch. Drugs 
are trapped onto the absorptive pad while water vapour and other gases pass through 
it. The patch has been used in a number of studies, including controlled drug 
administrations 336,342 and patient monitoring 300. One of the reported drawbacks 
associated with the use of sweat patches is the problem of drugs being reabsorbed into 
the skin (from the patch) which may contribute to the inter-subject variability 343. 
 
Another method of collecting sweat is with wipes/swabs. A commercially available 
immunochemical device called DrugWipe® has been proven useful in cases of DUID 344 
and in PK studies 345. Manufacturers reported fast detection (5 min) of up to seven drug 
groups. Furthermore, reports of using cotton swabs soaked in alcohol to collect sweat 
from the forehead of cocaine users’ children have also been published 346.   
 
Due to their non-invasive and easy sample collection, the use of fingerprints for drug 
testing has recently become a centre of focus. Deposited fingerprints carry a unique 
additional benefit of person identification based on the finger ridge detail. When a finger 
touches a surface, eccrine sweat, external contaminants and sebum leave an invisible 
(‘latent’) fingerprint pattern 347. Fingerprints can be collected simply on a piece of paper 
or glass. An alternative method suggested by Archer et al. involves a grooming 
procedure to mimic the natural composition of a sample as well as to minimise sample 
variability 348. The grooming procedure involves cleaning hands with an ethanol wipe 
and then using both hands to wipe specific areas of the face in a repetitive manner (10 
strokes/times), passing hands through hair (10 times) and finally rubbing fingertips 
together for a few seconds. 
1.3.6.3 Detection of drugs in sweat  
A number of studies have previously reported the detection of illicit drugs (either parent 
or Phase I metabolites) in sweat 157,349. Phase II metabolites have also been detected in 
fingerprint sweat before 350. GC-MS 336,342,343,345,351–354 and LC-MS/MS 300,350,355 have 
been applied extensively to the detection and quantification of drugs in sweat patches, 
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swabs and fingerprint sweat. Jacob et al. have detected methadone and EDDP in two 
single fingerprints collected on glass cover slips from eight patients on a methadone 
maintenance programme. Interestingly, the study also reported varying concentrations 
of methadone on deposited fingerprints from 3 different fingers. Authors suggested that 
the surface area of the fingertips and the amount of collected sebum and sweat may be 
a potential explanation 355. Moreover, the first study which reported the presence of a 
Phase II glucuronide metabolite in ten combined fingerprint deposits was published by 
Goucher et al. The detection of a Phase II metabolite in a sample is important from a 
forensic point of view because it indicates the drug has been metabolised and, 
therefore, excludes the possibility of environmental contamination 350. 
 
In addition to LC-MS/MS and GC-MS several other approaches have been reported for 
the detection of drugs in fingerprint sweat. Antibody-nanoparticles conjugates have 
been proven useful in the detection of drug metabolites in sweat deposited in latent 
fingerprints 356–358. Ambient imaging techniques, such as surface-assisted laser 
desorption/ionisation-mass spectrometry (SALDI-MS) 359, desorption electrospray 
ionisation-mass spectrometry (DESI-MS) 360–362, paper spray-mass spectrometry 363 and 
MALDI-MS imaging 362,364 have also been utilised. These imaging techniques can not only 
visualise the ridge detail but can also show the distribution of endogenous and 
exogenous components of sweat, which has been demonstrated in fingerprints from 
drug users 359,365 and in dusted fingerprints 359,361.  However, challenges related to 
analytical sensitivity and large inter-subject variability in the state of collected 
fingerprints still remain 364.  
 Importance of NPS detection in clinical and forensic drug 
testing settings 
Despite analytical challenges associated with detection of NPS (see 1.1.3 for more 
details), it is important to target new emerging drugs (including mephedrone) in clinical 
and forensic drug testing settings.  
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1.4.1 Clinical setting 
When biological samples are taken for drug testing from patients suffering from acute 
drug toxicity, results are usually not received in time to inform clinical management of 
patients, who remain in hospital on average 4-5 h 366. In addition, most hospitals do not 
have analytical technologies or methods capable of identifying NPS, especially the 
emerging ones. Nevertheless, identification of NPS via analytical screening is vital in 
informing clinicians about new patterns of toxicity, providing information to the 
legislative bodies about the risks associated with new substances and confirming the 
presence of NPS for when case reports or case series are published 13. 
1.4.2 Forensic setting 
In the forensic context, detection and identification of NPS is crucial in driving under the 
influence of drugs (DUID), drug facilitated sexual assault (DFSA), post-mortem analysis 
and in the workplace drug testing. 
 
Studies investigating the link between driving and synthetic cathinones are scarce. 
However, adverse effects associated with the use of synthetic cathinones (palpitations, 
dizziness, light-headedness, paranoia; see 1.2.9.1 for more detail) can have a major 
impact on driving ability 367. Blood cut-off concentrations in DUID cases have not been 
defined for NPS, but there are reported cases of individuals driving under the influence 
of NPS, including mephedrone 70,368. 
 
Another aspect of forensic toxicology where drug detection capabilities are crucial is 
DFSA. NPS are not usually associated with DFSA, but a recent publication identified 
methylone (synthetic cathinone) in 13% of 45 sexual assault samples analysed by the 
University of Miami Forensic Toxicology Laboratory 369. The authors hypothesised that 
methylone was used because it is capable of producing a mental state of confusion, but 
they also highlighted the need for monitoring new patterns of drug use. 
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Even though it can be difficult or even impossible to attribute post-mortem 
concentrations of NPS to recreational or excessive use, determination of the cause of 
death is equally important in forensic toxicology. Deaths caused by sole mephedrone 
use are rare (see 1.2.9.4 for more details related to mephedrone fatalities) but in 2018 
there were 125 deaths involving NPS, a significant increase from 61 deaths recorded in 
2017 in the UK 370. 
 
The use of drugs in the workplace is a growing problem that poses a potential health 
and safety risk to the drug users, their fellow colleagues and clients 371. The addition of 
the NPS (including mephedrone) to the library of drugs screened for in the workplace 
testing is, therefore, important because NPS can cause acute toxic effects and impaired 
judgement, presenting a significant risk to safety in situations where industrial 
machinery is operated, dangerous chemicals are handled or when driving motorised 
vehicles. Cut-off concentrations for NPS in urine, oral fluid or head hair have not been 
defined by the international bodies, such as the European Workplace Drug Testing 
Society. Therefore, laboratories tend to decide on the scope of substances included in a 
routine screen and adopt their own cut-off concentrations, which may vary widely 
between drug testing providers 13.  
1.4.3 Detection of mephedrone and its metabolites in alternative 
biological matrices 
Alternative biological matrices are being increasingly evaluated for use in clinical and 
forensic drug testing settings, but there is little available research investigating the 
viability of these biological matrices for detection of NPS, including mephedrone and its 
metabolites. This is illustrated in Table 1-2, which shows that mephedrone metabolites 
have not been widely targeted in alternative biological matrices. Mephedrone itself was 
only quantified by LC-MS/MS in authentic oral fluid, DBS and head hair samples. 
 
In oral fluid, several analytical methods for quantification of mephedrone by GC-MS 
372,373 or LC-MS 166,374,375 have been developed, but only two of them analysed real 
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samples. Strano-Rossi et al. published a LC-MS/MS screening method for the detection 
of NPS in oral fluid 374. When the method was applied to 400 real oral fluid samples from 
traffic control stops, mephedrone was not detected. In the other study, Mercolini et al. 
detected mephedrone at 38 ng/mL and 15 ng/mL in unstimulated oral fluid collected by 
a disposable plastic pipette from self-reported drug users 166. 
 
To date the only publication which reported a successfully validated method for the 
detection of 64 NPS (including mephedrone) in DBS (collected on filter paper) was 
published by Ambach et al. The method was applied to 21 authentic capillary blood 
samples but mephedrone was not detected 376. 
 
Mephedrone has been targeted in hair samples collected from suspected drug users and 
analysed as part of forensic casework 116,377–381. Quantitative results were only 
presented in some of these studies. Following LC-MS analysis, Salomone et al. detected 
mephedrone in two samples from proven MDMA and/or ketamine users at 50 pg/mg 
and 59 pg/mg 380. Martin et al. found mephedrone at higher concentrations of 
26.8 ng/mg (range: 0.2-313.2 ng/mg) in hair samples submitted to the ChemTox 
Laboratory in France 381. Post-mortem hair concentrations of mephedrone were 
reported by Torrance et al. who detected the drug at concentrations between 4.2 ng/mg 
and 4.7 ng/mg following GC-MS analysis 116. The only method which targeted 
mephedrone metabolites (nor-mephedrone and dihydro-nor-mephedrone) by LC-MS 
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Table 1-2. Summary of the studies reporting detection of mephedrone and its metabolites in 















n = 5 LC-MS/MS ✓  - 166 
n = 400 LC-MS/MS   - 382 
Head 
hair 
n = 67 GC-MS ✓  - 381 
n = 1 GC-MS ✓  - 116 
n = 16 LC-MS/MS   - 377 
n = 154 LC-MS/MS ✓ ✓  378 
n = 325 LC-MS/MS ✓  - 379 
n = 77 LC-MS/MS ✓  - 380 




 Aims and objectives 
The aim of this study was to conduct an ethically approved controlled single dose 
administration of nasally insufflated mephedrone to investigate the distribution of 
mephedrone and its major Phase I metabolites in head hair, oral fluid, sweat, DBS, 
breath, urine, plasma and whole blood. The secondary aim was to report for the 
first-time pharmacokinetic and pharmacodynamic information associated with 
mephedrone and its metabolites after nasal insufflation. Although a pilot study and the 
first reported controlled human mephedrone administration studies have been 
published (see 1.2.8 for more details), they have certain limitations that our research 
seeks to address. Firstly, by conducting a human administration study with mephedrone 
purchased from a certified commercial supplier, the exact dose and purity of the drug 
given to the participants will be known. This was not the case in the pilot study where 
the research team obtained mephedrone from police seizures while in the controlled 
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administration study mephedrone was obtained from the Spanish Ministry of Justice 
and the Ministry of Health. In both cases no information on drug purity was provided. 
Furthermore, there is limited data available on human oral bioavailability of 
mephedrone, thus it is difficult to determine how oral doses in the aforementioned 
studies compare to doses administered by the intranasal route used in our study. Finally, 
both research groups only collected conventional samples (plasma and urine) from the 
participants, whereas as part of this study several alternative biological matrices will be 
collected and analysed for mephedrone and its metabolites. It is hoped that the data 
gleaned from this PhD project will be of value in forensic (drug-related deaths and crime) 
and clinical (acute drug toxicity and drug dependence) toxicology as well as in the 
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CHAPTER 2  
MEPHEDRONE ADMINISTRATION STUDY, 
ANALYTICAL METHOD DEVELOPMENT AND 
VALIDATION 
 Design of the mephedrone administration study 
A controlled human drug administration study is the most insightful way of 
understanding drug metabolism, distribution and pharmacokinetics. Not only does it 
allow clinicians to control the dose and purity of a given drug, but it also ensures no poly 
drug use at the time of administration. This is crucial to fully understand the sole action 
of a drug which might be altered through CYP2D6 liver enzymes being induced or 
inhibited when taken with other illicit or prescribed substances. Moreover, the exact 
time of drug administration is known which is often not reported in clinical cases 
involving patients presenting to the Accident and Emergency Department. Furthermore, 
some patients suffering from acute drug toxicity may have problems remembering the 
name of the drug taken. Some drugs have similar names, such as mephedrone, 
methadone or methedrone, making it difficult for the patients to give an accurate 
description of the drug.  
 
Gamma-hydroxybutyrate 383, cocaine 284 and diazepam 350 are just few examples of drugs 
which have been administered to healthy volunteers in a controlled setting before. 
Controlled mephedrone administration studies reported by Olesti et al. 91,97 and 
Papaseit et al. 96,384, where doses of up to 200 mg were given orally to healthy male 
volunteers, formed the basis of the safety assessment of our study and helped to justify 
safe dosing. 
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Full ethical approval for the controlled mephedrone administration study was obtained 
from the Riverside National Research Ethics Service (16/LO/1342) and the approval 
letter can be found in Appendix A. 
2.1.1 Study advertisement 
The study was advertised on the King’s College London research recruitment website 
and in two local newspapers: Evening Standard and Metro. 
2.1.2 Inclusion and exclusion criteria 
Participants enrolled into the study were non-smokers between 18 and 40 years old. 
They were occasional users of mephedrone or other stimulant drugs but were drug-free 
2 weeks before the study day (i.e. mephedrone administration) and 30 days after the 
study day. Participants had no underlying hypertension (> 140/90 mmHg) and were not 
suffering from chronic cardiac/respiratory/renal diseases. In addition, participants were 
not taking over-the-counter/prescribed drugs and/or herbal/alternative remedies at the 
time of the study. Furthermore, those with a history of closed angle glaucoma or 
involved in another clinical trial were excluded. Female volunteers could not take part 
in the study due to the unknown effects of mephedrone in undetected pregnancy. 
 
Participants were asked not to cut, dye, perm or bleach their head hair over the period 
of 30 days from the day of mephedrone administration. These requirements were in 
place because hair treatments can affect drug concentration in hair. Additionally, only 
participants with hair length of more than 1.25 cm, which allowed for the collection of 
an adequate amount of hair for analysis, were accepted into the study.  
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2.1.3 Study visits 
Participants were required to attend 6 study visits: 
• Screening visit 30 days before mephedrone administration 
• Urine collection 1 week before mephedrone administration 
• Mephedrone administration (referred to here as a study day) 
• Day 2, Day 3 or 4 and Day 30 post mephedrone administration 
 
Screening visits and drug administration took place in the Clinical Research Facility (CRF) 
in St Thomas’ Hospital where cardiovascular monitoring and biological sampling was 
undertaken. Urine collection and post mephedrone administration visits took place at 
King’s College London. 
2.1.4 Screening visit 
At the screening visit potential participants had the opportunity to discuss the study with 
a specialist registrar. Participants also underwent a physical examination, 12-lead 
electrocardiogram (ECG), baseline observations (blood pressure, pulse, blood oxygen 
saturation, height, body weight and body temperature), and were asked about their 
medical history (including inclusion and exclusion criteria as well as history regarding 
current and previous recreational drug use). In addition, participants were asked not to 
take recreational drugs/NPS from 2 weeks prior to the study day to 30 days after it. This 
was to ensure that participants were mephedrone/metabolite free and, therefore, 
metabolites detected on the administration day were the result of administered 
mephedrone. From a safety perspective it was also crucial to eliminate the risk of 
drug-drug interaction due to poly drug use. 
2.1.5 Urine collection 
Seven days before the mephedrone administration day, a urine sample was collected 
from each participant and analysed using a standard stimulant (including mephedrone) 
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screen at Abbott (previously Alere Toxicology). This was done to ensure drug-free 
compliance. If a positive result was reported, the participant was removed from the 
study. If a negative result was reported, the participant was allowed to proceed with the 
study. 
2.1.6 Mephedrone administration day 
On the main study day there was a minimum of five research staff present in the CRF. 
At all times participants were attended by two doctors of at least registrar/specialist 
registrar grade and a consultant member of the Clinical Toxicology team was in the 
hospital available for advice or to attend if necessary. Furthermore, the CRF had a full 
resuscitation equipment if required and was supported by the St Thomas’ Hospital 
cardiac arrest team.  
 
Prior to the mephedrone administration (i.e. at -10 min) each participant had their 
baseline observations (heart rate, blood pressure, body temperature, blood oxygen 
saturations) checked. If participants fulfilled the criteria, baseline biological samples 
were taken. Participants were then asked to wear a disposable gown over their clothes, 
a pair of gloves and a hair cap while they self-administered a single 100 mg dose of 
mephedrone powder via nasal insufflation using a straw. This was done in a different 
room to avoid contamination and was overseen by someone not involved in the other 
aspects of the study. Participants were then asked to clean their hands and face with 
ethanol wipes and were taken back to the main study room where biological samples 
were collected at varying times over the next 6 h (Table 2-1). 
 
Participants had their cardiac rhythm continually monitored and recorded at each point 
of sampling or every 20 min (whichever was shorter). To determine whether participants 
were experiencing adverse neuropsychiatric effects, participants were regularly asked a 
series of questions using a validated score incorporating a visual analogue scale (VAS) 
385,386. This was done at -10 min and then every 15 min from the time of mephedrone 
administration until 2 h and then at 2.5 h, 3 h, 5 h and 6 h. The test assessed subjective 
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experiences of: “drug effect, bad effect, good drug effect, high, stimulated, sad, 
confused, fearful, liking, dizzy, experiencing changes in distance, light, hearing, body 
sensation, surrounding”. VAS was presented as 10 cm horizontal lines, where the 0 cm 
point indicated no effects/changes and the 10 cm point indicated extreme 
effects/changes. 
 
If at any point the heart rate exceeded 140 bpm, blood pressure exceeded 
180/100 mmHg, temperature exceeded 38.0°C or if the participant became agitated or 
developed adverse effects that were related to mephedrone and considered significant 
by the attending Clinical Toxicologist, the study was stopped. At this point no further 
biological samples were taken, continuous physiological monitoring continued, a 
12-lead ECG performed, and the participant was cared for by the attending Clinical 
Toxicology team. If additional medical treatment(s) were required to manage the heart 
rate, blood pressure and/or temperature a consultant Clinical Toxicologist determined 
whether admission overnight for ongoing observation was required. 
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Table 2-1. A detailed outline of the frequency and sample types taken after mephedrone 
administration 














-10 min x x x x x x x x 
100 mg mephedrone hydrochloride administrated by nasal insufflation 
5 min x   x   x  
10 min x    x   x 
15 min x   x     
20 min x    x  x  
30 min x   x     
45 min x    x x  x 
60 min x   x   x  
75 min x       x 
90 min x   x x x   
105 min x      x x 
2 h x   x   x  
2.5 h x   x     
3 h x    x x  x 
5 h x   x x x   
6 h x x     x x 
Day 2 x x  x x  x x 
Day 3 or 
Day 4 
x x  x x  x x 
Day 30 *  x x   x   
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2.1.7 Follow-up visits 
Participants were asked to come to King’s College London for the follow-up visits on Day 
2, Day 3 or 4 and Day 30 post mephedrone administration to enable the collection of 
biological samples (see Table 2-1) and to ensure participants’ well-being. 
2.1.8 Source of mephedrone powder 
Mephedrone hydrochloride powder was purchased from Chiron (Trondheim, Norway), 
who provided a certificate of authenticity and certificate of origin stating the purity of 
the drug. As an additional precaution, purchased mephedrone was further analysed 
in-house by LC-MS and proton nuclear magnetic resonance (H1 NMR) to ascertain 
structure authenticity and to ensure it met acceptable purity. 
 
Mephedrone hydrochloride was stored under the Schedule 1 licence held by the Drug 
Control Centre (DCC) at King’s College London. It was weighted under the supervision of 
a senior scientist and transported to St Thomas’ Hospital on the day of mephedrone 
administration where it was put in a safe in the CRF until required. 
2.1.9 Justification for the mephedrone dose 
The initial dose of mephedrone taken by recreational mephedrone users ranges 
between 15 mg and more than 300 mg for oral ingestion and between 5 mg and 250 mg 
for nasal insufflation 66. Because of mephedrone’s short duration of action, recreational 
users commonly re-dose a number of times in a single session such that they use up to 
1 g or more per session 68. Case reports and series of acute mephedrone toxicity have 
generally reported use of 300 mg to 7,000 mg 33,69. Moreover, in a dose-finding pilot 
study and recent human administration studies, 50-200 mg of mephedrone given orally 
were well tolerated 95,384. Therefore, the dose of 100 mg used in this study represented 
a safe dose for the participants and it was also a dose that ensured that the 
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concentrations of mephedrone and its metabolites as well as the pharmacokinetic data 
were relevant to both clinical and forensic cases. 
2.1.10  Chosen route of administration 
This is the first controlled human administration study where mephedrone was given via 
nasal insufflation, which is the most common route of administration by the recreational 
mephedrone users 33. In other studies, where healthy male volunteers were given 
mephedrone, the drug was given orally 91,95,97. 
2.1.11  Sample collection 
The collection times outlined in Table 2-1 were decided based on the information from 
the recreational mephedrone users which suggested that intranasal administration is 
associated with an onset of action of 2-10 min and a peak action within 30 min 33. This 
was the only information available at the time of writing the ethical approval in late 
2015. Detailed description of each sample type and the collection process is described 
below. 
 
❖ Whole blood and plasma 
To allow for multiple blood sampling without the need for repeated venepuncture, 
participants had an intravenous cannula inserted into their forearm. At each timepoint, 
a syringe was used to withdraw and discard 2 mL of blood which is a mixture of both 
saline and blood. A 5 mL blood sample was then collected into a vacutainer containing 
sodium fluoride/potassium oxalate (NaF/KOx; 12.5 mg/10 mg) preservative and the 
intravenous line was flushed with 5 mL of 0.9% sodium chloride solution. At each 
timepoint two aliquots of blood were collected, one of which was centrifuged at 2300 
rpm for 10 min to harvest plasma. Remaining blood samples collected on Day 2 to Day 
30 were taken by a trained phlebotomist using venepuncture of a forearm vein. Plasma 
and whole blood samples were stored at -20ᵒC and +4ᵒC, respectively, until analysis. 
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❖ Urine 
Urine samples were collected at time intervals outlined in Table 2-1 with extra samples 
being collected between the administration and 6 h if a participant felt the need to pass 
urine. The volume of excreted urine was recorded. Urine was collected into Nalgene® 
storage containers and stored at -20ᵒC until analysis. 
 
❖ Head hair 
Hair samples (7 mm in diameter) were collected before mephedrone administration and 
30 days after. Hair was cut as close to the scalp from the posterior vertex as possible 
(leaving approximately less than 0.25 mm in situ). Following hair collection, the proximal 
end of the samples was wrapped in a piece of tinfoil with the root end clearly marked. 
Hair samples were stored desiccated in envelopes at room temperature. 
 
❖ Oral fluid 
Oral fluid was collected by a Certus® collection device provided by Abbott (previously 
Alere Toxicology). Participants were asked to keep a swab under the tongue until the 
blue dye appeared, which indicated sufficient sample volume. The swab was then 
transferred to a buffer solution which was shaken for 30 s. The swab was removed from 
the solution and buffered oral fluid sample was stored at -20ᵒC until analysis. 
 
❖ Dried blood spots 
A finger was cleaned with an ethanol wipe and allowed to dry. A single-use lancet was 
then used to prick the finger and capillary blood was collected directly onto the filter 
paper and onto a Mitra® collection device. Filter papers and Mitra® devices were dried 
for 2 h at room temperature and were stored desiccated at -20ᵒC until analysis. The 
forefinger was usually used for sample collection but sometimes participants reported 
the pricked finger getting swollen causing them discomfort. In those cases, another 
finger was used for sample collection. 
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❖ Fingerprint sweat 
At -10 min and 10 min, fingertips were cleaned with an ethanol wipe and allowed to dry. 
A print from each finger of the hand that was not used for DBS collection was deposited 
onto the surface of a clean circular glass cover slip (two samples were collected at 
90 min, 3 h and 5 h). In parallel to the glass cover slips, fingerprint sweat was also 
collected onto triangular pieces of chromatography paper placed on top of a scale. 
Participants were asked to push down on the piece of paper for 10 s to give pressure 
between 800-1200 g. Glass cover slips were transferred into scintillation vials whereas 
triangular pieces of chromatography paper where kept desiccated in a box. All samples 
were stored at -20ᵒC until analysis. 
 
❖ Head sweat 
Sweat deposits were collected by wiping the surface of the forehead 5 times with a 
cotton swab. Swabs were then placed in glass vials and stored at -20ᵒC until analysis. 
 
❖ Breath 
A DrugTrap® device provided by SensAbues was used to collect breath. The device 
separates saliva and larger particles from the micro-particles of interest which are 
collected on a polymer filter inside the device. The sampling procedure was standardised 
by filling a plastic bag with approximately 20 L of exhaled breath after blowing for 1 min. 
DrugTrap® collection devices were sealed with plugs and stored at -20ᵒC until analysis. 
 
❖ Buccal swab 
At the beginning of the study two buccal samples were taken, one from each cheek. The 
inside of the cheek was gently rubbed with a sterile cotton swab for 10 s. Samples were 
placed in a tube and stored at +4ᵒC until analysis. 
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2.1.12  Sample analysis 
Collected samples were transported from the CRF to the following destinations using 
Human Tissue Act (HTA) approved procedures:  
• whole blood, plasma, urine, fingerprint sweat (collected onto glass cover slips), 
DBS (collected by the Mitra® device) and head hair samples were analysed using 
a validated LC-MS/MS method at King’s College London, UK 
• oral fluid was analysed using a validated LC-MS/MS method at Abbott (previously 
Alere Toxicology), UK 
• DBS (collected on the filter paper) were analysed at Ghent University, Belgium 
• aliquot of plasma samples was sent for the metabolomics analysis to the 
University of Zurich, Switzerland 
• extra fingerprint sweat samples collected onto glass cover slips at 90 min, 3 h 
and 5 h were analysed via DESI-MS by Waters Corporation, UK  
• fingerprint sweat samples collected on the triangular pieces of chromatography 
paper were analysed via paper spray-MS at the University of Surrey, UK 
• single strands of hair were analysed by MALDI-MS imaging at Sheffield Hallam 
University, UK 
• buccal swabs were analysed by the Massive Parallel Sequencing technology at 
King’s College London, UK 
2.1.13  Recruitment outcome 
Seven healthy male volunteers were recruited for the study. Six of them completed the 
study and one was not able to take mephedrone because of high blood pressure on the 
mephedrone administration day. All participants were compensated with London living 
wage for the time they participated in the study. Physical characteristics of the 
participants are presented in Table 2-2. 
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Table 2-2. Physical characteristics of the participants who completed the study 
* body mass index 
Participant 
Dose of mephedrone 
taken (mg) 
Weight (kg) Height (cm) BMI * 
M1 99.7 84.0 184 24.8 (healthy) 
M2 100 76.4 177 24.2 (healthy) 
M3 102 66.3 170 22.9 (healthy) 
M4 99.4 59.0 168 20.9 (healthy) 
M5 99.4 82.2 196 21.3 (healthy) 
M6 99.8 55.2 164 20.5 (healthy) 
 
 Statistical analysis 
Statistical analysis was performed in Microsoft Excel 2016 or in GraphPad Prism 
software (version 7.0). 
 
Standard deviation (SD) and the coefficient of variation (%CV) were calculated using 
Equation 2-1 and Equation 2-2, respectively.  
 
Equation 2-1. Equation for calculating standard deviation where ?̅? is a sample mean and N is a 
number of observations. 
 𝑆𝐷 = √𝛴(𝑥 − ?̅?)2  𝑁 − 1  
 
Equation 2-2. Equation for calculating the coefficient of variation (%CV) 
 %𝐶𝑉 =  𝑆𝐷𝑚𝑒𝑎𝑛 ∗ 100% 
 
The Pearson correlation coefficient was calculated according to Equation 2-3. One 
sample t-test (t, p-value < 0.05) was calculated using Equation 2-4. If the calculated t-
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value fell outside the range defined by the critical value from the 2-tailed t-Table, the t-
value was considered to be statistically significant. Both tests were performed in 
GraphPad Prism (version 7.0). 
 
Equation 2-3. Equation for calculating Pearson correlation coefficient, where ?̅? and ?̅? are 
sample means of each variable.  
 Pearson correlation coefficient = 𝛴(𝑥 − ?̅?)(𝑦 − ?̅?)√𝛴(𝑥 − ?̅?)2 𝛴(𝑦 − ?̅?)2 
 
Equation 2-4. Equation for calculating one sample t-test (t), where ?̅? is sample mean, µ is 
assumed population mean, s is sample standard deviation and n is sample size. 
 𝑡 = ?̅? − µ 𝑠√𝑛  
 
Grubbs' test (G, p < 0.05), shown in Equation 2-5, was used for checking data for outliers. 
If the G value calculated for a suspected outlier was greater than the value from the 
Grubbs’ table at the 95% confidence level, it was identified as an outlier and was 
rejected from the dataset. 
 
Equation 2-5. Equation for performing Grubbs' test, where ?̅? is sample mean, x is a suspected 
outlier and s is sample standard deviation. 
 𝐺 = |?̅? − 𝑥| 𝑠  
 
Bland–Altman analysis was performed in GraphPad Prism software (version 7.0) to 
assess the agreement between analytical methods. 
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 Pharmacokinetic calculations 
Pharmacokinetic data for mephedrone and its metabolites was determined both 
manually and by using a non-compartmental pharmacokinetics data analysis program 
(PK Solutions, version 2.0, Summit Research Services, Montrose, Colorado). Obtained 
data from the software was compared with the manually calculated data to ensure they 
were in agreement. 
 
Peak concentration (Cmax) and the time after dosing when it occurred (Tmax) were 
observed directly from the data for mephedrone and its metabolites. The apparent 
elimination half-life (t1/2) was calculated using a log-linear regression of the elimination 
phase by plotting drug concentration versus time using data points which produced R2 
of at least 0.97. The elimination rate constant (kel) was calculated using Equation 2-6. 
 
Equation 2-6. Equation for calculating the elimination rate constant (kel) 
 𝑘𝑒𝑙 = ln (2)𝑡1/2  
 
The area under the curve (AUC) from 0 to Day 3 or Day 4 was calculated using the 
trapezoidal method. Clearance (CL) was calculated using Equation 2-7 and was then 
adjusted for the individual’s weight. Renal clearance (CLr) was calculated as shown in 
Equation 2-8. 
 
Equation 2-7. Equation for calculating apparent oral clearance (CL) 
 𝐶𝐿 = dose𝐴𝑈𝐶 
 
Equation 2-8. Equation for calculating renal clearance (CLr) 
 𝐶𝐿𝑟 = 𝑡𝑜𝑡𝑎𝑙 𝑚𝑒𝑝ℎ𝑒𝑑𝑟𝑜𝑛𝑒 𝑒𝑙𝑖𝑚𝑖𝑛𝑎𝑡𝑒𝑑 𝑖𝑛 𝑢𝑟𝑖𝑛𝑒𝐴𝑈𝐶  
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The apparent volume of distribution (V) was calculated using Equation 2-9 and was then 
adjusted for the individual’s weight. 
 
 
Equation 2-9. Equation for calculating volume of distribution (V) 
 𝑉 = 𝐶𝐿𝑘𝑒𝑙 
 
 Method development 
2.4.1 Column selection 
Separation of mephedrone in biological samples is usually performed on a reverse phase 
liquid chromatography (RPLC) which provides favourable interactions between 
non-polar analytes and hydrophobic stationary phase. However, for the purpose of this 
project a suitable chromatographic method had to be developed allowing separation 
not only of mephedrone but also its metabolites which exhibit a range of polarities. 
Hydroxytolyl-mephedrone and 4-carboxy-mephedrone, two more polar metabolites, 
are poorly retained on a standard C18 stationary phase. These metabolites tend to 
co-elute with matrix interferences shortly after the start of the gradient which results in 
loss of sensitivity and inaccurate quantification. One way to overcome this problem and 
to improve the retention of polar analytes is to use highly aqueous mobile phase at the 
beginning of the gradient, but this approach leads to poor desolvation and ion 
suppression. Moreover, traditional reverse phase columns are not compatible with 
highly aqueous mobile phases (> 95% water) due to of a phenomenon known as ‘phase 
collapse’, where hydrophobic hydrocarbons on the stationary phase tend to ‘collapse’ 
onto themselves to avoid contact with a highly polar mobile phase, leading to poor 
column efficiency. Newer types of analytical columns incorporate polar end-capping 
groups, rendering stationary phases water wettable. It was therefore decided to test 
both: Waters ACQUITY HSS T3 column (2.1 mm x 150 mm, 1.8 μm) which can withstand 
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100% aqueous mobile phases, and a fully end-capped UCT Selectra® 
pentafluorophenylpropyl (PFPP) column (2.1 mm x 150 mm, 1.8 μm) which should 
provide more interactions with the polar metabolites.  
 
Chromatographic separation on both columns was performed on a Waters Acquity UPLC 
system equipped with a 2777 open architecture autosampler coupled to a Waters Xevo 
TQ-S triple quadrupole mass spectrometer. Mobile phase A was 0.3% formic acid in 
water and mobile phase B was 0.3% formic acid in acetonitrile. Strong needle wash was 
methanol and weak needle wash was acetonitrile:water (10:90 v/v). PFPP column was 
held at 60ᵒC with the flow rate of 0.5 mL/min. The start of the gradient was at 85% 
mobile phase A. Mobile phase B was then increased to 55% over 11 min and was held 
for 2 min. Over the next 0.5 min the gradient returned to the starting condition and the 
column was re-equilibrated at 85% mobile phase A for the remaining 1.5 min. The total 
run time was 15 min. The HSS T3 column was held at 40°C with a flow rate of 0.4 mL/min 
and a total run time of 20 min. The initial gradient was 100% mobile phase A for 0.5 min 
and was then decreased to 20% mobile phase A over 17.5 min. Over the next 0.5 min 
the gradient returned to 100% mobile phase A for 2 min and was held there for 1.5 min. 
Twenty microliters of extracted whole blood (see section 2.4.4 for more information 
about the extraction) samples (n=6) was injected on both columns using a 100 μL syringe 
with a 10 μL injection loop (full loop injection with loop overfill). The data was acquired 
and processed using MassLynx software (version 4.1). 
 
As shown in Table 2-3, all analytes were retained on both columns, however, PFPP 
column provided significantly improved retention. In addition, unexpected retention 
time shifts of approximately 0.25 min were observed for hydroxytolyl-mephedrone and 
4-carboxy-mephedrone in 2 out of 6 injections of the same sample on the HSS T3 
column. As a result, PFPP column was chosen for analysis. 
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Table 2-3. Comparison of the retention times on the HSS T3 and PFPP columns 
Analyte Retention time on HSS T3 Retention time on PFPP 
Mephedrone 3.71 min 5.85 min 
Dihydro-mephedrone 3.42 min 5.38 min 
Nor-mephedrone 3.25 min 5.00 min 
Hydroxytolyl-
mephedrone 
1.25 min 1.98 min 
4-carboxy-mephedrone 1.26 min 2.06 min 
Dihydro-nor-
mephedrone 
2.97 min 4.45 min 
 
2.4.2 Mass spectrometry  
Mass spectrometry (MS) analysis was performed using a Waters Xevo TQ-S triple 
quadrupole mass spectrometer equipped with a Z-spray electrospray ionisation source 
operated in positive ion mode. The following analytes were targeted: mephedrone 
hydrochloride (MEPH), dihydro‐mephedrone hydrochloride (DHM), mephedrone‐d3 
hydrochloride (MEPH‐d3), dihydro-mephedrone‐d3 hydrochloride (DHM‐d3), 
4-(2-aminoethyl) benzoic acid hydrochloride (AEBA), nor‐mephedrone hydrochloride 
(NOR), hydroxytolyl-mephedrone hydrochloride (HYDROXY), 4-carboxy-mephedrone 
hydrochloride (4-CARBOXY) and dihydro‐nor‐mephedrone (DHNM). 
 
All analytes were individually diluted in 0.3% formic acid (FA) in acetonitrile:water 
(50:50 v/v) to yield 10 ng/mL solutions. These solutions were infused and the method 
was optimised to give the following conditions: the source temperature was set to 
150°C, desolvation gas flow rate was 1000 L/h at a temperature of 500°C, capillary 
voltage was set to 2.22 kV, cone voltage was 45 V, source offset was 84 V, cone gas flow 
rate was set to 150 L/h, the nebulizer gas flow was 7.00 bar and the collision gas flow 
rate was 0.25 mL/min. 
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In addition, product ion scans were performed and collision energies (CE) optimised to 
yield the most abundant product ions (1 quantifier and 2 qualifier ions). These were then 
used to create two selected reaction monitoring (SRM) methods: one for the intact ions 
and the other one for the ions that gave water losses. Both SRM methods were 
compared in terms of generated peak intensities. Even though the SRM method based 
on the m/z values that included the in-source water loss generated less fragmentation 
(because of the lower m/z), it produced higher signal intensity and was therefore chosen 
as a preferred SRM method.  
 
SRM used to monitor analytes and internal standards are listed in Table 2-4. In addition 
to MEPH-d3 and DHM-d3, AEBA was used as an internal standard for 4-CARBOXY (whole 
blood only) to help minimise matrix effects. 
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Table 2-4. SRM transitions and CE for each ion 
* denotes a quantifying transition 












MEPH-d3 163.4 ** 148.4 19 




DHM-d3 165.4 ** 150.3 18 
















AEBA 166.1 149.1 10 
 
 
2.4.3 Synthesis of dihydro-nor-mephedrone 
DHNM, one of MEPH metabolites, was not commercially available at the time of this 
research. NOR was therefore used as a starting material for the synthesis of DHNM 
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(Figure 2-1). Ten milligrams of NOR (61.3 µmol) was reduced to DHNM following a 
method described elsewhere 387. Synthesised product was stored at -40°C and a small 
amount was analysed by high resolution MS (HRMS) on ThermoFisher Scientific 
Q-Exactive operated in positive mode to determine its accurate mass. Proton nuclear 




Figure 2-1. Synthesis of dihydro-nor-mephedrone from nor-mephedrone 
 
 
DHNM was successfully synthesised (yield: 51%). Formula C10H16NO; HRMS [M+H+] 
calculated m/z 166.1226, observed 166.1227. Observed MS/MS fragments with collision 
energy 20 eV were consistent with those reported in the literature 74. 1H NMR (CDCl3) δ 
7.22 (d, J=8.0 Hz, 2H, Ar-H), 7.16 (d, J=8.0 Hz, 2H, Ar-H), 4.50 (d, J=4.0 Hz, 1H, CH(OH)), 
3.19 (s, 1H, CH(CH3)), 2.35 (s, 3H, Ar-CH3) and 0.98 (d, J=8.0 Hz, 3H, CH(CH3)). 
2.4.4 Solid phase extraction: whole blood, plasma, urine 
Because at the beginning of the project, MEPH and DHM were the only affordable and 
easily accessible reference standards, initial method development was limited to these 
two analytes. Other reference standards required custom synthesis and were received 
at different points in time. As a result, some method development experiments were 
initially not performed with all analytes. 
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2.4.4.1 General approach 
Because MEPH and its metabolites exhibit a wide range of physico-chemical properties 
(Table 2-5), XtrackT® DAU High Flow (150 mg, 3 mL) solid phase extraction (SPE) 
cartridges were chosen for sample preparation. XtrackT® cartridges contain C8 
hydrophobic chains and benzoylsulfonate anions facilitating mixed mode 
reverse-phase/cation exchange, which allows simultaneous retention of non-polar and 
polar analytes. 
 
Table 2-5. pKa and logP values generated by the Marvin software (version 17.16.0) for 
mephedrone and its metabolites  
Analyte pKa logP 
MEPH 8.03 2.12 
DHM 9.55 1.83 
NOR 7.57 1.69 
HYDROXY 8.01 0.84 
4-CARBOXY 3.64 (acid), 8.03 (amine) -1.20 
DHNM 9.39 1.40 
 
 
The use of mixed mode SPE for an extraction of a wide range of drugs is a 
well-established approach in analytical toxicology 388. The stationary phase is firstly 
conditioned with methanol and equilibrated with phosphate buffer(aq) pH 6.0. After 
sample loading step, water is added to remove polar interferences which is followed by 
the addition of diluted acetic acid(aq), pH 3.3 to ionise basic functional groups. At this 
point basic analytes are ‘locked’, interacting with hydrophobic C8 chains and 
benzoylsulfonate anions, as shown in Figure 2-2. Methanol wash can also be employed 
at this stage to remove neutral matrix components. Samples are then dried to remove 
residual aqueous solution and analytes are eluted. Acidic and neutral analytes are 
usually eluted with an organic solvent which disrupts hydrophobic interactions whereas 
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basic analytes are eluted with an organic solvent containing ammonium ions which 
disrupt ionic interactions. If required, neutral and basic analytes can be eluted at the 







Figure 2-2. Ionic and hydrophobic interactions 
between protonated mephedrone and a mixed 
mode sorbent in the ‘acid-lock’ step  
 
2.4.4.2 Water wash step 
SPE optimisation began with a variation of the general mixed-mode SPE extraction 
described in 2.4.4.1. Whole blood samples prepared at 500 pg/mL were vortex mixed 
and 1 mL of 0.1 M phosphate buffer, pH 6.0 was added. After conditioning XtrackT® 
cartridges with 2 mL of methanol and 2 mL of 0.1 M phosphate buffer (pH 6.0), samples 
were loaded and washed with 2 mL of 0.1 M acetic acid(aq) followed by 2 mL of water 
and 2 mL of methanol. Samples were finally eluted with 4 x 1 mL of dichloromethane 
(DCM) : propanol (IPA) : ammonium hydroxide (78:20:2 v/v/v). 
 
Figure 2-3. Chemical structure of 4-CARBOXY 
and its pKa values 
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It was noted that compared to other analytes, 4-CABROXY resulted in poor recovery 
(14.5 ± 9.96%). 4‐CARBOXY is a zwitterionic compound (see Figure 2-3) which contains 
an acidic carboxylic acid group and a basic secondary amine group. As shown in Table 
2-5, the secondary amine has a pKa of 8.03 and the carboxylic acid has a pKa of 3.64. At 
the sample load stage (pH 6.0) both functional groups are ionised and so the compound 
exists as a zwitterion with a net neutral charge, being retained by the π-π interactions 
between the benzene ring on 4-CARBOXY and hydrophobic carbon chains of the sorbent. 
It was hypothesised that the first SPE wash, which was the addition of 2 mL of water, 
washed the analyte off the sorbent. The removal of the water wash has not significantly 
affected the recoveries of other analytes, but the recovery of 4-CARBOXY more than 
doubled albeit still remained relatively low compared to other analytes (Table 2-6). This 
may be because only about 80% of the carboxylic acid group is protonated upon the 
addition of diluted acetic acid (pH 2.9) during the second wash step in SPE. As a result, 
the remaining 20% of the molecules, which exist as a neutral zwitterion with no net 
charge, are removed following a methanol wash. The methanol wash disrupts the 
hydrophobic interaction of the ‘net neutral’ 4-CARBOXY with the hydrophobic carbon 
chains, causing a considerable proportion to be lost. The other analytes are all basic and 
as cations ionically interact with the benzoylsulfonate anion within the mixed mode 
stationary phase during the methanol wash, which results in higher recovery. As a result 
of this experiment, water wash step was excluded from the final SPE method. 
 
Table 2-6. Analyte recovery ± %CV under different SPE conditions 
SPE condition MEPH DHM 4-CARBOXY 
With water wash 88.9 ± 8.27% 89.5 ± 5.76% 14.5 ± 9.96% 
Without water wash 84.7 ± 0.171% 83.8 ± 1.90% 34.0 ± 2.00% 
 
2.4.4.3 Protein precipitation before solid phase extraction 
As described in 1.3.1, sample treatment is performed to remove proteins, salts or other 
matrix components which could not only act as chromatographic interferences or 
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precipitate out in a LC system causing blockages but could also form drug-protein 
complexes making total drug quantification inaccurate. Besides sample centrifugation 
and filtration, protein precipitation with organic solvents is the most widely used 
technique. An organic solvent, such as acetonitrile (ACN), displaces water molecules 
from the hydrophobic regions on the protein surface, thus decreasing its solvation layer. 
Increased electrostatic and dipole forces cause proteins to aggregate and precipitate out 
of the solution 389. For the protein precipitation experiment, 400 µL of ACN was added 
to 100 µL whole blood samples prepared at 500 pg/mL. Samples were then mixed for 
10 min at 1400 rpm and centrifuged at 13,200 g for 5 min. The supernatant was 
transferred to a clean tube and the solvent was evaporated at 45ᵒC in an Eppendorf 
Concentrator Plus®. Following the addition of 1 mL of 0.1 M phosphate buffer (pH 6.0) 
samples were taken through the SPE as described in 2.4.4.2.  
 
Table 2-7 compares the effect of sample treatment with the ACN (n=3) and without 
(n=3). Higher recoveries and better precision were observed for all analytes following 
the extraction procedure which did not involve protein precipitation (PPT). The extent 
of mephedrone (and its metabolites) binding to plasma proteins has not been 
determined in humans but mephedrone-protein binding has been shown to be 21.6 ± 
3.67% in Sprague-Dawley rats 92. If similar extent of protein binding occurs in humans, 
protein precipitation should in theory disrupt analyte-protein binding, leading to better 
recoveries. This was not the case here, which might suggest that the analytes are lost in 
the precipitate or other factors are at play. 
 
 
Table 2-7. Analyte recovery ± %CV following sample treatment with a protein precipitation 
solvent (n=3) and without (n=3) 
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2.4.5 Solid phase extraction: oral fluid 
Method validation and oral fluid sample analysis was carried out at Abbott (previously 
Alere Toxicology). Their in-house validated method for the detection of stimulant drugs 
(including mephedrone) was followed during sample analysis which meant that method 
development was not necessary. Extraction and instrumental details are detailed in 
Section 6.2.3 in Chapter 6. 
2.4.6 Chiral separation in whole blood 
Enantiomers usually differ in their biochemical activity, which may result in one 
enantiomer being biologically active while the other one is inactive or may even produce 
different/adverse effects. Enantiomers are commonly separated by chiral 
chromatography with the use of chiral stationary phases or mobile phase additives 390. 
However, chiral method development is time consuming whereas chiral columns are 
expensive and lose their resolving power over time 391. A different approach relies on 
reacting enantiomers with an optically pure reagent to form diastereoisomers. Unlike 
enantiomers, diastereoisomers have different chemical and physical properties which 
means that they can be separated on achiral stationary phases. 
 
In addition to the techniques described above, circular dichroism (CD) spectroscopy is 
often used to distinguish enantiomers based on their differential absorption of left- and 
right-handed circularly polarised light 391. An optically pure compound will rotate 
polarised light which results in a signal in the CD spectrum. The signal shows the extent 
to which the polarised light is rotated after passing through the sample 390, with a pair 
of enantiomers resulting in a mirrored CD spectrum. 
2.4.6.1 Supercritical fluid chromatography 
Supercritical fluid chromatography (SFC) uses a supercritical fluid, which can be any 
substance as long as it is heated above its critical temperature and compressed above 
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its critical pressure. Due to low critical pressure (73 atm) and critical temperature (31°C), 
low cost and low toxicity, carbon dioxide (CO2) is the most commonly used for this 
purpose 392. Because CO2 on its own is not polar enough to elute certain analytes, 
organic modifiers (such as methanol and acetonitrile) are often added to increase the 
polarity of the mobile phase, and thus to improve solubility of polar analytes. In addition, 
acidic or basic modifiers such as, dimethylamine, formic acid or trifluoroacetic acid can 
also be added to improve retention time and resolution. Even though the use of the 
additives and modifiers may extend the application of SFC, it is important to carefully 
consider the compatibility of additives with the detector and their potential impact on 
ionisation efficiency 393. SFC is predominantly coupled to MS but other detection 
methods include ultraviolet-visible spectroscopy, ultraviolet-visible spectrophotometry 
and flame ionization detector. 
 
Higher flow rates made possible by lower system pressure exerted by the supercritical 
fluid and optional additives deliver a fast and efficient separation without losses in 
resolution or efficiency 394. It has been shown that SFC provides at least two times faster 
separation than normal phase LC 395,396, which is one of the reasons why it has been used 
in pharmaceutical industry and drug discovery for the separation of racemic mixtures on 
chiral columns. Moreover, fraction collection with SFC does not require long drying 
times because CO2 evaporates quickly leaving behind analyte(s) and a small volume of 
organic additive. On the other hand, limited choice of mobile phases, reliance on bulky 
CO2 cylinders and unwanted reactions with the mobile phase may become problematic. 
 
The aim of this part of the project was to develop a method that would separate 
enantiomers of mephedrone and some of its metabolites. SFC coupled to diode array 
detection (DAD) was initially employed for this task. A selection of chiral columns (see 
Table 2-8) was screened with mobile phases containing trifluoroacetic acid (TFA) and 
isopropylamine as additives as well as propanol (IPA) or methanol (MeOH) as modifiers. 
In addition, run times, flow rates and mobile phase composition were varied and tested. 
As (S) and (R) enantiomers of mephedrone were not commercially available, pure 
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enantiomers of mephedrone analogues (cathinone and methcathinone) were run 
alongside mephedrone to indicate likely elution order of mephedrone enantiomers. 
 
Table 2-8. A list of chiral columns screened on SFC-DAD 





150 mm x 2 mm i.d., 3 µm 
DAICEL CHIRALPAK OD-3 
150 mm x 3 mm i.d., 3 µm 
 
DAICEL CHIRALPAK AD-3 
150 mm x 3 mm i.d., 3 µm 
 
DAICEL CHIRALPAK AS-3 
150 mm x 2.1 mm i.d., 3 µm 
 
 
After an extensive evaluation, only CHIRALPAK OD-3 column with 0.1% TFA and 0.1% 
isopropylamine in IPA as organic modifiers/additives separated mephedrone 
enantiomers in a 20 min run time (see Figure 2-4). During the isocratic run CO2 was kept 
at 97.5%, column temperature was 40ᵒC and the flow rate was 1 mL/min. Mobile phase 
prepared with only TFA or isopropylamine did not result in a separation which is in 
agreement with previous research where the combination of both additives was 
reported to give broader enantioselectivity of acidic, basic and neutral compounds 397. 
Basic amines, such as isopropylamine, mask the effects of the charged silanol groups 
which often result in a poor peak shape and low resolution when left available for 
non-specific retention of basic compounds 394. In addition, basic amines also provide 
interaction with neutral chiral selectors by neutralising charged groups on basic analytes 
393. Acidic additives, such as TFA, protonate amino groups leading to increased 
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interactions with the carbamate groups on the stationary phase, thus improving 
enantioselectivity 397.   
 
 
Figure 2-4. Separated mephedrone enantiomers on the CHIRALPAK OD-3 column on SFC-DAD 
 
2.4.6.2 GC-MS method on an achiral column 
Even though a desired separation was achieved, the reliance of separation on 
isopropylamine and TFA made the method unsuitable for coupling with a MS detector. 
TFA is a known ion-paring agent lingering in the LC-MS system and contributing to high 
background noise and signal suppression 398. In addition, isopropylamine has been 
previously reported to have negative impact on the MS detection 399. As a result, a new 
strategy of mephedrone derivatisaion with two enantiomerically pure chiral 
derivatisation reagents: (S)-(−)-N-(Trifluoroacetyl) pyrrolidine-2-carbonyl chloride 
(L-TPC) and (R)-(−)-α-Methoxy-α-(trifluoromethyl) phenylacetyl chloride (MTPA) to 
produce diastereoisomers of mephedrone (Figure 2-5) was investigated. 
Diastereoisomers have different chemical and physical properties and can be separated 
on achiral stationary phases.  
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Derivatisation was performed following a method described in the literature 400. One 
hundred microliters of 50 µg/mL solution of mephedrone prepared in water was 
aliquoted into a vial together with 125 µL of saturated aqueous solution of potassium 
carbonate, 1.5 mL of ethyl acetate and 12.5 µL of L-TPC or MTPA. Samples were stirred 
for 10 min at room temperature. The upper layer was transferred into a new vial and 
dried with anhydrous sodium sulfate. A small aliquot was then injected onto GC-MS 
following a method published before 401.  
 
As shown in Figure 2-6, diastereoisomers formed by both derivatisation reagents (L-TPC 
and MTPA) were separated on GC-MS, but different peak height ratios were observed. 
Diastereoisomers of L-TPC-mephedrone produced a ratio of about 2:1 (different to the 
separation achieved on SFC-DAD) whereas diastereoisomers of MTPA-mephedrone 
resulted in a more equal ratio of nearly 1:1. L-TPC is a commonly used derivatisation 
reagents for analytes containing a primary or secondary amine group. However, it has 
been reported to undergo racemisation due to keto-enol tautomerism of the α-proton 
on the chiral carbon and the carbonyl group 400. In contrast, MTPA does not have an 
α-proton on the chiral carbon and should therefore be more stable and produce more 
reliable peak height/area ratios 402, which in this case were similar to the 




Figure 2-5. L-TPC-mephedrone (left) and MTPA-mephedrone (right) 
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2.4.6.3 LC-MS method on an achiral column 
Because several methods aimed at quantification or detection of the enantiomers of 
synthetic cathinones by GC-MS had been published, it was recognised that a novel 
aspect with regards to this project would have to focus on the quantification of 
mephedrone enantiomers on a chiral column on a LC-MS system. Derivatisation 
products described in 2.4.6.2 were infused on a Waters Xevo TQ-S triple quadrupole and 
Figure 2-6. Separation of diastereoisomers of mephedrone on GC-MS after derivatisation with 
MTPA (bottom) and L-TPC (top) 
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SRM transitions were created. Following LC optimisation, L-TPC-mephedrone was 
partially separated on a UCT Selectra DA® column, but a 3:1 peak height ratio was 
observed. No separation was achieved for MTPA-mephedrone.  
 
A different chiral derivatisation reagent, N-(2,4-dinitro-5-fluorophenyl) L-valinamide 
(DNPV), was found to have been previously reported to aid stereoselective detection of 
MDMA enantiomers as well as its Phase I and Phase II metabolites 403. As a final effort 
20 µg/mL of mephedrone alongside 20 µg/mL of MDMA (which served as a positive 
control) were derivatised with 100 µL of DNPV (0.3% in acetone w/v) in the presence of 
100 µL of 0.1 M carbonate buffer (pH 9.0). After 30 min of mixing at 50ᵒC at 1200 rpm, 
the reaction was stopped by adding 20 µL of 1 M HCl(aq). Samples were diluted with the 
mobile phase and were infused. DNPV-mephedrone was not detected, demonstrating 
unsuccessful derivatisation. It was speculated that DNPV was unable to react with the 
secondary amine on mephedrone due to steric hinderance caused by the ketone group, 
which is not present in MDMA (see Figure 2-7). DNPV-MDMA produced a strong signal 
at m/z 474 which was in agreement with the literature 403.    
 
 
Figure 2-7. DNPV-MDMA (left) and a proposed structure of DNPV-mephedrone (right) 
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2.4.6.4 HPLC-DAD method on a chiral column 
At this stage the literature was reviewed, and a decision was made to screen chiral 
columns on a HPLC-DAD system. An instruction manual for CHIRALPAK AD columns 
suggested using MeOH:ethanol (50:50 v/v) as a mobile phase in an isocratic elution 
mode and a basic modifier, for example diethylamine (DEA). These conditions gave a 
partial separation of mephedrone and NOR enantiomers which were eventually fully 
resolved by changing the ratio of the alcohols to MeOH:ethanol (80:20 v/v, see Figure 
2-8). MEPH-d3 was also successfully separated under these conditions (data not shown). 




Figure 2-8. Separation of mephedrone (black) and NOR (red) enantiomers on the CHIRALPAK 
AD-3 column with 0.1% DEA in MeOH:ethanol (80:20 v/v) as mobile phase on HPLC-DAD 
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2.4.6.5 Determination of the elution order 
With the enantiomeric separation achieved on the LC-MS system, the remaining task 
was to determine the elution order of mephedrone enantiomers (the elution order of 
NOR enantiomers was not investigated because the method was not sensitive enough 
to detect NOR in whole blood samples from the administration study). Mephedrone 
enantiomers were separated on a semi-preparative column (Lux® 5 µm Amylose-1, 250 
x 10 mm), which is equivalent to CHIRALPAK AD-3, on Agilent HPLC 1050 system 
equipped with a manual injector coupled to DAD. Two injections of the mephedrone 
solution prepared at 5 mg/mL were performed and are referred to here as F1 and F2. 
Manually collected fractions were diluted 1 in 10 in the mobile phase and injected on 
the CHIRALPAK AD-3 column. This was done to select fractions containing only one pure 
enantiomer. Only the second eluting peak/enantiomer was isolated in pure form and 
brought forward for further characterisation. Pure fractions were dried overnight, 
dissolved in MeOH and combined. 
 
CD spectra were acquired on the Applied Photophysics Chirascan Plus spectrometer 
(Leatherhead, UK). One millimetre (Hellma UK) Quartz Suprasil rectangular cells were 
used in the region of 450-180 nm. The instrument was flushed continuously with pure 
evaporated nitrogen throughout the experiment. The following parameters were 
employed: 2 nm spectral bandwidth, 1 nm stepsize and 1.0 s accumulation time per 
point. The CD spectra were solvent baseline corrected and measured at +23ᵒC. The CD 
spectra were smoothed using the Savitzky-Golay method for better presentation. Data 
processing was done using APL Prodata Viewer (version 4.2.15) and spectra were 
modified in Origin (version 6.0). 
 
Alongside collected fractions (F1 at 1 mg/mL and F2 at 0.5 mg/mL), 1 mg/mL solutions 
of (R)-methcathinone and (S)-methcathinone were also analysed. Methcathinone differs 
from mephedrone by the absence of a methyl group on the benzene ring. Because the 
rest of the structure, including the chemical environment surrounding the chiral centre, 
Chapter 2 | Administration study, method development and validation 
 
Page | 136 
 
is identical, CD spectra of F1 and F2 should reveal the correct mephedrone enantiomer 
based on the reference CD spectra obtained by analysing methcathinone enantiomers.  
 
Figure 2-9 shows the CD spectrum of (S)-methcathinone and (R)-methcathinone, clearly 
demonstrating their enantiomeric nature. Compared to the spectrum in Figure 2-9, it 
can be observed that F1 and F2 (containing the second eluting peak in the chiral LC 
method) in Figure 2-10 correspond to the (S)-enantiomer with the CD spectrum 
transitioning from negative to positive CD values. This means that the first eluting peak 
in Figure 2-8 can be attributed to (R)-mephedrone and the second eluting peak is 
(S)-mephedrone. Of note, racemic mephedrone did not yield any significant peak due to 




Figure 2-9. CD spectrum of (S)-methcathinone 
(black) and (R)-methcathinone (red) 
Figure 2-10. CD spectrum of racemic 
mephedrone (black), F1 (red) and F2 (green) 
 
2.4.7 Dried blood spots 
2.4.7.1 Recovery with different extraction solvents 
Ten microliter Mitra® devices were dipped in either drug-free whole blood or in whole 
blood spiked with all analytes at 10 ng/mL. Mitra® devices were left to dry at room 
temperature for 2 h. Tips were then transferred into clean Eppendorf tubes and a range 
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of extraction solvents was tested: MeOH, ACN, ACN:H2O (50:50 v/v), 1% ammonium 
hydroxide in MeOH:ethyl acetate (50:50 v/v, MeOH:EtOAc), 1% NH4OH in ACN:H2O 
(50:50 v/v), ACN:H2O (70:30 v/v), 0.3% FA in MeOH, MeOH:2% zinc sulphate (ZnSO4), 8% 
ZnSO4(aq) and saturated ZnSO4(aq). Samples were sonicated for 15 min at 35kHz and 
vortex mixed for 5 min at 1300 rpm. Solvent was then transferred to a new Eppendorf 
tube, leaving the tip behind, and was evaporated under vacuum at 45°C in an Eppendorf 
Concentrator Plus®. Spiked whole blood samples were reconstituted with 100 µL of 0.1% 
FA in ACN:H2O (10:90 v/v) whereas drug-free whole blood samples were reconstituted 
with 100 µL of a solution containing all analytes prepared in 0.1% FA in ACN:H2O (10:90 
v/v). 
 
Based on the results presented in Figure 2-11 and Figure 2-12, 0.3% FA in MeOH gave 
the best recovery for all analytes, except MEPH which had better recovery in pure 
MeOH. In contrast, ACN gave the lowest recoveries for all analytes, with 4-CARBOXY not 
being detected in these samples at all. Zinc sulphate-based solvents extracted no more 


































Recovery after extraction with organic solvents
MEPH DHM NOR HYDROXY 4-CARBOXY DHNM
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Figure 2-12. Recovery ± %CV for each analyte after an extraction with two zinc sulphate-based 
solvents (n=3) 
 
2.4.7.2 Drying time 
The method described in 2.4.7.1 was followed (with 0.3% FA in MeOH used as the 
extraction solvent) but Mitra® devices were left to dry at room temperature for 60 min, 
90 min, 2 h, 2 h 30 min and 3 h. As shown in Figure 2-13, 2 h drying time at room 
temperature was optimal for all analytes, except for MEPH which had better recovery 
after 1 h of drying. The mean recovery after 2 h was 45.0 ± 0.1% for MEPH, 75.5 ± 2.4% 
for DHM, 57.3 ± 4.5% for NOR, 66.6 ± 5.3% for HYDROXY, 56.6 ± 7.9% for 4-CARBOXY 


















Recovery after extraction with zinc sulphate-based 
solvents
MEPH DHM NOR HYDROXY 4-CARBOXY DHNM
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Figure 2-13. Analyte recovery ± %CV from Mitra® devices after varying drying times (n=3) 
 
2.4.8 Fingerprint sweat 
2.4.8.1 Recovery with different extraction solvent 
Each finger was cleaned using an ethanol wipe and allowed to dry. A fingerprint was 
then deposited onto a clean circular cover slip (15 mm in diameter). Aliquots, 2 x 50 µL, 
of MEPH and DHM prepared in MeOH at 500 pg/mL were deposited onto the cover slips. 
A set of cover slips with deposited fingerprints but no analytes was also prepared. Once 
the solvent has evaporated, cover slips were transferred into 20 mL scintillation vials. 
Three hundred microliters of different extraction solvents of ranging polarities and 
varying pH were added to the scintillation vials. Tested solvents included ACN, MeOH, 
DCM, DCM:MeOH (50:50 v/v), DCM:MeOH (40:10 v/v), ethyl acetate, ACN:Water 
(50:50 v/v), 100 mM ammonium hydroxide:IPA (10:40 v/v), MeOH:Water (50:50 v/v), 
0.2% FA in MeOH:Water (50:50 v/v), 0.2% FA in ACN:Water (50:50 v/v) and 0.2% FA in 
ACN:Water with varying ratios of organic to aqueous solvents. Scintillation vials were 
then capped and sonicated in a water bath for 7 min at 35 kHz. Extracts were transferred 



















Recovery after different drying times
MEPH DHM NOR HYDROXY 4-CARBOXY DHNM
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concentrator at 45˚C. Before analysis, extracts were reconstituted with either 100 µL of 
0.3% FA(aq) or 100 µL of a solution containing all analytes prepared in 0.3% FA(aq). 
 
From the initial screen of 11 different extraction solvents (n=3), 0.2% FA in ACN:Water 
(1:1 v/v) gave the best recovery of 85.5 ± 0.3% for MEPH (Figure 2-14) and 96.5 ± 1.4% 
for DHM (Figure 2-15). 
 
 
Figure 2-14. Extraction solvents giving more than 50% recovery ± %CV for MEPH from 
fingerprint sweat deposited on glass cover slips (n=3) 
 
 
Figure 2-15. Extraction solvents giving more than 50% recovery ± %CV for DHM from 










Mephedrone recovery from fingerprint sweat








Dihydro-mephedrone recovery from fingerprint sweat
(showing solvents giving > 70% recovery)
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Even though 0.2% FA in ACN:Water (1:1 v/v) gave the best recovery, its high water 
content resulted in an evaporation time of 3 h. This prompted the efforts to increase the 
ratio of the organic solvent which would decrease the evaporation time without 
impacting recovery. The following ACN:water ratios were investigated 90:10, 80:20, 
70:30, 60:40, 50:50, and results are presented in Figure 2-16. 
 
 
Figure 2-16. MEPH and DHM recovery ± %CV from fingerprint sweat with varying ACN:water 
ratios 
 
MEPH recovery was very similar across solvents with different ACN to water ratios but 
0.2% FA in ACN:Water (60:40 v/v) resulted in best recovery of 88.1 ± 4.8%. Recoveries 
for DHM were more variable but were greater than 89% for all tested solvents, with 
0.2% FA in ACN:Water (90:10 v/v) giving the best recovery of 96.6 ± 2.5%. As it was 
crucial to decrease the dry-down time, 0.2% FA in ACN:Water (90:10 v/v) was chosen as 
the best compromise due to its high recovery and fast evaporation time of 30 min at 
45°C. HYDROXY and NOR reference standards were received shortly after the 
completion of the recovery experiments. Their recoveries, investigated with the chosen 
extraction solvent, were 90.2 ± 1.9% for NOR and 68.7 ± 6.6% for HYDROXY. 
 
ACN is a relatively polar solvent due to the electronegative nitrogen atom that attracts 







0.2% FA in ACN:Water
(90:10)
0.2% FA in ACN:Water
(80:20)
0.2% FA in ACN:Water
(70:30)
0.2% FA in ACN:Water
(60:40)
0.2% FA in ACN:Water
(50:50)
Recovery of mephedrone and dihydro-mephedrone
Mephedrone Dihydro-mephedrone
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This means that there is a slightly negative charge on the nitrogen atom and a slightly 
positive charge on the carbon atom. The addition of formic acid to the extraction solvent 
changes the pH to approximately 2 which ensures that the primary amine on NOR and 
secondary amine on MEPH, DHM and HYDROXY are fully protonated (predicted pKa 
values for all are in range 7.57-9.55). The mixture of ACN and water (a polar solvent) 
attracts ionised analytes of interests, and thus extracts them from the fingerprint sweat. 
2.4.9 Head hair 
Due to time constraints, an extraction method developed and validated for 
amphetamines and synthetic cathinones in head hair published on the LCGC website 
was followed 404. 
 Validation procedures 
Method validation, which was performed in all biological matrices, investigated the 
following: selectivity, linearity, inter‐ and intra‐day precision and accuracy, limit of 
detection (LOD) and limit of quantification (LOQ), recovery, matrix effect, carryover, 
dilution integrity and stability according to the Food and Drug Administration (FDA) 405 
validation guidelines and recommendations published by Peters et al 406. 
2.5.1 Selectivity 
Selectivity was assessed by analysing six blank matrix samples collected from drug‐free 
female (n=3) and male (n=3) donors. 
2.5.2 Linearity 
Matrix‐matched calibration curve was prepared by spiking drug‐free matrix with 
appropriate working solutions containing mephedrone and its metabolites. Each 
calibration standard was required to be within ± 15% of its target concentration, except 
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at the lowest level of quantification (LLOQ) where ± 20% variation was allowed. The 
upper level of quantification (ULOQ) was defined as the highest concentration of the 
calibration standard. The correlation coefficient (r2) of the curve had to be at least 0.990. 
A linear regression model with a weighting of 1/x was applied to all calibration curves. 
2.5.3 LOD and LOQ 
The LOD for each analyte in a matrix was defined as the lowest concentration where all 
three ions (two qualifiers and one quantifier) were present with a signal-to-noise ratio 
(S/N) equal to or greater than 3. The LOQ was defined as the lowest concentration at 
which analytes could be quantified with an acceptable precision and accuracy. The 
ULOQ was determined as the highest concentration of the calibration curve, which could 
be determined with an acceptable accuracy and precision without saturating the signal. 
2.5.4 Precision and accuracy 
Intra‐day (n=6) and inter‐day (n=3) precision and accuracy was determined by 
employing quality control (QC) samples spiked at low (Low), medium (Med), and high 
(High) concentrations. Intra‐day precision was calculated using six replicates obtained 
on the same day which were expressed as a coefficient of variation (%CV). Accuracy was 
calculated by dividing the mean measured concentration at each QC level by the 
theoretical spiked concentration and was expressed as a percentage of the theoretical 
spiked concentration. Inter‐day precision was evaluated for each QC level on three 
different days and expressed as %CV. According to the validation guidelines the mean 
value should be within 15% of the true value, except for the LLOQ where it should be 
within 20% of the true value. 
2.5.5 Recovery and matrix effect 
For recovery, blank matrix samples (n=6) were spiked at QC Low and QC High level and 
were taken through extraction. In parallel, a set of blank matrix samples (n=6) was 
Chapter 2 | Administration study, method development and validation 
 
Page | 144 
 
extracted and spiked after the evaporation step at the QC Low and QC High level. 
Recovery was expressed as a percentage by comparing the absolute peak areas of the 
samples spiked before extraction with samples spiked after extraction. 
 
For the IS‐corrected matrix effect, a set of blank matrix samples (n=6 from three female 
and three male donors) and a set of samples without matrix (n=6) was taken through 
extraction. All samples were reconstituted with a solution containing known amounts of 
the internal standard (IS) and analytes at QC Low and QC High levels. Matrix effect was 
evaluated by comparing peak area ratios in blank matrix samples spiked after extraction 
with peak area ratios in samples without matrix spiked after extraction. 
2.5.6 Carryover 
Carryover was assessed by injecting matrix blanks after the highest calibration standard. 
According to the validation guidelines, carryover should not exceed 20% of the LLOQ. 
2.5.7 Dilution integrity 
Highly concentrated samples falling outside the calibration range were diluted (see 
2.6.1-2.6.8 for dilution details). Dilution integrity was assessed by preparing QC dilutions 
at an appropriate concentration and in an appropriate matrix outside the calibration 
range and diluting them into the calibration range (n=6). Precision and accuracy were 
required to be within ± 15% of the target concentration.  
 
During sample analysis, QC dilutions (n=3) were prepared as described above and 
extracted alongside diluted samples. 
2.5.8 Stability 
Short-term and long-term stability as well as stability after a series of freeze-thaw cycles 
was assessed at QC Low and QC High levels. Samples were prepared in drug‐free human 
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matrix and depending on the method they were stored at different conditions and for 
different durations of time (see 2.6.1-2.6.8 for more details). At each sampling point, 
one tube at each QC level was removed from storage and six aliquots were extracted 
alongside freshly prepared QCs. Freezer and fridge temperatures were monitored and 
logged daily. 
 Validation results 
2.6.1 Whole blood (achiral method) 
A method for detection and quantification of MEPH and five of its Phase I metabolites 
was validated in human whole blood (NaF/KOx). Validation results have been recently 
published 125 but they are also summarised below. 
2.6.1.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
2.6.1.2 Linearity 
Mean linearity of r2 > 0.998 was achieved for each analyte in all three validation runs. 
2.6.1.3 LOD and LOQ 
LOD and LOQ of 50 pg/mL and 200 pg/mL, respectively, was achieved for all analytes 
except 4-CARBOXY for which LOD was 500 pg/mL and LOQ was 2000 pg/mL, 
respectively. Table 2-9 shows calibration parameters for all analytes. 
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Table 2-9. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 










Slope ± SD 
(n=3) 
r2 ± SD 
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2.6.1.4 Precision and accuracy 
Intra-day and inter-day precision and accuracy results, summarised in Table 2-10, were 
found to be within the acceptable limits. The intra-day inaccuracy for all metabolites 
was within ± 15% of the target concentration while accuracy ranged from 96.7-106% for 
MEPH, 91.1-109% for DHM, 89.7-97.0% for NOR, 94.3-115% for HYDROXY, 97.0-114% 
for 4-CARBOXY and 86.6-103% for DHNM. The intra-day imprecision was ≤ 7% and 
ranged from 1.44-4.33% for MEPH, 0.924-4.65% for DHM, 1.58-4.87% for NOR, 
1.55-6.57% for HYDROXY, 1.36-5.97% for 4-CARBOXY, 1.52-5.13% for DHNM. Inter-day 
precision and accuracy results were acceptable over the validated range with 
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Table 2-10. Precision and accuracy at QC Low, QC Med and QC High for all analytes in human 
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2.6.1.5 Recovery and matrix effect 
Recovery was found to be greater than 71.3% for all analytes, except for 4-CARBOXY for 
which recovery was 32.5 ± 6.8% at QC Low and 41.6 ± 0.5% at QC High. Reasons for such 
low recovery are explained in 0. Even though it is recommended for recovery to be 
greater than 50% 406, desired sensitivity as well as acceptable precision and accuracy 
were achieved for 4-CARBOXY (Table 2-10). 
 
IS-corrected matrix effect values were within ± 17% at both QC levels, except for 
HYDROXY at QC High which was suppressed by 29% (Table 2-11). This may be due to the 
lack of matching deuterated IS which is currently not commercially available. However, 
assay precision and accuracy for HYDROXY at QC High were within the acceptance 
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Table 2-11. Analyte recovery and matrix effect at QC Low and QC High in human whole blood 
(NaF/KOx) 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
QC LOW QC HIGH QC LOW QC HIGH 
MEPH 85.2% (1.84%) 88.3% (3.17%) 101% (8.16%) 99.0% (1.12%) 
DHM 83.6% (9.97%) 84.2% (2.70%) 105% (2.87%) 98.7% (0.792%) 
NOR 74.3% (3.78%) 76.6% (3.31%) 89.6% (5.89%) 91.7 % (3.25%) 
HYDROXY 71.3% (4.12%) 81.4% (2.62%) 83.8% (2.58%) 71.0% (6.00%) 
4-CARBOXY 32.5% (6.79%) 41.6% (0.522%) 103% (6.49%) 108% (5.99%) 
DHNM 78.6% (5.70%) 79.0% (5.41%) 93.0% (4.66%) 87.4% (4.94%) 
 
2.6.1.6 Carryover 
Carryover was not observed. 
2.6.1.7 Dilution integrity 
Dilution integrity was assessed for whole blood samples and is presented in Table 2-12. 
All analytes showed acceptable precision and accuracy following 1 in 20 dilution in whole 
blood (NaF/KOx). %CV ranged from 5.45% to 7.98% and accuracy was within ± 15% of 
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Table 2-12. Dilution integrity (1 in 20) for MEPH and its metabolites in human whole blood 
(NaF/KOx) 
Analyte 





%CV % accuracy 
MEPH 1 1.01 5.47% 101% 
DHM 1 0.983 5.63% 98.3% 
NOR 1 0.890 5.86% 89.0% 
HYDROXY 2 1.76 5.45% 87.9% 
4-CARBOXY 10 11.5 7.53% 115% 
DHNM 1 0.957 7.98% 95.7% 
 
2.6.1.8 Stability 
Stability was assessed after storage at +4ᵒC and -20ᵒC for 24 h 48 h, 4 days and 10 days. 
The results have been recently published (see Appendix C) 125 and are graphically 
summarised in Figure 2-17 - Figure 2-20. Analytes were considered unstable when they 
lost more than 10% of their initial concentration. 
 
At +4°C at QC Low, DHM and DHNM were stable over the 10-day period while HYDROXY 
and MEPH lost 18.6 ± 5.2% and 23.4 ± 6.3%, respectively, of their initial concentration. 
4-CARBOXY and NOR decreased in concentration by 48.1 ± 4.8% and 40.2 ± 6.7%, 
respectively, after 10 days (Figure 2-17). At QC High, DHM and DHNM were stable over 
the 10-day period while HYDROXY and MEPH lost 11.3 ± 3.2% and 14.2 ± 3.3%, 
respectively, of their initial concentration. 4-CARBOXY and NOR were most unstable and 
their concentration decreased by 44.6 ± 6.5% and 33.8 ± 4.2%, respectively, after 10 
days (Figure 2-18). 
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Figure 2-17. Analyte stability at QC Low in human whole blood (NaF/KOx) stored at +4°C 
 
 
Figure 2-18. Analyte stability at QC High in human whole blood (NaF/KOx) stored at +4°C 
 
 
At -20°C at QC Low, NOR and DHNM were most stable over the 10-day period while 
MEPH, 4-CARBOXY, HYDROXY and DHM lost 9.9 ± 2.4%, 9.6 ± 5.3%, 11.2 ± 4.8% and 12.0 
± 4.8%, respectively, of their initial concentration (Figure 2-19). At QC High, 4-CARBOXY 
was the most unstable and decreased in concentration by 22.6 ± 6.9% after 10 days. 
MEPH and DHM were stable over the 10-day period while DHNM, HYDROXY and NOR 
lost 7.6 ± 3.3%, 10.2 ± 2.2% and 6.6 ± 3.6%, respectively, of their initial concentration 
(Figure 2-20). 
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Figure 2-19. Analyte stability at QC Low in human whole blood (NaF/KOx) stored at -20°C 
 
 
Figure 2-20. Analyte stability at QC High in human whole blood (NaF/KOx) stored at -20°C 
 
 
Out of all metabolites, 4-CARBOXY was the most unstable at +4°C with significant losses 
observed already after 4 days (33.7 ± 6.1%) at QC Low and after 48 h (21.6 ± 4.3%) at QC 
High. Its stability was improved at -20°C where the highest loss of 22.6 ± 6.9% was 
observed after 10 days at QC High. NOR was much more stable at -20°C than 4°C where 
it lost 40.2 ± 6.7% at QC Low (versus no change at -20°C) and 33.8 ± 4.2% at QC High 
(versus 6.6 ± 3.6% at -20°C). HYDROXY was stable at -20°C but lost 18.6 ± 5.2% at +4°C 
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after 10 days at QC Low. DHM and DHNM remained stable at both storage conditions 
and concentration levels throughout the investigation with the latter showing a slight 
increase in its concentration after 10 days at +4°C at QC High. DHM and DHNM are the 
only two metabolites containing a hydroxyl group instead of a ketone at the β carbon 
which was previously reported to make ephedrines more stable than cathinones 121. 
2.6.2 Whole blood (chiral method) 
As mentioned in 0, the method was also able to separate NOR enantiomers in the same 
run. However, the assay (LOD of 15 ng/mL and LOQ of 60 ng/mL) was not sensitive 
enough to detect NOR enantiomers in whole blood samples from the administration 
study. As a result, method validation was only performed for (R)-mephedrone (R-MEPH) 
and (S)-mephedrone (S-MEPH). MEPH-d3 was used as the IS. 
2.6.2.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
2.6.2.2 Linearity 
Mean linearity of r2 > 0.999 was achieved for both enantiomers in all three validation 
runs. 
2.6.2.3 LOD and LOQ 
LOD of 2 ng/mL and LOQ of 8 ng/mL was achieved for both enantiomers. Table 2-13 
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Table 2-13. LOD, LOQ, calibration range and calibration parameters for R-MEPH and S-MEPH in 








Intercept ± SD 
(n=3) 
Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 
R-MEPH 2 8 8-200 9.60 ± 1.79 13.7 ± 0.9 
0.999 ± 
0.001 




2.6.2.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-14, were 
found to be within the acceptance criteria. The intra‐day inaccuracy for both 
enantiomers was within ± 12% of the target concentration while accuracy ranged from 
101-112% for R-MEPH and 101-110% for S-MEPH. The intra‐day imprecision was < 5.5% 
and ranged from 0.960-5.46% for R-MEPH and 1.13-4.70% for S-MEPH. Inter‐day 
precision and accuracy results were acceptable over the validated range with 
%CV ≤ 4.35% and inaccuracy within ± 10% of the target concentration. 
 
 
Table 2-14. Precision and accuracy at QC Low, QC Med and QC High for R-MEPH and S-MEPH in 
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2.6.2.5 Recovery and matrix effect 
As shown in Table 2-15, recovery for R-MEPH was found to be 82.4 ± 4.09% and 84.5 ± 
7.69% at QC Low and QC High, respectively. For S-MEPH, recovery of 71.3 ± 7.83% and 
85.9 ± 7.67% at QC Low and QC High, respectively, were reported. IS‐corrected matrix 
effect values were within ± 2.5% at both QC levels. 
 
Table 2-15. Analyte recovery and matrix effect for R-MEPH and S-MEPH at QC Low and QC High 
in human whole blood (NaF/KOx) 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
QC Low QC High QC Low QC High 
R-MEPH 82.4% (4.09%) 84.5% (7.69%) 102% (3.18%) 98.3% (1.81%) 
S-MEPH 71.3% (7.83%) 85.9% (7.67%) 102% (7.66%) 97.5% (5.20%) 
 
2.6.2.6 Carryover 
Carryover was not observed. 
2.6.2.7 Dilution integrity 
Dilution integrity was not investigated because with the ULOQ of 200 ng/mL samples 
were anticipated to fall within the calibration range. 
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2.6.2.8 Stability 
Stability was not assessed as samples were extracted immediately after collection. 
2.6.3 Plasma 
A method for detection and quantification of MEPH and five of its Phase I metabolites 
was validated in human plasma (NaF/KOx). 
2.6.3.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
2.6.3.2 Linearity 
Mean linearity of r2 > 0.996 was achieved for all analytes in all three validation runs. 
2.6.3.3 LOD and LOQ 
LOD of 25 pg/mL (LOQ of 100 pg/mL) for DHM, NOR and HYDROXY; 50 pg/mL (LOQ of 
200 pg/mL) for DHNM; and 100 pg/mL (LOQ of 400 pg/mL) for 4-CARBOXY and MEPH 
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Table 2-16. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 








Intercept ± SD 
(n=3) 
Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 

































2.6.3.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-17, were 
found to be within the acceptance criteria. The intra‐day inaccuracy was within ± 15% 
of the target concentration while accuracy ranged from 92.1-102% for MEPH, 97.2-106% 
for DHM, 89.6-101% for NOR, 85.5-104% for HYDROXY, 85.0-105% for 4-CARBOXY and 
87.1-99.2% for DHNM. The intra‐day precision was < 10.5% and ranged from 1.02-5.35% 
for MEPH, 1.10-1.90% for DHM, 0.690-5.28% for NOR, 1.44-8.28% for HYDROXY, 
1.06-10.4% for 4-CARBOXY and 1.60-4.65% for DHNM. Inter‐day precision and accuracy 
results were acceptable over the validated range with %CV < 10% and inaccuracy within 
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Table 2-17. Precision and accuracy at QC Low, QC Med and QC High for all analytes in human 
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2.6.3.5 Recovery and matrix effect 
As shown in Table 2-18, recovery was found to be greater than 68.0 ± 3.65% for all 
analytes, except 4‐CARBOXY for which recovery was 24.9 ± 6.50% at QC Low and 26.5 ± 
8.11% at QC High. Reasons for such low recovery are explained in 0. Even though it is 
recommended for recovery to be greater than 50% 406, desired sensitivity as well as 
acceptable precision and accuracy were achieved for 4‐CARBOXY (Table 2-17).  
 
IS-corrected matrix effect values were within ± 15% at both QC levels for all analytes, 
except for HYDROXY which was suppressed by 17.1 ± 4.33% at QC Low and by 15.7 ± 
4.57% at QC High. This may be due to the lack of matching deuterated IS which is 
currently not commercially available. However, assay precision and accuracy were 
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Table 2-18. Analyte recovery and matrix effect at QC Low and QC High in plasma (NaF/KOx) 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 83.9% (4.39%) 70.0% (2.14%) 92.9% (9.92%) 96.9% (1.33%) 
DHM 76.5% (1.84%) 69.8% (2.82%) 100% (3.72%) 101% (0.601%) 
NOR 68.5% (1.22%) 68.0% (3.65%) 92.1% (4.61%) 90.7% (1.13%) 
HYDROXY 69.8% (5.71%) 69.3% (7.34%) 82.9% (4.33%) 84.3% (4.57%) 
4-CARBOXY 24.9% (6.50%) 26.5% (8.11%) 95.1% (3.92%) 92.8% (4.07%) 
DHNM 73.8% (2.74%) 73.1% (4.28%) 98.6% (3.00%) 96.2% (1.14%) 
2.6.3.6 Carryover 
Carryover was not observed. 
2.6.3.7 Dilution integrity 
All analytes showed good precision and accuracy following 1 in 20 dilution in human 
plasma (NaF/KOx). As shown in Table 2-19, %CV ranged from 0.691-12.2% and 
inaccuracy was within ± 9.20% of the target concentration. 
 
Table 2-19. Dilution integrity (1 in 20) for MEPH and its metabolites in plasma (NaF/KOx) 
Analyte 





%CV % accuracy 
MEPH 
1.25 
1.16 2.91% 92.9% 
DHM 1.24 3.33% 98.9% 
NOR 1.14 2.82% 90.8% 
HYDROXY 1.24 2.00% 100% 
4-CARBOXY 1.20 12.2% 96.0% 
DHNM 1.20 0.691% 95.6% 
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2.6.3.8 Stability 
Long term stability of MEPH and its metabolites in human plasma (NaF/KOx) was 
assessed following storage for 105 days at -20°C at QC Low and QC High. As shown in 
Table 2-20, analytes did not lose more than 15% of the initial concentration under the 
investigated conditions, except for 4-CARBOXY which lost 21.2 ± 3.77% and 27.3 ± 5.65% 
at QC Low and QC High, respectively. 
 
In a separate experiment, stability samples were taken through 3 freeze-thaw (F/T) 
cycles from -20°C to room temperature (RT) to assess stability following sample thawing 
which may be required for sample re-analysis due to a failed batch or sample dilution. 
All analytes were stable following 3 F/T cycles, except for NOR which lost 18.6 ± 1.22% 
at QC High (Table 2-20). 
 
Table 2-20. Long term and freeze-thaw stability of MEPH and its metabolites in human plasma 
(NaF/KOx) following storage at -20°C 
Analyte 
Long term stability (%CV), n=6 F/T stability (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 88.1% (4.62%) 85.9% (1.98%) 101% (3.13%) 86.5% (2.06%) 
DHM 104% (2.40%) 100% (2.25%) 104% (2.82%) 101% (1.70%) 
NOR 102% (1.89%) 86.1% (1.85%) 97.5% (3.05%) 81.4% (1.22%) 
HYDROXY 96.9% (4.07%) 91.4% (4.85%) 96.9% (4.07%) 92.7% (1.96%) 
4-CARBOXY 78.8% (3.77%) 72.7% (5.65%) 89.0% (4.36%) 91.2% (3.34%) 
DHNM 99.2% (0.559%) 96.8% (1.55%) 97.8% (2.92%) 94.7% (2.72%) 
 
2.6.4 Urine 
A method for detection and quantification of MEPH and five of its Phase I metabolites 
was validated in human urine. 
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2.6.4.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
2.6.4.2 Linearity 
Mean linearity of r2 > 0.996 was achieved for all analytes in all three validation runs. 
2.6.4.3 LOD and LOQ 
LOD of 0.4 ng/mL (LOQ of 1.6 ng/mL) for MEPH, HYDROXY, 4-CARBOXY; 0.15 ng/mL (LOQ 
of 0.6 ng/mL) for DHM, NOR; and 0.08 ng/mL (LOQ of 0.6 ng/mL) for DHNM were 
achieved in this assay. Table 2-21 shows calibration parameters for all analytes. 
 
Table 2-21. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 










Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 
MEPH 0.4 1.6 1.6-50 0.353 ± 0.670 1.97 ± 0.04 
0.998 ± 
0.001 
DHM 0.15 0.6 0.6-50 -0.483 ± 0.363 13.8 ± 0.5 
1.00 ± 
0.00 
NOR 0.15 0.6 0.6-50 -0.407 ± 0.246 13.0 ± 1.0 
0.999 ± 
0.001 





0.4 1.6 1.6-50 -0.844 ± 0.871 4.81 ± 0.57 
0.996 ± 
0.001 
DHNM 0.08 0.6 0.6-50 -0.973 ± 0.214 16.2 ± 1.9 
0.999 ±  
0.000 
 
2.6.4.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-22, were 
found to be within the acceptance criteria. The intra‐day inaccuracy was within ± 11.3% 
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of the target concentration while accuracy ranged from 94.7-104% for MEPH, 98.5-107% 
for DHM, 90.8-102% for NOR, 89.7-104% for HYDROXY, 88.7-103% for 4-CARBOXY and 
94.3-102% for DHNM. The intra‐day imprecision was ≤ 9.39% and ranged from 
1.65-5.16% for MEPH, 1.44-6.61% for DHM, 0.978-4.18% for NOR, 1.89-5.23% for 
HYDROXY, 4.15-9.39% for 4-CARBOXY and 0.956-6.21% for DHNM. Inter‐day precision 
and accuracy results were acceptable over the validated range with %CV ≤ 7.63% and 
inaccuracy within ± 7.50% of the target concentration. 
 
 
Table 2-22. Precision and accuracy at QC Low, QC Med and QC High for all analytes in human 

























































































































40 38.6 40.0 40.1 1.23 
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2.6.4.5 Recovery and matrix effect 
As shown in Table 2-23, recovery was found to be greater than 74.7 ± 3.79% for all 
analytes, except 4‐CARBOXY for which recovery was 35.8 ± 7.18% at QC Low and 34.3 ± 
6.30% at QC High. Reasons for such low recovery are explained in 0. Even though it is 
recommended for recovery to be greater than 50% 406, desired sensitivity as well as 
acceptable precision and accuracy were achieved for 4‐CARBOXY (Table 2-22).  
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IS-corrected matrix effect values were within ± 20.6% at both QC levels, except for 
HYDROXY which was suppressed by 34.4 ± 7.37% at QC Low and by 32.6 ± 4.57% at QC 
High (Table 2-23). This may be due to the lack of matching deuterated IS which is 
currently not commercially available. However, assay precision and accuracy for 
HYDROXY at QC Low and QC High were within the acceptable limits (Table 2-22). 
 
Table 2-23. Analyte recovery and matrix effect at QC Low and QC High in human urine 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 91.7% (10.4%) 82.6% (5.56%) 98.3% (5.00%) 95.5% (0.761%) 
DHM 79.5% (6.01%) 82.4% (5.27%) 101% (0.984%) 98.6% (0.424%) 
NOR 74.7% (3.79%) 79.0% (5.36%) 93.2% (1.23%) 90.9% (0.489%) 
HYDROXY 84.3% (6.09%) 87.2% (6.02%) 65.6% (7.37%) 67.4% (4.57%) 
4-CARBOXY 35.8% (7.18%) 34.3% (6.30%) 80.3% (6.90%) 79.4% (4.98%) 
DHNM 90.3% (5.41%) 97.7% (5.48%) 91.4% (2.97%) 88.6% (1.05%) 
 
2.6.4.6 Carryover 
Carryover was not observed. 
2.6.4.7 Dilution integrity 
All analytes showed good precision and accuracy following 1 in 100 and 1 in 1000 
dilutions in human urine. For 1 in 100 dilution, %CV ranged from 4.44-11.0% and 
inaccuracy was within ± 6.0% of the target concentration (Table 2-24). For 1 in 1000 
dilution, %CV ranged from 2.43-6.57% and inaccuracy was within ± 7.0% of the target 
concentration (Table 2-25). 
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Table 2-24. Dilution integrity (1 in 100) for MEPH and its metabolites in human urine 
Analyte 





%CV % accuracy 
MEPH 
10 
9.98 4.44% 99.8% 
DHM 10.0 6.33% 100% 
NOR 9.75 6.35% 97.5% 
HYDROXY 10.2 11.0% 102% 
4-CARBOXY 10.6 10.7% 106% 
DHNM 9.82 8.60% 98.2% 
 
Table 2-25. Dilution integrity (1 in 1000) for MEPH and its metabolites in human urine 
Analyte 





%CV % accuracy 
MEPH 
10 
9.90 2.43% 99.0% 
DHM 10.3 3.83% 103% 
NOR 9.30 5.15% 93.0% 
HYDROXY 9.44 3.50% 94.4% 
4-CARBOXY 9.73 6.57% 97.3% 
DHNM 9.57 3.90% 95.7% 
 
2.6.4.8 Stability 
Long term stability of MEPH and its metabolites in human urine was assessed following 
storage for 105 days at -20°C at QC Low and QC High. As shown in Table 2-26, all analytes 
were within ± 15% of their initial concentration under the investigated conditions, 
except for DHNM at QC Low as well as HYDROXY and 4-CARBOXY at QC High which lost 
61.2 ± 2.90%, 33.4 ± 4.07% and 43.2 ± 8.89%, respectively. 
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In a separate experiment, stability samples were taken through 6 F/T cycles from -20°C 
to RT to assess stability following sample thawing which may be required for sample 
re-analysis due to a failed batch or sample dilution. All analytes were stable following 6 
F/T cycles, except 4-CARBOXY at QC High and DHNM at QC Low, which lost 17.2 ± 5.53% 
and 18.8 ± 5.25%, respectively. 
 
Table 2-26. Long term and freeze-thaw stability of MEPH and its metabolites in human urine 
following storage at -20°C 
Analyte 
Long term stability (%CV), n=6 F/T stability (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 101% (2.54%) 99.3% (1.26%) 102% (2.57%) 93.8% (0.783%) 
DHM 92.0% (1.69%) 102% (0.731%) 100% (1.80%) 98.5% (1.40%) 
NOR 102% (2.41%) 90.9% (1.21%) 97.5% (2.01%) 86.4% (1.87%) 
HYDROXY 89.3% (2.74%) 66.6% (4.07%) 102% (3.19%) 90.2% (3.42%) 
4-CARBOXY 94.6% (1.51%) 56.8% (8.89%) 103% (6.90%) 82.8% (5.53%) 
DHNM 38.8% (2.90%) 90.3% (1.09%) 81.2% (5.25%) 97.9% (1.06%) 
 
2.6.5 Oral fluid 
A method for detection and quantification of MEPH and three of its Phase I metabolites 
(DHM, NOR and DHNM) was validated in oral fluid. 
2.6.5.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
2.6.5.2 Linearity 
Mean linearity of r2 > 0.998 was achieved for all analytes in all three validation runs. 
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2.6.5.3 LOD and LOQ 
LOD of 0.1 ng/mL (LOQ of 0.5 ng/mL) for MEPH; 0.5 ng/mL (LOQ of 2 ng/mL) for DHM; 
and 1 ng/mL (LOQ of 4 ng/mL) for NOR and DHNM were achieved in this assay. Table 
2-27 shows calibration parameters for all analytes. 
 
 
Table 2-27. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 










Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 
MEPH 0.1 0.5 0.5-500 0.103 ± 0.138 0.064 ± 0.008 
0.998 ± 
0.002 
DHM 0.5 2 2-500 0.157 ± 0.046 0.046 ± 0.004 
0.999 ± 
0.001 
NOR 1 4 4-500 -0.251 ± 0.053 0.039 ± 0.008 
0.999 ± 
0.001 




2.6.5.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-28, were 
found to be within the acceptance criteria. The intra‐day inaccuracy was within ± 13% 
of the target concentration while accuracy ranged from 95.1-108% for MEPH, 87.8-110% 
for DHM, 92.1-106% for NOR, and 93.8-113% for DHNM. The intra‐day imprecision was 
≤ 10% and ranged from 2.50-9.95% for MEPH, 0.363-2.23% for DHM, 0.451-9.62% for 
NOR and 0.737-4.31% for DHNM. Inter‐day precision and accuracy results were 
acceptable over the validated range with %CV ≤ 10.8% and inaccuracy within ± 5.6% of 
the target concentration. 
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Table 2-28. Precision and accuracy at QC Low, QC Med and QC High for all analytes in oral 
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2.6.5.5 Recovery and matrix effect 
As shown in Table 2-29, recovery at 5 ng/mL was found to be greater than 62.6 ± 6.98% 
for all analytes. IS-corrected matrix effect values were within ± 9% at QC Low and within 
± 4% at QC High, demonstrating only small analyte signal enhancement/suppression. 
 
 
Table 2-29. Analyte recovery at 5 ng/mL and matrix effect at QC Low and QC High in oral fluid 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
5 ng/mL QC Low QC High 
MEPH 78.2% (3.36%) 100% (2.45%) 104% (1.88%) 
DHM 62.6% (6.98%) 100% (1.24%) 100% (1.49%) 
NOR 73.0% (4.45%) 109% (1.84%) 100% (3.11%) 
DHNM 62.7% (6.24%) 105% (4.14%) 98.7% (2.35%) 
 
2.6.5.6 Carryover 
Carryover was not observed. 
2.6.5.7 Dilution integrity 
Dilution integrity was not assessed. 
2.6.6 Dried blood spots 
A method for detection and quantification of MEPH and five of its Phase I metabolites 
was validated in human dried blood spots (DBS) collected by the Mitra® device. 
2.6.6.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
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2.6.6.2 Linearity 
Mean linearity of r2 > 0.997 was achieved for all analytes in all three validation runs. 
2.6.6.3 LOD and LOQ 
LOD of 2 ng/mL (LOQ of 8 ng/mL) for MEPH; 0.5 ng/mL (LOQ of 2 ng/mL) for DHM, 
HYDROXY, DHNM; and 1 ng/mL (LOQ of 4 ng/mL) for NOR, 4-CARBOXY were achieved in 
this assay. Table 2-30 shows calibration parameters for all analytes. 
 
 
Table 2-30. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 










Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 



































0.998 ±  
0.001 
DHNM 0.5 2 2-500 
-0.006 ±  
0.000 
0.041 ±  
0.003 
0.998 ±  
0.001 
 
2.6.6.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-31, were 
found to be within the acceptance criteria. The intra‐day inaccuracy was within ± 14% 
of the target concentration while accuracy ranged from 95.1-106% for MEPH, 99.0-113% 
for DHM, 87.1-104% for NOR, 99.2-114% for HYDROXY, 92.9-114% for 4-CARBOXY and 
94.6-104% for DHNM. The intra‐day imprecision was ≤ 14.3% and ranged from 
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2.20-10.9% for MEPH, 2.26-5.72% for DHM, 2.14-11.8% for NOR, 2.95-13.7% for 
HYDROXY, 2.76-14.3% for 4-CARBOXY and 1.55-5.13% for DHNM. Inter‐day precision 
and accuracy results were acceptable over the validated range with %CV ≤ 11.4% and 
inaccuracy within ± 12% of the target concentration. 
 
 
Table 2-31. Precision and accuracy at QC Low, QC Med and QC High for all analytes in dried 
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By collecting an accurate volume of matrix, Mitra® devices overcome the issues 
associated with the blood haematocrit (Hct) 274. Therefore, only 3 replicates at low (20% 
Hct) and high (60% Hct) Hct values were tested for accuracy and precision. As shown in 
Table 2-32, inaccuracy was within ± 11% at QC Low, ± 14% at QC Med and ± 15% at QC 
High of the target concentration across both Hct levels. Imprecision was ≤ 12.9% and 
ranged from 0.199-8.45% at QC Low, 1.60-8.37% at QC Med and 0.400-12.9% at QC High 
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Table 2-32. Precision and accuracy at 20% and 60% Hct at QC Low, QC Med and QC High in 
dried blood spots 
Analyte 

































































































































2.6.6.5 Recovery and matrix effect 
As shown in Table 2-33, recovery at 10 ng/mL was found to be greater than 81.5 ± 4.53% 
for all analytes, except 4‐CARBOXY for which recovery was 69.5 ± 4.51%. IS-corrected 
matrix effect values were within ± 17% at both QC levels, with NOR and DHNM being 
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Table 2-33. Analyte recovery at 10 ng/mL and matrix effect at QC Low and QC High in DBS 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
10 ng/mL QC Low QC High 
MEPH 81.5% (4.53%) 99.4% (2.69%) 85.4% (4.85%) 
DHM 97.2% (8.31%) 108% (10.8%) 104% (6.88%) 
NOR 84.9% (1.25%) 111% (4.50%) 116% (7.73%) 
HYDROXY 90.8% (1.26%) 86.6% (3.51%) 102% (6.34%) 
4-CARBOXY 69.5% (4.51%) 94.1% (2.27%) 113% (4.30%) 
DHNM 101% (1.85%) 105% (2.29%) 117% (6.56%) 
 
2.6.6.6 Carryover 
Carryover was observed for mephedrone. In order to tackle this problem, three 
methanol blanks followed by a matrix blank were run after the highest calibration 
standard and after samples suspected of high analyte concentration. Carryover was not 
seen for mephedrone in whole blood/plasma because the ULOQ in these two matrices 
was 50 times lower than in DBS. 
2.6.6.7 Dilution integrity 
Before sample analysis commenced, mephedrone had been anticipated to be the only 
analyte which would be found at concentrations outside the calibration range. 
Therefore, dilution integrity was only assessed for mephedrone. Due to the nature of 
DBS collection, dilution was impractical at the beginning of an extraction as it would 
normally be the case with blood or urine. Moreover, only one sample was collected at 
each timepoint during the administration study making repeated analysis impossible. 
Therefore, dilution was performed after sample reconstitution, when an appropriate 
volume of the reconstituted sample was diluted 1 in 10 in the reconstitution solvent. As 
a result, internal standard was also diluted 1 in 10. In order to still be able to detect the 
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internal standard after 1 in 10 dilution, concentration of the internal standard used in 
this method was increased to 250 ng/mL.  
 
Good precision (7.77%) and accuracy (107%) was achieved for mephedrone following 1 
in 10 dilution (Table 2-34). 
 
Table 2-34. Dilution integrity (1 in 10) for mephedrone in dried blood spots 
Analyte 





%CV % accuracy 
MEPH 100 107 7.77% 107% 
 
2.6.6.8 Stability 
Short term stability of mephedrone and its metabolites in DBS collected by the Mitra® 
device was assessed after storage in desiccated conditions for 10 days and 1 month at 
RT and +4ᵒC (stability after storage at -20ᵒC was not assessed due to time constraints) 
at QC Low and QC High. 
 
As shown in Table 2-35, analytes lost more than 15% of their initial concentration after 
storage, except for DHM and DHNM at both QC levels. HYDROXY and 4-CARBOXY 
showed the greatest losses with the analytes not being detectable at QC Low after 10 
days of storage at +4ᵒC and RT. As shown in Table 2-36, further losses were observed 
after 1 month of storage. DHM and DHNM considered stable under the investigated 
conditions after 10 days, showed instability greater than 15% of their initial 
concentration at QC Low. HYDROXY and 4-CARBOXY remained undetectable at QC Low 
and suffered losses of up to 99.9% at QC High. Even though one of the advantages of 
DBS is the ability to transport and store these samples in ambient conditions, this would 
not be recommended for mephedrone and its metabolites. The results demonstrate 
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that DBS samples should not be stored at +4ᵒC or at RT due to significant analyte 
instability even when desiccated. 
 
Table 2-35. 10-day stability of mephedrone and its metabolites in dried blood spots following 
storage at RT and +4°C; ND – not detected 
Analyte 
Storage at +4°C (%CV), n=6 Storage at RT (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 11.8% (13.2%) 10.4% (5.47%) 5.88% (14.7%) 5.44% (20.0%) 
DHM 89.1% (5.96%) 93.3% (9.29%) 91.1% (15.8%) 83.4% (3.81%) 













DHNM 97.4% (5.53%) 101% (6.24%) 99.2% (8.06%) 89.3% (4.14%) 
 
 
Table 2-36. 1-month stability of mephedrone and its metabolites in dried blood spots following 
storage at RT and +4°C; ND – not detected 
Analyte 
Storage at +4°C (%CV), n=6 Storage at RT (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 13.0% (12.4%) 6.45% (9.42%) 5.68% (6.14%) 2.09% (13.0%) 
DHM 81.5% (13.2%) 96.7% (6.92%) 61.1% (12.7%) 83.4% (5.52%) 













DHNM 81.4% (3.34%) 102% (4.44%) 84.3% (6.45%) 89.5% (9.15%) 
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2.6.7 Fingerprint sweat 
A method for detection and quantification of MEPH and five of its Phase I metabolites 
was validated in human fingerprint sweat. 
2.6.7.1 Selectivity 
No interferences were observed in the extracted blank matrix. 
2.6.7.2 Linearity 
Mean linearity of r2 > 0.996 was achieved for all analytes in all three validation runs. 
2.6.7.3 LOD and LOQ 
LOD of 50 pg/mL (LOQ of 200 pg/mL) for MEPH, NOR, DHNM; LOD of 40 pg/mL (LOQ of 
160 pg/mL) for DHM; LOD of 25 pg/mL (LOQ of 100 pg/mL) for HYDROXY, 4-CARBOXY 
were achieved in this assay. Table 2-37 shows calibration parameters for all analytes. 
 
Table 2-37. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 










Slope ± SD 
(n=3) 
r2 ± SD 
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2.6.7.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-38, were 
found to be within the acceptance criteria. The intra‐day inaccuracy was within ± 15% 
of the target concentration while accuracy ranged from 96.6-115% for MEPH, 101-105% 
for DHM, 90.9-106% for NOR, 85.6-111% for HYDROXY, 85.5-108% for 4-CARBOXY and 
88.3-107% for DHNM. The intra‐day imprecision was ≤ 13.8% and ranged from 
0.523-5.10% for MEPH, 1.58-4.48% for DHM, 2.04-8.95% for NOR, 2.64-9.09% for 
HYDROXY, 2.51-13.8% for 4-CARBOXY and 0.906-5.06% for DHNM. Inter‐day precision 
and accuracy results were acceptable over the validated range with %CV ≤ 14.5% and 
inaccuracy within ± 7.50% of the target concentration. 
 
 
Table 2-38. Precision and accuracy at QC Low, QC Med and QC High for all analytes in 






























































































NOR 0.8 0.774 0.805 0.745 0.775 
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2.6.7.5 Recovery and matrix effect 
As shown in Table 2-39, recovery was found to be greater than 60.6 ± 6.16% for all 
analytes, with NOR showing the lowest recovery of 60.6 ± 6.16% and 63.5 ± 4.32% at QC 
Low and QC High, respectively. The best recovery of 91.3 ± 5.53% and 91.1 ± 7.57% at 
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QC Low and QC High, respectively, was achieved for DHM. IS-corrected matrix effect 
values were within ± 7.3% at both QC levels for all analytes, showing no significant matrix 
effects affecting the assay. 
 
Table 2-39. Analyte recovery and matrix effect at QC Low and QC High in fingerprint sweat 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 72.2% (4.27%) 61.9% (5.67%) 101% (1.02%) 96.6% (1.77%) 
DHM 91.3% (5.53%) 91.1% (7.57%) 101% (1.34%) 99.1% (0.375%) 
NOR 60.6% (6.16%) 63.5% (4.32%) 99.8% (2.99%) 92.7% (1.43%) 
HYDROXY 82.5% (5.60%) 62.7% (4.32%) 97.9% (5.02%) 96.1% (6.63%) 
4-CARBOXY 83.4% (5.33%) 75.2% (4.24%) 98.6% (8.44%) 99.4% (6.24%) 
DHNM 84.9% (8.11%) 70.6% (5.30%) 102% (3.63%) 93.6% (2.39%) 
2.6.7.6 Carryover 
Carryover was not observed. 
2.6.7.7 Dilution integrity 
Dilution integrity was only assessed for mephedrone. Due to the nature of fingerprint 
sweat collection, dilution was impractical at the beginning of an extraction as it would 
normally be the case with blood or urine. Moreover, only one sample was collected at 
each timepoint during the administration study making repeated analysis impossible. 
Therefore, dilution was performed after sample reconstitution, when an appropriate 
volume of the reconstituted sample was diluted 1 in 100 in the reconstitution solvent. 
As a result, internal standard was also diluted 1 in 100. In order to still be able to detect 
the internal standard after 1 in 100 dilution, concentration of the internal standard used 
in this method was increased to 250 ng/mL. 
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Good precision (9.91%) and accuracy (92.9%) was achieved for mephedrone following 1 
in 100 dilution (Table 2-40). 
 
Table 2-40. Dilution integrity (1 in 100) for mephedrone in fingerprint sweat 
Analyte 





%CV % accuracy 
MEPH 1 0.929 9.91% 92.9% 
 
2.6.8 Head hair 
A method for detection and quantification of MEPH and five of its Phase I metabolites 
was validated in human head hair. 
2.6.8.1 Selectivity 
No interferences were observed in the extracted blank matrix collected from individuals 
with dyed and natural hair. 
2.6.8.2 Linearity 
Mean linearity of r2 > 0.992 was achieved for all analytes in all three validation runs. 
2.6.8.3 LOD and LOQ 
LOD of 10 pg/mg (LOQ of 40 pg/mg) for DHM and DHNM; 2.5 pg/mg (LOQ of 10 pg/mg) 
for HYDROXY; 5 pg/mg (LOQ of 20 pg/mg) for MEPH; and 1 pg/mg (LOQ of 4 pg/mg) for 
NOR and 4-CARBOXY were achieved in this assay. Table 2-41 shows calibration 
parameters for all analytes. 
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Table 2-41. LOD, LOQ, calibration range and calibration parameters for mephedrone and its 








Intercept ± SD 
(n=3) 
Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 





DHM 10 40 40-400 0.054 ± 0.016 




NOR 1 4 4-400 0.244 ± 0.088 











1 4 4-400 0.076 ± 0.039 
0.008 ±  
0.005 
0.995 ±  
0.001 






2.6.8.4 Precision and accuracy 
Intra‐day and inter‐day precision and accuracy results, summarised in Table 2-42, were 
found to be within the acceptance criteria. The intra‐day inaccuracy was within ± 15% 
of the target concentration while accuracy ranged from 85.8-111% for MEPH, 91.1-106% 
for DHM, 96.1-109% for NOR, 88.8-113% for HYDROXY, 87.1-101% for 4-CARBOXY and 
87.8-104% for DHNM. The intra‐day imprecision was ≤ 13.5% and ranged from 
2.15-7.34% for MEPH, 2.30-12.5% for DHM, 2.57-8.77% for NOR, 4.43-12.2% for 
HYDROXY, 2.87-13.5% for 4-CARBOXY and 3.02-11.7% for DHNM. Inter‐day precision 
and accuracy results were acceptable over the validated range with %CV ≤ 11.0% and 
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Table 2-42. Precision and accuracy at QC Low, QC Med and QC High for all analytes in head 
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2.6.8.5 Recovery and matrix effect 
As shown in Table 2-43, recovery was found to be greater than 37.6 ± 3.73% for all 
analytes, except 4‐CARBOXY for which recovery was 4.55 ± 1.82% at QC Low and 5.58 ± 
8.90% at QC High. However, it needs to be noted that presented recovery is not a true 
recovery because the extent of spiked analytes being incorporated into hair is unknown. 
 
IS-corrected matrix effect values were within ± 15% for all analytes at both QC levels, 
except for HYDROXY and 4-CARBOXY. HYDROXY was suppressed by 57.8 ± 20.5% at QC 
Low and by 22.8 ± 18.8% at QC High whereas 4-CARBOXY was suppressed by 31.6 ± 
3.59% at QC Low and by 20.4 ± 4.93% at QC High (Table 2-43). In addition, imprecision 
of 20.5% at QC Low and 18.8% at QC High was observed for HYDROXY. This may be due 
to the lack of matching deuterated IS which is currently not commercially available. 
However, assay precision and accuracy for all analytes were within the acceptance 
criteria (Table 2-42). 
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Table 2-43. Analyte recovery and matrix effect at QC Low and QC High in human head hair 
Analyte 
Recovery (%CV), n=6 Matrix Effect (%CV), n=6 
QC Low QC High QC Low QC High 
MEPH 51.8% (2.51%) 60.5% (6.43%) 115% (9.90%) 107% (8.49%) 
DHM 66.9% (4.06%) 72.5% (4.07%) 114% (8.63%) 100% (6.50%) 
NOR 37.6% (3.73%) 37.8% (3.45%) 101% (11.6%) 101% (13.1%) 
HYDROXY 41.6% (3.78%) 39.5% (4.96%) 42.2% (20.5%) 77.2% (18.8%) 
4-CARBOXY 4.55% (1.82%) 5.58% (8.90%) 68.4% (3.59%) 79.6% (4.93%) 
DHNM 73.1% (3.18%) 71.5% (3.99%) 89.3% (11.8%) 102% (3.67%) 
 
2.6.8.6 Carryover 
Carryover was not observed. 
2.6.8.7 Dilution integrity 
Dilution integrity was not assessed. 
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CHAPTER 3  
DETECTION AND PHARMACOKINETIC ANALYSIS OF 
MEPHEDRONE AND ITS METABOLITES IN WHOLE 
BLOOD, PLASMA AND DRIED BLOOD SPOTS 
 Whole blood (achiral method) 
3.1.1 Detection of mephedrone and its metabolites in whole 
blood 
Whole blood can provide information about recent drug use. Drugs are typically 
detected for up to 3 days in whole blood, but the detection window is dependent on the 
drug, route of administration and the dose. Even though whole blood is one of the most 
commonly tested biological matrices in forensic and clinical toxicology, there are no 
published studies on pharmacokinetics of mephedrone and/or its metabolites in this 
matrix following a controlled administration. 
3.1.2 Whole blood aims 
The aim of this study was to investigate for the first-time pharmacokinetics of 
mephedrone and its metabolites in human whole blood. 
 
 Chapter 3 | Whole blood, plasma and dried blood spots 
 




Mephedrone hydrochloride (MEPH), dihydro-mephedrone hydrochloride (DHM), 
mephedrone-d3 hydrochloride (MEPH-d3), dihydro-mephedrone-d3 hydrochloride 
(DHM-d3), 4-(2-aminoethyl) benzoic acid hydrochloride (AEBA) and sodium borohydride 
were purchased from Sigma-Aldrich (Dorset, UK). Nor-mephedrone hydrochloride 
(NOR) and mephedrone hydrochloride in powder form used for the human 
administration were purchased from Chiron (Trondheim, Norway). 
Hydroxytolyl-mephedrone hydrochloride (HYDROXY), 4-carboxy-mephedrone 
hydrochloride (4-CARBOXY) as well as nor-mephedrone hydrochloride used for the 
in-house synthesis of dihydro-nor-mephedrone (DHNM) were purchased from LGC 
Standards (Bury, UK). MEPH, MEPH-d3, DHM, DHM-d3 were purchased as certified 
reference materials. All reference standards were analysed in-house to verify their 
chemical structure. 
 
All solvents were HPLC grade unless stated otherwise. Methanol (MeOH), isopropyl 
alcohol (IPA), dichloromethane (DCM), acetonitrile (LC-MS grade for the preparation of 
the mobile phase and HPLC grade for other uses), formic acid, acetic acid, sodium 
phosphate monobase, sodium phosphate diabase and ammonium hydroxide (0.88, 
35%) were purchased from Fisher Scientific (Loughborough, UK). Ultrapure water 
(18 MΩcm) was prepared on an ELGA Purelab Maxima HPLC water purification system 
(High Wycombe, UK). Xtrackt® DAU High Flow (150 mg, 3 mL) cartridges were purchased 
from Chromatography Direct (Runcorn, UK). 
3.1.3.2 Blank matrix collection 
Drug-free whole blood was collected by trained phlebotomists into 5 mL vacutainers 
containing 12.5 mg of sodium fluoride and 10 mg of potassium oxalate (NaF/KOx). 
Ethical approval for the collection of drug-free matrix was granted by the Research 
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Ethics Committee at King’s College London (HR 16/17 4237) and can be found in 
Appendix B. 
3.1.3.3 Volunteer administration study and sample 
collection 
Six healthy male volunteers (referred to here as M1-M6) nasally insufflated 100 mg of 
mephedrone hydrochloride supplied as a racemic mixture (purity: 96.3 ± 0.5%). Whole 
blood (5 mL) was collected into vacutainers containing NaF/KOx preservative at -10 min 
(0 h, before administration), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 
75 min, 90 min, 105 min, 2 h, 2.5 h, 3 h, 5 h, 6 h, Day 2 and Day 3. Whole blood samples 
were stored at +4ᵒC and were extracted within 2 days of sample collection. Stability of 
mephedrone and five of its Phase I metabolites in human whole blood (NaF/KOx) stored 
at +4ᵒC and -20ᵒC has been published by our research group 125. 
3.1.3.4 Working solutions 
Working solutions used for the preparation of the calibration curve were made in 
MeOH:water (50:50 v/v) at 4, 8, 16, 20, 100, 160, 200 ng/mL for MEPH, DHM, NOR, 
DHNM; 4, 10, 20, 100, 200, 400, 500 ng/mL for HYDROXY; and 40, 100, 200, 500, 1000, 
1600, 2000 ng/mL for 4-CARBOXY. Working solution used for the preparation of the 
quality control (QC) samples at low, medium and high level were made in MeOH:water 
(50:50 v/v) at 5, 20, 160 ng/mL for MEPH, DHM, NOR, DHNM; 5, 40, 400 ng/mL for 
HYDROXY; and 50, 400, 1600 ng/mL for 4-CARBOXY. Internal standard (IS) solution 
containing MEPH-d3 and DHM-d3 at 50 ng/mL and AEBA at 500 ng/mL was prepared in 
MeOH:water (50:50 v/v). AEBA was used as an IS for 4-CARBOXY because it helped 
minimised matrix effects. 
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3.1.3.5 Calibration standards and quality control samples 
Matrix-matched calibration standards containing MEPH, DHM, NOR, DHNM at 0.2, 0.4, 
0.8, 1, 5, 8, 10 ng/mL; HYDROXY at 0.2, 0.5, 1, 5, 10, 20, 25 ng/mL; and 4-CARBOXY at 2, 
5, 10, 25, 50, 80, 100 ng/mL were prepared by the addition of an appropriate volume of 
the working solution to whole blood. QC Low (0.250 ng/mL for MEPH, DHM, NOR, 
DHNM, HYDROXY; and 2.5 ng/mL for 4-CARBOXY), QC Med (1 ng/mL for MEPH, DHM, 
NOR, DHNM; 2 ng/mL for HYDROXY; and 20 ng/mL for 4-CARBOXY) and QC High 
(8 ng/mL for MEPH, DHM, NOR, DHNM; 20 ng/mL for HYDROXY; and 80 ng/mL for 
4-CARBOXY) were prepared by the addition of an appropriate volume of the working 
solution to whole blood.  
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing whole blood but no IS and one sample containing whole blood and IS were 
also prepared and taken through the extraction. 
3.1.3.6 Sample preparation 
One hundred microliters of whole blood (NaF/KOx) was extracted using solid phase 
extraction (SPE). Where dilution was required, samples were diluted 1 in 20 in the blank 
matrix alongside 3 additional QCs prepared in the same manner. Ten microliters of the 
IS was added to the samples, calibration standards and QCs. All samples were vortex 
mixed and 1 mL of 0.1 M phosphate buffer (pH 6.0) was added. After conditioning the 
Xtrackt® SPE cartridges (mixed mode cation exchange containing C8 and 
benzoylsulfonate anion) with 2 mL of MeOH and 2 mL of 0.1 M phosphate buffer (pH 
6.0), samples were loaded and washed with 2 mL of 0.1 M acetic acid(aq) followed by 
2 mL of MeOH. Samples were eluted with 4 x 1 mL of DCM:IPA:ammonium hydroxide 
(78:20:2 v/v/v) and dried under nitrogen at 50°C. Samples were reconstituted with 
100 µL of 0.1% formic acid in ACN:water (10:90 v/v).  
 Chapter 3 | Whole blood, plasma and dried blood spots 
 
Page | 191 
 
3.1.3.7 LC-MS/MS conditions 
The analysis was performed by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) using a Waters Xevo TQ-S triple quadrupole mass spectrometer 
(Manchester, UK) coupled to Waters Acquity ultra performance liquid chromatograph 
system equipped with a CTC 2777 open architecture autosampler (Waters, UK). 
 
Extracted samples were analysed using electrospray ionisation operated in positive ion 
mode. The source temperature was set to 150°C. The desolvation gas flow rate was 
1000 L/h at a temperature of 500˚C, capillary voltage was set to 2.22 kV, cone voltage 
was 45 V and source offset was 84 V. The cone gas flow rate was set to 150 L/h, the 
nebuliser gas flow was 7.00 bar and the collision gas flow rate was 0.25 mL/min.  
 
Mephedrone metabolites and deuterated internal standards were monitored using 
selected reaction monitoring (SRM) as detailed in Table 3-1. In order to maximise 
sensitivity, all analytes except for 4-CARBOXY and HYDROXY had their dehydration 
products chosen as target precursor ions due to significant in-source fragmentation 
which is commonly observed in synthetic cathinones 74,125. 
 
 
Table 3-1. The retention time, SRM transitions and collision energy for each ion  
* denotes a quantifying transition 












MEPH 5.85 160.4 ** 
145.1* 15 
MEPH-d3 144.1 33 
91.1 28 
MEPH-d3 5.85 163.4 ** 148.4 19  
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91.3 26 
DHM-d3 5.38 165.4 ** 150.3 18  
NOR 5.00 146.0 ** 
131.1 25 
MEPH-d3 130.1* 25 
119.0 15 
HYDROXY 1.98 194.1 
158.1 17 
DHM-d3 146.0* 17 
131.1 23 
4-CARBOXY 2.06 
 146.0* 13 
AEBA 208.0 144.1 28 
 130.1 31 
DHNM 4.45 
 131.1* 13 
MEPH-d3 148.1 ** 116.2 23 
 91.1 25 
AEBA 1.77 166.1 149.1 10  
 
 
Chromatographic separation was performed on a 2.1 mm x 150 mm, 1.8 µm, 
pentafluorophenylpropyl (PFPP) Selectra® column (Bristol, US) held at 60°C. The strong 
needle wash was 0.3% formic acid in MeOH and the weak needle wash was 0.01% formic 
acid in acetonitrile:water (10:90 v/v). The flow rate was 0.5 mL/min with 0.3% formic 
acid in water as mobile phase A and 0.3% formic acid in acetonitrile as mobile phase B. 
The start of the gradient was at 85% mobile phase A. Mobile phase B was then increased 
to 55% over 11 min and was held for 2 min. Over the next 0.5 min the gradient returned 
to the starting condition and the column was re-equilibrated at 85% mobile phase A for 
the remaining 1.5 min. The total run time was 15 min. The injection volume was 20 µL 
and the data was acquired using MassLynx software (Version 4.1). TargetLynx (version 
4.1) was used for data processing and quantification. 
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3.1.3.8 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
3.1.3.9 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
3.1.4 Results 
3.1.4.1 Method validation 
Please refer to Section 2.6.1 in Chapter 2. 
3.1.4.2 Concentrations of mephedrone and its 
metabolites in whole blood (NaF/KOx) 
Mean whole blood concentrations ± standard deviation (SD) for mephedrone and its 
metabolites in 6 participants are presented in Figure 3-1 - Figure 3-6. Individual plots 
and raw data can be found in Appendix E. 
 
 
Figure 3-1. Mean mephedrone whole blood concentrations ± SD (n=6); note that mephedrone 
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Figure 3-2. Mean dihydro-mephedrone whole blood concentrations ± SD (n=6) 
 
Figure 3-3. Mean nor-mephedrone whole blood concentrations ± SD (n=6); note that 
nor-mephedrone was detected in one participant at 10 min at 0.293 ng/mL 
 
Figure 3-4. Mean hydroxytolyl-mephedrone whole blood concentrations ± SD (n=6); note that 
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Figure 3-5. Mean 4-carboxy-mephedrone whole blood concentrations ± SD (n=6); note that 
4-carboxy-mephedrone was detected in one participant at 5 min at 14.0 ng/mL 
 
Figure 3-6. Mean dihydro-nor-mephedrone whole blood concentrations ± SD (n=6); note that 




Following mephedrone administration, DHM and 4-CARBOXY were detectable in whole 
blood from 5 min, but 4-CARBOXY was only detected in one participant (M6) at this 
timepoint. NOR and HYDROXY were detected in whole blood after 10 min in M6 and 
after 20 min and 30 min in all other participants, respectively. DHNM appeared in whole 
blood after 45 min in M6, after 75 min in M1-M3 and after 150 min in M5. DHNM was 
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mephedrone also being detectable just above the limit of quantification (LOQ) on Day 2 
in M1. 
3.1.4.3 Pharmacokinetic analysis 
Whole blood drug concentrations were fitted with a single-dose, first-order elimination 
phase model and calculated mean pharmacokinetic (PK) parameters are summarised in 
Table 3-2. Individual PK data can be found in Appendix E. 
 
 
Table 3-2. Mean ± SD pharmacokinetic data from the analysis of mephedrone and its 
metabolites in whole blood from 6 male participants; kel and t1/2 could not be calculated for 











(ng mL-1 h) 
CL 














































































Mephedrone showed rapid absorption (Tmax of 55.0 ± 18.2 min) and a relatively fast 
half-life (t1/2) of 2.12 ± 0.33 h. Most mephedrone metabolites reached Tmax shortly after 
the parent drug, except for NOR and DHNM which peaked later at 133 ± 27.5 min and 
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300 ± 73.5 min, respectively. 4-CARBOXY reached the highest concentration and had the 
largest area under the curve (AUC) of 241 ± 113 ng/mL and 1104 ± 524 ng mL-1 h, 
respectively. Another metabolite which was present in high abundance was NOR, 
reaching Cmax of 5.12 ± 2.16 ng/mL and AUC of 53.7 ± 24.0 ng mL-1 h. 
 
With regards to elimination, mephedrone and 4-CARBOXY showed similar kinetics, 
including similar t1/2 (2.12 ± 0.33 h for mephedrone, 1.70 ± 0.26 h for 4-CARBOXY) and 
elimination rate constant (kel; 0.006 ± 0.001 min-1 for mephedrone, 0.007 ± 0.001 min-1 
for 4-CARBOXY). HYDROXY was eliminated with t1/2 of 1.52 ± 0.60 h while DHM and NOR 
were eliminated with t1/2 of 7.19 ± 4.19 h and 6.09 ± 2.64 h, respectively. t1/2 and kel were 
not determined for DHNM because the elimination phase was not observed from the 
data. 
3.1.5 Discussion 
Following mephedrone administration all analytes were successfully detected in whole 
blood, including NOR which is an active metabolite. NOR has been shown to cross the 
blood-brain barrier (BBB) in rats and to contribute to the psychoactive effects produced 
by mephedrone 91.  
 
Mephedrone has been shown to be metabolised by cytochrome P450 2D6 (CYP2D6) 
which is mainly responsible for hydroxylation of the benzene ring (which leads to the 
formation of HYDROXY and then 4-CARBOXY) and N-demethylation of the secondary 
amine to form NOR. 4-CARBOXY and NOR were the most abundant metabolites in whole 
blood. 4-CARBOXY reached nearly 2.5 times higher AUC compared to mephedrone. NOR 
represented 11.3% of the AUC of mephedrone, followed by DHM (3.38%), DHNM 
(1.69%) and HYDROXY (0.84%). Pharmacokinetic values obtained from the analysis of 
whole blood samples cannot be compared with the literature because, to our 
knowledge, this is the first study that presents this data. 
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According to a review describing cases of clinical mephedrone intoxication, mean 
mephedrone whole blood concentration from fatal cases was 2,663 ng/mL (range: 
51-22,000 ng/mL) compared to 166 ng/mL (range: 13-412 ng/mL) from non-fatal cases 
407. Additionally, in post-mortem blood mephedrone was found at 1200 ng/mL, 
5700 ng/mL and 5500 ng/mL in the three cases where it was detected as the only 
substance 116,408. In many of these cases the exact mephedrone dose was unknown and 
the route of administration varied between cases. In our study, mephedrone reached 
the Cmax of 101 ± 45.4 ng/mL after a nasal insufflation. In other controlled human 
administration studies, where higher mephedrone doses (150 mg and 200 mg) were 
given orally, plasma (whole blood samples were not analysed) mephedrone 
concentration reached 123-159 ng/mL, which is in a similar range to the one associated 
with the acute non-fatal toxicities (mean: 166 ng/mL) 407. 
3.1.6 Conclusion  
For the first-time pharmacokinetics of mephedrone and its metabolites has been 
investigated in whole blood following a controlled drug administration. Mephedrone 
was rapidly absorbed, which may explain why mephedrone users tend to re-dose several 
times in a single session. All metabolites were detectable in whole blood for up to 6 h, 
with 4-CARBOXY and NOR being the most abundant. 
 Whole blood (chiral method) 
3.2.1 Detection of mephedrone enantiomers in whole blood 
The distribution of mephedrone enantiomers has not been investigated in human 
biological matrices following a controlled drug administration. The only available data 
comes from animal studies and the analysis of human urine collected from music 
festivals. In rats, R-mephedrone has been shown to result in more stimulant-like effects 
due to its predominant interaction with dopaminergic receptors 86. A different study 
conducted by Castrignanò et al. investigated metabolism of mephedrone in vitro (in 
 Chapter 3 | Whole blood, plasma and dried blood spots 
 
Page | 199 
 
human liver microsomes) and in vivo (in rat urine and human urine collected from music 
festivals) looking specifically at the enantiomeric ratio of R-mephedrone (R-MEPH) and 
S-mephedrone (S-MEPH) in the samples 88. The researchers found human liver 
microsomes and human urine to be enriched with R-MEPH. In rat urine, S-MEPH was 
more abundant which likely highlights differences in metabolism between humans and 
rats. However, there is limited information about the purity of administered 
mephedrone to rats as authors only state that mephedrone powder was collected from 
the amnesty bins at a music festival in the UK in 2014 (at the time when mephedrone 
was sold as a racemic mixture). 
3.2.2 Whole blood aims 
The primary aim of the study was to carry out pharmacokinetic studies of S-MEPH and 
R-MEPH in human whole blood, and to investigate the possibility of enantioselective 
pharmacokinetics in humans. The secondary aim was to compare the data obtained for 
each enantiomer with total mephedrone concentrations found in whole blood (achiral 
method) in order to compare pharmacokinetic parameters between the analytes. 
3.2.3 Experimental 
3.2.3.1 Reagents 
In addition to the reagents described in 3.1.3.1, diethylamine (DEA) and ethanol (EtOH; 
LiChrosolv grade) were purchased from Sigma-Aldrich (Dorset, UK). MeOH (Optima 
LC/MS) was purchased from Fisher Scientific (Loughborough, UK). 
3.2.3.2 Blank matrix collection 
Please refer to 3.1.3.2. 
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3.2.3.3 Volunteer administration study and sample 
collection 
Whole blood samples from 5 participants (M2-M6) were used for chiral analysis. 
Samples from M1 were not analysed because the chiral method was not developed in 
time for that. Please refer to 3.1.3.3 for more details. 
3.2.3.4 Working solutions 
Working solutions used for the preparation of the calibration curve contained 
mephedrone only and were made in MeOH:water (50:50 v/v) at 160, 200, 400, 700, 
1000, 2000, 4000 ng/mL. Working solution used for the preparation of the QC samples 
at low, medium and high level were also made in MeOH:water (50:50 v/v) at 200, 800, 
3000 ng/mL. IS solution containing MEPH-d3 at 50 ng/mL was prepared in the same 
solvent. 
3.2.3.5 Calibration standards and quality control samples 
Matrix-matched calibration standards containing mephedrone at 8, 10, 20, 35, 50, 100, 
200 ng/mL were prepared by the addition of an appropriate volume of the working 
solution to whole blood. QC Low at 10 ng/mL, QC Med at 40 ng/mL and QC High at 
150 ng/mL were also prepared by the addition of an appropriate volume of the working 
solution to whole blood.  
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing whole blood but no IS and one sample containing whole blood and IS were 
also prepared and taken through the extraction. 
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3.2.3.6 Sample preparation 
Sample preparation described in 3.1.3.6 was followed, but samples were reconstituted 
in 0.1% DEA in EtOH:MeOH (20:80 v/v). Samples did not require dilution. 
3.2.3.7 LC-MS/MS conditions 
The same instrumentation and LC-MS/MS conditions were used as those described in 
3.1.3.7, except for the LC method. Chromatographic separation was performed on a 150 
mm x 3 mm, 3 µm CHIRALPAK AD-3 column (Illkirch, France) held at room temperature. 
The strong needle wash was 0.3% formic acid in MeOH and the weak needle wash was 
0.01% formic acid in ACN:water (10:90 v/v). The flow rate was 0.1 mL/min with 0.1% 
DEA in EtOH:MeOH (20:80 v/v) as mobile phase used in an isocratic mode. The total run 
time was 10 min. Monitored SRM transitions are presented in Table 3-3. 
 
 
Table 3-3. The retention time, SRM transitions and collision energy for S-MEPH and R-MEPH 












S-MEPH 5.9 160.4 
145.1* 15 
S-MEPH-d3 144.1 33 
91.1 28 
R-MEPH 4.9 160.4 
145.1* 15 
R-MEPH-d3 144.1 33 
91.1 28 
S-MEPH-d3 5.9 163.4 148.4 19  
R-MEPH-d3 4.9 163.4 148.4 19  
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3.2.3.8 Determination of the enantiomeric ratio of 
R-mephedrone and S-mephedrone in mephedrone 
hydrochloride powder by circular dichroism 
Ultraviolet and optical rotation spectra of mephedrone hydrochloride prepared at 
4 mg/mL in MeOH were acquired on the Applied Photophysics Chirascan spectrometer 
(Leatherhead, UK). A Calcite polariser was mounted on the end of the photomultiplier 
tube detector inside the sample chamber for optical rotation measurement. A 10 mm 
Suprasil rectangular cell (Hellma UK Ltd, UK) was employed in the region of 600-250 nm. 
The instrument was flushed continuously with pure evaporated nitrogen throughout the 
experiment. The following parameters were employed for standard wavelength 
acquisition: 2 nm spectral bandwidth, 1 nm step size and 0.5 s instrument time per point. 
Single wavelength kinetic measurements were used: 2 nm spectral bandwidth, 200 s or 
100 s time base with 100 points and accumulation of 5. Ten mg/mL of sucrose prepared 
in Milli-Q water was used to calibrate the instrument prior to samples measurements. 
All spectra were solvent baseline subtracted and measured at +20ᵒC. 
3.2.3.9 Determination of the enantiomeric ratio of 
R-mephedrone and S-mephedrone in mephedrone 
hydrochloride powder by LC-MS 
Mephedrone solution prepared at 50 ng/mL in 0.1% DEA in EtOH:MeOH (20:80 v/v) was 
injected (n=3) on the chiral column as described in 3.2.3.7. Peak areas of the two 
separated enantiomers were compared. 
3.2.3.10 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
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3.2.3.11 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
3.2.4 Results 
3.2.4.1 Method validation 
Please refer to Section 2.6.2 in Chapter 2. 
3.2.4.2 Enantiomeric ratio of R-mephedrone and 
S-mephedrone in mephedrone hydrochloride 
powder 
The enantiomeric ratio of R-MEPH and S-MEPH in mephedrone hydrochloride powder 
administered to healthy volunteers in the study was determined by circular dichroism 
spectroscopy and LC-MS. The optical rotation produced a flat line in the region of 
600-250 nm which showed that the mephedrone powder was supplied as a racemic 
mixture. This was further confirmed by the LC-MS analysis. Peak areas of R-MEPH and 
S-MEPH were 10404 ± 11 (n=3) and 10786 ± 23 (n=3), respectively, indicating an 
approximate 1:1 ratio. An example chromatogram showing the separation of the two 
enantiomers and their corresponding peak areas is presented in Figure 3-7. Peak areas 
of MEPH-d3 also showed an approximate 1:1 ratio (data not shown here). 
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Figure 3-7. A chromatogram showing the separation of R-MEPH (first peak) and S-MEPH 
(second peak) on a chiral column 
 
3.2.4.3 Concentration of S-mephedrone and 
R-mephedrone in whole blood (NaF/KOx) 
In order to highlight individual changes in analyte concentration, Figure 3-8 - Figure 3-12 
show concentration profiles for S-MEPH and R-MEPH in each participant (M2-M6). 
Individual raw data can be found in Appendix E. 
 
 








































































Separation of R-MEPH and S-MEPH on a chiral column































Retention time: 4.9 min 
Peak area: 10414 
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Figure 3-9. Concentrations of R-mephedrone and S-mephedrone in whole blood in M3 
 
Figure 3-10. Concentrations of R-mephedrone and S-mephedrone in whole blood in M4 
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Figure 3-12. Concentrations of R-mephedrone and S-mephedrone in whole blood in M6 
 
 
R-MEPH and S-MEPH were detected in whole blood between 5 min and 360 min, but 
R-MEPH reached higher concentrations between 20 min and 360 min. In M3, the first 
three samples collected at 5 min, 10 min and 15 min had high mephedrone 
concentrations which is likely due to contamination as mephedrone is not expected to 
reach Cmax at 5 min. Elevated levels of mephedrone were also found in the 5 min, 10 min 
and 15 min samples from M3 in the achiral whole blood analysis, suggesting 
contamination during extraction or sample collection.  
 
The enantiomeric fraction (EF) is used to show the proportion of enantiomers in a 
mixture. EF rather than the enantiomeric ratio is preferred for this determination 409,410 
and is calculated according to Equation 3-1. EF was expected to be 0.5 if both 
enantiomers were present in whole blood samples at 1:1 ratio (i.e. racemic mixture). 
 
Equation 3-1. Equation for calculating the enantiomeric fraction, where the enantiomer in the 
numerator is the (+) enantiomer 
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EF calculated for each participant at each timepoint between 5 min and 360 min is 
presented in Figure 3-13. EF values obtained from whole blood samples collected 
between 30 min and 360 min (where visible differences between the enantiomers were 
observed) ranged from 0.512 to 0.607 (mean: 0.535 ± 0.035). According to the one 
sample t-test (p-value < 0.0001 at 95% confidence interval), mean EF values were 
statistically different from the expected EF value of 0.5. Calibration standards and 




Figure 3-13. Changes in the EF with time post mephedrone administration for M2-M6; the 
orange dashed line at 0.500 shows the expected EF if both enantiomers were present in whole 
blood samples at 1:1 ratio; the black dotted line shows mean EF at each timepoint 
 
3.2.4.4 Pharmacokinetic analysis 
Whole blood drug concentrations were fitted with a single-dose, first-order elimination 
phase model and calculated mean pharmacokinetic parameters are summarised in 
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Table 3-4. Mean ± SD pharmacokinetic data from the analysis of R-mephedrone in whole blood 











(ng mL-1 h) 
CL 
(mL min-1 kg-1) 
V 
(L kg-1) 
M2 41.1 60 0.006 1.92 192 114 18.9 
M3 42.5 45 0.005 2.30 212 121 24.0 
M4 38.0 45 0.006 2.00 179 157 27.2 
M5 54.2 30 0.006 1.91 242 83.3 13.8 















Table 3-5. Mean ± SD pharmacokinetic data from the analysis of S-mephedrone in whole blood 











(ng mL-1 h) 
CL 
(mL min-1 kg-1) 
V 
(L kg-1) 
M2 36.8 45 0.007 1.69 150 146 21.4 
M3 37.9 45 0.006 2.01 171 150 26.1 
M4 35.7 45 0.007 1.57 130 216 29.4 
M5 49.7 30 0.008 1.45 157 128 16.2 
















Both enantiomers showed similar kinetics but S-MEPH peaked earlier at 39.0 ± 8.2 min 
and had shorter t1/2 of 1.63 ± 0.23 h compared to 45.0 ± 10.6 min and 1.94 ± 0.26 h, 
respectively, for R-MEPH. Differences in the AUC and CL were also observed. R-MEPH 
resulted in 1.3 times greater AUC compared to S-MEPH and had lower clearance of 124 
± 29 mL min-1 kg-1 compared with 161 ± 33 mL min-1 kg-1 for the other enantiomer. 
Volume of distribution was similar for R-MEPH (20.7 ± 5.1 L kg-1) and S-MEPH (22.8 ± 5.1 
L kg-1). Unpaired t-test was performed to check if the pharmacokinetic parameters 
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obtained for R-MEPH and S-MEPH were significantly different. At 95% confidence level, 
Cmax, Tmax, kel, t1/2, CL and V were not statistically different with the two-tailed p value of 
0.6220, 0.3466, 0.0840, 0.0887, 0.0942 and 0.5345, respectively. However, the 
difference in the AUC between two enantiomers was deemed to be statistically 
significant (p value of 0.0075). 
3.2.4.5 Comparison of the pharmacokinetic profile 
between total mephedrone and its enantiomers in 
whole blood 
As expected, mean total mephedrone concentration in whole blood (achiral method) 
was roughly two times higher than the mean concentration of each individual 
enantiomer (Figure 3-14).  
 
 
Figure 3-14. Mean concentration ± SD of R-mephedrone, S-mephedrone and total mephedrone 
in whole blood (M2-M5) 
 
R-MEPH showed comparable pharmacokinetic parameters to those obtained for total 
mephedrone in whole blood (achiral method). Both peaked at approximately 50 min, 
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mephedrone and 1.94 ± 0.26 h for R-MEPH. The Cmax of 101 ± 45.4 ng/mL was observed 
for total mephedrone, which was 2.26 times higher than the Cmax for S-MEPH and 2.08 
times higher than the Cmax for R-MEPH. 
3.2.5 Discussion 
Whole blood samples have been shown to be enriched with R-MEPH which reached 
higher Cmax, Tmax and had shorter t1/2 than S-MEPH (the difference was not statistically 
significant). The AUC of R-MEPH was approximately 1.31 times greater than that of 
S-MEPH which was found to be statistically different. These results are in agreement 
with previous research that found R-MEPH to be a predominant analyte in pooled 
human urine samples and in in vitro experiments performed in human liver microsomes 
87. Moreover, changes in the EF over time presented in Figure 3-13 showed whole blood 
samples collected between 30 min and 360 min to be statistically different from the EF 
value of 0.5. Even though statistical difference was reported, it is not fully understood if 
it is likely to be clinically significant given the mean difference in EF and Cmax of 
approximately 0.035 and 10%, respectively. 
 
Differences in concentrations of S-MEPH and R-MEPH may be a result of 
pharmacokinetic processes occurring at different rates during drug absorption, 
distribution, metabolism or excretion 411. Some drugs can be chemically or biochemically 
inverted in vivo in a unidirectional or bidirectional manner 412. Moreover, polymorphic 
drug metabolism, gender, age, disease state and medications could all affect whole 
blood enantiomer concentrations, although given the design of this study polymorphic 
drug metabolism is likely to play the most significant role. CYP2D6, responsible for 
mephedrone metabolism, is subject to genetic polymorphism which causes variations in 
CYP2D6 enzymatic activity. People can be poor metabolisers (25% Caucasians), 
intermediate metabolisers, extensive metabolisers or ultrafast metabolisers (most 
commonly people of Middle Eastern descent) 413. However, the mechanism leading to 
whole blood samples being enriched with R-MEPH in humans is not clear and warrants 
further studies. 
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3.2.6 Conclusion  
This is the first-time enantiomers of mephedrone were separated on a CHRALPAK® AD-3 
column and quantified in whole blood samples from a controlled drug administration. 
R-MEPH reached higher concentrations and had comparable pharmacokinetic 
parameters to total mephedrone. The enantiomeric fraction calculated from whole 
blood samples collected between 30 min and 360 min has been shown to be statistically 
different from the expected value of 0.5, suggesting enantioselective pharmacokinetics. 
However, it is not yet clearly understood if the difference is clinically significant. 
 Plasma  
3.3.1 Detection of mephedrone and its metabolites in plasma 
There has only been one dose-finding pilot study 75 and two controlled human 
mephedrone administration studies 96,97 published in the literature. The pilot study was 
a double-blind, randomised mephedrone administration study undertaken in Spain. The 
study recruited 9 occasional male users of psychostimulants who were given placebo, 
mephedrone or MDMA on 3 different occasions, with oral doses ranging from 50 mg to 
200 mg. Mephedrone has also been administered twice before to human volunteers. 
Papaseit et al. conducted a double-blind, randomised, crossover, controlled oral 
administration study where 12 healthy male volunteers took 200 mg of mephedrone, 
100 mg of MDMA or a placebo on 3 separate occasions 414. More recently, six male 
healthy volunteers ingested 150 mg of mephedrone as part of a controlled 
administration study. Plasma samples were collected at 1 h, 2 h, 4 h, 6 h, and 8 h post 
drug administration and were analysed by GC-MS 97 and LC-MS 91. In all studies mean 
mephedrone concentration peaked at approximately 1.25 h in plasma and displayed 
mean t1/2 of 2.2 h. The study analysing samples on LC-MS also focused on the 
quantification of mephedrone metabolites. 4-CARBOXY reached the highest 
concentration after 1.2 ± 0.2 h followed by NOR (Tmax = 1.5 ± 0.2 h) and DHM (Tmax = 1.7 
 Chapter 3 | Whole blood, plasma and dried blood spots 
 
Page | 212 
 
± 0.5 h) post drug administration. N-succinyl nor-mephedrone, being a derivative of 
NOR, peaked much later (Tmax = 3.7 ± 0.3 h). 
 
Depending on drug affinity to plasma proteins drugs might be free to distribute around 
the body or might be bound to proteins. The degree of protein-binding is an important 
consideration when drug concentrations are measured in different biological matrices. 
Whole blood is often the only specimen available in forensic investigations, such as 
driving under the influence of drugs and drug-facilitated crime, where immediate 
sample preparation does not usually take place 415. In contrast, clinical laboratories 
routinely analyse plasma and serum samples. Therefore, it is important to compare 
obtained results between these two matrices with care as whole blood to plasma drug 
distribution ratios are not always known 416. In particular little is known about whole 
blood to plasma distribution ratios of illicit drugs (except ethanol which has been 
extensively studied 417,418). Consideration of this issue is especially relevant when 
comparing drug concentrations in whole blood to data from pharmacokinetic studies 
where serum or plasma has been analysed. To my knowledge, whole blood to plasma 
distribution ratios have not been reported before for mephedrone and its metabolites. 
3.3.2 Plasma aims 
The primary aim was to investigate pharmacokinetics of mephedrone and its 
metabolites in plasma (especially clearance and volume of distribution which have not 
been reported before) and to compare the data to that obtained from whole blood 
analysis. The secondary aim was to evaluate whole blood to plasma distribution ratios 
and to assess the correlation between analyte concentrations in these two matrices.  
3.3.3 Experimental 
3.3.3.1 Reagents 
Please refer to 3.1.3.1.  
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3.3.3.2 Blank matrix collection 
Please refer to 3.1.3.2 for more details. Drug-free, pooled human plasma (NaF/KOx) 
used for preparation of calibration standards, QCs and blanks was purchased from Sera 
Laboratories International Ltd (Burgess Hill, UK). 
3.3.3.3 Volunteer administration study and sample 
collection 
Please refer to 3.1.3.3 for more details. At each timepoint two aliquots of blood were 
collected, one of which was centrifuged at 2300 rpm for 10 min to harvest plasma. 
3.3.3.4 Working solutions 
Working solutions used for the preparation of the calibration curve were made in 
MeOH:water (50:50 v/v) at 10, 20, 25, 125, 250, 625, 1250 ng/mL for MEPH and 
4-CARBOXY; 5, 12.5, 25, 125, 250, 625, 1250 ng/mL for DHNM; and 2.5, 10, 25, 125, 250, 
625, 1250 ng/mL for HYDROXY, DHM and NOR. Working solution used for the 
preparation of the QC samples at low, medium and high level were made in MeOH:water 
(50:50 v/v) at 12.5, 125, 625 ng/mL for MEPH and 4-CARBOXY; 10, 125, 625 ng/mL for 
DHNM; and 5, 125, 625 ng/mL for HYDROXY, DHM and NOR. IS solution containing 
MEPH-d3, DHM-d3 at 50 ng/mL was prepared in MeOH:water (50:50 v/v). 
3.3.3.5 Calibration standards and quality control samples 
Matrix-matched calibration standards containing MEPH and 4-CARBOXY at 0.4, 0.8, 1, 5, 
10, 25 and 50 ng/mL; DHNM at 0.2, 0.5, 1, 5, 10, 25 and 50 ng/mL; HYDROXY, DHM and 
NOR at 0.1, 0.4, 1, 5, 10, 25 and 50 ng/mL were prepared by the addition of an 
appropriate volume of the working solution to plasma. QC Low (0.5 ng/mL for MEPH and 
4-CARBOXY; 0.4 ng/mL for DHNM and 0.2 ng/mL for HYDROXY, DHM and NOR), QC Med 
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(5 ng/mL for all analytes) and QC High (25 ng/mL for all analytes) were prepared by the 
addition of an appropriate volume of the working solution to plasma.  
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing plasma but no IS and one sample containing plasma and IS were also 
prepared and taken through the extraction. 
3.3.3.6 Sample preparation 
Sample preparation procedure described in 3.1.3.6 was followed but 250 µL of plasma 
was taken through the extraction. 
3.3.3.7 LC-MS/MS conditions 
DHM-d3 was used as an IS for 4-CARBOXY. For other details please refer to 3.1.3.7. 
3.3.3.8 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
3.3.3.9 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
3.3.4 Results 
3.3.4.1 Method validation 
Please refer to Section 2.6.3 in Chapter 2. 
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3.3.4.2 Concentrations of mephedrone and its 
metabolites in plasma (NaF/KOx) 
Mean plasma concentrations ± SD for mephedrone and its metabolites in all 6 
participants are presented in Figure 3-15 - Figure 3-20. Individual plots and raw data can 




Figure 3-15. Mean mephedrone plasma concentrations ± SD (n=6) 
 
 
Figure 3-16. Mean dihydro-mephedrone plasma concentrations ± SD (n=6); note that 
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Figure 3-17. Mean nor-mephedrone plasma concentrations ± SD (n=6); note that 
nor-mephedrone was detected in one participant at 5 min (0.171 ng/mL) and in two 
participants on Day 2 (0.115 ng/mL and 0.138 ng/mL) 
 
 
Figure 3-18. Mean hydroxytolyl-mephedrone plasma concentrations ± SD (n=6); note that 
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Figure 3-19. Mean 4-carboxy-mephedrone plasma concentrations ± SD (n=6) 
 
 
Figure 3-20. Mean dihydro-nor-mephedrone plasma concentrations ± SD (n=6); note that 
dihydro-nor-mephedrone was detected in one participant at 45 min (0.422 ng/mL) 
 
 
Following the administration, MEPH and 4-CARBOXY were detectable in plasma from 
5 min. DHM, NOR and HYDROXY were also present in plasma at 5 min but only in M6. In 
other participants DHM, NOR and HYDROXY were detectable after 30 min, 15 min and 
20 min, respectively. DHNM appeared in plasma after 45 min in M6 and after 75 min in 
M1-M3. The analyte was not detected in M4 and M5. All analytes were present in 
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3.3.4.3 Whole blood to plasma distribution ratios 
Whole blood to plasma distribution ratios for mephedrone and its metabolites were 
calculated from the Cmax in both matrices (see Table 3-6). 
 
Assuming the mean haematocrit value of 0.45, calculated median and mean were 
greater than 1 for mephedrone, DHM, HYDROXY and DHNM and smaller than 1 for NOR 
and 4-CARBOXY. %CV ranged from 8.5% for mephedrone to 33.6% for NOR. 
 
 
Table 3-6. Mean, median, range, %CV and p-values obtained for the whole blood to plasma 
distribution ratios calculated from the Cmax; p-value could not be calculated for DHNM because 
the sample size was too small (DHNM was not detected in M4 in either matrix and it was only 
detected in M5 in plasma) 
Analyte Mean Median Range %CV p-value 
MEPH 1.14 1.11 1.02-1.27 8.5 0.018 
DHM 1.26 1.30 0.885-1.54 18.8 0.043 
NOR 0.750 0.765 0.433-1.13 33.6 0.045 
HYDROXY 1.13 1.16 0.899-1.32 13.8 0.092 
4-CARBOXY 0.899 0.973 0.571-1.06 21.1 0.248 
DHNM 1.26 1.27 0.961-1.55 24.9 - 
 
3.3.4.4 Correlation with whole blood 
Correlation between analyte concentrations in whole blood and plasma in each 
participant is presented in Figure 3-21 - Figure 3-26 (the blue dotted line shows a trend 
line). Individual correlation can be found in Appendix E. 
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Figure 3-21. Correlation between plasma and whole blood concentrations for mephedrone 
 
Figure 3-22. Correlation between plasma and whole blood concentrations for 
dihydro-mephedrone 
 
Figure 3-23. Correlation between plasma and whole blood concentrations for nor-mephedrone 
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Figure 3-24. Correlation between plasma and whole blood concentrations for 
hydroxytolyl-mephedrone 
 
Figure 3-25. Correlation between plasma and whole blood concentrations for 
4-carboxy-mephedrone 
 
Figure 3-26. Correlation between plasma and whole blood concentrations for 
dihydro-nor-mephedrone 
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Concentrations of mephedrone and its metabolites appear to be significantly correlated 
between plasma and whole blood as evidenced by the Pearson correlation coefficient 
being greater than 0.867. 
3.3.4.5 Whole blood and plasma - method comparison 
Bland-Altman analysis was performed to examine the agreement between 
concentrations obtained in whole blood and plasma. Bland-Altman plots, presented in 
Figure 3-27 - Figure 3-32, show the difference between paired concentrations from 
plasma and whole blood samples plotted against the mean of the two concentrations 
calculated for each individual sample. Dotted lines represent the 95% limits of 
agreement (mean difference ± 2 SD). 
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Figure 3-28. Bland-Altman analysis between plasma and whole blood for dihydro-mephedrone  
 
Figure 3-29. Bland-Altman analysis between plasma and whole blood for nor-mephedrone 
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Figure 3-31. Bland-Altman analysis between plasma and whole blood for 
4-carboxy-mephedrone 
 
Figure 3-32. Bland-Altman analysis between plasma and whole blood for 
dihydro-nor-mephedrone 
 
Bland-Altman plots show bias ± 2 SD between whole blood and plasma concentrations 
to be -8.8 ± 10.6 ng/mL for mephedrone, -0.37 ± 0.37 ng/mL for DHM, 1.3 ± 2.2 ng/mL 
for NOR, -0.05 ± 0.20 ng/mL for HYDROXY, 15.2 ± 57.9 ng/mL for 4-CARBOXY and 0.02 ± 
0.13 ng/mL for DHNM. More than 95% of datapoints were within ± 2 SD of the bias for 
mephedrone and 4-CARBOXY whereas DHM, NOR, HYDROXY and DHNM showed poorer 
agreement with less than 95% of datapoints being within ± 2 SD of the bias. In addition, 
M6 showed notable data spread, with datapoints at higher concentrations falling 
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3.3.4.6 Pharmacokinetic analysis 
Plasma drug concentrations were fitted with a single-dose, first-order elimination phase 
model and calculated mean pharmacokinetic parameters are summarised in Table 3-7. 
Individual PK data can be found in Appendix E. 
 
Table 3-7. Mean ± SD pharmacokinetic data from analysis of mephedrone and its metabolites 
in plasma from 6 male participants; kel and t1/2 could not be calculated for DHNM because the 
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Mephedrone showed rapid absorption (Tmax of 52.5 ± 20.7 min) and a relatively fast t1/2 
of 1.98 ± 0.30 h. Most mephedrone metabolites reached Tmax shortly after the parent 
drug, except for NOR and DHNM which peaked later at 130 ± 35.1 min and 285 ± 75 min, 
respectively. 4-CARBOXY reached the highest concentration and had the largest AUC of 
306 ± 244 ng/mL and 1154 ± 598 ng mL-1 h, respectively. Another metabolite which was 
present in high abundance was NOR, reaching Cmax of 7.87 ± 5.35 ng/mL and AUC of 67.5 
± 35.9 ng mL-1 h. For DHNM, the observed Tmax of 285 ± 75 min corresponded with the 
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Cmax of 0.609 ± 0.559 ng/mL. No other pharmacokinetic parameters were determined 
for DHNM because the elimination phase was not observed from the data. 
 
With regards to elimination, mephedrone and 4-CARBOXY showed similar kinetics, 
including similar t1/2 (1.98 ± 0.30 h for mephedrone and 1.94 ± 0.62 h for 4-CARBOXY) 
and kel (0.006 ± 0.001 min-1 for mephedrone and 0.006 ± 0.002 min-1 for 4-CARBOXY). 
HYDROXY was eliminated with t1/2 of 1.96 ± 1.06 h while DHM and NOR were eliminated 
with t1/2 of 6.06 ± 1.66 h and 4.02 ± 1.40 h, respectively. 
3.3.4.7 Comparison of pharmacokinetic parameters 
between whole blood and plasma 
The mean Cmax for mephedrone and its metabolites was similar in whole blood and 
plasma, except for NOR which reached higher concentration in plasma (7.87 ± 
5.35 ng/mL) compared to whole blood (5.12 ± 2.16 ng/mL). Mephedrone had a Cmax of 
89.8 ± 41.7 ng/mL in plasma and 101 ± 45.4 ng/mL in whole blood, DHM had a Cmax of 
1.25 ± 0.847 ng/mL in plasma and 1.45 ± 0.71 ng/mL in whole blood, HYDROXY had a 
Cmax of 1.50 ± 1.39 ng/mL in plasma and 1.75 ± 1.81 ng/mL in whole blood. 4-CARBOXY 
reached the highest concentration in both matrices (306 ± 244 ng/mL in plasma and 241 
± 113 ng/mL in whole blood). DHNM had the lowest Cmax in both matrices (0.609 ± 
0.559 ng/mL in plasma and 0.607 ± 0.505 ng/mL in whole blood). The two major 
metabolites detected at high concentrations in this study correspond well with a 
previously published administration study where 4-CARBOXY was the most 
predominant metabolite detected in plasma followed by NOR 91. 
 
The mean Tmax of approximately 55 min for mephedrone corresponded well between 
whole blood and plasma, indicating rapid absorption of the drug following nasal 
insufflation. All other analytes had a more delayed Tmax than mephedrone. DHNM had a 
Tmax of 285 ± 75 min and 300 ± 73.5 min in plasma and whole blood, respectively, with 
concentrations still rising at this point in both matrices. All analytes were detectable up 
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to 360 min (6 h) in plasma and whole blood, with mephedrone and NOR also being 
detected on Day 2 in some participants. 
 
With regards to elimination, mephedrone and 4-CARBOXY showed similar kinetics, 
including similar t1/2 and kel in both matrices. Mephedrone had a mean t1/2 of 2.12 ± 0.33 
h in whole blood and 1.98 ± 0.30 h in plasma whereas 4-CARBOXY had a t1/2 of 1.70 ± 
0.26 h in whole blood and 1.94 ± 0.62 h in plasma. DHM had a longer t1/2 than 
mephedrone in whole blood (7.19 ± 4.19 h) and in plasma (6.06 ± 1.66 h) while NOR had 
a t1/2 of 6.09 ± 2.64 h in whole blood and 4.02 ± 1.40 h in plasma. HYDROXY had a short 
t1/2 of 1.52 ± 0.60 h in whole blood and 1.96 ± 1.06 h in plasma. 
3.3.5 Discussion 
After the intranasal administration of 100 mg of mephedrone hydrochloride, the mean 
Cmax of mephedrone in plasma was 89.8 ± 41.7 ng/mL. The Cmax was approximately 50% 
lower than the reported Cmax of 179.0 ± 29.3 ng/mL following oral administration of 
150 mg of mephedrone hydrochloride 91 and approximately 42% higher than the 
reported Cmax of 51.7 ± 20.5 ng/mL following oral administration of 100 mg of 
mephedrone hydrochloride 75. Intranasal administration of drugs results in rapid drug 
absorption via the nasal mucosa and avoids hepatic and intestinal first-pass metabolism. 
Therefore, the same dose of drug given orally and intranasally would result in faster Tmax, 
higher Cmax and larger AUC after intranasal administration. As expected, mean Tmax in 
plasma was shorter in our study (0.88 ± 0.35 h) compared to the plasma Tmax of 1 h 
(range: 1-2 h) reported after an oral administration of 100 mg of mephedrone 
hydrochloride. Moreover, the AUC in plasma calculated for up to 8 h after oral 
administration of 100 mg of mephedrone hydrochloride was approximately 2.5 times 
smaller than the AUC reported in our study following a 100 mg intranasal insufflation. 
Pharmacokinetic results obtained from the analysis of whole blood samples cannot be 
compared with the literature because, to our knowledge, this is the first study that 
presents this data. 
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In this study, mephedrone has been shown to be rapidly absorbed, reaching mean 
plasma Tmax of 0.88 ± 0.35 h. This is in contrast with the plasma Tmax reported in other 
controlled administration studies of MDMA (2.3 ± 1.1 h after a 100 mg oral dose) 414, 
methamphetamine (2.8 ± 0.1 h after a 50 mg intranasal dose) 419 and cathinone (2.31 ± 
0.65 h after chewing 0.6 g of khat leaves per kg body weight for 1 h) 420. Mephedrone 
also had shorter t1/2 (1.98 ± 0.30 h) in plasma compared with MDMA (9.0 ± 2.3 h) 414 and 
methamphetamine (9.1 h (3-11 h)) 419. This explains why mephedrone users report 
taking 100-200 mg every hour or two hours, such that they use up to 1 g or more per 
“session” 30,68. 
 
The mean plasma t1/2 of mephedrone reported in this study (2.12 ± 0.33 h in whole blood 
and 1.98 ± 0.30 h in plasma) corresponds well with the published t1/2 in plasma from 
previous oral mephedrone administration studies (2.2 ± 0.1 h 91, 2.2 ± 0.28 h 97 and 2.2 
± 0.4 h 96). Regarding metabolites, Olesti et al. 91 have reported t1/2 of 4.5 ± 0.4 h, 5.7 ± 
0.8 h and 1.94 ± 0.62 h for NOR, DHM and 4-CARBOXY in plasma, respectively, which is 
also in good agreement with the values reported here. 
 
When centrifuged, whole blood can be separated into plasma and cellular components 
containing erythrocytes and leukocytes mixed with platelets 421. A drug that is equally 
distributed between plasma and erythrocytes will give a whole blood to plasma drug 
distribution ratio of 1 (unity). If a drug partitions into the erythrocytes the ratio will 
exceed 1 and if a drug partitions into plasma the ratio will be smaller than 1 415. For 
example, THC poorly distributes into red blood cells resulting in plasma concentration 
being twice that of whole blood (assuming normal haematocrit of 0.45) 422. Huestis et 
al. have developed a mathematical model for calculating cannabinoid plasma 
concentrations when only whole blood samples are available for analysis 423. The model 
proposes multiplying whole blood concentrations by a multiplying factor of 1.6. The 
model was applied by Giroud et al. to the analysis of 8 whole blood and plasma samples 
from regular cannabis users 424. The authors found whole blood to plasma distribution 
ratios to be about 1.6 for 3 cannabinoids and their corresponding %CV was smaller than 
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15.1%, suggesting plasma drug concentrations could be evaluated from whole blood 
concentrations when the multiplying factor of 1.6 is taken into account. Our study 
reports for the first-time concurrent concentrations of mephedrone and its metabolites 
in whole blood and plasma, allowing whole blood to plasma distribution ratios to be 
calculated. According to the p-values obtained from the one sample t-test (Table 3-6), 
median whole blood to plasma distribution ratios were statistically different from 1 
(unity) for mephedrone (median: 1.11), DHM (median: 1.30) and NOR (median: 0.765). 
However, due to the small sample size (n=6), further studies in this area are encouraged. 
Calculated %CV ranged from 8.5% for mephedrone to 33.6% for NOR but was generally 
higher than 15%. This could be partly due to differences in haematocrit between 
participants, which was not determined in this study. 
 
Inter-individual variations seen in the study might be due to genetic polymorphism of 
CYP2D6 which is responsible for mephedrone metabolism in humans 70. Olesti et al. have 
demonstrated that significantly altered mephedrone plasma concentrations are a result 
of CYP2D6 activity, with users having no or low CYP2D6 functionality being at risk of 
acute toxicity 75. Buccal swabs for CYP2D6 genotyping were collected from the 
participants in this study but were not analysed in time for the thesis submission. 
 
Bland-Altman analysis showed a negative bias of -8.8 ng/mL, -0.37 ng/mL and -0.05 
ng/mL for mephedrone, DHM and HYDROXY, respectively, suggesting whole blood 
concentrations were slightly overestimated. NOR, 4-CARBOXY and DHNM showed a 
positive bias of 1.25 ng/mL, 15.2 ng/mL and 0.02 ng/mL, respectively, suggesting whole 
blood concentrations being slightly underestimated. The agreement between methods 
might have also been affected by CYP2D6 polymorphism as well as plasma protein 
binding which influences the amount of unbound drug partitioning into the 
erythrocytes. This leads to an uneven distribution of a drug between plasma and the 
erythrocytes, which can result in concentration differences between whole blood and 
plasma. The extent of mephedrone or its metabolites binding to plasma proteins has not 
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been determined in humans but 21.6 ± 3.67% of mephedrone has been shown to bind 
to plasma proteins in Sprague-Dawley rats 92. 
3.3.6 Conclusion  
This is the first-time pharmacokinetic properties of mephedrone and its metabolites 
have been derived from whole blood and compared to concurrently collected plasma 
samples. Median whole blood to plasma distribution ratios have been shown to be 
statistically different from 1 (unity) for mephedrone, DHM and NOR. Inter-subject 
variability observed in the study might have been a result of CYP2D6 polymorphism and 
an unknown extent of analytes binding to plasma proteins in humans. 
 Dried blood spots 
3.4.1 Detection of mephedrone and its metabolites in dried 
blood spots 
Even though dried blood spots (DBS) are increasing evaluated for use in drug testing 
instead of venous whole blood, little is known about the distribution of mephedrone 
and its metabolites into this matrix. To date the only study which reported a successfully 
validated method for the detection of 64 NPS (including mephedrone) in DBS (collected 
on filter paper) was published by Ambach et al 376. The method was applied to 21 
authentic DBS samples (the paper does not specify where the samples were collected 
from) but mephedrone was not detected. 
3.4.2 Dried blood spots aims 
The primary aim was to investigate the distribution of mephedrone and its metabolites 
in dried blood spots following a controlled mephedrone administration. The secondary 
aim was to compare concentrations obtained in dried blood spots with those obtained 
in whole blood and plasma in order to assess correlation between these matrices. 
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Please refer to 3.1.3.1 for the information. Ten microliter Mitra® devices were 
purchased from Neotyrex (Torrance, USA). 
3.4.3.2 Blank matrix collection 
Please refer to 3.1.3.2. 
3.4.3.3 Volunteer administration study and sample 
collection 
Six healthy male volunteers nasally insufflated 100 mg of mephedrone hydrochloride 
supplied as a racemic mixture (purity: 96.3 ± 0.5%). Fingertips were wiped with an 
ethanol wipe and allowed to dry. A single-use lancet was used to prick a finger and 10 µL 
of capillary blood was directly collected onto the Mitra® device at -10 min (before 
administration), 5 min, 20 min, 60 min, 105 min, 120 min, 360 min, Day 2 and Day 3. 
Collected samples were then dried for 2 h at room temperature and stored desiccated 
at -20ᵒC until analysis. 
3.4.3.4 Working solutions 
Working solutions used for the preparation of the calibration curve were made in 
MeOH:water (50:50 v/v) at 100, 200, 500, 1250, 2500, 5000, 12500 ng/mL for NOR and 
4-CARBOXY; 50, 200, 500, 1250, 2500, 5000, 12500 ng/mL for DHM, HYDROXY, DHNM; 
and 200, 250, 500, 1250, 2500, 5000, 12500 ng/mL for MEPH. Working solution used for 
the preparation of the QC samples at low, medium and high level were made in 
MeOH:water (50:50 v/v) at 125, 1250, 10000 ng/mL for NOR and 4-CARBOXY; 100, 1250, 
10000 ng/mL for DHM, HYDROXY, DHNM; and 250, 1250, 1000 ng/mL for MEPH. IS 
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solution containing MEPH-d3 and DHM-d3 at 20 ng/mL was prepared in 0.3% formic acid 
in MeOH which was used as an extraction solvent. 
3.4.3.5 Calibration standards and quality control samples 
Calibration standards containing NOR and 4-CARBOXY at 4, 8, 20, 50, 100, 200, 
500 ng/mL; DHM, HYDROXY, DHNM at 2, 8, 20, 50, 100, 200, 500 ng/mL; and MEPH at 
8, 10, 20, 50, 100, 200, 500 ng/mL were prepared by the addition of an appropriate 
volume of the working solution to whole blood. QC Low (5 ng/mL for NOR and 
4-CARBOXY; 4 ng/mL for DHNM, HYDROXY, DHM and 10 ng/mL for MEPH), QC Med 
(50 ng/mL for all analytes) and QC High (400 ng/mL for all analytes) were prepared by 
the addition of an appropriate volume of the working solution to whole blood. 
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing whole blood but no IS and one sample containing whole blood and IS were 
also prepared and taken through the extraction. 
3.4.3.6 Sample preparation 
Dried tips from the Mitra® devices were transferred to Eppendorf tubes to which 0.3% 
formic acid in MeOH containing IS was added. 0.3% formic acid in MeOH which did not 
contain the IS was added to the blanks. All samples were sonicated at 35 kHz for 15 min 
and vortex mixed for 5 min at 1300 rpm. The solvent was vacuum evaporated at 45ᵒC 
and samples were reconstituted with 100 µL of 0.1% formic acid in ACN:water 
(10:90 v/v). Samples where visible precipitate has formed were centrifuged for 5 min at 
10,000 rpm.  
 
Due to the nature of the collected samples, dilution could not be performed at the 
beginning of an extraction. As a result, 1 in 5 dilution was performed after sample 
reconstitution (see Section 2.6.6.7 in Chapter 2 for more details). Where dilution was 
required, 3 additional QCs were extracted and diluted in the same manner. 
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3.4.3.7 LC-MS/MS conditions 
DHM-d3 was used as an IS for 4-CARBOXY. For other details please refer to 3.1.3.7. 
3.4.3.8 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
3.4.3.9 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
3.4.4 Results 
3.4.4.1 Method validation 
Please refer to Section 2.6.6 in Chapter 2. 
3.4.4.2 Concentrations of mephedrone and its 
metabolites in dried blood spots 
Mean DBS concentrations ± SD for mephedrone, NOR and 4-CARBOXY in all 6 
participants are presented in Figure 3-33 - Figure 3-36. The remaining analytes were only 
detected in a handful of samples. DHNM was quantified in M4 at 20 min (3.26 ng/mL). 
DHM was detected between 60 min and 120 min in M3 (2.10-3.17 ng/mL) and in M6 
(2.06-2.55 ng/mL). HYDROXY was present in M2 at 60 min (2.46 ng/mL), 120 min 
(2.23 ng/mL) and 360 min (2.57 ng/mL) as well as in M4 at 60 min (2.63 ng/mL) and in 
M6 at 150 min (2.01 ng/mL).  
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Figure 3-33. Mean mephedrone concentrations ± SD in DBS (n=6); the orange line shows the 
LOQ; the error bar at 360 min is not shown in its entirety for clarity (it extends 
from -1400 ng/mL to 3500 ng/mL) 
 
Figure 3-33 shows the Cmax at 360 min which is unlikely to occur so late for mephedrone. 
A closer look at the data reveals that the Cmax occurs at 360 min because the 
concentration detected in the 360 min sample in M4 was 5,782 ng/mL, roughly 5 times 
higher than any other detected concentration at this timepoint. When that datapoint 
was excluded from the data set, mephedrone concentration peaked at 120 min (660 ± 
1,004 ng/mL) and dropped to 69.9 ± 45.0 ng/mL at 360 min (Figure 3-34). 
 
 
Figure 3-34. Mean mephedrone concentrations ± SD in DBS (n=6 but with the 360 min 
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Figure 3-36. Mean 4-carboxy-mephedrone concentrations ± SD in DBS (n=6); the orange line 
shows the LOQ 
 
3.4.4.3 Comparison of analyte concentrations in dried 
blood spot and whole blood  
Mephedrone, NOR and 4-CARBOXY were detectable in all participants in whole blood 
and DBS. Mephedrone was detected at the first collection timepoint (5 min) in both 
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detected at 60 min in M1, M2, M3 and M6 in DBS. 4-CARBOXY was detected after 5 min 
in M6 and after 20 min in M1-M5 in both matrices. As shown in Figure 3-37 - Figure 3-39, 
NOR and mephedrone reached higher mean concentration in DBS whereas 4-CARBOXY 




Figure 3-37. Mean mephedrone concentrations ± SD in DBS and whole blood (n=6); note that 
whole blood concentrations are shown on the secondary axis on the right-hand side and the 
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Figure 3-39. Mean 4-carboxy-mephedrone concentrations ± SD in DBS and whole blood (n=6) 
 
3.4.4.4 Comparison of analyte concentrations in dried 
blood spots and plasma  
Mephedrone, NOR and 4-CARBOXY were detectable in all participants in plasma and 
DBS. Mephedrone was detected at the first collection timepoint (5 min) in both 
matrices. NOR first appeared in plasma after 20 min in all participants except for M6 
where it was detected after 5 min. In DBS NOR was detected after 60 min in M1, M2, 
M3 and M6 as well as after 105 min in M4. 4-CARBOXY was detected after 20 min in 
M1-M5 and after 5 min in M6 in DBS. In plasma, 4-CARBOXY was present in the samples 
after 5 min in M3-M6 and after 20 min in M1 and M2. As shown in Figure 3-40 - Figure 
3-42, NOR and mephedrone reached higher mean concentration in DBS whereas 
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Figure 3-40. Mean mephedrone concentrations ± SD in DBS and plasma (n=6); note that plasma 
concentrations are shown on the secondary axis on the right-hand side and the entirety of the 
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Figure 3-42. Mean 4-carboxy-mephedrone concentrations ± SD in DBS and plasma (n=6) 
 
3.4.4.5 Correlation with whole blood 
Correlation between analyte concentrations in whole blood and DBS for each participant 
is presented in Figure 3-43 - Figure 3-45 (the black dotted line shows a trend line). 
Individual correlation can be found in Appendix E. 
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Figure 3-44. Correlation between DBS and whole blood concentrations for nor-mephedrone 
 
 




Mephedrone did not correlate well between the two matrices as evidenced by the 
Pearson correlation coefficient of 0.002. NOR and 4-CARBOXY showed better correlation 
with the Pearson correlation coefficient of 0.544 and 0.957, respectively. 
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3.4.4.6 Correlation with plasma 
Correlation between analyte concentrations in plasma and DBS for each participant is 
presented in Figure 3-46 - Figure 3-48 (the black dotted line shows a trend line). 
Individual correlation can be found in Appendix E. 
 
 
Figure 3-46. Correlation between DBS and plasma concentrations for mephedrone 
 
 
Figure 3-47. Correlation between DBS and plasma concentrations for nor-mephedrone 
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Figure 3-48. Correlation between DBS and plasma concentrations for 4-carboxy-mephedrone 
 
 
Mephedrone and NOR did not correlate well between the two matrices as evidenced by 
the Pearson correlation coefficient of -0.042 and 0.354, respectively. 4-CARBOXY 
showed a much better correlation with the Pearson correlation coefficient of 0.920. 
3.4.4.7 Whole blood and dried blood spots - method 
comparison 
Bland-Altman analysis was performed to examine the agreement between 
concentrations obtained in whole blood and DBS. Bland-Altman plots, presented in 
Figure 3-49 - Figure 3-51, show the difference between paired concentrations from DBS 
and whole blood samples plotted against the mean of the two concentrations calculated 
for each individual sample. Dotted lines represent the 95% limits of agreement (mean 
difference ± 2 SD). 
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Figure 3-49. Bland-Altman plots comparing whole blood and DBS methods for mephedrone 
 
Figure 3-50. Bland-Altman plots comparing whole blood and DBS methods for nor-mephedrone 
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Bland-Altman plots showed bias ± SD between whole blood and DBS concentrations to 
be 235 ± 872 ng/mL for mephedrone, 2.15 ± 4.61 ng/mL for NOR and -34.0 ± 53.8 ng/mL 
for 4-CARBOXY. Whole blood mephedrone concentrations were in good agreement with 
DBS concentrations with more than 95% of datapoints being within ± 2 SD of the bias. 
The agreement was poorer for NOR and 4-CARBOXY where 94.1% and 91.8% of 
datapoints, respectively, were found to be within ± 2 SD of the bias. 
3.4.4.8 Plasma and dried blood spots - method 
comparison 
Bland-Altman analysis was performed to examine the agreement between 
concentrations obtained in plasma and DBS. Bland-Altman plots, presented in Figure 
3-52 - Figure 3-54, show the difference between paired concentrations from DBS and 
plasma samples plotted against the mean of the two concentrations calculated for each 
individual sample. Dotted lines represent the 95% limits of agreement (mean difference 
± 2 SD). 
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Figure 3-53. Bland-Altman plots comparing plasma and DBS methods for nor-mephedrone 
 
 
Figure 3-54. Bland-Altman plots comparing plasma and DBS methods for 
4-carboxy-mephedrone 
 
Bland-Altman plots showed bias ± SD between plasma and DBS concentrations to be 247 
± 889 ng/mL for mephedrone, 1.30 ± 5.78 ng/mL for NOR and -44.9 ± 82.8 ng/mL for 
4-CARBOXY. Concentration of mephedrone and NOR in plasma was in good agreement 
with DBS concentrations where more than 95% of datapoints were within ± 2 SD of the 
bias. The agreement was poorer for 4-CARBOXY where 93.8% of datapoints were found 
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3.4.4.9 Pharmacokinetic analysis 
DBS drug concentrations were fitted with a single-dose, first-order elimination phase 
model and calculated mean pharmacokinetic parameters are summarised in Table 3-8. 
For mephedrone and NOR pharmacokinetic parameters were only calculated from 3 
participants (M2, M3 and M6) while the data for 4-CARBOXY is based on 5 participants 
(M1, M2, M3, M4, M6). This is because insufficient number of samples was collected in 
the elimination phase or the log-linear regression did not produce R2 of at least 0.970. 
 
Table 3-8. Mean ± SD pharmacokinetic data from analysis of mephedrone and its metabolites 
in dried blood spots 
* From 3 male participants (mean Cmax, Tmax, AUC is based on 6 participants) 















143 ± 108 
0.002 ± 
0.002 
6.83 ± 4.02 
13065 ± 
27719 
NOR * 12.4 ± 6.85 141 ± 125 
0.003 ± 
0.001 
4.29 ± 0.94 130 ± 102 
4-CARBOXY 
** 
144 ± 65 85.0 ± 27.9 
0.006 ± 
0.001 
1.98 ± 0.44 658 ± 175 
 
 
Due to the small sample size (n=3), large standard deviation was associated with the 
Cmax, Tmax, kel, t1/2 and AUC obtained for mephedrone, making the results unreliable. 
Pharmacokinetic parameters associated with NOR and 4-CARBOXY did not show large 
variability and will be discussed here. NOR reached a Cmax of 12.4 ± 6.85 ng/mL at 141 ± 
125 min which was later than 4-CARBOXY which peaked at 85.0 ± 27.9 min (Cmax of 144 
± 65 ng/mL). Moreover, 4-CARBOXY had larger AUC of 658 ± 175 ng mL-1 h compared to 
NOR (AUC of 130 ± 102 ng mL-1 h). With regards to elimination, 4-CARBOXY had a t1/2 of 
1.98 ± 0.44 h (kel of 0.006 ± 0.001 min-1) while NOR was eliminated with t1/2 of 4.29 ± 
0.94 h (kel of 0.003 ± 0.001 min-1). 
 
 Chapter 3 | Whole blood, plasma and dried blood spots 
 
Page | 246 
 
3.4.4.10 Comparison of pharmacokinetic parameters 
between dried blood spots, whole blood and 
plasma 
Mephedrone and five Phase I metabolites were detected in whole blood and plasma but 
only mephedrone, NOR and 4-CARBOXY were detected in DBS. As mentioned in 3.4.4.9, 
pharmacokinetic data associated with mephedrone in DBS had large standard deviation 
and could not be reliably compared with whole blood and plasma. 
 
NOR and 4-CARBOXY displayed similar Tmax between DBS, whole blood and plasma. NOR 
had a Tmax of 130 ± 35 min in plasma, 133 ± 37.5 min in whole blood and 141 ± 125 min 
in DBS. 4-CARBOXY peaked at 70.0 ± 18.2 min in plasma, 85.0 ± 24.5 min in whole blood 
and 85.0 ± 27.9 min in DBS. NOR had a t1/2 of 6.09 ± 2.64 h and 4.02 ± 1.40 h in whole 
blood and plasma, respectively. Mean t1/2 of 4.29 ± 0.94 h in DBS corresponded well with 
the value in plasma but was smaller than the t1/2 in whole blood. 
 
Interestingly, mean Cmax obtained for NOR was higher in DBS whereas mean Cmax 
obtained for 4-CARBOXY was higher in whole blood and plasma. These findings 
correspond well with the concentrations profiles presented in Figure 3-37 - Figure 3-39 
for whole blood and in Figure 3-40 - Figure 3-42 for plasma where NOR reached higher 
concentrations in DBS while 4-CARBOXY reached higher concentrations in plasma/whole 
blood at all timepoints. 
3.4.5 Discussion 
Lipophilic drugs can readily cross capillary membranes while hydrophilic drugs do it 
more slowly at a rate that is inversely proportional to their molecular mass. 4-CARBOXY, 
being a more polar metabolite than NOR is, therefore, likely to be mostly confined to 
venous blood. This may explain why 4-CARBOXY reached lower concentrations in DBS 
compared to whole blood and plasma. On the other hand, NOR is a more lipophilic 
metabolite than 4-CARBOXY. Mean concentrations of NOR in DBS were higher than the 
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concentrations measured in whole blood and plasma. It has been hypothesised that this 
may be due to the concentration difference between capillary and venous blood. 
Capillary blood collected from a finger prick is a mixture of arterial and venous blood, 
but it also contains interstitial and intracellular fluids. Capillary blood is generally said to 
resemble arterial blood more than venous blood 425. Significant differences between 
capillary and venous paracetamol concentrations have been previously reported during 
the absorption phase (up to 1 h post oral administration) 283, suggesting that an 
equilibrium throughout the blood and body fluids needs to be achieved for reliable 
comparison. Higher concentrations of artemisinin (up to 500 min after administration) 
426 and tacrolimus 425 in capillary blood have also been reported but authors found it 
difficult to explain. The concentration difference may be attributed to the change in the 
glycation state of haemoglobin in dried blood possibly causing extraction bias 427, but 
this requires further studies. 
 
The first sample collected at 5 min from all participants showed high mephedrone 
concentrations, some of which reached the highest concentration across all collected 
samples. This was, however, not the case for the metabolites (4-CARBOXY and NOR) 
which suggests that samples must have become contaminated with mephedrone only. 
Even though participants nasally insufflated mephedrone in a separate room, wore 
gloves and cleaned their hands before and after drug administration, it is possible that 
they used fingers to wipe their nose after the intranasal mephedrone insufflation, 
inadvertently picking up residual mephedrone powder which was not effectively 
removed by cleaning fingertips with an ethanol wipe. Samples can also be prone to 
contamination during extraction, but mephedrone was not present in the blank samples 
extracted alongside DBS samples. Even though contamination was observed in samples 
collected at 5 min, it is unlikely to have an impact on DBS collection in real life where 
samples would not be collected so quickly after mephedrone use. 
 
The Pearson correlation coefficient showed very strong correlation between 4-CARBOXY 
DBS concentrations and both whole blood (Pearson = 0.957) and plasma (Pearson = 
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0.920) concentrations. All other analytes demonstrated poor to moderate correlation. 
NOR showed good correlation between DBS and whole blood (Pearson = 0.544) but was 
poorly correlated between DBS and plasma (Pearson = 0.354). Poor agreement was also 
observed for mephedrone between DBS and whole blood (Pearson = 0.002) as well as 
plasma (Pearson = -0.042), which might be related to differences in concentrations 
between capillary and venous blood. Bland-Altman analysis showed that more than 95% 
of the observed concentrations were within ± 2 SD of the bias for mephedrone and NOR 
in plasma and within ± 2 SD of the bias for mephedrone in whole blood. Negative bias 
of -34.0 ng/mL and -44.9 ng/mL was observed for 4-CARBOXY in whole blood and 
plasma, respectively, suggesting DBS concentrations were overestimated. Mephedrone 
and NOR showed positive bias in whole blood (235 ng/mL and 2.15 ng/mL, respectively) 
and plasma (247 ng/mL and 1.30 ng/mL, respectively), suggesting DBS concentrations 
were underestimated. No trend in variation over the concentration range was observed. 
3.4.6 Conclusion  
This is the first-time mephedrone and two of its metabolites (NOR and 4-CARBOXY) were 
detected in DBS collected from a controlled administration study. Even though the 
strongest correlation was reported for 4-CARBOXY between DBS and whole 
blood/plasma concentrations, Bland-Altman analysis showed wide confidence intervals 
demonstrating poor agreement between the methods. However, the agreement might 
have been affected by the differences in concentrations between capillary and venous 
blood. 
 Pharmacodynamics 
3.5.1 Pharmacodynamics aims 
The aim was to analyse the responses to the visual analogue scale (VAS), which 
measures the changes in the subjective effects following drug intake. The secondary aim 
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was to investigate changes in the psychological effects (heart rate, blood pressure, body 
temperature, blood oxygen saturation) after mephedrone administration.  
3.5.2 Experimental details 
To determine whether participants were experiencing neuropsychiatric effects of 
mephedrone, participants were asked a series of questions using a validated score 
incorporating a VAS. This was done at -10 min (before mephedrone administration) and 
then at every 15 min from the time of mephedrone administration until 2 h and then at 
2.5 h, 3 h, 5 h and 6 h 386. VAS assessed subjective experience of: “drug effect, bad effect, 
good drug effect, high, stimulated, sad, confused, fearful, liking, dizzy, experiencing 
changes in distance, light, hearing, body sensation, surrounding”. VAS was presented as 
10 cm horizontal lines, where the 0 cm point indicated no effects/changes and the 10 cm 
point indicated extreme effects/changes. VAS used in the administration study can be 
found in Appendix D. 
 
In addition, each participant had their baseline observations (heart rate, blood pressure, 
body temperature, blood oxygen saturation) checked before mephedrone 
administration and then continually monitored and recorded at each point of sampling 
or every 20 min (whichever was shorter) after mephedrone administration until 6 h. 
3.5.3 Results 
As shown in Table 3-9, mephedrone administration caused mean increases in all VAS 
parameters, except for “bad drug effects” and “sadness” which were not reported. Most 
subjective effects commenced after 15 min, except for “changes in light” which was 
reported after 30 min. All subjective effects other than “changes in distance” and 
“changes in light” also peaked at 15 min and returned to baseline levels after 
60-300 min. Individual data can be found in Appendix E. 
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(cm ± SD, min) 
Peak 
(cm ± SD, min) 
Return to baseline 
(min) 
Drug effect 6.5 ± 3.5, 15 6.5 ± 3.5, 15 150 
Bad drug effect Not reported Not reported Not reported 
Good drug effect 5.6 ± 4.2, 15 5.6 ± 4.2, 15 300 
High 5.7 ± 3.5, 15 5.7 ± 3.5, 15 180 
Stimulated 5.8 ± 2.5, 15 5.8 ± 2.5, 15 120 
Sadness Not reported Not reported Not reported 
Confused 2.1 ± 2.2, 15 2.1 ± 2.2, 15 150 
Fearful 0.58 ± 0.58, 15 0.58 ± 0.58, 15 60 
Liking 6.5 ± 2.9, 15 6.5 ± 2.9, 15 120 
Dizzy 2.8 ± 1.8, 15 2.8 ± 1.8, 15 75 
Changes in 
distance 
0.58 ± 0.66, 15 0.75 ± 1.2, 45 75 
Changes in light 0.33 ± 0.52, 30 0.58 ± 1.4, 60 90 
Changes in hearing 1.1 ± 1.7, 15 1.1 ± 1.7, 15 75 
Changes in body 
sensation 
5.3 ± 2.6, 15 5.3 ± 2.6, 15 90 
Changes in 
surrounding 
1.2 ± 1.3, 15 1.2 ± 1.3, 15 75 
 
 
Detailed changes over time in VAS “drug effects”, “high” and “liking” are presented for 
each participant in Figure 3-55 - Figure 3-57 (errors are omitted for clarity but are listed 
in Table 3-9). While VAS “drug effects”, “high” and “liking” declined after peaking for 
M1-M5, M6 experienced longer effects (10 cm on the VAS scale) which lasted 60 min 
(“drug effects”, “high”) and 75 min (“liking”) after peaking. 
 Chapter 3 | Whole blood, plasma and dried blood spots 
 
Page | 251 
 
 
Figure 3-55. c 
 
 
Figure 3-56. Changes in VAS "high" over time in each participant on a 0-10 cm scale  
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Mephedrone administration was also associated with changes in heart rate, systolic 
blood pressure (SBP) and diastolic blood pressure (DBP). As shown in Table 3-10, SBP 
and DBP increased from the baseline level by 29 ± 13 mmHg and 18 ± 5 mmHg, 
respectively. SBP peaked (155 ± 17 mmHg) after 7.5 ± 4.2 min and lasted until 102 ± 
54 min, representing an 11-35% increase above the pre-dose levels. DBP peaked (95 ± 
9 mmHg) after 16 ± 15 min and lasted until 93 ± 67 min, representing 13-32% increase 
above the pre-dose levels. Moreover, heart rate (HR) increased by 38 ± 19 bpm from the 
baseline level (84 ± 12 bpm). HR peaked at 122 ± 30 bpm within 16 ± 9 min and returned 
to the baseline level after 113 ± 108 min. No significant changes in body temperature or 
blood oxygen saturations were observed. Individual data can be found in Appendix E. 
 
 
Table 3-10. Mean ± SD changes in DBP (mmHg), SBP (mmHg), HR (bpm) after mephedrone 
administration 
DBP SBP HR 
Baseline (mmHg or bpm) 77 ± 7 126 ± 13 84 ± 12 
Peak (mmHg or bpm) 95 ± 9 155 ± 17 122 ± 30 
Increased by (mmHg or bpm) 18 ± 5 29 ± 13 38 ± 19 
Peak (min) 16 ± 15 7.5 ± 4.2 16 ± 9 
Return to baseline (min) 93 ± 67 102 ± 54 113 ± 108 
 
3.5.4 Discussion 
Mephedrone produced increases in several VAS parameters related to stimulant-like 
effects and changes in perception. All subjective effects, except for “changes in light”, 
commenced and peaked after 15 min. VAS parameters returned to the pre-dose levels 
after 60-180 min, except for “good drug effect” which returned to baseline after 
300 min. In the only other published study reporting changes in VAS parameters after 
oral mephedrone administration (200 mg), subjective effects commenced at 15 min, 
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peaked at approximately 45 min and were close to the pre-dose levels 2-3 h after 
administration 414. Earlier peak in subjective effects observed in our study is linked to 
the route of administration being nasal insufflation. In contrast, subjective effects 
produced by a 100 mg oral dose of MDMA commenced slightly later (at approximately 
45 min) and peaked between 1 h and 1.5 h. Subjective effects were experienced for 2-3 h 
and returned to the pre-dose levels 4 h after administration 414. 
 
Mephedrone administration produced stimulant-like cardiovascular effects which were 
manifested by a mean increase from the baseline in HR (38 ± 19 bpm), SBP (29 ± 
13 mmHg) and DBP (18 ± 5 mmHg) which occurred at 16 ± 9 min, 7.5 ± 4.2 min and 16 ± 
15 min, respectively. DBP was the first to returned to baseline levels after 93 ± 67 min, 
followed by SBP after 102 ± 54 min and HR after 113 ± 108 min. In a previous study, 
where a higher dose of mephedrone (200 mg) was administered orally mephedrone 
produced greater mean increases from the baseline in HR (46 ± 31 bpm), SBP (54 ± 
33 mmHg) and DBP (14 ± 17 mmHg) after approximately 45 min 414. When 100 mg of 
mephedrone was given orally, HR increased by 10 ± 4 bpm, SBP by 9.7 ± 7.6 mmHg and 
DBP by 15 ± 5 mmHg from the baseline but the time-course of these effects was not 
reported 75. Similarly to mephedrone, 100 mg of orally administered MDMA to 12 
healthy volunteers resulted in mean increases in HR (19 ± 12 bpm) after 1.5 h as well as 
in SBP (33 ± 9 mmHg) and DBP (15 ± 5 mmHg) after 1 h 414. HR, SBP and DBP returned to 
the pre-dose levels 6 h after administration. 
 
Pharmacokinetic data did not reflect the pharmacodynamic observations very well. 
Mephedrone reached Tmax in whole blood at approximately 55.0 ± 18.2 min and was 
close to undetectable levels on Day 2. Most subjected effects measured by VAS and the 
physiological effects commenced and peaked at approximately 15 min after drug 
administration, lasted 60-300 min and declined in parallel with mean whole blood 
mephedrone concentrations.  
 Chapter 3 | Whole blood, plasma and dried blood spots 
 
Page | 254 
 
3.5.5 Conclusion 
Following an intranasal administration of 100 mg of mephedrone hydrochloride, 
increases in heart rate, systolic blood pressure and diastolic blood pressure were 
observed. Moreover, mephedrone administration resulted in stimulant-like effects and 
changes in perception reported on the VAS scale. Subjective and physiological effects 
peaked earlier than the Tmax reached by mephedrone in whole blood. 
 Overall conclusion 
Analytical methods for quantification of mephedrone and five of its Phase I metabolites 
have been developed and successfully validated in whole blood, plasma and DBS. All 
analytes were detected in whole blood and plasma whereas only mephedrone, NOR and 
4-CARBOXY were detected in the majority of DBS. Pharmacokinetic parameters were 
similar between whole blood and plasma, demonstrating rapid absorption of 
mephedrone following nasal insufflation. The mean whole blood to plasma drug 
distribution ratios suggest that mephedrone, DHM, HYDROXY and DHNM partition into 
the erythrocytes while NOR and 4-CARBOXY distribute into plasma. Even though a 
moderate to strong correlation was observed between plasma, DBS and whole blood 
concentrations, Bland-Altman analysis showed wide confidence intervals demonstrating 
poor agreement between methods. Moreover, enantiomers of mephedrone were 
successfully separated on a chiral column and quantified in whole blood for the 
first-time. The enantiomeric fraction calculated for samples collected between 30 min 
and 360 min has been shown to be statistically different from the expected value of 0.5, 
suggesting enantioselective pharmacokinetics. However, it is not yet clearly understood 
if the difference is clinically significant. Finally, mephedrone administration increased 
heart rate, systolic blood pressure, diastolic blood pressure and most of the visual 
analogue scale parameters. 
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CHAPTER 4  
DETECTION OF MEPHEDRONE AND ITS 
METABOLITES IN FINGERPRINT SWEAT 
 Detection of mephedrone and its metabolites in fingerprint 
sweat 
Non-invasive, easy and quick sample collection coupled with marked subject 
acceptability have recently made fingerprint sweat an attractive matrix for drug testing.  
A number of studies have previously reported the detection of illicit drugs (either parent, 
Phase I or Phase II metabolites) in sweat 157,349,350 but this is the first study investigating 
distribution of mephedrone and its metabolites in fingerprint sweat. 
 Fingerprint sweat aims 
The primary aim of this study was to investigate the distribution of mephedrone and its 
metabolites in fingerprint sweat after a controlled administration. The secondary aim 
was to compare concentrations obtained in fingerprint sweat with those obtained in 
whole blood in order to assess correlation between the two matrices. Finally, the 
viability of fingerprint sweat for drug detection was evaluated. 
 Experimental 
4.3.1 Reagents 
Please refer to Section 3.1.3.1 in Chapter 3. 
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4.3.2 Blank matrix collection 
‘Blank’ fingerprint sweat was collected from drug-free volunteers. Ethical approval for 
this collection of drug-free matrix was granted by the Research Ethics Committee at 
King’s College London (HR 16/17 4237) and can be found in Appendix B. Fingertips were 
wiped with an ethanol wipe and allowed to dry. Glass cover slips (15 mm in diameter) 
were placed inside clean weighing boats and fingerprints were deposited on the surface 
of the cover slips. 
4.3.3 Volunteer administration study and sample collection 
Fingerprint sweat was collected from each finger (labelled as F1-F5, where F1 was the 
thumb and F5 was the little finger) of the right hand from 6 participants (referred to 
here as M1-M6) at -10 min (before administration), 10 min, 20 min, 45 min, 90 min, 3 h, 
5 h, Day 2 and Day 3 after nasal insufflation of 100 mg of mephedrone. Before 
the -10 min and 10 min sample collection, fingertips were wiped with an ethanol wipe 
and allowed to dry. Fingertips were only cleaned at these two timepoints to remove 
external contamination at the -10 min sample collection and to wash off any residual 
mephedrone powder at 10 min after nasal insufflation. Natural sweat excretions were 
collected at all other timepoints. Fingerprint sweat was deposited on clean glass cover 
slips placed inside clean weighing boats. Glass cover slips were then transferred to 20 mL 
scintillation vials which were stored at -20°C until analysis. On several occasions glass 
cover slips broke under applied pressure. Broken pieces of the cover slips were also 
transferred to scintillation vials. 
4.3.4 Calibration standards and quality control samples 
Calibration standards were prepared in methanol (MeOH) at the following 
concentrations: mephedrone (MEPH), dihydro-nor-mephedrone (DHNM), 
nor-mephedrone (NOR) at 0.2, 1, 5, 10, 20, 40, 50 ng/mL; hydroxytolyl-mephedrone 
(HYDROXY) and 4-carboxy-mephedrone (4-CARBOXY) at 0.1, 1, 5, 10, 20, 40, 50 ng/mL; 
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and dihydro-mephedrone (DHM) at 0.16, 0.5, 1, 5, 10, 25, 50 ng/mL. Fingerprint sweat 
samples from drug-free users were deposited on the glass cover slips as described in 
4.3.2. Two x 50 µL of each calibration standard was aliquoted on a cover slip and allowed 
to dry. QC Low (0.8 ng/mL for MEPH, DHNM, NOR; 0.5 ng/mL for HYDROXY and 
4-CARBOXY; and 0.4 ng/mL for DHM), QC Med (10 ng/mL for MEPH, DHNM, NOR, 
HYDROXY, 4-CARBOXY; 5 ng/mL for DHM) and QC High (40 ng/mL for all analytes) were 
prepared in the same way as calibration standards. Internal standard (IS) containing 
MEPH-d3 and DHM-d3 at 250 ng/mL was prepared in MeOH. 
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing fingerprints but no IS and one sample containing a fingerprint and IS were 
also prepared and taken through the extraction. 
4.3.5 Sample preparation 
Fifty microliters of the IS was aliquoted on the glass cover slips and allowed to evaporate. 
Cover slips were then transferred into scintillation vials and 300 µL of 0.2% formic acid 
in ACN:Water (90:10 v/v) was added. Vials were sonicated for 7 min at 35 kHz and vortex 
mixed for 1 min at 1200 rpm. The extraction solvent was transferred to clean 1.5 mL 
Eppendorf tubes and evaporated at 45°C. Samples were reconstituted with 100 µL of 
0.1% formic acid in ACN:Water (10:90 v/v). 
 
Due to the nature of the collected samples, dilution could not be performed at the 
beginning of an extraction. As a result, 1 in 100 dilution was performed after sample 
reconstitution (see Section 2.6.7.7 in Chapter 2 for more details). Where dilution was 
required, 3 additional QCs were extracted and diluted in the same manner. 
4.3.6 LC-MS/MS conditions 
DHM-d3 was used as an IS for 4-CARBOXY. For other details please refer to Section 
3.1.3.7 in Chapter 3. 
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4.3.7 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
4.3.8 Validation procedures 
Please refer to Section 2.5 in Chapter 2. 
 Results 
4.4.1 Method validation 
Please refer to Section 2.6.7 in Chapter 2. 
4.4.2 Detection of mephedrone and its metabolites in fingerprint 
sweat 
Mephedrone was detected in 163 (62%) of the 264 fingerprint sweat samples collected 
from 10 min until Day 3 and in the sweat from at least one finger in all participants 
(Figure 4-1). Mephedrone was first detected at 10 min in M1 in all fingers except F5, in 
M2 and M3 in all fingers, in M5 in all fingers except F2 and in M6 in F1 and F5 only. In 
M4 mephedrone was detected after 10 min in F3, after 90 min in F2 and F4 and after 3 h 
in F1. In F5 the analyte was only detected at 3 h. The last detected concentration was 
determined at the limit of detection (LOD) of 0.2 ng/mL and was observed between 5 h 
and Day 3 for M1-M6, except for F5 in M4 where it was detected at 3 h. Mephedrone 
was detected above the LOD in 11 (37%) fingerprint sweat samples collected on Day 2 
and in 7 (23%) fingerprint sweat samples collected on Day 3. The analyte was present in 
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Figure 4-1. Concentration of mephedrone in A) M1, B) M2, C) M3, D) M4, E) M5, F) M6 in sweat 
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NOR was detected in 7 (2.7%) fingerprint sweat samples above the limit of quantification 
(LOQ; 0.2 ng/mL) and in 10 (3.8%) fingerprint sweat samples above the LOD (0.05 ng/mL) 
in M1 and M2 only (Table 4-1). HYDROXY was only detected in M1 F1 at 20 min at 
0.399 ng/mL (LOQ of 0.1 ng/mL). Other analytes were not detected. 
 
 
Table 4-1. NOR concentrations (in ng/mL) detected above the LOQ of 0.2 ng/mL and LOD of 
0.05 ng/mL (ticks) in fingerprint sweat (F1-F5) in M1 and M2 
 
M1 M2 
F1 F2 F3 F4 F5 F1 F2 F3 F4 F5 
-10 min           
10 min           
20 min 1.64          
45 min 0.622          
90 min 0.209     ✓ 0.214    
3 h      ✓ 0.217 0.260   
5 h      0.296  ✓   
Day 2           
Day 3           
 
4.4.3 Pharmacokinetic analysis 
Pharmacokinetic parameters could not be accurately determined due to the significant 
inter- and intra-individual variation in detected concentrations of mephedrone (Figure 
4-1). Therefore, it was decided to provide observed ranges for the Cmax and Tmax. In M1 
Cmax (range: 0.713-4792 ng/mL) was observed between 20 min and 5 h. In M2 Cmax 
(range: 1.54-248 ng/mL) was observed at 3 h, except for F1 where the concentration 
peaked at 90 min. In M3 smaller variability in Cmax (range: 1.10-3.51 ng/mL) was 
observed but Tmax was between 45 min and 5 h. In M4, Cmax (range: 0.411-1.92 ng/mL) 
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was reached at 5 h, except for F5 where Tmax was observed at 3 h. In M5, Cmax of 
14.5 ng/mL and 17.7 ng/mL was observed after 10 min in F1 and F5, respectively. In the 
other fingerprints, Cmax (range: 0.985-2.37 ng/mL) was observed between 45 min and 
5 h. In M6, Cmax (range: 1.15-18.8 ng/mL) was reached between 10 min and 5 h. The 
same Cmax of 1.15 ng/mL was observed at 90 min and 5 h in F3 whereas Cmax of 
18.8 ng/mL was observed at 10 min in F5.  
 
Pharmacokinetic parameters could not be determined from the NOR data because it 
was only quantified in 7 samples (across only 3 fingers and 2 participants). 
4.4.4 Comparison with whole blood 
Mephedrone detection window was longer in fingerprint sweat collected from M1, M2, 
M3 and M6 compared to whole blood whereby mephedrone was detected up to 6 h, 
except for M1 which was also detected on Day 2 (see Table 4-2). Moreover, mephedrone 
was detectable in sweat collected from at least one finger 72 h (Day 3) after drug 
administration in M1, M2 and M3. 
 
 
Table 4-2. Comparison of mephedrone concentrations detected above the LOQ of 0.2 ng/mL in 
both whole blood and fingerprint sweat (F1-F5) on Day 2 and Day 3 in M1-M6 
 
M1 M2 M3 
Blood Sweat Blood Sweat Blood Sweat 
Day 2 ✓ F1-F4  F2, F4  F1-F3 
Day 3  F1-F4  F1  F4, F5 
       
 M4 M5 M6 
 Blood Sweat Blood Sweat Blood Sweat 
Day 2      F2 
Day 3       
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Due to large intra- and inter-subject variability, correlation between concentrations 
found in whole blood and fingerprint sweat could not be reliably assessed.  
 Discussion 
4.5.1 Inter-subject variability 
A large inter-subject variability in mephedrone concentrations was observed, with 
concentrations in the same finger ranging from 4,792 ng/mL in M1 F1 to 2.68 ng/mL in 
M3 F1. There are several factors which could have contributed to the variability in this 
study. The difference in the pressure applied during fingerprint deposition, the angle 
and duration of contact with the glass cover slips were not controlled but have been 
shown to greatly vary between individuals or even between samples collected from the 
same individual on different occasions 428,429. Furthermore, the ‘amount’ of collected 
fingerprint sweat was not measured during the collection process which might have led 
to inaccurate results. Several strategies could be employed to help overcome these 
limitations in future studies and in clinical or forensic practice. Bailey et al. controlled 
the pressure at which fingerprints were deposited by placing glass slides on a scale and 
making sure individuals applied a pressure of 400-1000 g 362. An even more accurate 
method was developed by Fieldhouse who designed a device where a finger is placed on 
a slide and is pressed down with constant pressure from above for a required duration 
of time. The device produced reproducible and consistent results within and between 
participants and improved the quality of fingerprint deposits 428,430. Moreover, 
compounds found in high abundance in sweat, such as creatinine or serine, could also 
be measured alongside analytes of interest as demonstrated by Goucher et al 350. For 
example, concentration of creatinine in human sweat has been reported to be directly 
proportional to the concentration in plasma. Therefore, when a drug or its metabolite 
passes from whole blood to sweat, the ratio of drug to creatinine would be independent 
of the amount of sweat deposited on a glass cover slip. Furthermore, targeting 
endogenous compounds present in sweat could demonstrate that sweat was deposited 
on the collection device which could help explain situations like the one observed in this 
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study for M3 F5 where mephedrone concentration dropped at 90 min to 1.10 ng/mL 
and increased to 3.51 ng/mL at 3 h (Figure 4-1 C). 
 
Interestingly, the highest mephedrone concentration between 10 min and 5 h was 
detected in the thumbs (F1) which might be linked to the ‘amount’ of sweat collected 
due to their big surface area and/or due to higher pressure applied 431. Mephedrone 
concentrations were lower in the index fingers (F2) compared to thumbs but were 
significantly higher than those in the middle (F3), ring (F4) and little fingers (F5). This 
could be due to the index finger being a more dominant finger with more muscle 
strength. 
 
Excessive sweating following drug use can also influence the volume of excreted sweat 
which may impact the results of sweat analysis. Mephedrone is a sympathomimetic drug 
which is expected to increase sweating. Sweating was reported in the first published 
case of analytically confirmed acute mephedrone toxicity 432 and in 5-10% of 150 acute 
mephedrone toxicity calls to the Swedish Poisons Information Centre 4,433. However, it 
is not known what the overall effect of mephedrone or other sympathomimetic drugs is 
on the sweat gland function and how it impacts their concentration in fingerprint sweat.   
4.5.2 Detected analytes 
Mephedrone and NOR were found above the LOQ in 62% and 2.7% of all post 
amdinistration fingerprint sweat samples, respectively. The parent drug is expected to 
be found in the matrix but some of its more polar metabolites may not effectively 
incorporate into sweat. This has been observed in other studies where analysis of 
fingerprint sweat from drug users (methamphetamine) 434 or from a controlled 
administration (cocaine, codeine) 435 resulted in the parent drug being detected at high 
concentrations in the samples whereas the metabolite(s) were not detected or were 
detected at much lower concentrations. The evidential value of fingerprint sweat 
samples where metabolites are not detected is questionable because it does not exclude 
the possibility of external contamination, which is of particular concern in recreational 
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drug users handling mephedrone supplied as powder. However, more research looking 
at the effect of hand/finger washing after coming in contact with mephedrone is 
needed. In addition, it is suspected that a relatively low dose of administrated 
mephedrone contributed to low detectability of its metabolites in fingerprint sweat. 
Mephedrone users report taking 100-200 mg every hour or two hours, such that they 
use up to 1 g or more per session 30,68. It is, therefore, likely that in high-dose clinical or 
forensic cases of mephedrone abuse this method would demonstrate the presence of 
both parent and one (or potentially more) of its metabolites.  
 
To further increase analytical sensitivity fingerprint sweat from all fingers could be 
deposited onto the same cover slip, providing a cumulative measurement. Moreover, a 
more sensitive analytical approach, such as capillary-liquid chromatography coupled to 
nanospray mass spectrometry could be employed to quantify mephedrone metabolites 
in individual fingerprints. 
4.5.3 Collection procedure 
Collection of fingerprint sweat is an easy and quick process but some problems were 
encountered during the study. Glass cover slips are very thin and fragile. They broke on 
several occasions under excessive pressure applied during fingerprint deposition. 
Moreover, glass cover slips had to be transferred from weighing boats into scintillation 
vials which made them likely to be dropped in the process and might have also 
introduced a potential for contamination related to the clinicians handling cover slips 
after collection and then prior to the next collection. A more user-friendly method could 
involve collecting fingerprint sweat samples on bigger slides or on a drug screening 
cartridge developed by Intelligent Fingerprinting, if a point of care test is required 436. 
Even though it has been shown that the deposition surface plays an important role in 
analyte stability and recovery, other surfaces (e.g. paper) could be explored. The use of 
triangular pieces of chromatography paper would allow a direct mass spectrometry 
analysis by paper spray 363, which has been explored in collaboration with the University 
of Surrey (data not shown here). 
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Even though participants nasally insufflated mephedrone in a separate room, wore 
gloves and washed their hands after drug administration, it is likely they used fingers to 
wipe their nose after nasally insufflating mephedrone, inadvertently picking up residual 
mephedrone powder which was not effectively removed by cleaning fingertips with an 
ethanol wipe. This might explain high concentration of mephedrone seen at 10 min or 
considerably higher concentrations of mephedrone in M1. Samples can also be prone to 
contamination during extraction, but analytes were not present in the blank samples 
extracted alongside fingerprint sweat samples. 
 
Another problem with collecting fingerprint sweat is the inability to collect more than 
one sample at any time. This is because most (if not all) sweat would be deposited on 
the first cover slip leaving no (or very little) sample to be deposited on the subsequent 
cover slips. The lack of back-up samples presents a problem when a sample needs to be 
re-extracted, diluted or analysed as part of incurred sample reanalysis. 
 
As mentioned before, the volume of excreted sweat was not controlled during sample 
collection. Moreover, the rate of sweat excretion is highly variable between individuals 
and depends on their diet, medication, age and psychological state 437. Sears et al. have 
shown that a good quality fingerprint can be collected 120 min after washing hands with 
soap and water, suggesting a longer wait time between sample collections could be 
beneficial but not necessarily practical 437. 
 Conclusion  
A relatively small dose of administered mephedrone coupled with analyte detection in 
individual fingerprints resulted in only mephedrone and nor-mephedrone being 
detected in the samples. Compared to whole blood, mephedrone was detectable in 
fingerprint sweat collected from 3 participants 72 h after drug administration. Large 
inter- and intra-subject variability was observed which can be attributed to the 
differences in pressure applied during fingerprint deposition, the angle and duration of 
contact with the deposition surface coupled with the inability to control the ‘amount’ of 
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collected sweat. Given these limitations fingerprint sweat may not be ideal for use in 
quantitative analysis until practical solutions to the problems discussed in this chapter 
are found. 
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CHAPTER 5  
DETECTION OF MEPHEDRONE AND ITS 
METABOLITES IN URINE 
 Detection of mephedrone and its metabolites in urine 
Due to the ease of collection and high drug concentrations, urine screens are one of the 
most common methods in drug testing. Only two controlled human administration 
studies have investigated the distribution of mephedrone and some of its metabolites 
in urine. In the first study 6 recreational drug users orally ingested 150 mg of 
mephedrone. Urine samples were collected between 0-4 h, 4-8 h, 8-12 h, 12-24 h and 
24-48 h post drug administration and were analysed by LC-MS 91 and GC-MS 97. The 
authors found 4-carboxy-mephedrone (4-CARBOXY) to be the most abundant analyte, 
reaching concentrations roughly 10 times higher than those of mephedrone (MEPH). 
Dihydro-mephedrone (DHM), nor-mephedrone (NOR) and N-succinyl nor-mephedrone 
were also detected but at lower concentrations. Mephedrone showed low urinary 
recovery, with only about 1.15% of total administered dose being recovered following 
LC-MS analysis 91 and 15.4 ± 2.6% following GC-MS analysis 97. Renal clearance of 5.6 ± 
2.6 L/h confirmed rapid elimination of mephedrone but was not reported for the 
metabolites. In another study, healthy subjects orally ingested different doses of 
mephedrone (n=3 took 50 mg and 100 mg; n=6 took 150 mg and 200 mg) 75. Detected 
concentration were not reported as the publication focused on urinary recovery of the 
analytes following drug administration. The authors found that the urinary recovery of 
mephedrone and its metabolites was proportional to the administered doses 75. 
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 Urine aims 
The primary aim of this study was to quantify mephedrone and its metabolites in urine. 
The secondary aim was to investigate urinary recoveries and renal clearance which has 
not been reported before for mephedrone metabolites. The final aim was to compare 
the window of detection between urine and whole blood, looking specifically for 
metabolites which would be good markers of mephedrone use. 
 Experimental 
5.3.1 Reagents 
Please refer to Section 3.1.3.1 in Chapter 3. 
5.3.2 Blank matrix collection 
Urine was collected from drug-free volunteers into polyethylene Nalgene® bottles. 
Ethical approval for the collection of drug-free matrix was granted by the Research 
Ethics Committee at King’s College London (HR 16/17 4237) and can be found in 
Appendix B. 
5.3.3 Volunteer administration study and sample collection 
Six healthy male volunteers nasally insufflated 100 mg of mephedrone hydrochloride. 
Urine samples were collected into polyethylene Nalgene® bottles at -10 min (0 h, before 
administration), 6 h, Day 2, Day 3 and Day 30. Urine samples were also collected 
between -10 min and 6 h if a participant felt the need to pass urine. The volume of 
excreted urine was recorded. Urine samples were stored at -20ᵒC until analysis. 
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5.3.4 Working solutions 
Working solutions used for the preparation of the calibration curve were prepared in 
MeOH:water (50:50 v/v) at 15, 50, 125, 250, 500, 1000, 1250 ng/mL for DHM, NOR, 
dihydro-nor-mephedrone (DHNM); and at 40, 100, 200, 250, 500, 1000, 1250 ng/mL for 
mephedrone, hydroxytolyl-mephedrone (HYDROXY), 4-CARBOXY. Working solution 
used for the preparation of the quality control (QC) samples at low, medium and high 
level were made in MeOH:water (50:50 v/v) at 25, 250, 1000 ng/mL for DHM, NOR, 
DHNM and at 50, 250, 1000 ng/mL for mephedrone, HYDROXY, 4-CARBOXY. Internal 
standard (IS) solution containing MEPH-d3 and DHM-d3 at 50 ng/mL was prepared in 
MeOH:water (50:50 v/v). 
5.3.5 Calibration standards and quality control samples 
Matrix-matched calibration standards containing DHM, NOR and DHNM at 0.6, 2, 5, 10, 
20, 40, 50 ng/mL; and mephedrone, HYDROXY, 4-CARBOXY at 1.6, 4, 8, 10, 20, 40, 
50 ng/mL were prepared by the addition of an appropriate volume of the working 
solution to urine. QC Low (1 ng/mL for DHM, NOR and DHNM; and 2 ng/mL for 
mephedrone, HYDROXY, 4-CARBOXY), QC Med (10 ng/mL for all analytes) and QC High 
(40 ng/mL for all analytes) were prepared by the addition of an appropriate volume of 
the working solution to urine.  
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing urine but no IS and one sample containing urine and IS were also prepared 
and taken through the extraction. 
5.3.6 Sample preparation 
Sample preparation described in Section 3.1.3.1 in Chapter 3 was followed but 250 µL 
of urine was taken through the extraction. Where dilution was required, samples were 
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diluted 1 in 100 or 1 in 1000 in the blank matrix alongside 3 additional QCs prepared in 
the same manner. 
5.3.7 LC-MS/MS conditions 
DHM-d3 was used as an IS for 4-CARBOXY. For other details please refer to Section 
3.1.3.7 in Chapter 3. 
5.3.8 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
5.3.9 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
 Results 
5.4.1 Method validation 
Please refer to Section 2.6.4 in Chapter 2. 
5.4.2 Concentrations of mephedrone and its metabolites in urine 
Concentrations of mephedrone and its metabolites in urine collected from 6 participants 
(M1-M6) are shown in Figure 5-1 - Figure 5-6. Where data for Day 2, Day 3 or Day 30 is 
not shown, analytes were not detected at these timepoints. A urine sample was not 
provided in the first 2 h post administration by M6 and so there is no data available for 
that time period. Analytes were not detected in the pre-administration (-10 min) urine 
samples (data not shown). 
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Figure 5-1. Concentration of mephedrone in urine collected from M1-M6 
 
 
Figure 5-2. Concentration of dihydro-mephedrone in urine collected from M1-M6 
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Figure 5-4. Concentration of hydroxytolyl-mephedrone in urine collected from M1-M6 
 
 
Figure 5-5. Concentration of 4-carboxy-mephedrone in urine collected from M1-M6 
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4-CARBOXY reached the highest concentrations in urine (range: 2.45-29,757 ng/mL), 
followed by mephedrone (range: 1.83-6,898 ng/mL) and NOR (range: 0.955-377 ng/mL). 
DHM (range: 0.675-177 ng/mL) and HYDROXY (range: 16.2-167 ng/mL) were detected 
at lower concentrations. DHNM was found at the lowest concentration, ranging from 
0.600 ng/mL to 93.1 ng/mL. Mephedrone concentration peaked within 2 h and then 
started to decline as the metabolite concentrations started to rise. The highest 
concentration of mephedrone, DHM, NOR and DHNM between 0-6 h were detected in 
M3, which showed considerably higher mephedrone and NOR concentrations compared 
to other participants. 
 
Analytes exhibited a wide range of detection windows in urine. Mephedrone was 
present in three participants (M1, M2, M5) on Day 2 but was undetectable on Day 3. 
DHM was detected in four participants (M1, M3, M5, M6) on Day 2 but only in M1 on 
Day 3. NOR, 4-CARBOXY and DHNM were all detectable in all participants on Day 2, with 
4-CARBOXY and DHNM also being detectable in participants on Day 3. HYDROXY was 
detectable up to 6 h but declined to undetectable levels on Day 2 in all participants. No 
analytes were detected on Day 30. 
5.4.3 Comparison with whole blood 
Table 5-1 compares analytes detected above the LOD and LOQ on Day 2 in whole blood 
and urine. In whole blood, mephedrone was the only analyte detected after 6 h but only 
in M1 on Day 2. On Day 2 in urine mephedrone was detectable in M1, M2 and M5 
whereas DHM was found in all participants except M4. NOR, 4-CARBOXY and DHNM 
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Table 5-1. Comparison of analytes detected above the LOD (ticks) and LOQ (in ng/mL) in whole 
blood and urine samples collected on Day 2; ND – not detected 





Urine 5.13 9.56 2.64 ND 213 16.5 
Blood 0.212 ND ND ND ND ND 
M2 
Urine ✓ ✓ ✓ ND 4.00 1.29 
Blood ND ND ND ND ND ND 
M3 
Urine ND 16.0 10.9 ND 32.6 24.9 
Blood ND ND ND ND ND ND 
M4 
Urine ND ND ✓ ND 16.8 0.600 
Blood ND ND ND ND ND ND 
M5 
Urine 1.83 1.98 0.955 ND 12.9 1.22 
Blood ND ND ND ND ND ND 
M6 
Urine ND 0.675 0.525 ND 37.6 3.00 
Blood ND ND ND ND ND ND 
 
5.4.4 Urinary recovery 
The minimum, maximum and mean urinary recovery of mephedrone relative to the 
administered dose of 100 mg in the first 6 h post administration is shown in Table 5-2. 
Only 1.36 ± 1.75% of unchanged mephedrone was recovered in urine. The highest 
urinary recovery of 4.85% (27.4 µmol) was seen in M3 while the lowest urinary recovery 
of 0.153% (0.864 µmol) was reported for M6. Standard deviation (SD) presented in Table 
5-2 was larger than the mean due to exceptionally high mephedrone concentrations in 
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M1 0.759 4.28 
M2 0.604 3.41 
M3 4.85 27.4 
M4 1.21 6.85 
M5 0.549 3.10 
M6 0.153 0.864 
Mean 1.36 7.65 
SD 1.75 9.86 
Minimum recovery 0.153 0.864 
Maximum recovery 4.85 27.4 
 
 
Urinary recovery of mephedrone metabolites expressed as a percentage of the total 
dose and as a percentage of recovered mephedrone is presented in Table 5-3. DHM, 
NOR, HYDROXY and DHNM excretions were 3.90 ± 3.99%, 5.90 ± 8.46%, 5.26 ± 1.81% 
and 2.28 ± 1.76% of the total mephedrone eliminated in urine, respectively. 4-CARBOXY 




Table 5-3. Minimum, maximum and mean urinary recoveries (% of the total dose) for 
mephedrone metabolites calculated from the time of drug administration up to 6 h (n=6) 
Analyte 
Mean recovery 





% of recovered 
MEPH ± SD 
DHM 0.053 ± 0.054 0.012 0.149 3.90 ± 3.99 
NOR 0.080 ± 0.115 0.008 0.313 5.90 ± 8.46 
HYDROXY 0.072 ± 0.025 0.044 0.099 5.26 ± 1.81 
4-CARBOXY 12.3 ± 2.20 8.77 15.4 904 ± 162 
DHNM 0.031 ± 0.024 0.012 0.069 2.28 ± 1.76 
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5.4.5 Renal clearance 
Renal clearance is defined as the volume of plasma cleared of a drug by kidneys per unit 
of time. Renal clearance, presented in Table 5-4, was calculated for all analytes and 
participants for the first 6 h post administration. HYDROXY displayed the greatest renal 
clearance (507 ± 226 mL/min), followed by 4-CARBOXY (349 ± 133 mL/min) and DHNM 
(252 ± 294 mL/min). NOR had the lowest renal clearance of 53.6 ± 67.0 mL/min. Renal 
clearance could not be determined for DHNM in M4 and M5 because the analyte was 
not detected in plasma samples in these participants. Renal clearance calculated for all 
analytes in M6 was considerably smaller compared to other participants. 
 
 
Table 5-4. Summary of renal clearance (mL/min) calculated for all analytes and participants 
based on the data collected up to 6 h post mephedrone administration 




M1 55.9 294 35.2 701 423 16.6 
M2 41.1 134 24.0 443 359 320 
M3 383 378 187 601 435 640 
M4 117 125 45.3 671 335 - 
M5 43.6 94.2 27.8 540 448 - 
M6 5.55 27.2 2.22 87.2 92.3 31.3 
Mean 108 175 53.6 507 349 252 
SD 140 132 67.0 226 133 294 
Minimum 
clearance 
5.55 27.2 2.22 87.2 92.3 16.6 
Maximum 
clearance 
383 378 187 701 448 640 
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5.4.6 Renal clearance compared to the total body clearance 
Drugs are removed from the blood by different mechanisms, pathways and organs. Liver 
and kidneys are usually thought to be the main clearing organs, but some drugs can be 
cleared by the lungs, bile or other organs/pathways. Therefore, renal clearance is only 
one component which constitutes total body clearance. 
 
Table 5-5 compares renal clearance with total body clearance reported for plasma in 




Table 5-5. Comparison of renal clearance (mL min-1 kg-1) calculated for all analytes and 
participants based on the data collected for up to 6 h post mephedrone administration with the 
total body clearance (mL min-1 kg-1) 




M1 0.67 3.49 0.42 8.35 5.04 0.20 
M2 0.54 1.75 0.31 5.80 4.70 4.19 
M3 5.78 5.70 2.82 9.07 6.57 9.66 
M4 1.98 2.11 0.77 11.4 5.68 - 
M5 0.53 1.15 0.34 6.57 5.44 - 
M6 0.10 0.49 0.04 1.58 1.67 0.57 
Mean 1.6 2.4 0.8 7.1 4.9 3.7 
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 Discussion 
4-CARBOXY was the most abundant metabolite in urine, followed by NOR and HYDROXY. 
In a controlled administration study performed by Olesti et al. 4-CARBOXY was also the 
major metabolite detected in urine reaching concentrations roughly 10 times higher 
than mephedrone 91. Inter-subject variability was observed, with M3 showing the 
highest concentrations of mephedrone, DHM, NOR and DHNM between 0-6 h. This 
could be due to the polymorphic nature of CYP2D6 which is responsible for mephedrone 
metabolism 70, but other factors not yet defined could also be at play. 
 
Polar Phase II metabolites conjugated with charged species, such as glutathione, sulfate, 
glycine or glucuronic acid, are readily excreted in urine. Conjugated metabolites are 
often cleaved during toxicological analysis via hydrolysis (performed enzymatically with 
β-glucuronidase or chemically with hydrochloric acid or sodium hydroxide), which 
increases concentrations of Phase I metabolites in urine. In this study, hydrolysis was 
not carried out nor were the intact Phase II metabolites targeted. In other studies, Phase 
II metabolites of mephedrone conjugated with glucuronic acid were detected in rat 
urine 73, in rat liver hepatocytes 71 and in human urine 74. Interestingly, mephedrone 
conjugation with succinic acid has also been reported in human urine 74 whereas 
following the analysis of rat urine NOR has been shown to conjugate with succinic, 
glutaric and adipic acid 73. 
 
According to a review describing cases of clinical mephedrone intoxication, mean 
mephedrone urinary concentration was 50,476 ng/mL, ranging from 1 ng/mL to 
198,000 ng/mL 407. However, in many of these cases the exact mephedrone dose was 
unknown and the route of administration varied between cases. To my knowledge only 
one study has reported the presence of mephedrone metabolites in a urine sample 
collected from a forensic traffic case in Denmark. DHM, NOR, HYDROXY and 4-CARBOXY 
were detected but concentrations were not reported, except for HYDROXY which was 
found at 40 µg/kg 70. In our study, mephedrone concentrations were between 
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1.83 ng/mL and 6,898 ng/mL (mean: 1,001 ng/mL). In other controlled human 
administration studies, mephedrone urinary concentrations over a 4 h period were 
298 ng/mL (after a 50 mg oral dose), 845 ng/mL (after a 100 mg oral dose) and 2,824 
ng/mL (after a 150 mg oral dose) 407. 
 
Compared to whole blood, where mephedrone was detected in one sample collected 
on Day 2, urine offered a longer detection window. 4-CARBOXY and DHNM were the 
only metabolites detectable in the majority of urine samples on Day 3, making them 
promising markers of mephedrone use. 
 
From the total administered dose of 100 mg only about 1.36% (1.36 mg or 7.65 µmol) 
of mephedrone was recovered in urine in a 6 h period. That is in close agreement with 
a previously reported total urinary recovery of about 1.15% (9.45 ± 2.92 µmol) 
calculated from urine samples collected continuously for 48 h following an oral 
administration of 150 mg of mephedrone hydrochloride 91. In our study, urine samples 
were not collected between the 6 h timepoint and Day 2, where mephedrone was still 
likely excreted, and so the 1.36% urinary recovery does not represent total urinary 
recovery. 
 
Mephedrone has been shown to be rapidly eliminated with mean renal clearance of 108 
± 140 mL/min (6.48 ± 8.40 L/h). Previously reported renal clearance of 5.6 ± 2.6 L/h for 
mephedrone was based on urine samples collected over a 48 h period following an oral 
administration of 150 mg of mephedrone hydrochloride 97. Moreover, renal clearance 
of mephedrone metabolites has been reported for the first-time in our study. The two 
most polar metabolites (HYDROXY and 4-CARBOXY) had the largest renal clearance, 
which has likely resulted in HYDROXY not being detectable in urine after 6 h. DHNM had 
a moderate renal clearance of 252 ± 294 mL/min and was still detectable in urine on Day 
2 and in urine samples from four participants on Day 3. 
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As expected, renal clearance was lower than the total body clearance. However, it needs 
to be noted that renal clearance was calculated from the data collected up to 6 h 
whereas total body clearance was calculated from the data collected up to Day 3 post 
mephedrone administration. Moreover, urine samples were not subjected to hydrolysis 
which would have cleaved the analytes from their intact Phase II conjugates nor were 
the Phase II metabolites targeted. Consequently, conjugated analytes are not accounted 
for in the results presented here, likely underestimating renal clearance.  
 Conclusion  
Following nasal insufflation of mephedrone all analytes were detected in urine, where 
4-CARBOXY was the most abundant. 4-CARBOXY and DHNM were the only metabolites 
detectable in urine samples on Day 3, making them promising markers of mephedrone 
use. This is a crucial finding for the clinical and forensic toxicologists who by targeting 
4-CARBOXY and DHNM in urine may be able to prove mephedrone use. 
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CHAPTER 6  
DETECTION OF MEPHEDRONE AND ITS 
METABOLITES IN HEAD HAIR AND ORAL FLUID 
 Head hair 
6.1.1 Detection of mephedrone and its metabolites in head hair 
Head hair is a unique matrix which allows retrospective detection of drug use. However, 
results of head hair analysis can be difficult to interpret due to many factors (e.g. hair 
colour, hair treatment, medication, age) impacting the degree of drug incorporation into 
hair 173,216. Moreover, environmental contamination, which can often lead to 
false-positive results, is a significant pitfall of hair testing 217. Currently, the Society of 
Hair Testing (SoHT) recommends the following four approaches to differentiate drug 
administration from external contamination: the use of cut-off levels, targeting 
metabolites, analysis of washes collected during hair decontamination and calculation 
of metabolite to parent drug concentration ratios 215. The cut-off concentrations for 
both screening and confirmatory analysis for the well-established drugs (e.g. cocaine 
and amphetamines) have been proposed by SoHT 215 and by the Substance Abuse and 
Mental Health Services Administration 177, but they do not exist for new psychoactive 
substances, such as mephedrone. 
 
Mephedrone (MEPH) has been targeted in hair samples collected from suspected drug 
users and analysed as part of forensic casework 116,377–381. Quantitative results were only 
presented in some of these studies. Following LC-MS analysis, Salomone et al. detected 
mephedrone in two samples from proven MDMA and/or ketamine users at 50 pg/mg 
and 59 pg/mg 380. Martin et al. found mephedrone at higher concentrations of 
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26.8 ng/mg (range: 0.2-313.2 ng/mg) in hair samples submitted to the ChemTox 
Laboratory in France 381. Post-mortem hair concentrations of mephedrone were 
reported by Torrance et al. who detected the drug at concentrations between 4.2 ng/mg 
and 4.7 ng/mg following GC-MS analysis 116. The only method which targeted 
mephedrone metabolites (nor-mephedrone and dihydro-nor-mephedrone) by LC-MS 
did not detect them in the hair samples from 154 healthy volunteers 378. 
6.1.2 Head hair aims 
The primary aim of this study was to determine the concentration of mephedrone and 
its metabolites in head hair. The second aim was to calculate the concentration ratios 
between metabolites and mephedrone, which have not been reported before. 
6.1.3 Experimental 
6.1.3.1 Reagents 
In addition to the reagents described in Chapter 3 (Section 3.1.3.1), sodium hydroxide 
was purchased from VWR (Lutterworth, UK). The pulveriser (Pulverisette 23) and metal 
beads used for pulverising hair were purchased from Fritsch (Brackley, UK). 
6.1.3.2 Blank matrix collection 
Hair samples (approximately 7 mm thick) were collected from drug-free volunteers. 
Samples were collected from the posterior vertex by cutting as close to the scalp as 
possible. The root end was clearly marked and stored in a paper envelope kept in the 
dark and at room temperature. Ethical approval for the collection of drug-free matrix 
was granted by the Research Ethics Committee at King’s College London (HR 16/17 4237) 
and can be found in Appendix B. 
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6.1.3.3 Preparation of the blank matrix 
Hair samples were washed with acetone (3 x 2 mL) and were left to dry overnight. 
Washes were collected individually, dried down, reconstituted in 100 µL of 0.1% formic 
acid in ACN:water (10:90 v/v) and analysed as described in 6.1.3.8. Washed hair samples 
were cut into 1 cm long segments using a scalpel blade and were pulverised at 35 Hz for 
10 min or until fine powder was obtained. Ten ± 1 mg of pulverised hair was weighed 
out and transferred into glass tubes. Pulverised hair was then spiked with an appropriate 
solution as described in 6.1.3.6. The pulveriser, which was used to increase sample 
homogeneity, was thoroughly cleaned with methanol and water after every use.  
6.1.3.4 Volunteer administration study and sample 
collection 
Six healthy male volunteers nasally insufflated 100 mg of mephedrone hydrochloride. 
Head hair samples were collected at two timepoints as described in 3.1.3.2: -10 min 
(before administration) and Day 30. For the samples collected at -10 min, 0-1 cm hair 
segments were analysed whereas for the Day 30 samples, 0-1 cm and 1-2 cm hair 
segments were analysed (see 6.1.3.7 for sample preparation details). 
 
The initial ethics application did not mention sample collection at -10 min and so these 
samples were not collected from the first 3 participants (M1-M3). The ethics application 
was later amended to allow the -10 min sample collection from the last 3 participants 
(M4-M6). Hair colour and type is presented in Table 6-1 (note that participant M4 had 
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Table 6-1. Hair type and colour of the six participants who took part in the study 
Participant Hair type Hair colour 
M1 Straight Brown 
M2 Straight Brown 
M3 Straight Black 
M4 Straight Black/Purple (dyed) 
M5 Curly Brown 
M6 Straight Brown 
 
6.1.3.5 Working solutions 
Working solutions used for the preparation of the calibration curve were prepared in 
methanol (MeOH) at 2, 6, 8, 10, 12, 15, 20 ng/mL for MEPH; 0.4, 0.8, 1.5, 2, 8, 15, 
20 ng/mL for dihydro-nor-mephedrone (DHNM); 0.4, 1, 2, 4, 15, 25, 40 ng/mL for 
nor-mephedrone (NOR); 1, 2.5, 5, 6, 10, 20, 40 ng/mL for hydroxytolyl-mephedrone 
(HYDROXY); 4, 10, 15, 20, 25, 35, 40 ng/mL for 4-CARBOXY and DHM. Working solution 
used for the preparation of the quality control (QC) samples at QC Low (5 ng/mL for 
MEPH; 0.5 ng/mL for DHNM; 0.8 ng/mL for NOR; 2 ng/mL for HYDROXY; and 8 ng/mL for 
4-CARBOXY and DHM), QC Med (10 ng/mL for MEPH; 2 ng/mL for DHNM; 4 for NOR; 
6 ng/mL for HYDROXY; and 19 ng/mL for 4-CARBOXY and DHM) and QC High (17 ng/mL 
for MEPH; 16 ng/mL for DHNM; 33 ng/mL for NOR; 28 ng/mL for HYDROXY; and 
34 ng/mL for 4-CARBOXY and DHM) were prepared in MeOH. 
6.1.3.6 Calibration standards and quality control samples 
Matrix-matched calibration standards containing MEPH at 20, 60, 80, 100, 120, 150, 
200 pg/mg; DHM and 4-CARBOXY at 40, 100, 150, 200, 250, 350, 400 pg/mg; NOR at 4, 
10, 20, 40, 150, 250, 400 pg/mg; HYDROXY at 4, 8, 15, 20, 80, 150, 200 pg/mg; and DHNM 
at 4, 8, 15, 20, 80, 150, 200 pg/mg were prepared by aliquoting 100 µL of an appropriate 
working solution to pulverised hair (10 ± 1 mg). QC Low (50 pg/mg for MEPH; 80 pg/mg 
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for DHM and 4-CARBOXY; 8 pg/mg for NOR; 20 pg/mg for HYDROXY; 5 pg/mg for 
DHNM), QC Med (100 pg/mg for MEPH; 190 pg/mg for DHM and 4-CARBOXY; 8 pg/mg 
for NOR; 20 pg/mg for HYDROXY; 5 pg/mg for DHNM) and QC High (170 pg/mg for 
MEPH; 340 pg/mg for DHM and 4-CARBOXY; 330 pg/mg for NOR; 280 pg/mg for 
HYDROXY; 160 pg/mg for DHNM) were prepared in the same way as calibration 
standards. Internal standard (IS) solution containing MEPH-d3 and DHM-d3 was prepared 
at 50 ng/mL in MeOH. 
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing pulverised hair but no IS and one sample containing pulverised hair and IS 
were also prepared and taken through the extraction.  
6.1.3.7 Sample preparation 
Hair samples collected from the participants were washed, pulverised and weighed as 
described in 6.1.3.3. Following the addition of 50 µL of the IS into glass tubes with 
pulverised hair, 1 mL of 0.1 M sodium hydroxide(aq) was added. Tubes were capped, and 
samples were incubated at room temperature for 30 min with shaking. Following 
centrifugation at 2300 rpm for 5 min, samples were extracted by solid phase extraction 
(SPE) as described in Chapter 3 (Section 3.1.3.6). Samples did not require dilution. 
6.1.3.8 LC-MS/MS conditions 
DHM-d3 was used as an IS for 4-CARBOXY. For other details please refer to Section 
3.1.3.7 in Chapter 3. 
6.1.3.9 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
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6.1.4 Results 
6.1.4.1 Method validation 
Please refer to Section 2.6.8 in Chapter 2. 
6.1.4.2 Concentrations of mephedrone and metabolites in 
head hair 
As shown in Figure 6-1, mephedrone was detected in 0-1 cm hair segments collected on 
Day 30 from M1-M6. Mephedrone was quantified in M3 (48 pg/mg) and M6 (22 pg/mg) 
on Day 30 in the 0-1 cm segment and it was also detected below the limit of 
quantification (LOQ; 20 pg/mg) in M1, M4 and M5. In addition, mephedrone was found 
above the limit of detection (LOD; 5 pg/mg) on Day 30 in the 1-2 cm hair segment in M5. 
The concentrations shown below the LOQ in Figure 6-1 and Figure 6-2 cannot be reliably 




Figure 6-1. Mephedrone concentrations in head hair samples (1 cm segments) collected before 
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As shown in Figure 6-2, NOR was not detected in the 1-2 cm segment on Day 30 but was 
present above the LOQ (4 pg/mg) in the 0-1 cm segment in M3 at 9.10 pg/mg on Day 30. 
In addition, NOR was found above the LOD (1 pg/mg) on Day 30 in the 0-1 cm hair 




Figure 6-2. Nor-mephedrone concentrations in head hair samples (1 cm segments) collected 
before mephedrone administration (M4-M6) and on Day 30 (M1-M6) 
 
 
Interestingly, mephedrone and NOR were also detected in the 0-1 cm hair segment from 
M4 and M5 collected before mephedrone administration (-10 min). Surface 
contamination of the hair was not detected in the acetone washes. 
 
Other mephedrone metabolites were not detected, except for DHM which was found 
below the LOQ (40 pg/mg) and DHNM detected at 10.1 pg/mg in M3 in the 0-1 cm hair 
segment collected on Day 30. 
6.1.4.3 Metabolite to parent drug concentration ratios 
Metabolite to parent drug concentration ratios could only be calculated for one sample 
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above the LOQ. Calculated NOR:MEPH and DHNM:MEPH ratios were 0.19 and 0.21, 
respectively.  
6.1.5 Discussion 
The two polar metabolites (HYDROXY and 4-CARBOXY) were not detected in head hair. 
Even though polar metabolites are less likely to get incorporated into hair, there are 
reported cases of water-soluble metabolites, such as ecgonine methyl ester (cocaine 
metabolite), being found in hair samples obtained from the National Institute of 
Toxicology and Forensic Sciences 438 and from a controlled intranasal (100 mg) cocaine 
administration 439. Even when polar metabolites get incorporated into hair, they may be 
easily washed off during regular haircare routine. In this study, poor recovery of 
4-CARBOXY (4.55 ± 1.82% at QC Low and 5.58 ± 8.90% at QC High) might have also 
contributed to the absence of this analyte in head hair. 
 
Interestingly, -10 min samples collected from M4 and M5 before mephedrone 
administration were positive for mephedrone. In addition, NOR was detected in 
the -10 min sample collected from M5. Participants in the study were occasional 
recreational drug users, including mephedrone. The study protocol asked participants 
to abstain from taking drugs 2 weeks before the administration day. The abstinence was 
confirmed by the analysis of a urine sample collected 7 days before the administration 
day, which was negative in all cases. M4 came to the screening visit on the 25th April and 
took mephedrone on the 11th June whereas M5 was screened on the 1st May and 
attended the administration day on the 18th June. In both cases the time period between 
the screening visit and the administration day was over a month. This likely created an 
opportunity for the participants to take drugs, including mephedrone, which would not 
have been against the study protocol if it had happened earlier than 2 weeks before the 
administration day. However, participants were not asked about the drug use between 
the screening visit and the administration day. Samples can also become contaminated 
during sample extraction, but this is highly unlikely as analytes were not detected in the 
blanks run directly before the -10 min samples. 
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The mechanism of drug incorporation into hair is not yet fully understood. Active or 
passive diffusion from the bloodstream or diffusion from sweat have been suggested 
174. The diffusion of analytes from sweat, sebum or other excretions onto the scalp is 
especially problematic because it leads to the growing or mature hair shafts bathing in 
these secretions. Xiang et al. monitored the diffusion of ketamine and norketamine from 
sweat and sebum by swabbing the posterior vertex after administration of a 10 mg 
ketamine dose 440. All cotton swabs were positive for both analytes which demonstrated 
that the head hair was contaminated by sweat and sebum. In this study the posterior 
vertex was not swabbed and so the impact of skin excretions on analyte concentrations 
in hair cannot be established but it should be investigated in future studies. 
 
Natural hair colour has been shown to play an important role in drug incorporation into 
hair. Drugs of abuse bind to melanin which is present as either eumelanin (black and 
brown hair) or pheomelanin (red and blond hair) 171,199. Darker hair has higher melanin 
content resulting in greater drug binding. In this study, all participants had brown hair, 
except for M3 and M4 who had black hair. The highest concentration of mephedrone 
and NOR was detected in M3. This might suggest that the increased incorporation of 
these two analytes into hair could be due to larger eumelanin content. M4, the only 
other participant with black hair, did not show high concentrations of mephedrone or 
NOR which was likely due to the hair having purple highlights. The concentration of 
melanin was not determined but it might be a useful recommendation for future studies. 
 
Metabolite to parent drug concentration ratios are one of the recommended criteria by 
the SoHT for differentiating external drug contamination from drug consumption. 
Contamination usually occurs through passive exposure to smoked drugs or drug 
powders and has been previously reported for cocaine 441, cannabis 442 and heroin 443. 
Proposed metabolite to parent drug ratios indicative of cocaine ingestion are greater 
than 0.05 for the benzoylecgonine to cocaine ratio 215 and greater than 1.3 for the 
6-monoacetylmorphine to morphine ratio in case of heroin consumption 443. Recently, 
the ratio has also been proposed for MDMA and its metabolite, methamphetamine 444. 
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In this study, NOR:MEPH and DHNM:MEPH ratios were 0.19 (n=1) and 0.21 (n=1), 
respectively. The sample size is too small to suggest robust metabolite:MEPH cut-off 
levels, but this information may be useful in future research where a distinction between 
a drug user and a single dose administration could be made. 
 
It is worth mentioning that current GC-MS and LC-MS analytical methods require 
extensive sample preparation which is time consuming and destructive to samples. 
Novel methods, such as MALDI-MS imaging 445 and DART-MS 251, have been used to 
identify analytes in an intact hair strand or a lock of hair. The use of MALDI-MS imaging 
for the analysis of intact strands of hair has been explored in collaboration with Sheffield 
Hallam University (data not shown here). 
6.1.6 Conclusion  
For the first-time mephedrone and its metabolites (NOR, DHM and DHNM) were 
detected in human head hair after a single intranasal dose of mephedrone 
hydrochloride. Metabolite to mephedrone ratios have also been reported for the 
first-time but a larger sample size is required before a useful cut-off level can be 
established. 
 Oral fluid 
6.2.1 Detection of mephedrone and its metabolites in oral fluid 
Analysis of oral fluid permits the detection of very recent drug use, and has increasingly 
been considered for use in the workplace and roadside drug testing 131. Several 
analytical methods for quantification of mephedrone in oral fluid have been developed 
by GC-MS 372,373 and LC-MS 166,374,375, but only two of them analysed real biological 
samples. Strano-Rossi et al. published a LC-MS/MS screening method for the detection 
of new psychoactive substances in oral fluid 374. When the method was applied to 400 
real oral fluid samples from traffic control stops, mephedrone was not detected. In the 
 Chapter 6 | Head hair and oral fluid 
 
Page | 292 
 
other study, Mercolini et al. detected mephedrone at 38 ng/mL and 15 ng/mL in 
unstimulated oral fluid collected by a disposable plastic pipette from self-reported drug 
users 166. 
6.2.2 Oral fluid aims 
The primary aim was to investigate the distribution of mephedrone and its metabolites 
in oral fluid. The secondary aim was to compare concentrations obtained in oral fluid 
with those obtained in whole blood/plasma in order to assess correlation between these 
two matrices. 
6.2.3 Experimental 
Oral fluid samples were extracted and analysed at Abbott (previously Alere Toxicology). 
All analytes were targeted as described before, except for two polar mephedrone 
metabolites, HYDROXY and 4-CARBOXY. 
6.2.3.1 Reagents 
In addition to the reagents described in Chapter 3 (Section 3.1.3.1), hydrochloric acid 
(HCl; 36%) was purchased from VWR (Lutterworth, UK). Certus® collection devices were 
provided by Abbott (previously Alere Toxicology). 
6.2.3.2 Blank matrix collection 
Blank oral fluid was collected from drug-free volunteers according to the ethical 
approval granted by the Research Ethics Committee at King’s College London (HR 16/17 
4237) which can be found in Appendix B. 
 
Oral fluid was collected by the Certus® collection devices. Participants were asked to 
keep a swab under the tongue until the blue dye appeared indicating sufficient sample 
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volume. The swab was then transferred to a buffer solution (pH 6) which was shaken for 
30 s. The swab was removed from the solution and buffered oral fluid was stored 
at -20ᵒC until analysis. 
6.2.3.3 Volunteer administration study and sample 
collection 
Six healthy male volunteers nasally insufflated 100 mg of mephedrone hydrochloride. 
Oral fluid samples were collected as described in 6.2.3.2 at -10 min (0 h, before 
administration), 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 2.5 h, 5 h, Day 2 and Day 3. 
Insufficient volume of oral fluid was collected at 60 min (M2) and 90 min (M3) due to 
dry mouth. These samples were not analysed. 
6.2.3.4 Working solutions 
Working solutions used for the preparation of the calibration curve were prepared in 
methanol (MeOH) at 10, 20, 200, 1000, 2500, 5000, 10000 ng/mL for MEPH; 40, 160, 
200, 1000, 2500, 5000, 10000 ng/mL for DHM; and 80, 200, 500, 1000, 2500, 5000, 
10000 ng/mL for NOR and DHNM. Working solution used for the preparation of the 
quality control (QC) samples at low, medium and high level were made in MeOH at 10, 
1000, 5000 ng/mL for MEPH; 80, 1000, 5000 ng/mL for DHM; and 170, 1000, 5000 ng/mL 
for NOR and DHNM. Internal standard (IS) solution containing MEPH-d3, DHM-d3 at 
400 ng/mL was prepared in MeOH. 
6.2.3.5 Calibration standards and quality control samples 
Matrix-matched calibration standards containing MEPH at 0.5, 1, 10, 50, 125, 250, 
500 ng/mL; DHM at 2, 8, 10, 50, 125, 250, 500 ng/mL; NOR and DHNM at 4, 10, 25, 50, 
125, 250, 500 ng/mL were prepared by the addition of an appropriate volume of the 
working solution to buffered oral fluid. QC Low (0.5 ng/mL for MEPH; 2 ng/mL for DHM; 
7 ng/mL for NOR and DHNM), QC Med (50 ng/mL for MEPH, DHM, NOR, DHNM) and QC 
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High (250 ng/mL for MEPH, DHM, NOR, DHNM) were prepared by the addition of an 
appropriate volume of the working solution to buffered oral fluid.  
 
Calibration standards and QCs were prepared fresh on the day of sample analysis. Blanks 
containing buffered oral fluid but no IS and one sample containing buffered oral fluid 
and IS were also prepared and taken through the extraction.  
6.2.3.6 Sample preparation 
Four hundred microliters of buffered oral fluid was extracted using SPE. Twenty 
microliters of the IS was added to buffered oral fluid, calibration standards and QCs. 
Twenty microliters of MeOH was added to the blanks. All samples were vortex mixed 
and 200 µL of 0.1 M HCl:MeOH (50:50 v/v) was added. After conditioning a mixed mode 
MCX µElution plate with 200 µL of MeOH and 200 µL of 0.1 M HCl(aq), samples were 
loaded and washed with 200 µL of 0.1 M HCl(aq) followed by 200 µL of ACN:water 
(30:70 v/v). Samples were eluted with 4 x 25 µL of MeOH:NH4OH (97:3 v/v) and dried 
under nitrogen at 25°C. Samples were reconstituted with 50 µL of 0.1% formic acid in 
water. Sample dilution was not require. 
6.2.3.7 LC-MS/MS conditions 
The analysis was performed on Q-Exactive Focus Orbitrap MS (Thermo Scientific, UK) 
coupled to UltiMate 3000 (Thermo Scientific, UK) UPLC system. Extracted samples were 
analysed in full scan and MS/MS mode using a heated electrospray ionisation source 
(HESI-II) operated in positive ion mode. Full scans were acquired from m/z 100 to 750 
with 70,000 FWHM (full width at half-maximum, scan speed 3 Hz) resolution with the 
automatic gain control (AGC) target set to 1×106. S-lens radio frequency was set to 25 V, 
skimmer voltage was 15 V and the spray voltage was 3.75 kV. Auxiliary gas temperature 
was kept at 375°C, capillary temperature was 320°C, sheath gas flow rate was 50 and 
the auxiliary gas flow rate was 5. In the MS/MS mode the instrument was operated using 
an inclusion list containing appropriate precursor ions, an optimised collision energy of 
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60 eV and a product ion scan range of m/z 50 to 200. The mass spectrometer acquired 
MS/MS scans at a resolution of 17,500 FWHM with the AGC target of 5×105. 
 
Chromatographic separation was performed using a Thermo Accucore C18 column (100 
x 2.1 mm, 2.6 µm) held at 40°C. The needle wash was MeOH:water (50:50 v/v). The flow 
rate was 0.5 mL/min with 0.1% formic acid in water as mobile phase A and 0.1% formic 
acid in ACN as mobile phase B. The start of the gradient was at 95% mobile phase A and 
was kept for 2 min. Mobile phase B was then increased to 95% over 2 min and was held 
for 0.5 min. Over the next 0.1 min the gradient returned to the starting condition and 
the column was re‐equilibrated at 95% mobile phase A for the remaining 0.4 min. The 
total run time was 5 min. The injection volume was 10 µL and the data was acquired 
using Xcalibur® software (version 14.0). 
6.2.3.8 Pharmacokinetic calculations 
Please refer to Section 2.3 in Chapter 2. 
6.2.3.9 Validation procedure 
Please refer to Section 2.5 in Chapter 2. 
6.2.4 Results 
6.2.4.1 Method validation 
Please refer to in Section 2.6.5 in Chapter 2. 
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6.2.4.2 Concentrations of mephedrone and its 
metabolites in oral fluid 
Mean oral fluid concentrations ± SD for mephedrone and NOR in 6 participants are 
shown in Figure 6-3 and Table 6-2, respectively. Dihydro-mephedrone (DHM) and 




Figure 6-3. Mean mephedrone oral fluid concentrations ± SD (n=6); the black dashed line 
represents the limit of quantification (LOQ) 
 
 
Following the administration, mephedrone was first detected in oral fluid after 5 min, 
peaked at 90 min and was undetectable on Day 2 and Day 3. Error bars at 30 min and 
60 min were disproportionally large because mephedrone concentrations in M1 and M2 
were approximately 4 times higher compared to other participants. 
 
Interestingly, the elimination profile for M5 and M6 showed a decrease in mephedrone 
concentration at 30 min followed by an increase at 90 min before the concentrations 
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Figure 6-4. Mephedrone concentrations in oral fluid in M5 and M6 
 
 
As shown in Table 6-2, NOR was detected in 33 (56.9%) oral fluid samples above the LOQ 
(4 ng/mL) and in 45 (77.6%) oral fluid samples above the LOD (1 ng/mL). NOR was 
detected above the LOD between 5 min and 300 min, except in M5 where the analyte 
was first detected after 15 min. Mean NOR concentration (12.8 ± 2.0 ng/mL) peaked at 
90 min and was undetectable on Day 2 and Day 3. 
 
 
Table 6-2. Nor-mephedrone concentrations (expressed in ng/mL) above the LOQ of 4 ng/mL 
and LOD (ticks) in oral fluid for M1-M6 at each timepoint; NA - sample not collected due to dry 
mouth; ND - not detected 
Timepoints 
(min) 
M1 M2 M3 M4 M5 M6 
Mean ± 
SD 
5 10.1 ✓ 10.3 ✓ ND ✓ 
10.2 ± 
0.1 
15 11.7 ✓ 11.3 ✓ ✓ ✓ 
11.4 ± 
0.3 
30 12.4 11.8 11.6 ✓ 11.1 11.1 
11.6 ± 
0.5 
60 13.8 NA 11.2 10.2 11.2 11.4 
11.6 ± 
1.3 





























Mephedrone (M5 and M6)
M5
M6
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120 12.8 11.4 11.0 11.5 11.6 11.3 
11.6 ± 
0.6 
150 12.2 11.9 10.2 ✓ 10.2 11.7 
11.2 ± 
1.0 
300 10.8 ✓ ✓ ✓ ✓ 10.4 
10.6 ± 
0.3 
Day 2 ND ND ND ND ND ND - 
Day 3 ND ND ND ND ND ND - 
 
6.2.4.3 Pharmacokinetic analysis 
Oral fluid drug concentrations were fitted with a single-dose, first-order elimination 
phase model and the calculated mean pharmacokinetic (PK) parameters are 
summarised in Table 6-3. Pharmacokinetic parameters (other than Cmax and Tmax) were 
not determined for NOR because an insufficient number of datapoints was observed 
from the elimination phase. Mean Cmax and Tmax for NOR were 12.7 ± 1.8 ng/mL and 90 
± 33 min, respectively. 
 
 
Table 6-3. Mean ± SD mephedrone pharmacokinetic data from the analysis of oral fluid 











(ng mL-1 h) 
CL 
(mL min-1 kg-1) 
V 
(L kg-1) 
M1 164 90 0.047 0.25 303 65.2 1.39 
M2 167 90 0.006 2.00 213 103 17.8 
M3 22.7 15 0.011 1.05 34.2 705 68.5 
M4 68.5 15 0.011 1.05 62.6 449 41.0 
M5 39.0 15 0.023 0.50 47.6 424 18.4 
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Mephedrone reached the mean Cmax of 89.6 ± 61.9 ng/mL at 40.0 ± 38.7 min, with both 
M1 and M2 showing higher Cmax and delayed Tmax. With regards to elimination, 
mephedrone had mean kel of 0.017 ± 0.016 min-1 and mean t1/2 of 1.09 ± 0.64 h. The 
smallest AUC was recorded for M3 (34.2 ng mL-1 h) which was approximately 9 times 
smaller than the largest AUC (303 ng mL-1 h) recorded for M1. Mean V for mephedrone 
was 31.1 ± 23.6 L kg-1 and CL was 345 ± 254 mL min-1 kg-1. M1 had the smallest V and CL 
of 1.39 L kg-1 and 65.2 mL min-1 kg-1, respectively, while M3 had the largest V of 68.5 L kg-
1 and CL of 705 mL min-1 kg-1. 
6.2.4.4 Comparison of the pharmacokinetic parameters in 
oral fluid, plasma and whole blood 
As shown in Table 6-4, mephedrone concentrations peaked earlier in oral fluid (40.0 ± 
38.7 min) compared to whole blood (55.0 ± 18.2 min) and plasma (52.5 ± 20.7 min). Even 
though delayed Tmax was observed in whole blood and plasma, similar Cmax values were 
obtained in all matrices. Mephedrone was eliminated with t1/2 of approximately 2 h in 
whole blood/plasma (kel of 0.006 ± 0.001 min-1) compared to 1.09 ± 0.64 h (kel of 0.017 
± 0.016 min-1) in oral fluid. A smaller mean AUC was calculated in oral fluid compared to 
whole blood (54.1 ± 15.9 mL min-1 kg-1) and plasma (66.5 ± 23.6 mL min-1 kg-1). Larger CL 
and V were also observed in oral fluid. 
 
Pharmacokinetic parameters, other than Cmax and Tmax, were not determined for NOR in 
oral fluid. The analyte peaked at 90 ± 33 min compared to 133 ± 27.5 min in whole blood 
and 130 ± 35.1 min in plasma. NOR reached the highest Cmax of 12.7 ± 1.8 ng/mL in oral 
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Table 6-4. Comparision of mephedrone pharmacokinetic parameters between whole blood, 











(ng mL-1 h) 
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6.2.4.5 Oral fluid correlation with whole blood 
Correlation between analyte concentrations detected in oral fluid and whole blood has 
been investigated for each participant as shown in Figure 6-5 and Figure 6-6 (the black 
dotted line shows a trend line). Individual correlation can be found in Appendix E. 
 
Mephedrone did not correlate well between the two matrices as evidenced by the 
Pearson correlation coefficient of 0.361 whereas NOR showed moderate correlation 




Figure 6-5. Correlation of oral fluid and whole blood concentrations for mephedrone (n=6) 
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Figure 6-6. Correlation of oral fluid and whole blood concentrations for nor-mephedrone (n=6) 
 
6.2.4.6 Oral fluid correlation with plasma 
Correlation between analyte concentrations detected in oral fluid and plasma has been 
investigated for each participant as shown in Figure 6-7 and Figure 6-8 (the black dotted 
line shows a trend line). Individual correlation can be found in Appendix E. 
 
Mephedrone did not correlate well between the two matrices as evidenced by the 
Pearson correlation coefficient of 0.286 whereas NOR showed better correlation with 
the Pearson correlation coefficient of 0.608. 
 
 
Figure 6-7. Correlation of oral fluid and plasma concentrations for mephedrone (n=6) 
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Figure 6-8. Correlation of oral fluid and plasma concentrations for nor-mephedrone (n=6) 
 
6.2.4.7 Whole blood and oral fluid – method comparison 
Bland-Altman analysis was performed to examine the agreement between 
concentrations obtained for whole blood and oral fluid. Bland-Altman plots (Figure 6-9 
and Figure 6-10) show the difference between paired concentrations from oral fluid and 
whole blood samples plotted against the mean of the two concentrations calculated for 
each individual sample. Dotted lines represent the 95% limits of agreement (mean 
difference ± 2 SD). 
 
 
Figure 6-9. Bland-Altman plots comparing whole blood and oral fluid methods for mephedrone 
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Figure 6-10. Bland-Altman plots comparing whole blood and oral fluid methods for 
nor-mephedrone 
 
Bland-Altman plots showed bias ± SD between whole blood and oral fluid concentrations 
to be -17.2 ± 42.8 ng/mL for mephedrone and 6.72 ± 3.80 ng/mL for NOR. Whole blood 
NOR concentrations were in good agreement with oral fluid concentrations with > 95% 
of datapoints being within ± 2 SD of the bias. The agreement was poorer for 
mephedrone with only 92.2% of datapoints being within ± 2 SD of the bias. 
6.2.4.8 Plasma and oral fluid – method comparison 
Bland-Altman analysis was performed to examine the agreement between 
concentrations obtained for plasma and oral fluid. Bland-Altman plots (Figure 6-11 and 
Figure 6-12) show the difference between paired concentrations from oral fluid and 
plasma samples plotted against the mean of the two concentrations calculated for each 
individual sample. Dotted lines represent the 95% limits of agreement (mean difference 
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Figure 6-11. Bland-Altman plots comparing plasma and oral fluid methods for mephedrone 
 
 
Figure 6-12. Bland-Altman plots comparing plasma and oral fluid methods for nor-mephedrone 
 
 
Bland-Altman plots showed bias ± SD between plasma and oral fluid concentrations to 
be -18.2 ± 48.4 ng/mL for mephedrone and -43.9 ± 35.7 ng/mL for NOR.. 87.8% and 
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6.2.5 Discussion 
Mephedrone and NOR concentrations peaked earlier in oral fluid compared to whole 
blood and plasma which may have been due to the buccal contamination with 
mephedrone following nasal insufflation. Moreover, significantly faster clearance of 
mephedrone in oral fluid resulted in a shorter detection window compared to whole 
blood and plasma. Mephedrone was detected in five participants up to 5 h after 
administration in oral fluid but was undetectable on Day 2 and Day 3. This is in contrast 
with whole blood and plasma where mephedrone was detected in all participants up to 
6 h and in one participant on Day 2 in whole blood. 
 
Drugs of abuse usually contain an ionisable amine group which is characterised by a pKa 
value greater than the pH of oral fluid (6.7-7.4) 131. Once a basic drug gets incorporated 
into oral fluid, it becomes ionised which prevents its back diffusion into the blood (pH 
7.4). Basic drugs will, therefore, be present for longer and at higher concentrations in 
oral fluid than acidic drugs, such as cannabis (THC and its carboxy metabolite) 137. DHM 
(pKa = 9.55) and DHNM (pKa = 9.39) should in theory get incorporated into oral fluid but 
were not detected in this study. The reason for that may be the fact that DHM and 
DHNM are minor metabolites of mephedrone. In whole blood DHM and DHNM 
represented only 3.38% and 1.69% of the AUC of mephedrone, respectively (see Section 
3.1.4.3 in Chapter 3 for more details). In addition, a relatively small dose of 100 mg of 
intranasally administered mephedrone might have resulted in DHM and DHNM not 
being detected in oral fluid under the reported experimental conditions. 
 
Potential contamination of the oral cavity following smoking, snorting or swallowing 
drugs can in general be observed for several hours after drug intake. In this study 
mephedrone was administered via nasal insufflation which might have resulted in 
mephedrone particles clinging to the mucus membranes of the nostrils and turbinates 
where direct vascular absorption took place. In addition, smaller particles of 
mephedrone might have travelled deeper into the respiratory tract where they got 
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trapped by the mucus present in nasopharynx, trachea, bronchi and terminal 
bronchioles. As a result, respiratory contamination might have contributed to the 
detected mephedrone concentrations in oral fluid 169. It is difficult to determine the 
extent of oral fluid contamination, but disproportionally large error bars at 30 min and 
60 min in M1 and M2 were observed for mephedrone. 
 
Inter-individual variation in detected mephedrone concentrations was also observed. As 
this is the first controlled mephedrone administration study targeting mephedrone and 
its metabolites in oral fluid, it is not possible to compare the level of variability. However, 
inter-individual variations in oral fluid samples were reported in other controlled 
administration studies of cocaine 151,169, codeine/norcodeine 446 and 
amphetamine/methamphetamine 152. The variation could be due to the efficiency of 
mephedrone absorption after nasal insufflation, the small number of participants, 
differences in oral fluid pH (not measured in this study) and the rate of oral fluid 
production. In M5 and M6 different elimination profiles were observed, with a decrease 
in mephedrone concentration at 30 min followed by an increase at 90 min before the 
concentrations declined again at 120 min. The spike in mephedrone concentration at 
15 min and 90 min could have been due to contamination of the oral cavity after taking 
the drug or the residual mephedrone in the nasal cavity being re-absorbed.  
 
The Pearson correlation coefficient indicated moderate correlation between NOR 
concentrations in oral fluid and both whole blood (Pearson = 0.437) and plasma (Pearson 
= 0.608). Poor agreement was observed for mephedrone between oral fluid 
concentrations and whole blood as well as plasma concentrations as evidenced by the 
Pearson correlation coefficient of 0.361 and 0.286, respectively. Bland-Altman analysis 
showed that more than 95% of the observed NOR concentrations were within ± 2 SD of 
the bias in whole blood but not in plasma. In addition, less than 95% of the observed 
mephedrone concentrations were within ± 2 SD of the bias in plasma and whole blood. 
Negative bias of -17.2 ng/mL and -18.2 ng/mL was observed for mephedrone in whole 
blood and plasma, respectively, suggesting oral fluid concentrations were 
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overestimated. NOR showed positive bias in whole blood (6.72 ng/mL) and negative bias 
in plasma (-43.9 ng/mL), suggesting oral fluid concentrations were underestimated in 
whole blood and overestimated in plasma. Interestingly, poorer correlation was 
observed at higher concentrations which might be linked to the oral contamination 
following intranasal administration of mephedrone. Poor correlation may also be a 
result of protein binding which affects drug distribution and elimination. The extent of 
mephedrone or its metabolites binding to plasma proteins has not been determined in 
humans but 21.6 ± 3.67% of mephedrone has been shown to bind to proteins in 
Sprague-Dawley rats 92. 
6.2.6 Conclusion  
This is the first-time mephedrone and one of its metabolites, nor-mephedrone, were 
detected in oral fluid samples after a controlled administration study. Poor to moderate 
correlation between oral fluid and whole blood/plasma analyte concentrations was 
observed with Bland-Altman analysis showing wide confidence levels demonstrating 
poor agreement between the methods. However, poor correlation might be linked to 
the contamination of the oral cavity with mephedrone or analyte binding to plasma 
proteins. 
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CHAPTER 7  
OVERALL CONCLUSIONS AND FUTURE WORK 
 Summary 
7.1.1 Background 
In recent years, there has been an increasing interest in the use of alternative biological 
matrices, such as oral fluid, dried blood spots (DBS), head hair, breath and sweat for 
determining drug use. The collection of these samples is usually non-invasive, fast and 
cost effective which allows for drug testing in the workplace, by the roadside or in 
addiction treatment centres. Moreover, alternative biological matrices are usually easier 
and cheaper to transport than the conventional biological matrices, and some of them 
(head hair, DBS in some cases) can be stored at ambient conditions. 
 
Mephedrone is a synthetic cathinone known for its psychostimulant properties 30–32. 
Synthetic or substituted cathinones, which are chemically derived from an alkaloid 
naturally present in the leaves of Catha edulis (Khat), are one of the biggest groups of 
new psychoactive substances. Even though mephedrone use has declined since its ban 
in April 2010 in the UK, there is evidence that its use in London remains popular 63 and 
there are reports describing an increasing problem of people injecting the drug 64. 
Nevertheless, there is little known about the distribution of mephedrone and its 
metabolites in the alternative and conventional biological matrices as only two 
controlled mephedrone administration studies 91,97,414 and one dose-finding pilot study 
75 have been conducted. 
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7.1.2 Methodologies 
A single dose administration study of 100 mg mephedrone hydrochloride via nasal 
insufflation to six healthy male volunteers was performed to determine the distribution 
and pharmacokinetics of mephedrone and its metabolites in conventional and 
alternative biological matrices. Samples were collected at different timepoints after 
mephedrone administration and were analysed for the presence of mephedrone, 
dihydro-mephedrone (DHM), nor-mephedrone (NOR), hydroxytolyl-mephedrone 
(HYDROXY), 4-carboxy-mephedrone (4-CARBOXY) and dihydro-nor-mephedrone 
(DHNM) by validated LC-MS/MS methods. 
7.1.3 Conclusions 
Fully validated methods for the quantification of mephedrone and five of its Phase I 
metabolites have been developed and successfully applied to the analysis of samples 
collected during the controlled mephedrone administration. The development of these 
methods took up to two years and was challenging for a number of reasons. 
Simultaneous extraction and chromatographic separation of the analytes with a wide 
range of polarities required time-consuming method optimisation. Problems were also 
encountered during the development of the chiral method aimed at separating 
mephedrone enantiomers. Unsuccessful work with various chiral columns on 
supercritical fluid chromatography was followed by an extensive evaluation of 
derivatisation reagents and other analytical methods until a satisfactory separation was 
achieved. 
7.1.3.1 Sample analysis 
Plasma samples have been previously collected and analysed after an oral 
administration of mephedrone but to my knowledge there are no reported studies 
describing concentrations of mephedrone and five of its Phase I metabolites in whole 
blood or in plasma after nasal insufflation of mephedrone. In this study, all analytes were 
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detected in whole blood and plasma, where 4-CARBOXY reached the highest 
concentration. NOR was the second most abundant metabolite whereas DHNM had the 
lowest Cmax in both matrices. This is in agreement with a previously published oral 
mephedrone administration study 91 which reported that 4-CARBOXY was the 
predominant metabolite detected in plasma followed by NOR. Moreover, 
pharmacokinetic parameters corresponded well between whole blood and plasma and 
a previously published half-life from orally administrated mephedrone. As expected, 
Tmax was shorter following 100 mg of mephedrone given intranasally compared with oral 
doses of up to 200 mg. In addition, statistical analysis showed that median whole blood 
to plasma distribution ratios, reported here for the first time, were statistically different 
from 1 (unity) for mephedrone (median: 1.11), DHM (median: 1.30) and NOR (median: 
0.765). In DBS mephedrone, NOR and 4-CARBOXY were the only analytes detected in 
the majority of samples. Interestingly, capillary NOR concentrations were higher than 
the concentrations measured in whole blood and plasma. Pharmacodynamics was also 
evaluated by monitoring changes in subjective and physiological effects following 
mephedrone administration. Stimulant-like cardiovascular effects were manifested by 
increases in heart rate, systolic blood pressure and diastolic blood pressure. 
Mephedrone also produced increases in several visual analogue scale parameters 
related to stimulant-like effects and changes in perception. 
 
This is the first study that reports R-mephedrone (R-MEPH) and S-mephedrone 
(S-MEPH) concentrations in whole blood and investigates their pharmacokinetics after 
a controlled administration. R-MEPH reached higher concentrations than S-MEPH and 
had comparable pharmacokinetic parameters to total mephedrone. These results are in 
agreement with previous research which found R-MEPH to be a predominant analyte in 
pooled human urine samples collected from a music festival and in in vitro experiments 
with human liver microsomes 87. This research shows that the two enantiomers of 
mephedrone exhibit different pharmacokinetic profiles in humans, but the clinical 
significance of this finding is not yet fully understood. 
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A sensitive LC-MS method targeting mephedrone and its metabolites in head hair 
allowed the detection of the analytes at low pg/mg level. It has been shown for the 
first-time that mephedrone metabolites (NOR, DHM and DHNM) can be detected in 
human head hair one month after mephedrone administration. Moreover, metabolite 
to mephedrone ratios, which are used to differentiate external drug contamination from 
drug consumption, have been evaluated for the first-time. Calculated NOR:mephedrone 
and DHNM:mephedrone ratios were 0.19 (n=1) and 0.21 (n=1), respectively. The sample 
size was too small to suggest robust metabolite to mephedrone ratio cut-off levels, but 
this information may be useful in future research where a distinction between a drug 
user and a single dose administration could be made. 
 
Another novel aspect of the project focused on determination of mephedrone and its 
metabolites concentrations in fingerprint sweat and oral fluid. Mephedrone and NOR 
were detected above the limit of detection in 62% and 3.8% of all post administration 
samples, respectively. Inter- and intra-subject variability was observed, which can be 
attributed to the differences in pressure applied during fingerprint deposition, the angle 
and duration of contact with the deposition surface coupled with the inability to control 
the ‘amount’ of collected sweat. Given these limitations fingerprint sweat may not be 
ideal for use in quantitative analysis until practical solutions to these problems are 
found. In oral fluid mephedrone, DHM, NOR and DHNM were targeted but only 
mephedrone and NOR were detected in the majority of samples. Mephedrone and NOR 
concentrations peaked earlier in oral fluid compared to whole blood and plasma which 
may be due to the buccal contamination with mephedrone following nasal insufflation.  
7.1.3.2 Correlation 
The relationship between analyte concentrations in whole blood, plasma, DBS and oral 
fluid was investigated to further explore the viability of alternative matrices for the 
detection of drugs and their metabolites. Good to moderate correlation was observed 
for the analytes, which might have also been affected by CYP2D6 polymorphism, plasma 
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protein binding and, in case of oral fluid, contamination of the oral cavity with 
mephedrone. 
7.1.3.3 Window of detection 
The window of detection, which describes how long drugs can be detected in a biological 
sample above a cut-off level, is an important consideration in forensic toxicology. Many 
factors influence the window of detection, such as the frequency of drug use (chronic or 
acute), amount taken, rate of metabolism, body fat or medical conditions (liver or kidney 
disease) which may influence metabolism/elimination. Drugs are usually detected in 
urine for longer than in whole blood/plasma whereas head hair provides a historic 
record of drug use, with the detection window being dependent on hair length. 
 
In this study, analytes exhibited a wide range of detection windows. As seen in Figure 
7-1, 4-CARBOXY and DHNM were the only metabolites detectable in the majority of 
urine samples on Day 3, making them promising markers of mephedrone use. This is a 
crucial finding for the clinical and forensic toxicologists who by targeting 4-CARBOXY and 
DHNM in urine may be able prove mephedrone use. Moreover, by selectively targeting 
mephedrone and its metabolites in biological matrices exhibiting different detection 
windows it might be possible to determine the time of mephedrone use. In head hair, 
mephedrone and NOR had the longest detection windows, with the analytes being 
detected 1 month after administration. On the other hand, HYDROXY had the shortest 
detection window as it was detectable in whole blood, plasma and urine for only up to 
6 h. However, it needs to be re-emphasised that with a more sensitive method and a 
higher dose of administered mephedrone, which would be more representative of the 
amount mephedrone users report to take, longer detection windows may be achieved 
for some analytes. 
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Figure 7-1. Comparison of the detection windows for each analyte detected in the majority of 
samples analysed in the study 
 
 Future work 
Due to time constraints, breath and head sweat samples collected during the 
administration study were not analysed. In the future, it would be beneficial to develop 
and validate suitable analytical methods for quantification of mephedrone and its 
metabolites in these two matrices. 
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Low detectability of mephedrone and its metabolites in several biological matrices, such 
as fingerprint sweat and oral fluid, has been partially attributed to a single and relatively 
low dose of administered mephedrone. Future research would benefit from conducting 
a controlled mephedrone administration study with higher and/or repeated doses and 
larger sample size. The latter would also help minimise inter-subject variability which 
was observed in the study. Another cause of variability might be CYP2D6 genetic 
polymorphism. Buccal swabs for CYP2D6 genotyping were collected from the 
participants in this study but were not analysed in time for the thesis submission. 
 
Several international and national collaborations have been established during this PhD 
project. Plasma samples were sent to the University of Zurich for metabolomics analysis, 
hair strands were analysed by MALDI-MS imaging in Sheffield Hallam University, 
fingerprint sweat samples collected on triangular pieces of chromatography paper were 
analysed by paper spray at University of Surrey and DBS collected on filter paper were 
sent for analysis to Ghent University. All collaborations are briefly mentioned in the 
thesis and the results will be submitted for publication in due course. 
 
It has been shown that mephedrone enantiomers exhibit different pharmacokinetic 
profiles in humans which might be a result of pharmacokinetic processes occurring at 
different rates during drug absorption, distribution, metabolism or excretion. The 
mechanism responsible for the difference in concentrations has not been explored and 
warrants further work. In addition, clinical significance of this finding is not yet fully 
understood. So far neurochemical and behavioural effects of R-MEPH and S-MEPH have 
only been investigated by a receptor binding assay 447 and in vivo in rats 86. The next 
useful step would be to conduct a controlled study involving an administration of each 
enantiomer to human subjects. Such a study would benefit from a large sample size split 
into a control (placebo) and treatment (R-MEPH and S-MEPH administration) groups. 
Ethical approval would have to be obtained and the enantiomers of mephedrone would 
have to be synthesised in a laboratory with an appropriate licence because they are not 
currently available for purchase. 
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Even though mephedrone and its metabolites have been detected and quantified in 
samples collected from controlled administration studies, more translational research 
involving the analysis of clinical and forensic samples is needed. To my knowledge only 
one other study has reported the presence of mephedrone metabolites (DHM, NOR, 
HYDROXY and 4-CARBOXY) in urine and blood samples collected from road traffic cases 
70. It is especially important to target NOR which has been shown to be an active 
metabolite able to cross the blood-brain barrier and contribute to the psychostimulant 
effects of mephedrone 91. Lastly, metabolites which have demonstrated longer windows 
of detection should be targeted in clinical and forensic studies where they could be used 
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Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
You should notify the REC once all conditions have been met (except for site approvals 
from host organisations) and provide copies of any revised documentation with updated 
version numbers. Revised documents should be submitted to the REC electronically 
from IRAS. The REC will acknowledge receipt and provide a final list of the approved 
documentation for the study, which you can make available to host organisations to 
facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given permission 
for the research to proceed (except where explicitly specified otherwise).  
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 






The final list of documents reviewed and approved by the Committee is as follows: 
Document   Version   Date   
Copies of advertisement materials for research participants [KCL 
study advertisement]  
Version 3.0  01 September 2016 
IRAS Application Form [IRAS_Form_04092016]    04 September 2016 
IRAS Application Form XML file [IRAS_Form_04092016]    04 September 2016 
IRAS Checklist XML [Checklist_04092016]    04 September 2016 
Letter from funder [BBSRC funding letter]    07 May 2015  
Other [Glossary of Terms and Abbreviations]  Version 1.0  08 March 2016  
Other [Mephedrone assessment form]  Version 1.0  23 November 2015  
Other [Table and Figures]  Version 1.0  08 March 2016  
Other [Confirmation that the study is not a CTIMP]  Version 1.0  17 May 2016  
Other [16 LO 1342 Response to the provisional opinion]  Version 1.0  23 August 2016  
Other [Mephedrone newspaper advertisment]  Version 3.0  01 September 2016 
Other [Support Letter Mephedrone Study]  Version 1  30 May 2016  
Other [Alere Toxicology funding letter]  Version 1  03 June 2016  
Other [Controlled Drug Licence]  Version 1  23 August 2016  
Other [Email from the Home Office about the licence]  Version 1  23 August 2016  
Participant consent form [Mephedrone participant consent form]  Version 1.0  23 November 2015  
Participant information sheet (PIS) [Participant information leaflet]  Version 3.0  01 September 2016 
Research protocol or project proposal [Mephedrone administration Version 1.0  14 February 2016  
protocol]  
Summary CV for student [Joanna Czerwinska CV]    18 August 2016  
Summary CV for supervisor (student research) [Paul Dargan CV]    23 August 2016  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 





The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 




We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
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11 April 2017 
Dear Mark,  
Study Title: Collection of biological samples for developing drug detection assays 
Study Reference: HR-16/17-4237
I am pleased to inform you that full approval for your project has been granted by the BDM Research Ethics Subcommittee .
For your information, ethical approval has been granted for 3 years from 11 April 2017. If you need approval beyond this point, you will need to apply for an extension at least
two weeks before this. You will be required to explain the reasons for the extension.   However, you will not need to submit a full re-application unless the protocol has
changed.
Ethical approval is required to cover the data-collection phase of the study. This will be until the date specified in this letter.  However, you do not need ethical approval to cover
subsequent data analysis or publication of the results. For secondary data-analysis, ethical approval is applicable to the data that is sensitive or identifies participants.  
Please ensure that you follow the guidelines for good research practice as laid out in UKRIO’s Code of Practice for research:
http://www.kcl.ac.uk/innovation/research/support/conduct/cop/index.aspx 
Please note you are required to adhere to all research data/records management and storage procedures agreed to as part of your application.  This will be expected even after
the completion of the study.  
If you do not start the project within three months of this letter, please contact the Research Ethics Office. 
Please note that you will be required to obtain approval to modify the study.  This also encompasses extensions to periods of approval. Please refer to the URL below for further
guidance about the process:  
http://www.kcl.ac.uk/innovation/research/support/ethics/applications/modifications.aspx
Please would you also note that we may, for the purposes of audit, contact you from time to time to ascertain the status of your research. 
If you have any query about any aspect of this ethical approval, please contact the Research Ethics Office:
(http://www.kcl.ac.uk/innovation/research/support/ethics/contact.aspx)
We wish you every success with this work.
Yours sincerely,
Senior Research Ethics Officer
For and on behalf of
Chair of the BDM Research Ethics Subcommittee  
Cc: Supervisor
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Mephedrone is a new psychoactive substance known to be unstable in biological matrices 
stored at room temperature or refrigerated. While the instability of mephedrone has been 
investigated before, there is currently no data regarding the stability of mephedrone 
metabolites. In this study, a liquid chromatography tandem mass spectrometry method for 
the quantification of mephedrone and five of its phase I metabolites (dihydro-mephedrone, 
nor-mephedrone, hydroxytolyl-mephedrone, 4-carboxy-mephedrone and dihydro-nor-
mephedrone) in human whole blood has been developed and validated. Samples were 
extracted by a mixed mode solid phase extraction and analyzed on a pentafluorophenylpropyl 
column. The method was successfully validated for selectivity, linearity (0.2-2 to 10-100 
ng/mL), limits of detection (50-500 pg/mL) and quantification (200-2000 pg/mL), precision 
(0.924-8.27%), accuracy (86.6-115%), carryover, recovery (32.5-88.3%) and matrix effects 
(71.0-108%). Analyte stability in human whole blood preserved with sodium 
fluoride/potassium oxalate was assessed at +4°C and -20°C after 24 h, 48 h, 4 days and 10 
days of storage. Instability was observed in samples stored at +4°C with nor-mephedrone and 
4-carboxy-mephedrone losing 40.2 ± 6.7% and 48.1 ± 4.8%, respectively, of their initial 
concentration at low concentration level and 33.8 ± 4.2% and 44.6 ± 6.5%, respectively, at 
high concentration level after 10 days.  All analytes were more stable at -20°C where the 
highest loss of 22.6 ± 6.9% was observed for 4-carboxy-mephedrone after 10 days. This is the 
first time stability of mephedrone metabolites in human whole blood has been assessed, 







Mephedrone (4-methylmethcathinone) is a synthetic cathinone derivative which has a similar 
chemical structure and desired/adverse effects to other stimulant recreational drugs such as 
amphetamine 1,2. Mephedrone was first introduced to the United Kingdom (UK) recreational 
drug market in 2007/8 and over the last few years it has established itself as a widely used 
new psychoactive substance, responsible for significant morbidity and mortality 2,3. 
Despite being classified in April 2010 as a Class B drug under the UK Misuse of Drugs Act of 
1971 there is some evidence suggesting that mephedrone use in the UK and in particular in 
London remains popular 4. Mephedrone was detected in 1.0% (n=34) of the death cases 
analyzed by the Toxicology Unit at Imperial College London in 2014 and this number increased 
to 1.5% (n=22) in 2015 4. There is also evidence describing an increasing problem with people 
injecting mephedrone which leads to higher rates of hepatitis C, HIV and acute toxicity 5. 
Studies investigating the metabolism of mephedrone have been performed in vitro 6,7 and in 
vivo, both in animal (rat) models 8 and in humans 9. The main phase I metabolic pathways 
include N-demethylation of the secondary amine to yield nor-mephedrone (NOR), reduction 
of the ketone moiety to the hydroxyl group to produce dihydro-mephedrone (DHM) and 
oxidation of the tolyl moiety, leading to the formation of hydroxytolyl-mephedrone 
(HYDROXY) and 4-carboxy-mephedrone (4-CARBOXY). A simultaneous reduction of the 
ketone moiety and N-demethylation of the secondary amine produces dihydro-nor-
mephedrone (DHNM). Hepatic CYP2D6 was found to be the main enzyme responsible for the 
metabolism of mephedrone in humans, with only a negligible contribution from other CYP 
enzymes 6.  
 
Figure 1. Mephedrone and five of its phase I metabolites 
 
The stability of mephedrone has previously been investigated in human whole blood 
containing different preservatives and stored under different conditions 10–13. Mephedrone 
has been reported to be most stable at -20°C when preserved with acidic preservatives 
(NaF/KOx and NaF/citrate buffer). The underlying cause of its instability in biological matrices 
is unknown but the previous study looking at mephedrone degradation in alkaline solution 
suggests the involvement of oxidants such as dissolved oxygen 14. 
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In this study, we investigated the stability of mephedrone and five of its phase I metabolites 
(Figure 1) in human whole blood fortified with NaF/ KOx as a preservative and anti-coagulant, 
respectively. A systematic stability study of the main mephedrone metabolites in whole blood 
has not been reported previously and therefore, this is an important investigation relevant to 
both clinical and forensic toxicologists. 
3 Materials and methods 
3.1 Reagents 
Mephedrone hydrochloride (MEPH), dihydro-mephedrone hydrochloride (DHM), 
mephedrone-d3 hydrochloride (MEPH-d3), dihydro-mephedrone-d3 hydrochloride (DHM-d3), 
4-(2-aminoethyl) benzoic acid hydrochloride (AEBA) and sodium borohydride were purchased 
from Sigma-Aldrich (Dorset, UK). Nor-mephedrone hydrochloride (NOR) was purchased from 
Chiron (Trondheim, Norway). Hydroxytolyl-mephedrone hydrochloride (HYDROXY), 
4-carboxy-mephedrone hydrochloride (4-CARBOXY) as well as nor-mephedrone 
hydrochloride used for the in-house synthesis of dihydro-nor-mephedrone (DHNM) were 
purchased from LGC Standards (Bury, UK). MEPH, MEPH-d3, DHM, DHM-d3 were purchased 
as certified reference materials. All reference standards were analyzed in-house to verify their 
chemical structure. 
All solvents were HPLC grade unless stated otherwise. Methanol (MeOH), isopropyl alcohol 
(IPA), dichloromethane (DCM), acetonitrile (LC-MS grade for the preparation of the mobile 
phase and HPLC grade for other uses), formic acid, acetic acid, sodium phosphate monobase, 
sodium phosphate diabase and ammonium hydroxide (0.88, 35%) were purchased from 
Fisher Scientific (Loughborough, UK). Ultrapure water (18 MΩcm) was prepared on an ELGA 
Purelab Maxima HPLC water purification system (High Wycombe, UK). Xtrackt® DAU High 
Flow (150 mg, 3 mL) cartridges were purchased from Chromatography Direct (Runcorn, UK). 
Drug-free whole blood (5 mL) was collected by trained phlebotomists into vacutainers 
containing NaF/KOx (0.25% w/v/0.1% w/v). Ethical approval for the collection of drug-free 
matrix was granted by the Research Ethics Committee at King’s College London 
(HR-16/17-4237). 
3.2 Synthesis of dihydro-nor-mephedrone (DHNM) 
Ten mg of NOR (61.3 µmol) was reduced to DHNM following a method described elsewhere 
15. Synthesized product was stored at -40°C and a small amount was characterized using high 
resolution mass spectrometry to determine its accurate mass (ThermoFisher Scientific 
Q-Exactive operated in positive electrospray ionization mode). Nuclear magnetic resonance 
(NMR) was also performed on a Bruker Avance DRX 400 MHz instrument. 
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3.3 Working solutions 
Working solutions used for the preparation of the calibration curve were made in 
MeOH:water (50:50 v/v) at 4, 8, 16, 20, 100, 160, 200 ng/mL for MEPH, DHM, NOR, DHNM; 4, 
10, 20, 100, 200, 400, 500 ng/mL for HYDROXY; and 40, 100, 200, 500, 1000, 1600, 2000 ng/mL 
for 4-CARBOXY. Working solution used for the preparation of the quality control samples at 
low, medium and high level were made in MeOH:water (50:50 v/v) at 5, 20, 160 ng/mL for 
MEPH, DHM, NOR, DHNM; 5, 40, 400 ng/mL for HYDROXY; and 50, 400, 1600 ng/mL for 
4-CARBOXY. Internal standard (IS) solution containing MEPH-d3, DHM-d3 at 50 ng/mL and 
AEBA at 500 ng/mL was prepared in MeOH:water (50:50 v/v). 
3.4 Calibration standards (STD) and quality control (QC) samples 
Matrix-matched calibration standards containing MEPH, DHM, NOR, DHNM at 0, 0.2, 0.4, 0.8, 
1, 5, 8 and 10 ng/mL; HYDROXY at 0, 0.2, 0.5, 1, 5, 10, 20 and 25 ng/mL; and 4-CARBOXY at 0, 
2, 5, 10, 25, 50, 80 and 100 ng/mL were prepared by the addition of an appropriate volume 
of the working solution to whole blood. QC Low (0.250 ng/mL for MEPH, DHM, NOR, DHNM, 
HYDROXY; and 2.5 ng/mL for 4-CARBOXY), Medium (1 ng/mL for MEPH, DHM, NOR, DHNM; 
2 ng/mL for HYDROXY; and 20 ng/mL for 4-CARBOXY) and High (8 ng/mL for MEPH, DHM, 
NOR, DHNM; 20 ng/mL for HYDROXY; and 80 ng/mL for 4-CARBOXY) were prepared by the 
addition of an appropriate volume of the working solution to whole blood. Calibration 
standards and QCs were prepared fresh on the day of sample analysis. 
3.5 Sample analysis 
One hundred µL of whole blood (NaF/KOx) was extracted using solid phase extraction (SPE). 
Ten µL of IS or 10 µL of MeOH:water (50:50 v/v) was added to the samples and solvent/matrix 
blanks, respectively. All samples were vortex mixed and 1 mL of 0.1 M phosphate buffer (pH 
6.0) was added. After conditioning the SPE cartridges (mixed mode cation exchange 
containing C8 and benzoylsulfonate anion) with 2 mL of MeOH and 2 mL of 0.1 M phosphate 
buffer (pH 6.0), samples were loaded and washed with 2 mL of 0.1 M acetic acid(aq) followed 
by 2 mL of MeOH. Samples were eluted with 4 x 1 mL of DCM:IPA:ammonium hydroxide 
(78:20:2 v/v/v) and dried under nitrogen at 50°C. Samples were reconstituted with 100 µL of 
0.1% formic acid in ACN:water (10:90 v/v). 
3.6 LC-MS/MS conditions 
The analysis was performed by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) using a Waters Xevo TQ-S triple quadrupole mass spectrometer (Manchester, UK) 
coupled to Waters Acquity ultra performance liquid chromatograph system equipped with a 
CTC 2777 open architecture autosampler (Waters, UK). 
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Extracted samples were analyzed using electrospray ionization operated in positive ion mode. 
The source temperature was set at 150°C. The desolvation gas flow rate was 1000 L/h at a 
temperature of 500°C, capillary voltage was set to 2.22 kV, cone voltage was 45 V and source 
offset was 84 V. The cone gas flow rate was set to 150 L/h, the nebulizer gas flow was 7.00 bar 
and the collision gas flow rate was 0.25 mL/min. Mephedrone metabolites and deuterated 
internal standards were monitored using selected reaction monitoring (SRM) as detailed in 
Table 1. In order to maximize sensitivity, all analytes except for 4-CARBOXY and HYDROXY had 
their dehydration products chosen as target precursor ions due to significant in-source 
fragmentation which is commonly observed in synthetic cathinones 9,16. 
Chromatographic separation was performed using a 2.1 mm x 150 mm, 1.8 µm, 
pentafluorophenylpropyl Selectra® column (Bristol, US) held at 60°C. The strong needle wash 
was 0.3% formic acid in MeOH and the weak needle wash was 0.01% formic acid in 
acetonitrile:water (10:90 v/v). The flow rate was 0.5 mL/min with 0.3% formic acid in water 
as mobile phase A and 0.3% formic acid in acetonitrile as mobile phase B. The start of the 
gradient was at 85% mobile phase A. Mobile phase B was then increased to 55% over 11 min 
and was held for 2 min. Over the next 0.5 min the gradient returned to the starting condition 
and the column was re-equilibrated at 85% mobile phase A for the remaining 1.5 min. The 
total run time was 15 min. The injection volume was 20 µL and the data was acquired using 
MassLynx (version 4.1) software. TargetLynx (version 4.1) was used for data processing and 
quantitation. 
 













MEPH 5.85 160.4 
145.1* 15 
MEPH-d3 144.1 33 
91.1 28 
MEPH-d3 5.85 163.4 148.4 19  
DHM 5.38 162.4 
147.3* 19 
DHM-d3 131.4 17 
91.3 26 
DHM-d3 5.38 165.4 150.3 18  
NOR 5.00 146.0 
131.1 25 
MEPH-d3 130.1* 25 
119.0 15 








 146.0* 13 
AEBA 208.0 144.1 28 
 130.1 31 
DHNM 4.45 
 131.1* 13 
MEPH-d3 148.1 116.2 23 
 91.1 25 
AEBA 1.77 166.1 149.1 10  
 
3.7 Stability 
Stability samples prepared at QC Low and QC High levels in drug-free human whole blood 
(NaF/KOx) were aliquoted into tubes and stored at +4°C and -20°C for 24 h, 48 h, 4 days and 
10 days. At each sampling point, one tube at each QC level was removed and six aliquots 
extracted. Freezer and fridge temperatures were monitored and logged daily. 
4 Method validation 
Validation experiments determined selectivity, linearity, inter- and intra-day precision and 
accuracy, limit of detection (LOD) and limit of quantification (LOQ), recovery, matrix effect, 
carryover and stability according to the validation guidelines published by the Food and Drug 
Administration (FDA) 17 and recommendations published by Peters at el. 18 
4.1 Selectivity 
Selectivity was assessed by analyzing 6 blank whole blood samples collected from 3 drug-free 
female and 3 drug-free male donors.  
4.2 Linearity 
Matrix-matched calibration curve was prepared by fortifying drug-free whole blood 
(NaF/KOx) with appropriate working solutions containing mephedrone and its metabolites. 
Each calibration standard was required to be within ± 20% of its target concentration and the 
correlation coefficient (r2) of the line to be at least 0.99. A linear regression model with a 
weighting of 1/x was applied to the calibration curve. 
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4.3 LOD and LOQ 
The LOD for each analyte was defined as the lowest concentration where all 3 ions (2 qualifier 
and 1 quantifier) were present with a signal-to-noise ratio equal to or greater than 3. The LOQ 
was defined as the lowest concentration at which analytes could be quantified with an 
acceptable precision and accuracy (± 20%). The upper limit of quantification was determined 
as the highest concentration of the calibration line, which could be determined with an 
acceptable accuracy and precision (± 20%) without saturating the instrument signal. 
4.4 Precision and accuracy 
Intra-day (n=6) and inter-day (n=3) precision and accuracy was determined by employing QC 
samples spiked at low, medium and high concentrations. Intra-day precision was calculated 
using 6 replicates obtained on the same day and expressed as a percentage relative standard 
deviation (% RSD). Accuracy was calculated by dividing the mean measured concentration at 
each QC level by the theoretical spiked concentration and expressed as a percentage of the 
theoretical spiked concentration. Inter-day precision was evaluated for each QC level run on 
three different days and expressed as % RSD. Values of ± 20% are acceptable according to the 
guidelines. 
4.5 Recovery and matrix effect 
For recovery, a set of whole blood samples (n=6) was fortified at QC Low and QC High level 
and was taken through the SPE. In parallel, a set of blank whole blood samples (n=6) was 
extracted and fortified after the evaporation step at QC Low and QC High level. Recovery was 
calculated as a percentage by comparing the absolute peak areas of the samples spiked 
before extraction with samples spiked after extraction. 
For the IS-corrected matrix effect, a set of blank whole blood samples (n=6, from 3 female 
and 3 male individuals) and a set of water samples (n=6) was taken through the extraction. 
All samples were reconstituted with a solution containing known amounts of the internal 
standard and analytes at QC Low and QC High levels. Matrix effect was evaluated by 
comparing peak area ratios in blank whole blood samples fortified after extraction with peak 
area ratios in water samples fortified after extraction. 
4.6 Carryover 
Carryover was assessed by injecting methanol blanks after the highest calibration standard. 
9 
 
5 Results and Discussion 
5.1 DHNM synthesis  
DHNM was successfully synthesized (yield: 51%). Formula C10H16NO+; HRMS [M+H+] 
calculated m/z 166.1226, observed 166.1227 (+0.001 ppm); observed MS/MS fragments with 
collision energy 20 eV were consistent with those reported in the literature 9. 1H NMR (CDCl3): 
δ 7.22 (d, J=8.0 Hz, 2H, Ar-H), 7.16 (d, J=8.0 Hz, 2H, Ar-H), 4.50 (d, J=4.0 Hz, 1H, CH(OH)), 3.19 
(br , 1H, CH(CH3)), 2.35 (s, 3H, Ar-CH3) and 0.98 (d, J=8.0 Hz, 3H, CH(CH3)). 1H NMR data is 
consistent with the literature except for the signal at 3.19 ppm being previously reported as 
a multiplet 15.  
5.2 Method validation 
Selectivity 
No interferences were observed in the extracted blank matrix. 
Linearity 
Mean linearity of r2 > 0.998 was achieved for each analyte in all 3 validation runs. 
LOD and LOQ 
LOD and LOQ of 50 pg/mL and 200 pg/mL, respectively, was achieved for all analytes except 
4-CARBOXY for which LOD and LOQ was 500 pg/mL and 2000 pg/mL, respectively. Table 2 
shows calibration parameters for all analytes. 
 








Intercept ± SD 
(n=3) 
Slope ± SD 
(n=3) 
r2 ± SD 
(n=3) 
MEPH 50 200 0.2-10 -0.0127 ± 0.0263 3.15 ± 0.1290  0.999 ± 0.0000 
DHM 50 200 0.2-10 -0.0324 ± 0.0043 2.81 ± 0.0529 0.998 ± 0.0010 
NOR 50 200 0.2-10 -0.0147 ± 0.0088 1.65 ± 0.0608 0.997 ± 0.0000 
HYDROXY 50 200 0.2-25 -0.000510 ± 0.0096 1.21 ± 0.1300 0.998 ± 0.0010 
4-CARBOXY 500 2000 2-100 6.85 ± 5.8800 27.9 ± 23.6000 0.997 ± 0.0015 





Precision and accuracy 
Intra-day and inter-day precision and accuracy results, summarized in Table 3, were found to 
be within the acceptable limits. The intra-day accuracy for all metabolites was within ± 15% 
of the target concentration and ranged from 96.7-106% for MEPH, 91.1-109% for DHM, 
89.7-97.0% for NOR, 94.3-115% for HYDROXY, 97.0-114% for 4-CARBOXY and 86.6-103% for 
DHNM. The intra-day precision was < 7% and ranged from 1.44-4.33% for MEPH, 0.924-4.65% 
for DHM, 1.58-4.87% for NOR, 1.55-6.57% for HYDROXY, 1.36-5.97% for 4-CARBOXY, 
1.52-5.13% for DHNM. Inter-day precision and accuracy results were acceptable over the 
validated range with % RSD < 8.5% and accuracy within ± 9.0% of the target concentration. 
 





























































































































































































































































Recovery and matrix effect 
Recovery was found to be greater than 71.3% for all analytes, except for 4-CARBOXY for which 
recovery was 32.5 ± 6.8% at QC Low level and 41.6 ± 0.5% at QC High level. 4-CARBOXY is a 
zwitterionic compound which contains an acidic carboxylic acid group and a basic secondary 
amine group. According to Marvin (chemistry software package, version 17.16.0), the 
secondary amine has a pKa of 8.0 and the carboxylic acid has a pKa of 3.6, similar to the pKa 
values of mephedrone and benzoic acid, respectively. Secondary amines become fully 
protonated upon the addition of diluted acetic acid (pH 2.9) during the wash step in SPE, 
whereas only about 80% of the carboxylic acid group is protonated under this pH. Therefore, 
about 20% of the molecule exists as a neutral zwitterion with no net charge. A subsequent 
wash with 2 mL of MeOH to remove neutral and acidic interferents, such as free fatty acids, 
will also disrupt the hydrophobic interaction of this ‘net neutral’ metabolite with the C8 alkyl 
chains, causing a considerable proportion to be lost which might explain lower recovery for 
4-CARBOXY. The other analytes are all basic and as cations will ionically interact with the 
benzoylsulfonate anion within the mixed-mode stationary phase during the MeOH wash, 
which results in higher recovery. Even though it is recommended for the recovery to be 
greater than 50% 18, desired sensitivity as well as acceptable precision and accuracy were 
achieved for 4-CARBOXY (Table 4).   
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IS-corrected matrix effect values were within ± 17% at both QC Low and QC High level, except 
for HYDROXY at QC High which was suppressed by 29.0% (Table 4). This may be due to the 
lack of matching deuterated IS which is currently not commercially available. However, assay 
precision and accuracy for HYDROXY at QC High was within the acceptable limits (Table 3). 
 
Table 4. Analyte recovery and matrix effect at QC Low and QC High 
Analyte 
Recovery (% RSD), n=6 Matrix Effect (% RSD), n=6 
QC LOW QC HIGH QC LOW QC HIGH 
MEPH 85.2% (1.84%) 88.3% (3.17%) 101% (8.16%) 99.0% (1.12%) 
DHM 83.6% (9.97%) 84.2% (2.70%) 105% (2.87%) 98.7% (0.792%) 
NOR 74.3% (3.78%) 76.6% (3.31%) 89.6% (5.89%) 91.7 % (3.25%) 
HYDROXY 71.3% (4.12%) 81.4% (2.62%) 83.8% (2.58%) 71.0% (6.00%) 
4-CARBOXY 32.5% (6.79%) 41.6% (0.522%) 103% (6.49%) 108% (5.99%) 
DHNM 78.6% (5.70%) 79.0% (5.41%) 93.0% (4.66%) 87.4% (4.94%) 
 
Carryover 
Carryover was not observed. 
5.3 Stability 
Stability data together with corresponding % RSD is presented in Table 5 and showed 
graphically in Figures 2-5. Analytes were considered unstable when they lost more than 10% 
of their initial concentration. 
At +4°C at QC Low, DHM and DHNM were stable over the 10-day period while HYDROXY and 
MEPH lost 18.6 ± 5.2% and 23.4 ± 6.3%, respectively, of their initial concentration. 4-CARBOXY 
and NOR decreased in concentration by 48.1 ± 4.8% and 40.2 ± 6.7%, respectively, after 10 
days (Figure 2). At QC High, DHM and DHNM were stable over the 10-day period while 
HYDROXY and MEPH lost 11.3 ± 3.2% and 14.2 ± 3.3%, respectively, of their initial 
concentration. 4-CARBOXY and NOR were most unstable and their concentration decreased 





Figure 2. Analyte stability at QC Low at +4°C 
 
 
Figure 3. Analyte stability at QC High at +4°C 
 
At -20°C at QC Low, NOR and DHNM were most stable over the 10-day period while MEPH, 
4-CARBOXY, HYDROXY and DHM lost 9.9 ± 2.4%, 9.6 ± 5.3%, 11.2 ± 4.8% and 12.0 ± 4.8%, 
respectively, of their initial concentration (Figure 4). At QC High, 4-CARBOXY was the most 
unstable and decreased in concentration by 22.6 ± 6.9% after 10 days. MEPH, DHM, NOR and 
DHNM were stable over the 10-day period while HYDROXY lost 10.2 ± 2.2% of its initial 





Figure 4. Analyte stability at QC Low at -20°C 
 
 
Figure 5. Analyte stability at QC High at -20°C 
 
Out of all metabolites, 4-CARBOXY was the most unstable at +4°C with significant losses 
observed already after 4 days (33.7 ± 6.1%) at QC Low and after 48 h (21.6 ± 4.3%) at QC High. 
Its stability was improved at -20°C where the highest loss of 22.6 ± 6.9% was observed after 
10 days at QC High. NOR was much more stable at -20°C than 4°C where it lost 40.2 ± 6.7% at 
QC Low (versus no change at -20°C) and 33.8 ± 4.2% at QC High (versus 6.6 ± 3.6% at -20°C). 
HYDROXY was stable at -20°C but lost 18.6 ± 5.2% at +4°C after 10 days at QC Low. DHM and 
DHNM were most stable at +4°C at both concentration levels with the latter showing a slight 
increase in its concentration after 10 days at QC High. DHM and DHNM are the only two 
15 
 
metabolites containing a hydroxyl group instead of a ketone at the β carbon which was 
previously reported to make ephedrines more stable than cathinones 11. 
 
Table 5. QC Low and QC High concentrations ± % RSD (% loss/gain) for each analyte after 24 h, 48 h, 





24 h 48 h 4 Days 10 Days 

























































































































































































































































































































Studies investigating the stability of mephedrone in human whole blood have been published 
before. Sørensen 11 investigated the stability of cathinones (including mephedrone) and 
related ephedrines in human whole blood spiked with analytes at 100 µg/mL and preserved 
with NaF/KOx or NaF/citrate buffer. Samples were stored at either +4°C or +20°C for up to 5 
or 6 days. After 5 days of storage mephedrone was more stable at +4°C than +20°C. Busardò 
et al. 12 reported on the stability of mephedrone in ante-mortem and post-mortem blood 
preserved with NaF/KOx or EDTA. Whole blood samples were spiked at 1 mg/mL and stored 
at -20°C, +4°C or +20°C for up to 185 days. Mephedrone was shown to be most stable in ante-
mortem samples at all tested storage conditions, with -20°C being the best storage 
temperature. This study showed that mephedrone stability is pH dependent and acidic 
preservatives are better suited (6.6% vs 9.4% loss after 185 days at -20°C when preserved 
with NaF/KOx rather than EDTA). Johnson and Botch-Jones 10 investigated the stability of four 
designer drugs (including mephedrone) stored at -20°C, +4°C or +22°C over 14 days. Human 
whole blood (preservative not stated), plasma and urine samples were spiked at 1 µg/mL. This 
study showed a mean 48% reduction in mephedrone concentration in whole blood kept at 
+4°C for 14 days. Over the same period of time mephedrone was undetected when stored at 
room temperature whilst there was no measurable degradation at -20°C. The most recent 
study looked at the stability of mephedrone and other synthetic cathinones in bovine blood 
fortified with NaF/KOx at 100 ng/mL (QC Low) and 1,000 ng/mL (QC High) stored at -20°C, 
+4°C, +20°C and +32°C. At QC Low a complete degradation of mephedrone was observed after 
11 days when stored at the elevated temperature. Degradation was much slower at +4°C and 
-20°C where a 20% loss was observed after 55 days and 130 days, respectively 13. These results 
follow the stability pattern seen in our study where mephedrone and its metabolites have 
been shown to be more stable at -20°C than +4°C. 
Low concentrations of mephedrone and its metabolites were chosen for this degradation 
study to help distinguish subtle changes from initial values that may not be so easily detected 
if much higher initial concentrations were chosen. However, it is possible that the losses 
17 
 
observed were independent of the initial concentrations and, if so, the relative rates of 
instability will not apply in most casework where much higher concentrations are typically 
observed. It would be of interest in the future to investigate whether the relative losses 
observed are germane to higher concentrations. In the interim, when evaluating cases 
concerning mephedrone and its metabolites where sample storage conditions may be 
considered a factor, hopefully the overarching recommendations and conclusions of our 
investigation will be considered of value. 
6 Conclusion 
A fully validated method for the simultaneous quantification of mephedrone and five of its 
phase I metabolites in human whole blood (NaF/KOx) has been developed. Mephedrone’s 
stability in whole blood has been previously investigated but this is the first time stability of 
its metabolites has been assessed, indicating -20°C to be the recommended storage condition 
for all analytes. 
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No drug effect Drug effect 
No bad drug effect Bad drug effect 
Not feeling stimulated Feeling stimulated 
No changes in distances Changes in distances 
No difference in body sensation 
No good drug effect Good drug effect 
Different body sensation 
Not feeling high Feeling high 
Not confused Confused 
No fear Fear 
Not liking Liking 
Not dizzy Dizzy 
No changes in lights Changes in lights 
No changes in hearing Changes in hearing 
No difference in surrounding Different surrounding 
Not feeling sad Feeling sad 
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1. Individual raw data showing changes in analyte concentration over 
time in whole blood 
 
Table 1. Changes in mephedrone concentration over time in M1-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 49.1 26.5 81.8 34.5 61.5 179 
10 63.5 41.5 78.9 48.5 71.4 158 
15 63.9 47.0 74.2 54.7 85.4 150 
20 64.3 70.4 68.8 63.7 86.8 140 
30 65.6 76.3 67.1 74.4 108 173 
45 64.3 88.2 69.7 76.7 92.8 189 
60 65.0 91.1 66.8 69.9 96.2 161 
75 69.1 81.9 73.8 65.5 75.6 134 
90 65.7 79.7 59.4 62.5 65.9 119 
105 55.2 69.1 51.2 60.4 64.0 95.1 
120 55.1 65.6 47.6 52.2 57.2 99.4 
150 47.7 49.0 39.4 44.5 47.7 72.4 
180 43.5 37.4 34.6 35.7 39.1 67.6 
300 25.9 19.6 19.3 16.3 18.3 40.4 
360 20.1 16.9 14.8 13.6 13.1 29.4 
Day 2 0.212 0.044 BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 2. Changes in dihydro-mephedrone concentration over time in M1-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 0.309 BLQ BLQ BLQ 0.206 0.584 
10 0.407 BLQ 0.215 BLQ 0.264 0.612 
15 0.434 BLQ 0.234 0.224 0.324 0.849 
20 0.459 0.267 0.262 0.250 0.358 0.809 
30 0.564 0.399 0.403 0.317 0.496 1.34 
45 0.585 0.660 0.850 0.389 0.569 2.25 
60 0.775 1.06 1.22 0.432 0.716 2.37 
75 0.903 1.30 1.48 0.451 0.696 2.30 
90 1.25 1.40 1.79 0.473 0.876 2.47 
105 1.36 1.40 1.89 0.483 0.868 2.43 
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120 1.28 1.44 1.75 0.475 0.787 2.22 
150 1.45 1.34 1.71 0.483 0.762 2.42 
180 1.55 1.29 1.69 0.402 0.743 2.04 
300 1.44 0.907 1.53 0.280 0.546 1.56 
360 1.33 0.901 1.39 0.274 0.480 1.58 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 3. Changes in nor-mephedrone concentration over time in M1-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ BLQ 
10 BLQ BLQ BLQ BLQ BLQ 0.293 
15 0.219 BLQ 0.286 BLQ BLQ BLQ 
20 0.368 0.371 0.571 0.228 0.284 0.900 
30 0.894 0.980 1.14 0.644 0.706 2.32 
45 1.43 2.32 2.67 1.20 1.16 5.90 
60 2.33 4.04 3.75 1.45 1.86 7.13 
75 3.65 5.24 4.50 1.66 2.16 7.31 
90 5.49 5.76 5.57 1.85 3.00 7.75 
105 6.27 5.33 5.29 1.89 3.08 6.99 
120 6.08 5.78 4.44 1.97 2.84 7.15 
150 6.67 5.77 4.32 2.25 2.47 7.93 
180 6.50 5.68 4.05 1.96 2.47 6.90 
300 5.87 3.91 3.17 1.29 1.76 5.49 
360 5.34 3.74 2.87 1.25 1.61 5.10 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 4. Changes in hydroxytolyl-mephedrone concentration over time in M1-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ BLQ 
10 BLQ BLQ BLQ BLQ BLQ 0.488 
15 BLQ 0.200 BLQ BLQ BLQ 0.912 
20 BLQ 0.312 0.289 0.203 BLQ 1.27 
30 0.247 0.597 0.431 0.440 0.349 3.51 
45 0.263 1.10 1.15 0.493 0.459 5.38 
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60 0.489 1.47 1.11 0.441 0.740 3.89 
75 0.622 1.40 1.03 0.480 0.761 3.53 
90 0.770 1.35 0.979 0.449 1.14 2.43 
105 0.860 1.05 0.807 0.412 0.821 2.31 
120 0.690 0.891 0.621 0.413 0.442 1.88 
150 0.559 0.783 0.510 0.409 0.323 1.62 
180 0.431 0.766 0.373 0.274 BLQ 0.989 
300 0.264 0.310 BLQ BLQ BLQ 0.387 
360 BLQ 0.213 BLQ BLQ BLQ 0.265 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 5. Changes in 4-carboxy-mephedrone concentration over time in M1-M6 in whole blood;  
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ 14.0 
10 2.83 3.17 5.81 4.57 8.20 59.2 
15 13.2 19.0 11.2 15.1 23.8 62.0 
20 22.0 33.4 26.4 25.3 53.2 113 
30 46.4 95.6 47.3 73.3 73.2 253 
45 84.6 172 103 127 119 398 
60 71.2 254 106 131 170 454 
75 103 194 167 143 232 352 
90 116 200 166 148 253 394 
105 134 175 125 158 244 381 
120 162 150 119 146 215 361 
150 103 131 79.1 138 153 242 
180 106 107 61.2 102 109 212 
300 53.5 39.6 23.8 31.0 62.7 103 
360 46.2 33.2 20.4 24.7 65.1 62.4 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 6. Changes in dihydro-nor-mephedrone concentration over time in M1-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ BLQ 
10 BLQ BLQ BLQ BLQ BLQ BLQ 
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15 BLQ BLQ BLQ BLQ BLQ BLQ 
20 BLQ BLQ BLQ BLQ BLQ BLQ 
30 BLQ BLQ BLQ BLQ BLQ BLQ 
45 BLQ BLQ BLQ BLQ BLQ 0.324 
60 BLQ BLQ BLQ BLQ BLQ 0.516 
75 BLQ 0.209 0.227 BLQ BLQ 0.658 
90 0.203 0.278 0.289 BLQ BLQ 0.796 
105 0.241 0.280 0.348 BLQ BLQ 0.910 
120 0.261 0.343 0.286 BLQ BLQ 0.940 
150 0.300 0.411 0.344 BLQ 0.200 1.11 
180 0.328 0.448 0.349 BLQ BLQ 1.16 
300 0.475 0.395 0.381 BLQ 0.227 1.30 
360 0.473 0.417 0.392 BLQ 0.217 1.49 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
2. Individual raw data showing changes in analyte concentration over 
time in whole blood (chiral) 
Table 7. Changes in R-mephedrone concentration over time in M2-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ 
5 11.9 46.5 15.3 26.1 89.9 
10 18.1 41.0 22.3 30.2 92.7 
15 18.1 40.4 26.4 37.6 72.5 
20 32.2 35.7 29.4 42.0 51.1 
30 33.9 38.3 34.7 54.2 64.2 
45 41.0 42.5 38.0 44.1 66.7 
60 41.1 38.9 34.3 45.0 63.6 
75 40.1 34.5 34.2 36.9 56.3 
90 36.3 34.2 30.8 32.7 47.9 
105 33.3 28.9 29.4 31.3 41.5 
120 32.5 25.1 26.2 28.1 35.4 
150 24.9 22.6 24.0 24.0 23.2 
180 17.5 20.2 17.7 21.6 15.1 
300 9.32 11.2 8.07 9.43 10.8 
360 7.18 8.61 6.80 6.85 6.37 
Day 2 BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ N/C 
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Table 8. Changes in S-mephedrone concentration over time in M2-M6 in whole blood; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ 
5 11.7 47.3 14.8 26.3 87.7 
10 17.4 41.9 22.3 30.1 90.1 
15 17.8 40.6 27.4 37.3 71.9 
20 29.1 36.0 28.6 40.4 49.7 
30 33.1 35.7 33.0 49.7 63.2 
45 36.8 37.9 35.7 39.4 62.6 
60 34.7 34.4 31.1 39.2 59.5 
75 34.8 29.6 30.8 29.2 52.7 
90 31.3 29.5 26.1 24.2 44.8 
105 27.6 24.1 25.4 23.7 38.8 
120 26.6 21.6 20.8 21.0 32.6 
150 20.3 17.8 18.0 17.0 20.7 
180 13.7 16.4 12.6 14.3 13.1 
300 6.63 7.81 5.10 4.96 8.95 
360 4.90 6.35 3.90 3.41 4.73 
Day 2 BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ N/C 
3. Individual raw data showing changes in analyte concentration over 
time in plasma 
Table 9. Changes in mephedrone concentration over time in M1-M6 in plasma; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 53.3 22.3 65.1 26.8 48.3 131 
10 53.5 35.0 69.1 35.4 54.5 140 
15 53.4 39.4 56.4 39.5 70.1 127 
20 60.4 68.2 53.3 46.0 76.9 103 
30 60.5 78.8 66.5 56.4 87.3 152 
45 58.7 86.0 65.0 60.3 74.8 162 
60 57.8 89.1 62.4 55.1 65.4 169 
75 64.4 85.3 50.1 48.0 54.5 171 
90 56.9 76.9 47.7 45.2 49.4 130 
105 45.6 70.7 46.3 40.1 45.0 111 
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120 43.9 59.6 43.9 38.3 43.6 94.2 
150 40.4 41.9 35.5 32.9 35.5 69.2 
180 37.0 29.7 31.2 25.0 29.3 52.1 
300 19.5 15.5 17.9 12.1 13.1 32.9 
360 N/C 12.8 13.6 9.37 9.64 23.7 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 10. Changes in dihydro-mephedrone concentration over time in M1-M6 in plasma; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ 0.261 
10 BLQ BLQ BLQ BLQ BLQ 0.356 
15 BLQ BLQ 0.100 BLQ 0.128 0.398 
20 0.136 0.103 0.157 BLQ 0.161 0.447 
30 0.189 0.179 0.274 0.144 0.253 0.951 
45 0.289 0.385 0.699 0.214 0.336 1.69 
60 0.408 0.777 0.950 0.253 0.485 2.02 
75 0.596 0.862 1.17 0.262 0.550 2.54 
90 0.839 1.01 1.55 0.296 0.783 2.75 
105 0.869 0.945 1.44 0.308 0.723 2.79 
120 0.933 0.943 1.28 0.328 0.779 2.61 
150 1.00 1.02 1.35 0.343 0.764 1.97 
180 0.990 0.878 1.32 0.349 0.685 1.93 
300 0.993 0.703 1.16 0.259 0.523 1.68 
360 N/C 0.633 1.02 0.241 0.446 1.32 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 11. Changes in nor-mephedrone concentration over time in M1-M6 in plasma; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ 0.171 
10 BLQ BLQ 0.189 BLQ BLQ 0.601 
15 0.236 0.193 0.353 0.199 0.182 1.04 
20 0.448 0.453 0.855 0.357 0.343 1.37 
30 0.887 1.18 1.65 0.909 0.857 3.64 
45 1.52 2.82 3.90 1.87 1.38 9.06 
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60 2.39 4.84 5.52 1.82 2.29 10.9 
75 3.56 6.35 6.41 2.26 2.66 15.7 
90 4.81 7.14 7.24 2.47 4.14 16.4 
105 4.64 6.95 6.68 2.52 6.04 18.3 
120 5.11 7.20 6.37 2.73 5.60 16.3 
150 5.40 7.26 5.83 2.96 5.86 13.7 
180 5.43 6.77 5.31 2.61 2.81 11.3 
300 4.81 5.33 4.11 1.64 1.91 8.61 
360 N/C 4.60 3.68 1.45 1.78 7.59 
Day 2 0.115 BLQ 0.138 BLQ N/C N/C 
Day 3 BLQ N/C 0.122 BLQ BLQ N/C 
 
Table 12. Changes in hydroxytolyl-mephedrone concentration over time in M1-M6 in plasma; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ 0.186 
10 BLQ BLQ BLQ BLQ BLQ 0.670 
15 0.174 0.181 0.101 BLQ BLQ 0.970 
20 0.204 0.318 0.229 0.148 0.150 1.26 
30 0.250 0.573 0.356 0.326 0.337 3.24 
45 0.369 0.981 0.835 0.348 0.458 4.27 
60 0.583 1.24 0.934 0.374 0.662 3.90 
75 0.621 1.29 0.868 0.327 0.727 2.91 
90 0.851 1.11 0.977 0.338 1.272 2.87 
105 0.706 1.05 0.705 0.297 0.653 2.78 
120 0.647 0.960 0.535 0.269 0.706 2.17 
150 0.511 0.781 0.408 0.312 0.518 1.47 
180 0.439 0.710 0.323 0.263 0.155 1.06 
300 0.235 0.271 0.159 BLQ 0.100 0.352 
360 N/C 0.210 0.120 BLQ BLQ 0.283 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 13. Changes in 4-carboxy-mephedrone concentration over time in M1-M6 in plasma; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ 0.626 0.243 0.421 17.1 
10 4.00 3.36 12.9 5.79 7.08 46.2 
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15 18.1 16.9 18.0 19.0 17.8 56.5 
20 30.6 34.5 41.9 28.5 33.5 78.3 
30 44.1 129 102 121 46.9 216 
45 49.5 194 125 202 131 542 
60 91.8 250 162 198 185 586 
75 122 215 150 155 207 795 
90 152 187 140 176 272 446 
105 126 182 126 186 261 486 
120 109 136 106 176 199 505 
150 94.8 136 87.2 179 173 198 
180 92.5 97.0 66.3 122 48.2 222 
300 57.8 42.6 40.3 39.9 38.6 130 
360 N/C 31.7 32.9 30.9 31.3 86.2 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
 
Table 14. Changes in dihydro-nor-mephedrone concentration over time in M1-M6 in plasma; 
Pre: pre-administration, BLQ: below level of quantification, N/C: not collected 
 M1 M2 M3 M4 M5 M6 
Timepoint (min) Concentration (ng/mL) 
Pre BLQ BLQ BLQ BLQ BLQ BLQ 
5 BLQ BLQ BLQ BLQ BLQ BLQ 
10 BLQ BLQ BLQ BLQ BLQ BLQ 
15 BLQ BLQ BLQ BLQ BLQ BLQ 
20 BLQ BLQ BLQ BLQ BLQ BLQ 
30 BLQ BLQ BLQ BLQ BLQ BLQ 
45 BLQ BLQ BLQ BLQ BLQ 0.422 
60 BLQ BLQ 0.277 BLQ BLQ 0.588 
75 BLQ BLQ 0.212 BLQ BLQ 0.859 
90 BLQ 0.205 0.311 BLQ BLQ 1.00 
105 BLQ 0.209 0.318 BLQ BLQ 1.27 
120 BLQ 0.225 0.295 BLQ BLQ 1.21 
150 0.205 0.267 0.333 BLQ BLQ 1.46 
180 0.253 0.295 0.359 BLQ BLQ 1.26 
300 0.307 0.291 0.389 BLQ BLQ 1.37 
360 N/C 0.293 0.408 BLQ BLQ 1.45 
Day 2 BLQ BLQ BLQ BLQ N/C N/C 
Day 3 BLQ N/C BLQ BLQ BLQ N/C 
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4. Individual plots showing changes in analyte concentrations over time 
in whole blood 
 
 
Figure 1. Changes in mephedrone concentration over time (above LOQ) in whole blood in M1-M3 
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Figure 2. Changes in dihydro-mephedrone concentration over time (above LOQ) in whole blood in 
M1-M3 (top) and M4-M6 (bottom) 
 
 
Figure 3. Changes in nor-mephedrone concentration over time (above LOQ) in whole blood in M1-
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Figure 4. Changes in hydroxytolyl-mephedrone concentration over time (above LOQ) in whole blood 
in M1-M3 (top) and M4-M6 (bottom) 
 
 
Figure 5. Changes in 4-carboxy-mephedrone concentration over time (above LOQ) in whole blood in 
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Figure 6. Changes in dihydro-nor-mephedrone concentration over time (above LOQ) in whole blood 
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5. Individual plots showing changes in analyte concentrations over time 
in plasma 
 
Figure 7. Changes in mephedrone concentration over time (above LOQ) in plasma in M1-M3 (top) 
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Figure 8. Changes in dihydro-mephedrone concentration over time (above LOQ) in plasma in M1-M3 
(top) and M4-M6 (bottom) 
 
 
Figure 9. Changes in nor-mephedrone concentration over time (above LOQ) in plasma in M1-M3 

















































































































Page | 393 
 
 
Figure 10. Changes in hydroxytolyl-mephedrone concentration over time (above LOQ) in plasma in 
M1-M3 (top) and M4-M6 (bottom) 
 
 
Figure 11. Changes in 4-carboxy-mephedrone concentration over time (above LOQ) in plasma in 
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Figure 12. Changes in dihydro-nor-mephedrone concentration over time (above LOQ) in plasma in 
M1 M3 (top) and M4-M6 (bottom) 
6. Individual pharmacokinetic data from whole blood 












(ng mL-1 h) 
CL 
(mL min-1 kg-1) 
V 
(L kg-1) 
M1 69.1 75 0.004 2.74 448 44.2 10.5 
M2 91.1 60 0.006 1.94 422 51.9 8.72 
M3 73.8 75 0.005 2.19 372 68.9 13.1 
M4 76.7 45 0.006 2.00 359 78.2 13.5 
M5 108 30 0.006 1.81 475 42.4 6.65 
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(ng mL-1 h) 
M1 1.55 180 0.001 13.9 19.4 
M2 1.44 120 0.003 4.47 14.3 
M3 1.89 105 0.001 10.9 21.1 
M4 0.483 105 0.003 3.35 4.62 
M5 0.876 90 0.002 5.20 11.0 
M6 2.47 90 0.002 5.34 25.4 
 












(ng mL-1 h) 
M1 6.67 150 0.001 11.4 78.3 
M2 5.77 150 0.002 5.69 59.4 
M3 5.57 90 0.002 4.82 46.7 
M4 2.25 150 0.003 4.30 20.3 
M5 3.08 105 0.002 4.65 35.9 
M6 7.93 150 0.002 5.73 81.4 
 
Table 18. Pharmacokinetic data from analysis of hydroxytolyl-mephedrone in whole blood from 6 











(ng mL-1 h) 
M1 0.860 105 0.006 2.04 2.28 
M2 1.47 60 0.006 1.79 5.94 
M3 1.15 45 0.009 1.31 2.35 
M4 0.493 45 0.005 2.18 1.39 
M5 1.14 90 0.021 0.55 1.38 
M6 5.38 45 0.009 1.24 11.2 
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(ng mL-1 h) 
M1 162 120 0.005 2.18 905 
M2 254 60 0.007 1.68 905 
M3 197 75 0.008 1.47 572 
M4 158 105 0.008 1.46 729 
M5 253 90 0.007 1.66 1675 
M6 454 60 0.006 1.78 1842 
 
Table 20. Pharmacokinetic data from analysis of dihydro-nor-mephedrone in whole blood from 6 
male participants (M1-M6); N/D: not detected. Note: kel and t1/2 were not determined because the 











(ng mL-1 h) 
M1 0.475 300 - - 5.97 
M2 0.448 180 - - 5.64 
M3 0.392 360 - - 5.23 
M4 N/D N/D N/D N/D N/D 
M5 0.227 300 - - 4.06 
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7. Individual pharmacokinetic data from plasma 












(ng mL-1 h) 
CL 
(mL min-1 kg-1) 
V 
(L kg-1) 
M1 64.4 75 0.005 2.35 392 50.5 10.2 
M2 89.1 60 0.007 1.66 360 60.8 8.74 
M3 66.5 30 0.005 2.36 333 77.0 15.7 
M4 60.3 45 0.006 1.92 257 109.1 18.2 
M5 87.3 30 0.007 1.77 354 56.9 8.73 
M6 171 75 0.006 1.81 674 44.7 7.00 
 
Table 22. Pharmacokinetic data from analysis of dihydro-mephedrone in plasma from 6 male 
participants (M1-M6); kel and t1/2 were not determined in M1 because not enough data points were 











(ng mL-1 h) 
M1 1.00 150 - - 13.3 
M2 1.02 150 0.002 420 10.1 
M3 1.55 90 0.001 506 15.8 
M4 0.35 180 0.002 328 3.77 
M5 0.78 90 0.002 314 10.03 
M6 2.79 105 0.003 251 22.7 
 












(ng mL-1 h) 
M1 5.43 180 0.003 3.68 68.2 
M2 7.26 150 0.002 5.41 73.8 
M3 7.24 90 0.002 5.98 63.8 
M4 2.96 150 0.003 3.32 25.0 
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M5 6.04 105 0.005 2.26 43.4 
M6 18.3 105 0.003 3.46 131 
 












(ng mL-1 h) 
M1 0.851 90 0.006 1.96 4.39 
M2 1.29 75 0.006 1.78 5.63 
M3 0.977 90 0.007 1.76 3.38 
M4 0.374 60 0.003 3.99 1.09 
M5 1.27 90 0.012 1.00 1.90 
M6 4.27 45 0.009 1.27 11.3 
 












(ng mL-1 h) 
M1 152 90 0.004 3.10 961 
M2 250 60 0.007 1.68 895 
M3 162 60 0.005 2.11 744 
M4 202 45 0.007 1.77 922 
M5 272 90 0.009 1.36 1044 
M6 795 75 0.007 1.64 2358 
 
Table 26. Pharmacokinetic data from analysis of dihydro-nor-mephedrone in plasma from 6 male 
participants (M1-M6); N/D: not detected. Note: kel and t1/2 were not determined in M1, M2, M3 and 











(ng mL-1 h) 
M1 0.307 300 - - 3.64 
M2 0.295 180 - - 3.91 
M3 0.389 300 - - 5.46 
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M4 N/D N/D N/D N/D N/D 
M5 N/D N/D N/D N/D N/D 
M6 1.45 360 - - 19.6 
8. Individual VAS data 
Table 27. Changes in VAS “drug effect”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 10 3.0 7.5 1.5 7.0 10 7.3 
30 5.0 3.0 2.5 1.5 3.0 10 3.0 
45 2.5 5.0 1.0 3.5 1.0 10 3.0 
60 2.0 3.0 1.0 1.0 0 10 1.5 
75 1.0 0.5 1.0 0.5 0 10 0.8 
90 0.5 0.5 0 0.5 0 8.0 0.5 
105 0.2 0.5 0 0 0 6.0 0.1 
120 0.1 0.5 0 0 0 5.0 0.1 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 28. Changes in VAS “stimulated”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 9.0 3.0 7.0 4.0 8.0 4.0 5.5 
30 6.0 4.5 2.0 3.5 4.0 4.5 4.3 
45 3.0 5.0 1.0 2.5 0.5 4.5 2.8 
60 2.0 2.0 0.5 1.0 0 0 0.8 
75 1.0 1.0 0.5 0.5 0 0 0.5 
90 0.5 0.5 0 0.5 0 0 0.3 
105 0.5 0.1 0 0.5 0 0 0.1 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
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300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 29. Changes in VAS “high”, expressed as cm on the VAS scale, after internasal mephedrone 
administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 7.0 2.0 6.0 1.0 8.0 10 6.5 
30 4.0 4.0 1.5 1.0 5.0 10 4.0 
45 4.0 4.5 1.0 3.0 0.5 10 3.5 
60 3.0 3.0 0.5 0.5 0.5 10 1.8 
75 1.0 3.0 0.5 0.5 0 10 0.8 
90 0.5 3.0 0 0.5 0 8.0 0.5 
105 0.5 1.0 0 0 0 7.0 0.3 
120 0 0.5 0 0 0 6.0 0 
150 0 0.5 0 0 0 4.0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 30. Changes in VAS “liking”, expressed as cm on the VAS scale, after internasal mephedrone 
administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 6.0 2.0 6.0 5.5 9.5 10 6.0 
30 6.0 1.5 1.5 4.0 6.0 10 5.0 
45 6.0 1.0 1.0 4.0 4.0 10 4.0 
60 5.5 5.0 0 3.0 4.0 10 4.5 
75 5.0 4.0 0 0 4.0 10 4.0 
90 5.0 2.0 0 0 4.0 10 3.0 
105 3.0 0.5 0 0 4.0 8.0 1.8 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
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Table 31. Changes in VAS “dizzy”, expressed as cm on the VAS scale, after internasal mephedrone 
administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 0.5 1.0 5.0 4.0 2.0 4.0 3.0 
30 0 2.0 3.5 3.0 1.0 0 1.5 
45 0 2.0 2.0 1.0 0 0 0.5 
60 0 0.5 0 1.0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 32. Changes in VAS “good drug effect”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 7.5 4.0 1.0 1.0 10 10 5.8 
30 4.0 4.5 1.0 1.0 6.0 10 4.3 
45 4.0 5.0 0 3.0 0 10 3.5 
60 2.0 2.0 0 0.5 0 10 1.3 
75 1.0 2.0 0 0 0 10 0.5 
90 0.5 2.0 0 0 0 9.0 0.3 
105 0.2 1.0 0 0 0 6.0 0.1 
120 0 0 0 0 0 6.0 0 
150 0 0 0 0 0 6.0 0 
180 0 0 0 0 0 4.0 0 
300 0 0 0 0 0 0 0 
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Table 33. Changes in VAS “confused”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 3.0 0.5 2.0 0.5 0.5 6.0 1.3 
30 0 1.0 1.0 0.5 0.5 4.0 0.8 
45 0 1.0 1.0 0.5 0.5 4.5 0.8 
60 0 0 0 0 0 4.0 0 
75 0 0 0 0 0 4.0 0 
90 0 0 0 0 0 3.0 0 
105 0 0 0 0 0 1.5 0 
120 0 0 0 0 0 1.5 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 34. Changes in VAS “fearful”, expressed as cm on the VAS scale, after internasal mephedrone 
administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 0 1.0 0 0.5 0.5 1.5 0.5 
30 0 1.0 0 0.5 0.5 0 0.3 
45 0 1.0 0 0 0.5 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
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Table 35. Changes in VAS “changes in lights”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 1.0 1.0 0 0 0 0 
45 0 2.5 0.5 0 0 0 0 
60 0 0 3.5 0 0 0 0 
75 0 0 1.5 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 36. Changes in VAS “changes in distance”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 1.0 0 1.0 1.5 0 0 0.5 
30 0 1.0 0 1.0 0 0 0 
45 0 2.0 0 2.5 0 0 0 
60 0 0.5 0 0.5 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
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Table 37. Changes in VAS “changes in hearing”, expressed as cm on the VAS scale, after internasal 
mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 0 0 0 2.5 0 4.0 0 
30 0 0 0 1.5 0 4.5 0 
45 0 2.5 0 0.5 0 0 0 
60 0 1.0 0 0.5 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
 
Table 38. Changes in VAS “changes in body sensations”, expressed as cm on the VAS scale, after 
internasal mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 3.5 4.5 8 2.5 9.0 4.0 4.3 
30 1.0 5.5 1.0 3.0 5.0 4.0 3.5 
45 1.0 6.0 1.0 4.5 0 4.5 2.8 
60 0 2.5 0.5 0.5 0 4.5 0.5 
75 0 2.5 0.5 0 0 4.0 0.3 
90 0 0.5 0 0 0 1.0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
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Table 39. Changes in VAS “changes in surrounding”, expressed as cm on the VAS scale, after 
internasal mephedrone administration 
Timepoint M1 M2 M3 M4 M5 M6 Median 
Pre 0 0 0 0 0 0 0 
15 2.5 1.0 0.5 3.0 0 0 0.8 
30 1.0 1.0 0 1.0 0.5 0 0.8 
45 0.5 3.0 0 2.5 0 0 0.3 
60 0 1.0 0 0.5 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
150 0 0 0 0 0 0 0 
180 0 0 0 0 0 0 0 
300 0 0 0 0 0 0 0 
360 0 0 0 0 0 0 0 
9. Individual blood pressure and heart rate results 
Table 40. Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) 
















Pre 136 85 88 134 79 94 
5 160 96 98 148 84 128 
10 175 88 125 140 100 140 
15 145 89 133 141 90 140 
20 144 93 96 141 92 139 
30 140 85 92 142 92 157 
45 145 82 88 140 89 133 
60 140 83 93 140 91 132 
75 142 87 86 118 70 125 
90 135 77 82 130 80 126 
105 132 73 78 128 81 115 
120 126 81 74 128 88 116 
140 132 76 76 120 71 116 
150 140 73 72 120 68 115 
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170 117 71 69 109 67 119 
180 133 67 73 124 69 110 
200 129 82 82 122 68 100 
220 127 70 77 117 53 95 
240 125 65 78 119 67 100 
260 127 70 72 111 61 98 
280 126 73 73 110 67 98 
300 124 76 73 119 65 99 
320 121 63 70 120 76 102 
340 129 76 71 123 69 92 
360 125 67 77 123 76 101 
 
Table 41. Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) 
















Pre 139 74 68 103 65 75 
5 155 87 73 126 81 84 
10 144 81 84 125 78 71 
15 141 84 82 124 73 97 
20 139 88 77 125 75 90 
30 136 71 71 121 74 68 
45 133 89 68 116 69 70 
60 132 78 68 124 74 69 
75 122 70 66 113 69 68 
90 119 72 63 112 68 69 
105 117 73 65 107 69 61 
120 120 76 53 107 71 68 
140 122 63 54 110 71 68 
150 115 76 62 105 74 69 
170 109 64 55 109 64 65 
180 120 74 62 106 78 63 
200 124 73 56 114 76 56 
220 118 76 58 118 73 63 
240 111 61 61 110 74 63 
260 110 55 58 110 69 68 
280 102 54 61 108 67 69 
300 106 49 61 108 64 66 
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320 106 60 66 109 65 67 
340 103 54 63 110 65 68 
360 110 67 63 111 68 68 
 
Table 42. Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) 
















Pre 121 75 81 124 82 99 
5 159 91 105 142 100 152 
10 120 87 105 152 108 151 
15 153 96 106 167 108 149 
20 153 83 110 151 93 140 
30 146 86 97 150 105 140 
45 123 79 89 148 93 128 
60 136 79 79 147 90 127 
75 122 67 65 132 90 109 
90 124 74 68 131 91 110 
105 121 69 64 131 91 111 
120 129 73 60 128 88 114 
140 108 64 70 127 84 112 
150 112 65 64 129 86 113 
170 120 79 61 124 85 109 
180 125 73 64 121 81 104 
200 127 69 65 120 80 105 
220 133 61 74 119 77 104 
240 119 64 70 117 79 102 
260 126 65 73 121 78 103 
280 125 69 76 119 74 94 
300 123 76 85 128 78 96 
320 118 67 86 122 76 99 
340 116 73 82 123 80 98 
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Figure 13. Correlation between whole blood and plasma concentrations for mephedrone in 
M1-M6 























































































































































































































Figure 14. Correlation between whole blood and plasma concentrations for dihydro-mephedrone 
in M1-M6 




































































































































































































































































































































































































































Figure 15. Correlation between whole blood and plasma concentrations for nor-mephedrone in 
M1-M6 
Appendix 



























































































































































































































Figure 16. Correlation between whole blood and plasma concentrations for 
hydroxytolyl-mephedrone in M1-M6 
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Figure 17. Correlation between whole blood and plasma concentrations for 
4-carboxy-mephedrone in M1-M6 
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Figure 18. Correlation between whole blood and plasma concentrations for 
dihydro-nor-mephedrone in M1-M6; the analyte was not detected in M4 and M5 (plasma) 
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11. Individual correlation between DBS and whole blood 
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Figure 20. Correlation between whole blood and DBS concentrations for nor-mephedrone in 
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12. Individual correlation between DBS and whole blood 
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Figure 23. Correlation between plasma and DBS concentrations for nor-mephedrone in M1-M6; the 
analyte was not detected in DBS in M5 
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Figure 25. Correlation between oral fluid and whole blood concentrations for mephedrone in 
M1-M6 
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Figure 26. Correlation between oral fluid and whole blood concentrations for nor-mephedrone in 
M1-M6 
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Figure 27. Correlation between oral fluid and plasma concentrations for mephedrone in M1-M6 
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Figure 28. Correlation between oral fluid and plasma concentrations for nor-mephedrone in 
M1-M6 
